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ABSTRACT 
 
Hypoxia and hypoxia-reoxygenation (H-R) are pathogenic factors in many liver diseases and 
lead to hepatocyte death as a result of reactive oxygen species (ROS) accumulation. 
Activation of the Tumour Necrosis Factor-α (TNFα) super-family member CD40 by its 
cognate ligand CD154 can induce hepatocyte apoptosis via induction of autocrine/paracrine 
Fas Ligand/CD178 expression but the relationship between CD40 activation, ROS 
generation and hepatocyte cell death is poorly understood. Therefore, human hepatocytes 
were isolated from liver tissue and exposed to an in vitro model of hypoxia and H-R in the 
presence or absence of CD154 and/or various inhibitors. Hepatocyte ROS production, 
apoptosis, necrosis and autophagy were determined by a four-colour reporter flow cytometry 
assay. The in vivo regulation of liver injury by CD40 and CD154 was determined using a 
murine model of partial liver ischaemia. Exposure of human hepatocytes to recombinant 
CD154 or platelet-derived soluble CD154 augmented ROS accumulation during H-R 
resulting in NADPH oxidase-dependent apoptosis and necrosis. The cyto-protective 
mechanism of autophagy limited apoptotic cell death during hypoxia and H-R. CD40 and 
CD154 knockout mice but not wild type mice were protected from ischaemic liver injury. 
Hence, CD40:CD154 mediate hepatocytes cell death in vitro and in vivo during hypoxia and 
H-R.  
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1.1 Overview 
1.1.1 Liver Transplantation & Hepatic Ischaemia-Reperfusion Injury 
The first orthotopic liver transplant (OLT) was performed in 1963 by Dr Thomas Starzl in 
Denver, Colorado on a three year-old child with biliary atresia. Unfortunately, the child died 
during the operation from overwhelming haemorrhage and it took over four years from the 
initial attempts at OLT for the first patient to survive one year. Much of these early problems 
encountered by the nascent field of liver transplantation were technical in nature. The 
surgical and anaesthetic techniques required for successful liver transplantation were in 
development and immunosuppression following transplantation was not to become common 
clinical practice until the 1980’s. Yet despite the above advancements liver allografts still 
sustained significant injury following transplantation and many allografts failed to function 
adequately in the post-operative period. These latter observations were in large part due to 
the as yet unknown entity of ischaemia-reperfusion injury (IRI). Furthermore despite nearly 
50 years of experience with OLT worldwide, IRI is the primary cause of initial poor allograft 
function and primary non-function of the liver allograft.  
The phenomenon of IRI was first suggested by experimental studies conducted in the 
1970’s. IRI is now understood to be a common and important mechanism of injury in many 
different organ systems and in many different clinical scenarios. For instance, IRI is seen 
during and after myocardial infarctions [1], strokes [2], acute kidney injury [3], 
haemodynamic shock [4] and systemic shock [5]. IRI is a common feature in all deceased 
donor solid organ transplantation. Both clinical and experimental data demonstrates that IRI 
has deleterious short- and long-term effects upon allografts after transplantation [6, 7]. 
Following OLT, IRI can manifest as increased episodes of acute rejection and chronic 
allograft dysfunction [8].  
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As emphasised above, IRI is of particular relevance to the field of liver transplantation. 
There is a well publicised shortage of donor liver organs available for transplantation and the 
number of patients requiring a liver transplant continues to rise year on year across the 
United Kingdom and Europe [9]. Current estimates show that 4% of liver transplants are 
subject to organ dysfunction after transplantation and 2% sustain primary graft non-function 
as a result of IRI [10]. Moreover, IRI is responsible for 81% of all liver re-transplantations, 
demonstrating the extent of the clinical impact of liver IRI [11, 12]. This clinical impact of 
IRI has become more pronounced during the last decade due to the increase in the utilisation 
of extended criteria donor livers [13]. This particular group of organs includes livers 
retrieved from elderly patients, steatotic livers and non-heart beating donor livers. These 
allografts are more susceptible to IRI and hence to organ dysfunction after OLT when 
compared to standard criteria donors [14]. Importantly it is well known that IRI hinders liver 
regeneration [15] and therefore limiting allograft injury after OLT would have dual benefits 
upon patient outcome following transplantation. Minimising the adverse effects of hepatic 
IRI could potentially increase the number of suitable allografts for transplantation and also 
enhance the number of patients who successfully recover from OLT. Amelioration of IRI 
would also potentially reduce the need for re-transplantation and improve patient morbidity 
and mortality after OLT. Therefore investigating the fundamental biological aspects of 
hepatic IRI represents an important area of research within the field of transplantation. 
Paramount to achieving the goal of improved understanding of the IRI process is gaining a 
complete understanding of the molecular mechanisms involved in hepatic IRI. In order to 
obtain the understanding of the effects of IRI upon human liver physiology after OLT it is 
essential that the effects of IRI are studied upon human livers and human liver cells. This 
information would better serve in developing strategies to limit IRI in the clinical scenario of 
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OLT. However this approach has obvious practical and ethical barriers. Although limited 
studies have investigated the effects of IRI upon the human liver [16] these studies have 
largely looked at the effects of IRI upon hepatic architecture [17] and limited physiological 
responses [16]. As a result, studies have utilised murine [18-20] and rodent models [21, 22] 
of IRI to investigate the deleterious effects of IRI upon liver physiology. Whilst these studies 
have obvious merit there is likely to exist differences between these models and the clinical 
events following OLT. 
In vivo models of IRI have the obvious advantage of studying the liver within the whole 
organism and can be akin to the clinical setting encountered after organ transplantation. 
However, it is well appreciated that the hepatocyte is the main cellular target of hepatic IRI 
[23]. Therefore in vivo models of IRI by their very nature do not allow the delineation of 
specific hepatocyte responses during IRI. However, the in vitro modelling of IRI also has the 
obvious disadvantage of studying the cell type of interest outside its normal physiological 
and anatomical parameters. Indeed, the in vitro modelling of IRI is unlikely to reflect the in 
vivo microenvironment during and after IRI. Nonetheless understanding the specific 
response of individual cell types to IRI would allow the delineation of cellular and molecular 
mechanisms that contribute to IRI.   
As discussed above all cell types within the liver are affected by IRI but the main cell type 
targeted by the injurious process during IRI is the hepatocyte. The response of hepatocytes, 
and particular human hepatocytes, to IRI is surprisingly not well studied or well known. 
Early studies and more recent studies have investigated the effects of IRI upon hepatocytes 
using human hepatoma cell lines such as HepG2 cells in experimental models [24, 25]. 
These hepatoma cells were found to be relatively resistant to in vitro IRI [26, 27] and thus 
have led to the widely accepted notion that hepatocytes are relatively resistant to IRI. 
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However, more recent studies utilising a variety of primary animal hepatocytes have shown 
that hepatocytes may be more susceptible to IRI than first thought [28-32]. These latter 
studies using different animal hepatocyte have however led to much confusion and 
discrepancies within the literature regarding hepatocyte responses to IRI. This is in large part 
due to the different models of IRI used in these studies. For instance these studies have used 
differing times of ischemia, differing times of reperfusion and differing oxygen tensions and 
concentrations. Taken together these experiments have not assisted in clarifying the role and 
response of hepatocytes to IRI.  
Despite this large body of literature there have been no studies to date that have investigated 
the effects of IRI upon isolated primary human hepatocytes. This has left a large void within 
the literature regarding the role of human hepatocytes in IRI and in the general 
understanding of hepatic IRI. The reasons for the paucity of this data are in part due to the 
complexities and technical demands of routine human hepatocyte isolation [33], the 
establishment of an efficient and effective in vitro IRI model for human hepatocytes and the 
development of reliable assays for measuring meaningful outputs for IRI. There are also 
other added difficulties in using human hepatocytes to investigate the mechanisms of IRI. 
Human hepatocytes can be isolated from both diseased and normal liver tissue [34]. Indeed, 
normal liver can encompass both donor livers and/or normal resected liver tissue. The latter 
describes livers that have been resected from patients with neoplastic disease following 
which liver tissue has been obtained from macroscopically normal liver well away from the 
primary liver lesion. As stated above authors have used hepatoma cells as a surrogate for 
primary hepatocytes assuming that these cells would have very similar physiological 
responses to extracellular cues such as ischaemia/hypoxia because both these cell types 
express similar intracellular enzymes [35]. Importantly, this latter hypothesis has not been 
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objectively tested in any studies to date and recent studies do reveal fundamental differences 
between these two cell types [36]. The study of human hepatocyte responses to IRI would be 
of undoubted benefit to understanding the fundamental responses of human hepatocytes to 
hypoxic stress as well as providing potential therapeutic targets to manipulate with drug 
therapy that will ultimately improve patient outcome after OLT. Without an understanding 
of the response of primary human hepatocytes during IRI the precise mechanisms involved 
in the whole process of IRI will remain elusive and poorly understood.  
 
1.1.2 Mechanisms Regulating Hepatic Ischaemia-Reperfusion Injury  
 
Cerra et al were among the first groups to describe the phenomenon of IRI in 1975 using 
experimental canine models [37]. In these studies the authors examined the myocardial 
pedicles of canine hearts after myocardial IRI and found that increased ischaemic times were 
associated with increased sub-endothelial haemorrhagic necrosis within the heart. In the 
same year the first study documenting IRI within the liver was reported by Toledo-Pereyra et 
al [38]. This landmark study established the detrimental effects of IRI within the liver. In a 
series of elegant experiments the authors reported that intravenous pre-treatment of dogs 
with isoproterenol, allopurinol and heparin significantly reduced liver injury prior to 
auxiliary liver transplantation. However, it was not apparent from these early experiments as 
to the mechanism of protection of the aforementioned drugs. Since these early experimental 
studies the understanding of IRI [39] and in particular hepatic IRI [40] has increased 
substantially. Many studies have investigated the effects of hepatic IRI both in vitro and in 
vivo and a large body of literature is now established on the subject. Hepatic IRI is now 
recognised as a highly complex cascade of events that includes interactions between vascular 
endothelium, interstitial compartments, circulating cells and numerous biochemical entities 
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[41]. The aetiology of IRI is a multi-factorial process and many of the mechanisms involved 
have been extensively discussed in many recent reviews [7, 41-43]. 
As discussed above, IRI is well known to be an obligatory part of all solid organ 
transplantation. In general, ischaemia or hypoxia is a state of tissue oxygen deprivation 
accompanied by a reduced clearance of the resulting toxic metabolites. During liver 
ischaemia, liver parenchymal damage occurs from both direct micro-vascular dysfunction 
and the subsequent inflammatory response [44]. Acute ischaemia leads to oxygen 
deprivation and adenosine triphosphate (ATP) depletion resulting in direct parenchymal 
damage through tissue apoptosis and necrosis [23]. During hepatic IRI all parenchymal and 
non-parenchymal cells resident within the liver are exposed to ischaemia. In general, 
previous studies have shown that parenchymal cells and in particular hepatic sinusoidal 
endothelial cells (HSEC) are more susceptible to cell death during the ischaemic portion of 
IRI than hepatocytes [45]. The responses of other parenchymal cells such as cholangiocytes 
have not yet been fully investigated and remain the subject of ongoing research. Moreover, 
as stated above the effects of IRI upon human hepatocytes has not been objectively studied 
and thus it remains to be determined whether these particular cells are also relatively 
resistant to cell death during ischaemia/hypoxia. Acute ischaemia also triggers a vigorous 
immune response and causes the activation of the endothelium resulting in increased 
permeability and increased expression of adhesion molecules such as Intracellular Adhesion 
Molecule-1 (ICAM-1), p-selectin and E-selectin [46]. Hence during ischaemia as well as 
parenchymal cell death the endothelial cells acquire an adhesive, thrombogenic surface that 
latter amplifies liver injury through the recruitment of effector cells [46]. 
Following the ischaemic portion of IRI, reperfusion restores blood flow to the ischemic 
tissue. Despite the unequivocal benefit of reperfusion of blood to the ischaemic tissue, 
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reperfusion itself can and does elicit a cascade of adverse reactions that paradoxically injure 
tissue [41]. Upon restoration of blood flow to the ischaemic tissue, a ‘no-flow’ phenomenon 
occurs. Capillaries and microcapillaries are not perfused, potentiating further tissue damage. 
Reperfusion is a much more complex process than ischaemia in that it has diverse effects 
upon parenchymal and non-parenchymal cells. The sequelae of events described above leads 
to direct microvascular dysfunction and further parenchymal injury. The primed endothelial 
cells are more adhesive, and upon, reperfusion, inflammatory cells attach to the endothelium 
[46]. In addition, shear stress, the tangential component of haemodynamic forces, can also 
activate cellular signalling pathways within liver endothelial cells during IRI [47]. Moreover 
shear stress can induce the expression various molecules upon liver endothelial cells such as 
Vascular Adhesion Protein-1 (VAP-1), ICAM-1 and VCAM-1 [48]. These adhesion 
molecules can then regulate the adhesion and transmigration of effector cells during IRI that 
then perpetuates liver injury. However, shear stress may also be beneficial during liver IRI 
thorough the release of Nitric Oxide (NO) that induces vasodilatation counteracting 
microvascular dysfunction [49] and also by promoting liver regeneration [47].    
Reactive oxygen species (ROS), cytokines, chemokines and adhesion molecules are also 
generated, secreted and released augmenting the pro-inflammatory reaction [40]. The 
combination of vascular permeability and increased cellular signalling augments the 
recruitment and infiltration of circulating leukocytes into the post-ischaemic liver tissue [46]. 
Reperfusion also causes the swelling of non-parenchymal cells resident within the liver such 
as Kupffer cells (KC) and liver resident macrophages, which then upon activation release a 
plethora of pro-inflammatory mediators such as ROS and cytokines [50]. Although the 
effects of infiltrating and resident inflammatory cells during reperfusion has been well 
studied the effects of reperfusion upon parenchymal cells is less well defined. In general, 
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work in rodent and murine hepatocytes has shown that during reperfusion hepatocytes 
undergo cell death primarily in the form of necrosis due to the depletion of ATP and the lack 
of oxygen [51]. When ATP is present, cells preferentially die via apoptosis [23, 51]. Some 
authors have argued that both forms of cell death occur within the liver during IRI and have 
termed this overall process as necro-apoptosis [52, 53]. In vivo this appears 
histopathologically as hepatocyte blebbing and causes the detachment of hepatocytes from 
the sinusoidal plate and may lead to the obstruction of sinusoidal flow and the phenomenon 
of secondary necrosis [54]. HSEC undergo necrosis and can cause disruption to the hepatic 
microcirculation once again leading to secondary necrosis [40]. The pro-inflammatory 
response seen during IRI has been shown in both experimental models of hepatic IRI and the 
limited human studies performed in livers after ischaemia [16, 39]. The overall process 
results in tissue destruction, organ dysfunction and in the case of organ transplantation 
possible allograft failure.  
The relationships between the signalling pathways involved in hepatic IRI are highly 
complex and are yet to be fully ascertained. Figure 1.1 shows the current paradigm for the 
processes thought to be involved in and regulate hepatic IRI. Among the important 
regulators of hepatic IRI are Nitric Oxide (NO), Tumour Necrosis Factor-α (TNFα), Nuclear 
Factor kappa B (NFκB) and both the innate and adaptive immune system. A brief 
description of the key regulators and mediators of hepatic IRI is discussed below. This 
section is not exhaustive and recent reviews give a much more comprehensive review of all 
the potential mechanisms involved in hepatic IRI [39, 40, 43]. 
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Figure 1.1 The Major Regulators of Hepatic IRI 
The overall mechanisms involved during the process of hepatic IRI. In general IRI is a pro-
inflammatory process and during the ischaemic portion of IRI the hepatic endothelium is 
primed and has a thrombotic adhesive surface due to effects of pro-inflammatory cytokines 
such as TNFα and Interleukin-1 (IL-1). Upon reperfusion of the liver the classical model of 
IRI describes the activation of KCs. These liver resident macrophages release a plethora of 
pro-inflammatory cytokines such as TNFα and ROS. These soluble mediators induce the 
expression of adhesion molecules and induce the influx of leukocytes and 
polymorphonuclear cells into the liver that perpetuate liver parenchymal injury. Extracellular 
ROS released by KCs also induce parenchymal injury, as does the generation of intracellular 
ROS. IRI also causes the activation of innate and later the adaptive immune system that also 
induces liver injury. EC, endothelial cells; CAM, cellular adhesion molecules; PMN, 
polymorphonuclear leukocyte neutrophil; ROS, reactive oxygen species, TNF, Tumour 
Necrosis Factor; GM-CSF, granulocyte macrophage colony stimulating factor; PAF, platelet 
activating factor; CXC, CXC chemokines; C5a, activated complement factor; SLP, secretory 
leukocyte protease inhibitor. (Taken from Jaeschke H, American Journal Physiology. 2003 
284; G15-G26). 
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1.1.2.1 The Immune System 
Inflammation is known to be a key mediator of IRI and considerable data exists 
demonstrating the key role of the innate and adaptive immune system in the process [39, 55]. 
The inflammatory response to acute ischaemia in the classic model of IRI is predominantly 
an innate immune response [56, 57]. In liver IRI there is no microbial infection present and 
the innate immune response is triggered by non-infectious stimuli [40]. These non-infectious 
stimuli contribute to the initiation of an inflammatory response in part by signalling via Toll-
like receptor (TLR) mediated signalling pathways [56]. TLRs are a family of pattern 
recognition receptors that are activated by specific components of microbes and certain other 
molecules. TLRs form the first line of immune defence and are expressed on antigen-
presenting cells (APCs), macrophages, dendritic cells and B-cells [58]. Specifically, TLR4 is 
involved in innate immunity primarily by recognising lipopolysaccharides (LPS). Activation 
of TLR4 is linked to NFκB activation and secretion of pro-inflammatory cytokines (TNFα, 
IL-β) as well as inducible NO synthase and ICAM-1 [59]. TLR4 activation is likely to play 
an important role in KCs activation during liver IRI [60]. Indeed, TLR4 deficient mice are 
less prone to liver IRI [61]. These findings suggest that endogenous TLR ligands are the 
primary stimuli initiating liver IRI through the innate immune system. As well as TLRs, 
complement and DCs have a profound effect upon the development of liver IRI [40]. DCs in 
particular are likely to be one of the key regulators for the development of an adaptive 
immune response during IRI [62]. In addition to TLR4 and DCs, the damage-associated 
molecular pattern (DAMPs) molecules may also key initiators of the immune response seen 
during IRI. These molecules regulate immune responses in non-infectious inflammatory 
scenarios. Specifically, the DAMP molecules, high-mobility group box 1 (HMGB1) and 
interferon regulatory factor 1 (IRF-1) have been shown mediate the progression liver IRI 
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[63]. In addition, recently histones have been identified as a new class of DAMP molecules 
that link initial damage and the subsequent activation of innate immunity during sterile 
inflammation [64]. These observations collectively demonstrates that many mediators are 
involved in triggering the innate immune response seen during liver IRI. 
T-lymphocytes constitute one of the primary arms of the adaptive immune response during 
IRI. According to classical immunological dogma, these cells were not suspected to play a 
role in IRI [46]. However recent studies have shown that mice lacking CD4/CD8 T-
lymphocytes are protected from IRI and adoptive transfer of T-lymphocytes into T- 
lymphocyte knockout mice restores ischaemic injury [65]. More recent studies have refined 
these observations and have shown that CD4-positive T-lymphocytes are the mediators of 
late liver injury during IRI [66].  
 
1.1.2.2 Reactive Oxygen Species 
Of undoubted importance in the development of parenchymal injury during IRI is the 
generation of ROS [43]. ROS are a family of oxygen intermediates that can cause cellular 
damage. In the classical model of hepatic IRI it is thought to be extracellular ROS released 
by KCs and PMN that is responsible for parenchymal injury [40]. Some studies have 
evaluated the role of intracellular ROS production by hepatocytes during IRI [67, 68]. These 
early experiments proposed xanthine oxidase (XO) was the main generator of ROS in 
hepatocytes [69]. However, more recent data has shown that the mitochondria are likely to 
be the main ROS generators in hepatocytes [70, 71]. Controversy still exists as to whether it 
is intracellular or extracellular ROS that is of primary importance with regard to 
parenchymal injury during IRI. ROS is likely to have multiple effects during IRI [43]. These 
include direct oxidation of cellular components and lipids (lipid peroxidation), activation of 
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inflammatory gene transcription and possible activation of the innate immune response. ROS 
can also generate other potentially harmful compounds such as peroxynitrites [42]. The 
specific role of ROS in hepatic IRI is discussed in more detail in section 1.1.3.  
 
1.1.2.3 NO & Haem Oxygenase (HO) 
The role of NO during hepatic IRI remains controversial [72]. Some studies have stated that 
NO exerts a beneficial effect during IRI by limiting liver injury [73] whilst others report 
detrimental effects [74]. The discrepancy is likely to arise from the fact that endothelial NO 
synthase (eNOS)-derived NO production is protective in IRI whereas inducible NO synthase 
(iNOS)-derived NO may contribute to IRI. This may be a function of the NO generation 
kinetics from the two isoforms in IRI. eNOS may help abrogate microcirculatory stress but 
iNOS-derived NO takes several hours to be generated because of the requirement of 
transcriptional activation [75]. Excessive levels of iNOS-derived NO maybe detrimental 
through the generation of peroxynitrites [42] (see section 1.1.3). NO can also promote 
apoptosis through inducing cytochrome c release and caspase activation [76].   
HO, a rate-limiting enzyme, catalyses the degradation of heme into free iron, carbon 
monoxide (CO) and biliverdin. HO overexpression is protective in IRI and has anti-
inflammatory and anti-apoptotic effects [77]. These effects are likely to be mediated by the 
by-products of HO-1 activity namely biliverdin, bilirubin, ferritin, and CO.  
 
1.1.2.4 TNFα & NFκB 
Similar to NO, TNFα, have been reported to be both protective and injurious during IRI [78]. 
For example the deleterious effects of TNFα in local and systemic damage associated with 
hepatic IRI is well established [79]. However TNFα is also an important mediator of hepatic 
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regeneration [80]. Indeed pre-treatment with low-dose TNFα is known to be highly 
protective against hepatic IRI [81]. The differential effects observed for TNFα can be 
attributed to the differential activation of transcription factors. For further discussion on the 
wider role of the TNFα family members in regulating hepatic IRI see section 1.1.4. 
It is well known that NFκB can regulate various downstream pathways and thus has the 
potential to be both pro- and anti-apoptotic [82, 83]. It is likely that NFκB has a myriad of 
effects on cellular processes such as anti-apoptosis and reducing pro-inflammatory cytokine 
activation. Indeed NFκB inhibition decreases neutrophil accumulation after partial liver IRI 
and protects against liver injury [84].  
 
1.1.2.5 Neutrophils/Polymorphonuclear (PMN) cells 
PMN cells have been shown to be the major leukocytes found in necrotic liver tissue 
following ischaemic injury [85]. Neutrophils are thought to be the early cellular mediators of 
local microvascular changes and parenchymal damage [86]. Monocytes and macrophages 
infiltrate the liver later in IRI and likely extend and amplify the early injury phase [87]. 
Activation of neutrophils has been implicated in hepatic microvascular dysfunction and 
parenchymal damage associated with IRI [46]. It is thought that the expression of ICAM-1 
and p-selectin may facilitate neutrophil accumulation in the liver after ischaemia [88]. 
However, mechanical factors such as vasoconstriction, oedema, and reduced membrane 
flexibility may also trap these leukocytes in liver sinusoids. Due to the HSEC damage that is 
seen during reperfusion, neutrophils have direct access to hepatocytes and may perpetuate 
parenchymal injury [40].  
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1.1.2.6  Hypoxia Inducible Factor-1α (HIF-1α) and ischaemic pre-conditioning (IPC) in 
IRI 
The transcription factor HIF-1α is involved in regulating a wide variety of cellular signalling 
pathways during hypoxia. Specifically, the role of HIF-1α in mediating liver ischaemic 
injury was initially reported in the late 1990’s [89]. These studies showed that HIF-1α 
protein levels were up-regulated and that HIF-1α was activated during ischaemia. Moreover 
the upregulation of HIF-1α was associated with cytoprotection.  
These experimental observations lead several groups worldwide to assess whether IPC could 
ameliorate liver injury after OLT. IPC involves short periods of liver ischaemia induced by 
total hepatic vascular occlusion. IPC has been comprehensively reviewed recently [90-92]. 
Studies indicated that 10 minutes of occlusion increased HIF-1α levels as well as other 
hepatoprotective factors within the liver and reduced liver injury although this did not reach 
statistical significance when compared to the control group [93]. In addition, IPC increases 
levels of NO and attenuates the overproduction of ROS and IRI induced inflammation [94]. 
Hence, IPC may protect the liver from IRI via an Akt-eNOS-NO-HIF-1α dependent pathway 
[94]. Moreover studies suggest that HIF-1α is the main factor involved in the protective 
effects of IPC and may protect hepatocytes in particular from the detrimental effects of 
hypoxia [90, 95].  
The use of IPC clinically is determined by personal surgeon preference but allied strategies 
to IPC such as post-conditioning may further enhance the protective effects of IPC and 
increase its use during liver surgery [96, 97]. In general, IPC appears to be hepato-protective 
by in part up-regulating HIF-1α levels but further clinical trials are required before it can be 
widely adopted.  
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1.1.3 ROS & Hepatic IRI 
Pro-oxidants or oxidative agents are molecules that abstract electrons from other molecules. 
Oxidative stress occurs when pro-oxidants overwhelm cellular anti-oxidants defence 
mechanisms. In hepatocytes the antioxidant defences are primarily in the form of 
intracellular glutathione [42, 98-100]. Therefore oxidant stress can result from either 
excessive generation of oxidizing agents or a relative deficiency of anti-oxidants.  The 
oxidizing species most implicated in oxidative stress include the superoxide anion, hydrogen 
peroxide, the hydroxyl radical, hypochlorous acid, chloramines, singlet oxygen, and 
peroxyradicals [6]. In most systems superoxide anions are often the initial toxic oxygen 
species generated during oxidative stress. Superoxides, within hepatocytes, are generally 
generated during physiological activities in mitochondria, microsomes and peroxisomes 
[101, 102]. Indeed, 1%-2% of oxygen consumed by mitochondria undergoes reduction to 
form superoxide anions by the coenzyme Q and the reduced nicotinamide adenine 
dinucleotide (NADH)-coenzyme Q reductase complex (see Figure 1.2). Disruption of the 
mitochondrial electron transport chain can lead to increased production of superoxide anions 
[103]. In mammalian cells, enzymatic dismutation of superoxide anions to hydrogen 
peroxide occurs rapidly by the enzyme superoxide dismutase. Subsequently, hydrogen 
peroxide can be converted to the highly reactive hydroxyl radical by transition metal-
catalysed reactions [103]. In the liver, hepatic microsomes through the activity of the 
cytochrome P450 can also generate superoxide anions and hydrogen peroxide [104].  
Reoxygenation injury is defined as cellular injury caused by reintroduction of physiological 
concentrations of oxygen to viable cells that have been exposed to injurious but non-lethal 
hypoxic conditions. Reoxygenation injury results from the generation of toxic oxygen 
species generated after reintroduction of oxygen to ischaemic tissues. Upon the 
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reintroduction of oxygen to ischaemic hepatocytes reduced mitochondrial electron carriers 
generate a burst of superoxide anions as a result of increased auto-oxidation rates of 
complexes III and I in pre-mitochondrial respiratory chain [26, 27]. The lack of oxygen as a 
terminal electron carrier for the mitochondrial respiratory chain immediately interrupts 
electron flow, causing the respiratory chain to become reduced as opposed to its usual 
aerobic oxidised state. The mitochondria no longer accept electron from substrates and hence 
a reduction of pyridine nucleotides occurs resulting in an increase in the intracellular 
NADH/oxidized NAD+ ratio [103]. The cessation of oxidative phosphorylation rapidly leads 
to cellular ATP depletion once glycolytic substrates have been used. If the hypoxic insult is 
reversed in the early stages then mitochondrial function can recover and cell death prevented 
[105]. 
Cytosolic oxidases can also generate ROS [106-108]. The most widely studied cytosolic 
system within hepatocytes is the XO-xanthine dehydrogenase enzyme system [109]. As a 
result of oxidative stress xanthine dehydrogenase activity is converted to XO function. ATP 
hydrolysis as is seen during IRI results in the production of xanthine, the substrate for XO, 
and results in the production of superoxide anion. Other cytosolic enzymes such as 
cyclooxygenase and lipoxygenase activity can also generate ROS but their function within 
hepatocytes remains to be established [106, 107]. The role of cytosolic enzymes production 
of ROS during reoxygenation remains controversial. Indeed, no studies have evaluated the 
role of these cytosolic enzymes in the production of ROS in human hepatocytes.  
Extracellular ROS also plays an important role in hepatic IRI [40]. Neutrophils form 
superoxide anions and hypochlous anion through a membrane-associated reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and myleoperoxidase, 
respectively, which plays a key role in neutrophil-mediated cytotoxicity [110]. Activated KC 
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generate superoxide anions by NADPH oxidase activity [111]. Macrophages, KC and 
endothelium can also generate NO, by the conversion of L-arginine to L-citrulline by NO 
synthase [72]. Recent studies suggest that NO reacts with superoxide anions to form 
peroxynitrate ions [42, 112]. This anion can oxidise sulfhydryl groups and when protonated 
may decompose to form nitrogen and superoxide anion-like species.  
In many models of cell injury superoxide anions are thought to be the cytotoxic bullet 
generated during oxidative injury [76]. Toxic oxygen species are thought to cause cell 
necrosis via oxidation of critical cellular proteins, DNA and lipids [113]. In general 
oxidation of critical thiols leads to loss of protein function, oxidation of cytoskeletal proteins 
may lead to bleb formation, whereas oxidative damage to mitochondria causes a loss of 
oxidative phosphorylation and ATP depletion [113]. In addition oxidative stress can cause 
permeability transition of the inner mitochondrial membrane which contributes to cell death 
in the form of apoptosis [43]. Most early changes in hypoxic cell injury occur in the 
mitochondria.  
Despite this large body of literature the precise role of ROS in human hepatocytes during IRI 
is not known. Moreover, the precise role of the mitochondrion and cytosolic enzymes in 
generating ROS within human hepatocytes remains to be established.  
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Figure 1.2 The Mitochondrial Electron Transport Chain and the Generation of ROS 
The main mechanisms for mitochondrial ROS generation are illustrated above. Reduced 
substrates synthesized in metabolic pathways supply electrons (e¯) to complex I (CI) and 
complex II (CII) of the electron transport chain. The main centres for superoxide formation 
are complex I and complex III (CIII), although small amounts can be formed at complex II 
and complex IV (CIV). The electron carrier of complex III ubiquinone (Q) is reduced to 
ubiquinol that transfers an electron to cytochrome c (Cyt c) through an iron protein. The 
resulting semiubiquinone is oxidized back to ubiquinone by cytochrome b and can also 
transfer electrons to oxygen to form superoxide anions. Rotenone, a complex I inhibitor, 
inhibits electron flow proximal to superoxide generation. 
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1.1.4 The Role of TNFα Family Members in Hepatic IRI 
1.1.4.1 Introduction 
The TNFα superfamiliy of ligands and receptors consist of approximately 50 membrane and 
soluble proteins that can modulate a wide range of cellular function including cellular 
differentiation, survival and production of inflammatory cytokines and chemokines [114]. 
The most widely studied molecule within the superfamily is TNFα itself. Most of the TNFα 
superfamily ligands and receptors are expressed by or primarily target cells of the immune 
system. However, epithelial cells, endothelial cells and stromal cells also express molecules 
of the TNFα superfamily. In addition, the superfamily is an important regulator of 
inflammatory, neoplastic and autoimmune disease processes. Hence the TNFα superfamily 
in an important regulator of the pro-inflammatory hepatic IRI process. Selected members of 
the TNFα superfamily involved in regulating hepatic IRI are discussed below.  
 
1.1.4.2 TNFα 
TNFα is a pro-inflammatory cytokine that as discussed in section 1.1.2.4 regulates diverse 
functions such as cell proliferation, apoptosis and survival [78]. It represents the most widely 
studied TNFα superfamily member. TNFα has two cognate receptors, TNFR1 and TNFR2. 
TNFR1 is efficiently activated by soluble TNFα whereas TNFR2 is activated by membrane 
bound TNFα. Binding of TNFα to its type I receptor (TNFR1) results in the sequential 
formation of two signalling complexes. The rapidly formed complex I is assembled on the 
receptor’s cytoplasmic tail and consists of the adaptor TNF-α receptor death domain-
associated protein (TRADD), the protein kinase Receptor Interacting Protein-1 (RIP1) and 
the signal transducer TNF-α Receptor Associated Factor-2 (TRAF2). This complex signals 
inflammation and survival through IκB kinase (IKK)-dependent activation of NFκB [79]. 
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Subsequently, complex I dissociate from the receptor and TRADD together with RIP1 
associate with the adaptor protein Fas-associated Death Domain (FADD) and procaspase 8 
to form complex II. Activation of caspase 8 can lead to the proteolytic activation of the 
executioner caspase 3 and subsequent apoptosis. TNFR2 has no death domain and interacts 
directly with TRAF2. TNFα induced death signals usually require mitochondrial signals 
whereas Fas-dependent death signalling pathways are mitochondrial independent. TNFR2 
exclusively activates pro-inflammatory pathways but not apoptosis [79].  
The role of TNFα in pro-inflammatory liver disease has been recently reviewed [78]. In 
general the inhibition of TNFα function has improved liver IRI [115]. The mechanism of 
action of TNFα is likely to be multifactorial including generation of ROS, modulation of 
immune cell function and pro-inflammatory cytokine secretion.  
 
1.1.4.3 CD40:CD154  
The main function of CD40:CD154 was thought to be in providing the essential second 
signal in the initiation and maintenance of T-lymphocyte dependent immune responses 
[116]. However, a large body of research has investigated the role of the TNFα family 
members, CD40 and CD154, within the context of liver physiology and patho-physiology 
[19, 117-122]. CD40 is a type I trans-membrane receptor that is expressed upon a wide range 
of cells within the liver including hepatocytes, HSEC, cholangiocytes, immune cells and 
macrophages [123]. For further details of the role of CD40:CD154 in liver physiology see 
Chapter 4. The function of CD40 within cholangiocytes [118] and HSEC [120] has been 
well studied but its role in hepatocytes and particularly human hepatocytes remains to be 
fully determined. Specifically, the signalling pathways employed by CD40 following 
activation remain elusive. The delineation of these pathways is important as CD40 itself has 
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no intrinsic kinase activity [123]. Furthermore, the effect of hypoxia and H-R upon CD40 
activated signalling pathways is unknown. CD154 is the cognate receptor for CD40 and has 
a much more limited expression repertoire being expressed upon immune cells and released 
by activated platelets [124]. The activation of CD40 by CD154 is likely to play an important 
role in IRI and in parenchymal injury [19]. However the effects upon human hepatocyte 
physiology and susceptibility to cell death remain to be determined. In particular whether 
CD40 activation can couple to ROS generation within human hepatocytes and regulate cell 
death is not known.  
A number of studies investigating hepatic IRI have examined the role of CD40 and CD154 
in vivo [19, 117]. These studies have uniformly shown that genetic deletion of either the 
receptor or ligand protects the liver against IRI. However, the studies have not investigated 
whether the protection is afforded by reduction in ROS generation or tissue hypoxia within 
parenchymal cells. Indeed the efficacy of CD154-targetted therapy to prevent rejection and 
to induce tolerance in some transplant models has been established [125]. Much less is 
known about the role of CD154 signalling in antigen-independent inflammatory responses 
triggered by IRI. It is known that disruption of CD154 co-stimulation or treatment with 
CD154 monoclonal antibody prevents hepatic IRI in mice whereas gene transfer of CD40 
immunoglobulin protects rat livers from IRI [19]. However, the effects of CD40 activation 
upon hepatocytes during hypoxia and H-R are not known. Although it is known that CD40 
activation upon human hepatocytes during normoxic conditions can induce apoptosis [122]. 
Therefore the investigation of the effects of hypoxia and H-R upon human hepatocyte 
function in the presence and absence of CD154 and its effect upon ROS generation will 
allow fundamental underpinning of the responses of cells to important pro-inflammatory 
ligands.  
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1.1.4.4 Fas: Fas Ligand (FasL) 
The Fas receptor is a death receptor that is expressed upon numerous cells within the liver 
and leads to apoptosis following activation by its cognate ligand, FasL [126]. Previous 
studies have shown that following CD40 activation in human hepatocytes these cells can 
express FasL and can then induce autocrine/paracrine apoptosis [122]. This latter 
observation illustrates the complex role of TNFα family members in liver physiology. The 
role of Fas:FasL has been well studied with respect to hepatic IRI. The silencing of Fas 
ameliorates hepatic IRI within rodent models of liver transplantation [127] and in patients 
undergoing OLT the levels of soluble Fas and soluble FasL are found to be significantly 
higher during reperfusion implying their role in mediating liver injury [128, 129]. Following 
Fas activation, intracellular signalling pathways lead to the activation of caspases and in 
particular caspase 3 that ultimately lead to apoptosis. Certainly blockade of Fas:FasL may 
offer therapeutic options for IRI [130], inflammatory liver disease and liver cancer [131].  
 
1.1.4.5 TNFα-related Apoptosis-inducing Ligand (TRAIL) 
TNFα-related apoptosis-inducing ligand (TRAIL) also known as Apo2L is also a member of 
the TNFα family. It induces apoptotic death in a variety of cell types [132]. TRAIL binds to 
five membrane-bound death receptors: TRAIL-R1/DR4, TRAIL-R2/DR5, TRAIL-R3/DcR1, 
TRAIL-R4/DcR2 and the soluble osteoprotegerin receptor [132]. Among these, only DR4 
and DR5 possess cytoplasmic tails containing a death domain that can induce apoptosis 
[133]. Studies in human hepatoma cell line have shown that TRAIL can induce apoptosis 
[133]. Whether the same is observed in primary human hepatocytes is not known. Early 
studies did question whether TRAIL could induce hepatocyte apoptosis during H-R [134] 
but more recent studies have shown TRAIL is hepatotoxic [23]. Much of the research 
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focusing upon TRAIL effects upon liver physiology have been centred upon its role in 
Hepatitis C Virus [135, 136] and the role of TRAIL in IRI remains to be firmly established.  
 
1.1.4.6 TNF-α-related Apoptosis-inducing Ligand (TWEAK):Fibroblast Growth 
Factor-inducible 14 (Fn14) 
TWEAK is also a member of the TNFα superfamily. TWEAK functions as a type II 
transmembrane protein and is the ligand for the receptor Fn14 [137]. TWEAK treatment of 
freshly isolated monocytes can induce apoptosis [138] but also promotes proliferation of 
vascular endothelial cells [139]. TWEAK may also have a role in cell migration and 
secretion of pro-inflammatory cytokines and adhesion molecules [137]. With regard to IRI 
no studies have evaluated the role of TWEAK:Fn14 in hepatic IRI but studies in models of 
renal IRI have shown that TWEAK:Fn14 promotes cell death and fibrosis after IRI [140].  
 
1.1.4.7 Other TNFα Super-family Members 
TNFα-related ligands usually share a number of common features. With the exception of 
nerve growth factor (NGF) and TNF-β, all ligands are synthesized as type II transmembrane 
proteins that contain a short cytoplasmic segment and a relatively long extracellular region 
[141]. In general, TNFα superfamily members form trimeric structures, and their monomers 
are composed of β-strands that orient themselves into a two sheet structure [141]. As a 
consequence of the trimeric structure of these molecules, it is suggested that the ligands and 
receptors of the TNSF and TNFRSF superfamily undergo "clustering" during signal 
transduction. A complete review of all TNFα family members and their individual role in 
hepatic IRI is beyond the scope of this thesis. Indeed no studies have evaluated the role of 
other TNFα superfamily members during liver IRI. Limited studies have assessed the role of 
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CD27 during renal IRI showing it to be pro-apoptotic and having deleterious effects upon 
renal physiology [142].  
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1.1.5 Aims of the Thesis 
The broad aim of the thesis was to establish a standardised protocol for human hepatocyte 
isolation, establish an in vitro model of human hepatocyte IRI, investigate the response of 
human hepatocyte to hypoxia and H-R and investigate the effects of CD40 and CD154 upon 
liver physiology in vivo. More precisely the specific aims were:  
 
I. To establish a stringent protocol for the isolation and successful culture of 
primary human hepatocytes. 
II. To assess the effects of hypoxia and H-R upon human hepatocytes in vitro in 
terms of ROS production and susceptibility to cell death.  
III. To assess the effects of CD40 activation upon human hepatocytes with CD154 
during hypoxia and H-R in terms of ROS generation and susceptibility to cell 
death 
IV. To ascertain the role of CD40 and CD154 in regulating hepatic IRI in vivo.  
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CHAPTER 2 - HUMAN HEPATOCYTE ISOLATION 
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2.1 Introduction 
To enable the study of the effects of hypoxia and H-R upon human hepatocyte physiology 
and susceptibility to cell death the isolation and regular culture of primary cells needs to be 
standardised. This would ensure that reproducible and high quality data is obtained from in 
vitro experimental models. Furthermore, high quality primary human hepatocytes represent a 
valuable resource for biomedical research, commercial and, potentially, therapeutic 
purposes. For instance, isolated human hepatocytes infusions are used clinically in the 
treatment of children with in-born errors of metabolism [143]. Furthermore, to assess the 
effects that IRI has upon human livers and in particular how parenchymal/hepatocyte injury 
is induced, the regular isolation and culture of human hepatocytes is indispensible. It is 
becoming widely accepted that the majority of hepatocyte and hepatoma cell lines, such as 
HepG2 cells, may not be representative of primary hepatocyte function and are unlikely to 
be used therapeutically in the clinical scenarios discussed above [144-146]. Indeed, studies 
carried out by several groups have consistently shown that hepatoma cell lines do not 
accurately reflect the responses of primary hepatocytes [36]. Therefore, for research focusing 
upon hepatocytes the use of primary cells is not only desirable but should be considered 
mandatory. Primary hepatocytes are also becoming increasingly used in drug development 
as an experimental model for the evaluation of key human-specific drug properties such as 
metabolic fate, drug-drug interactions, and drug toxicity. However, anecdotal evidence from 
many research groups worldwide suggests the quality and metabolic/functional activity of 
the cells may be highly variable. Meaningful human hepatocyte research requires the regular 
availability of cells isolated from human liver tissue ethically provided by hepatobiliary and 
transplant programs.  
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Previously authors have suggested protocols for successful human hepatocyte isolation but 
these have applied exclusively to donor liver tissue [147, 148] or normal resected liver tissue 
[34]. Human hepatocytes have been used for commercial and experimental research for over 
two decades. Research has encompassed the fields of toxicology, cell transplantation and 
phenotypic studies. This research without exception has focused on the use of normal 
resected livers and donor liver tissue as the source of human hepatocytes [34, 149-154]. 
Thus for research involving human hepatocytes to be reflective and applicable to hepatic 
patho-physiology, comparative studies need to be carried out in cells isolated from different 
hepatic diseases. To date no systematic studies evaluating the success of human hepatocytes 
from all types of livers have been conducted. Clearly for research involving human 
hepatocytes to be undertaken the latter point is of paramount importance.  
The isolation of human hepatocytes has been difficult from steatotic livers [150]. Although 
some groups have detailed protocols that may lead to successful routine isolation, most 
groups show that overall results of human hepatocyte isolation can be unacceptably variable 
in terms of yield and quality of cells to the point where it can impact on the economic 
considerations and time constraints of laboratory investigations [34, 150]. Therefore in 
general, previous studies have reported outcomes of human hepatocyte isolation from 
normal resected and donor liver tissue [34, 148].  
For large-scale research utilising human hepatocytes a protocol that establishes 
methodology, success rate and the types of livers to use is urgently demanded. To investigate 
the responses of human hepatocyte to a variety of stimuli or environments the establishment 
of the above protocol would be an essential first step.  
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2.2 Methods & Materials 
2.2.1 Ethics Statement 
Human liver tissue was obtained from surgical procedures carried out at the Queen Elizabeth 
Hospital, Birmingham, United Kingdom. These livers included donor livers that were 
surplus to requirement for liver transplantation, liver tissue obtained from hepatic resections 
carried out for colorectal metastatic disease and benign hepatic diseases and explanted livers 
after transplantation. The Local Research Ethics Committee (LREC) (reference number 
06/Q702/61) granted ethical approval for the study. Informed written consent was obtained 
from all participants involved in the study.   
 
2.2.2 Human Hepatocyte Isolation 
All liver tissue was obtained from fully consenting patients undergoing liver transplantation 
for a variety of end-stage liver diseases. Human hepatocytes were isolated from explanted 
diseased livers from patients with alcoholic liver disease (ALD), biliary cirrhosis (primary 
biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and a variety of other end-
stage liver diseases (Cystic Fibrosis, Cryptogenic Fibrosis, Alpha-1-antitypsin Deficiency, 
Autoimmune Hepatitis and Non-alcoholic Steatohepatitis). Human hepatocytes were also 
isolated from tissue taken from patients who had undergone hepatic resections for liver 
metastasis arising from colorectal carcinoma, hepatic resections carried out for benign 
disease (recurrent cholangitis, focal nodular hyperplasia and haemangiomas), cut-down 
specimens and normal donor tissue surplus to surgical requirements. For the purposes of 
analysis, liver tissue obtained from resections for benign lesions was included in the normal 
liver group whereas liver tissue obtained from hepatic resections carried out for metastatic 
disease was classified as normal resected tissue as is referred to as this hereafter. All the 
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patients included in this latter group had received pre-operative chemotherapy to reduce 
tumour mass prior to surgery.  
For all liver tissue specimens a stringent and rigorous procurement and isolation protocol 
was adopted and adhered too for the entire duration of the study. Following explantation or 
resection, specimens were immediately placed on ice in a sterile sealed drawstring bag and 
processed within 1 hour if logistically possible. There were however exceptions to this, in 
cases were hepatic resections or liver transplants were carried out at in the late evening or at 
night, liver tissue was kept sterile on ice overnight in sterile conditions. The significant 
exception to this protocol was in the use of donor liver tissue. In all cases the donor liver was 
assessed for transplantation by the clinical liver transplantation team at the Queen Elizabeth 
Hospital, Birmingham and if deemed unsuitable for liver transplantation it was then used for 
hepatocyte isolation. Precise time delays between explantation or resection of the liver and 
commencement of the isolation procedure were recorded in each case and isolation.   
In isolation procedures where donor liver or liver explants were used, liver wedges were 
obtained from either the segments II/III or segments V/VI. The reason for this being that 
these segments of the liver offered suitably shaped liver wedges conducive to cannulation. In 
procedures where normal resected tissue was used for isolating human hepatocytes, only 
patients who had undergone right hemi-hepatectomies were deemed suitable by the trained 
pathologist to obtain normal resected liver tissue from. Again tissue was only possible from 
these latter specimens if adequate clearance from the tumour could be obtained. This was 
obtained in all cases from segments V/VI. Liver wedges were cut and weighed by a trained 
pathologist. To eliminate interperson variability, the subsequent hepatocyte isolation 
procedures were carried out by a single individual (Ricky Harminder Bhogal) using a 
standardised protocol that is described below.   
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Hepatocyte isolations were carried out using a modified ‘two-stage’ collagenase procedure 
originally developed by Berry and Friend [155]. This method was originally described for 
the isolation of rodent hepatocytes but has been adapted by several laboratories worldwide to 
isolate human hepatocytes. After the liver wedge was cut from the appropriate segment of 
the liver it was weighed and was then placed into ice-cold Dulbecco’s Modified Eagles 
Medium (DMEM) (Gibco, Paisley, UK). The liver was then transferred to sterile CAT2 
laboratory hood were it was then washed through the exposed, cut, vessels with Phosphate-
buffered Saline (PBS), pH 7.2. This was to remove any remaining blood from within the 
liver wedge and to identify two suitable vessels that could be used for cannulation and 
subsequent perfusion of buffers. The vessels for cannulation were chosen using two criteria. 
Firstly, when washing the liver through with PBS, it is apparent which parts of the wedge 
were being ‘perfused’ by that particular vessel, hence the greater the liver area ‘perfused’ the 
more favourable the vessel was thought to be and secondly the two vessels should be in 
different parts of the liver wedge to ensure optimum perfusion of the whole wedge. These 
criteria were used in all cases of liver perfusion. Subsequently two 20-gauge cannulae 
(Becton-Dickinson, Oxford, UK) were sutured into the chosen vessels using a 3/0 prolene 
(Covidien, Hampshire, UK) purse string suture (Figure 2.1). The cannulae were then primed 
with PBS to ensure that subsequent buffers used for perfusion would run correctly. The final 
stage of preparing the liver wedge involved oversewing any major vessels that were present 
on the cut surface of the liver wedge, to ensure minimal loss of perfusion fluids. This also 
helped maintain pressure within the liver wedge throughout the hepatocyte isolation 
procedure.      
The perfusion circuit was set up according to the widely established routine protocol detailed 
by previous groups (Figure 2.2). One end of the perfusion tube was fed into the perfusion 
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buffer, the central segment of the tubing was within the peristaltic pump (Model IP 505Du, 
Watson-Marlow Ltd, Falmouth, UK), and the two outlets of the tubing were connected to the 
sutured cannulae. The liver wedge was held over a container during the procedure. This 
container also contained the waste tubing that connected the container to the waste reservoir. 
At the commencement of the procedure, all rubber tubing remained ‘open’ allowing the free 
flow of perfusion and waste fluids. All buffers used in the isolation procedure were pre-
warmed to 420C in a water bath. At this stage, liver wedges were first perfused with ‘non-
recirculating’ wash buffer (10 mM 4-(2-hydroxylethyl)-1-piperazineethanesulfonic acid 
(HEPES) pH 7.2) (Sigma, Dorset, UK) at room temperature using a flow rate of 75 ml/min, 
ensuring flushing out of any remaining blood from within the liver vasculature. After this, 
the wedge was perfused with chelating solution (non-recirculating) (10 mM HEPES, 0.5 mM 
Ethylene Glycol Tetraacetic Acid (EGTA), pH 7.2) (Sigma) in order to disrupt cell adhesion 
to the underlying matrix. This was followed by further perfusion with (non-recirculating) 
wash buffer to remove any remaining EGTA from the liver vasculature, as the enzymes used 
to dissociate the liver are dependent upon calcium and magnesium for activation. At this 
point the waste tubing was clamped to allow recirculation of the enzymatic buffer. Enzyme 
buffer perfusion solution was made up as follows:  Fresh aliquots of enzymes were removed 
from -200C storage and dissolved in Hank’s Balanced Salt Solution (HBSS) (Gibco, Paisley, 
UK) that had been supplemented with calcium chloride (5 mM) and magnesium chloride (5 
mM). Following enzyme dissolution the solution was filtered through a 0.5 μm sterile filter 
(Miltenyi Biotec Ltd, Surrey, UK) back into the HBSS solution. Specifically, 0.5% w/v 
Collagenase A (from Clostridium Histolyticum, Roche, Hertford, UK, Lot number 
70273822), 0.25% w/v Protease (Type XIV from Streptomyces Griseus, Sigma, Lot number 
076K1177, 4.5 units/mg), 0.125% w/v Hyaluronidase (from bovine testes, Sigma, Lot 
 34
number 025K7015, 451 units/mg) and 0.05% w/v Deoxyribonuclease (from bovine 
pancreas, Sigma, Lot number 107K7013, 552 units/mg) were the enzymes used. The liver 
wedge was perfused with the recirculating enzyme solution at 370C using a flow rate 
75ml/min for between 1-19 min, this time was designated to be the perfusion time. The 
decision to stop perfusion was made when the cut surface of the liver allowed the admission 
of a digit into the substance of the liver. At this point the perfusion tubing and cannulae were 
removed and the liver was then transferred to a sterile glass dish and dissociated using 
manual force whilst in DMEM supplemented with 10% v/v heat inactivated foetal calf serum 
(Gibco), 2mM glutamine (Gibco), 20,000 units/l Penicillin, and 20mg/ml Streptomycin 
(Gibco) and 2.5 μg/ml Gentamycin (Gibco). Following manual dissociation of the liver 
wedge the suspension was passed through a sterile nylon mesh of 250 μm (John Staniar Ltd, 
Manchester, UK) followed by a sterile nylon mesh of 60 μm (John Staniar Ltd). Suspensions 
were then washed three times at 50 x g for 10 min at 40C in supplemented media.  
Immediately after washing, cell viability was determined by trypan blue dye exclusion and 
deemed acceptable if greater than >50% at this stage. Hepatocytes were then plated out in 
supplemented media. If viability was lower than 50% but total cell yield was high (> 2 
million viable cells/ cell), Percoll density gradient centrifugation of cell suspensions was 
carried out to improve yield of viable cells. Percoll (Sigma) was made by adding to PBS pH 
7.2 to density of 4.5 g/ml. Percoll was added to cell suspensions and washed at 300xg for 30 
min at room temperature. Cell viability was again determined by trypan blue dye exclusion 
and if improved to >50% cells were plated out at 5 x 105 per well in supplemented media for 
2 hours onto type 1 rat collagen coated plates to allow adherence of cells. After this period, 
the media was changed to Arginine-free Williams E media (Sigma) containing 
Hydrocortisone (2 ug/ml), Insulin (0.124 U/ml), Glutamine (2 mM), Penicillin (20,000 
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units/l), Streptomycin (20 mg/l) and Ornithine (0.4 mmol/l). The media was exchanged 
every 24 hours and for subsequent functional studies, cells were used within 2 days of 
isolation. Liver samples from the normal liver category were histopathologically evaluated 
on formalin fixed paraffin-embedded sections. Steatosis was reported by the percentage of 
steatotic hepatocytes present and grouped accordingly: minimal/none=0-5%, mild=5-33%, 
moderate=33-66% and severe=>66%. 
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Figure 2.1 The Preparation of Liver Wedges Prior to Collagenase Perfusion 
Isolation of human hepatocytes was performed from liver wedges that had been cut from 
either donor liver tissue, normal resected liver tissue or explanted livers (50–413 g). Liver 
wedges had one cut face (CF) with the remainder of the hepatic capsule being left intact. 
This was important to retain all perfusion fluids within the liver and prevent leakage. After 
washing the liver through exposed vessels with PBS, 20 G cannulae were sutured into 
suitable vessels with 3/0 prolene purse string sutures. The remaining vessels were oversewn 
using continuous 3/0 prolene sutures (arrowed). The liver wedge was then ready to be used 
for the perfusion isolation protocol. This processing of liver tissue was used in all cases of 
liver perfusions.   
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Figure 2.2 Schematic Diagram Illustrating the Set-up of Apparatus for Liver Wedge 
Perfusion 
Illustrating the typical set-up of apparatus prior to the commencement of perfusion of liver 
wedges. Inlet piping (red) is connected to the relevant perfusion buffer (see Methods & 
Materials section) and then passed through a peristaltic pump and connected to the liver 
wedge via cannulae (Figure 2.1). The liver wedge and buffer are kept sterile in a CAT2 
laboratory hood (dashed line). The liver is placed in a glass container that contains waste 
tubing (blue) that is finally connected to a waste pot. This apparatus set-up was used for all 
liver perfusion without exception. Following perfusion of buffers the waste tubing was 
clapped to allow non-recirculating perfusion of the enzymatic buffer. Once the liver was 
adequately perfused with the enzymatic buffer the liver was disconnected from all tubing 
and cannulae and broken up with mechanical disruption in a sterile bowl in the CAT2 
laboratory hood.  
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2.2.3 Urea Synthesis Assay 
Confirmation of urea synthesis by isolated human hepatocytes was performed using 
quantitative colorimetric urea determination (QuantiChrom™ urea assay kit-DIUR-500) 
(Bioassay Systems, Hayward, CA, USA). Urea is primarily produced in the liver and 
secreted by the kidneys. Urea is the major end product of protein catabolism in animals. It is 
the primary vehicle for removal of toxic ammonia from the body. The QuantiChrom assay 
kit measures urea directly in biological samples without any pretreatment. The adapted Jung 
method [156] utilises a chromogenic reagent that forms a coloured complex specifically with 
urea. The intensity of the colour, measured at 520 nm, is directly proportional to the urea 
concentration in the relevant sample. The optimised formulation substantially reduces 
interference by substances in the raw samples. Biological samples were assayed in triplicate 
and sample concentration of urea was determined by reference to standard curve and using 
the formula below: 
 
[Urea]  =  OD sample – OD Blank/OD standard – OD blank x n x [STD] (mg/dL) 
 
OD sample, OD blank and OD standard are OD values of sample, standard and water, 
respectively. n is the dilution factor. [STD] = 50 
 
 
2.2.4 Albumin Synthesis Assay 
Albumin is the most abundant plasma protein in humans. It accounts for about 60% of the 
total serum protein. Importantly albumin is synthesised by hepatocytes and is a reliable 
marker of hepatocyte function. Albumin synthesis by isolated human hepatocytes was 
confirmed using a colometric assay kit (Abnova, USA, Catalogue number KA1612).  The 
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albumin kit quantified albumin using a colometric assay that utilizes the ability of 
bromcresol green to form a coloured complex specifically with albumin. The intensity of the 
colour was measured at 620 nm and the intensity was directly proportional to the albumin 
concentration in the sample. Albumin standard solutions were used to generate a standard 
curve.  
To ascertain the precise concentration of albumin in a sample the reading for blank OD was 
subtracted from the standard OD values and these OD were plotted against the standard 
concentrations. This then generated a standard curve that was used to determine the sample 
albumin concentration (0.1 g/dL albumin equals 15 μM, 0.1% or 1000 ppm).  
 
2.2.5 Immunostaining Human Hepatocytes for Cytokeratin 18, EpCAM, Cytokeratin 
19 
Following successful isolations, cytospins of hepatocytes were made on Poly-L-lysine 
coated glass slides and fixed for 5 min in acetone. Cells were then incubated with 20% 
normal rabbit serum (Dako, Cambridge, UK) in 2-Amino-2-(hydroxymethyl)-1,3-
propanediol (Tris)-buffered saline pH 7.4 (TBS) for 30 min. Monoclonal antibody to 
Cytokeratin 18 diluted 1:100 (clone DC10, Dako) or monoclonal antibody to Cytokeratin 19 
diluted 1:100 (clone RCK108, Dako) or monoclonal antibody to CD326 (Epithelial Cell 
Adhesion Molecule (EpCAM) diluted 1:100 (clone HEA125, Progen, Heidelberg, Germany) 
was applied for 60 min, followed by polyclonal rabbit-anti mouse IgG antibody (1:25 
dilution, Dako) for 30 min and finally anti-alkaline phosphatase (APAAP) complex (1:50 
dilution in TBS) for 30 min. After each incubation step cytospins were washed x3 in TBS. 
Antibody binding was visualised with 0.2 mg/ml naphthol-AS-MX-phosphate dissolved in 
Dimethylforamide, (Sigma), 1mg/ml Fast Red (Sigma) in 0.1 M Tris buffer (pH 8.2) and 
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0.25 mg/ml Levamisole (Sigma) for 15 min followed by counterstaining with Mayer’s 
haematoxylin (Dako). Control cytospins were included where primary antibody was 
substituted with isotype-matched immunoglobulin. Slides were then mounted with 
Immunoblot mounting medium (Dako) and assessed for positivity using light microscopy.   
 
2.2.6 Enzyme-linked Immunosorbent Assay (ELISA) of Human Hepatocytes and 
HSEC for Cytokeratin 18, Cytokeratin 19 and CD31 
Cells (hepatocytes or HSEC) were plated on rat type 1 collagen-coated 96-well flat-bottom 
plates for 24 hours after successful isolation. Cells were then fixed in ice cold methanol for 5 
min. Non-specific binding of monoclonal antibodies was inhibited by pre-incubation of cells 
for 1 hour at 37°C with 4% goat serum (Sigma) before the addition of mouse anti-human 
monoclonal antibody (IgG Isotype-matched control (Invitrogen) CD31 (Dako), cytokeratin 
19 (Dako), cytokeratin 18 (Invitrogen) for 1 hour at 37°C. The cells were then washed 
thoroughly before incubation with peroxidase-conjugated goat anti-mouse secondary 
antibody (Dako). The ELISA was developed using O-phenylenediamine substrate (OPD, 
Dako) according to the manufacturer’s instructions and the enzymatic reaction was stopped 
using 0.5 mol/L H2SO4 (Fisher Scientific, Leicestershire, UK). Colorimetric analysis was 
performed by measuring absorbance values at 490 nm using a Dynatech Laboratories MRX 
plate reader. All treatments were performed in triplicate for each experiment. 
 
2.2.7 Statistical Analysis 
For human hepatocyte isolations, univariable analysis was performed to test the effect of 
specific factors upon outcome measures, human hepatocyte cell viability following a 
preparation, total cell count after preparation and success. Success was defined as 
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maintenance of cell adherence and morphological integrity 48 hours after plating onto type I 
rat collagen and their subsequent use in functional studies. The specific factors analysed 
were hepatic disease type, time delay between hepatectomy and beginning of the liver 
perfusion, weight of liver wedge, perfusion time, the level of steatosis in the normal liver 
cohort, and the use of Percoll enrichment. In univariable analysis, Mann-Whitney tests were 
used for the time and weight variables, as these variables did not to follow a normal 
distribution, with Fisher’s Exact test being used for the categorical variables. Multivariable 
analysis was performed by considering all specific factors simultaneously and assessing the 
effect upon the said outcome measures. For this analysis logistic regression models were 
used. 
Repeated-measures ANOVA was utilised to analyse the synthesis of albumin and urea by 
human hepatocytes isolated from normal, PBC/PSC, ALD and normal resected liver tissue.  
All data are expressed as mean ± S.E. Statistical comparisons between groups were analysed 
by Student’s t test. All differences were considered statistically significant at a value of 
p<0.05. All data are expressed as mean ± S.E. Statistical comparisons between groups were 
analysed by using the Mann-Whitney test. All differences were considered statistically 
significant at a value of p<0.05. 
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2.3 Results 
2.3.1 Morphology of Isolated Primary Human Hepatocytes 
Liver wedges were prepared as shown in Figure 2.1 and processed as detailed in the 
Methods & Materials section above. Figure 2.3 shows representative images of primary 
human hepatocytes, isolated from PBC livers, in culture for the first week after isolation. 
Similar morphological changes were observed during the first week after successful cell 
isolation from normal, PSC, ALD and normal resected liver tissue. Indeed, Figure 2.4 
demonstrates the morphological features of primary human hepatocytes isolated from these 
various livers 3 days after successful isolation. The morphology of primary human 
hepatocytes after 3 days in culture was maintained for at least one week after successful 
isolation. 
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Figure 2.3 Morphology of Primary Human Hepatocytes after Isolation in Culture 
Comparison of the morphological appearance of primary human hepatocytes isolated from 
PBC attached to collagen-coated plates at (i) 2 hours after isolation (magnification 20x), (ii) 
1 day after isolation, (iii) 2 days after isolation, (iv) 3 days after isolation and (v) 1-week 
after isolation using light microscopy. The representative images show the change in 
morphology of primary human hepatocytes isolated from PBC livers during 1-week in 
culture. Immediately after isolation, cells appear ovoid and phase bright. Following 1 day in 
culture the cells appear binucleate and have formed a confluent monolayer. Primary human 
hepatocytes maintain this morphology throughout the one-week culture period. Similar 
morphological changes were observed for human hepatocytes isolated from normal, ALD 
and normal resected liver tissue.  
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Figure 2.4 Morphology of Primary Human Hepatocytes in Culture at 3 Days 
Representative images of the morphology of human hepatocytes isolated from normal, 
PBC/PSC, ALD and normal resected liver tissue are shown in culture 3 days after successful 
cell isolation. Human hepatocytes demonstrated and maintained this morphology for at least 
one week following successful isolation. (i) Demonstrates the morphology of human 
hepatocytes isolated from normal liver tissue and macro-steatotic liver tissue (magnification 
20x). Primary human hepatocytes isolated from normal liver tissue display the typical cubic 
binucleate cell morphology. In contrast, primary human hepatocytes isolated from overtly 
macro-steatotic livers demonstrate obvious micro-vesicular steatosis. (ii) Human hepatocytes 
isolated from end stage biliary cirrhosis (PBC/PSC) again show the typical features of cells 
in culture with a cubic and binucleate morphology. (iii-iv) Cells isolated from ALD and 
normal resected liver show similar morphological features to human hepatocytes isolated 
from normal non-steatotic livers and biliary cirrhosis but also exhibit micro-vesicular 
steatosis. 
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2.3.2. Types of Liver Used and Success of Primary Human Hepatocytes Isolations 
The type of livers used and the main results of all human hepatocyte isolations are shown in 
Table 2.1. In total 149 livers were processed and used for the isolation of primary human 
hepatocytes. A variety of liver diseases were used including ALD, biliary cirrhosis (PBC and 
PSC), normal resected liver and normal liver tissue (donor liver tissue, resections for benign 
liver disease, in-situ splits and cut-down specimens). A large proportion of livers used were 
from cirrhotic, end stage liver diseases (49%). Normal resected liver tissue was defined as 
liver tissue from patients with colorectal metastasis accounted for 18% of livers used. All 
these latter patients had received pre-operative chemotherapy for reduction of tumour mass 
prior to surgery.  
Overall, for all human hepatocyte isolations a median cell viability of 37% was observed. 
Human hepatocytes isolated from biliary cirrhosis (PBC and PSC) had the highest median 
cell viability (57%). Univariable and multivariable analysis showed the only factor, which 
had an effect upon improving cell viability, was the time delay between hepatectomy and 
beginning of the perfusion procedure (p<0.05, Mann-Whitney test). Complete processing 
within 3 hours resulted in a significantly higher cell viability (> 50%), compared to time 
delays greater than 5 hours (p<0.05, Odds Ratio = 3.594). Whether the delay is 3-5 hours or 
more than 5 hours did not have a significant effect on the likelihood of the cell viability 
being greater than 50% (p=0.375, Odds Ratio = 1.725). These data are summarised in Table 
2.2. Percoll density gradient centrifugation was used to enrich hepatocytes purity where cell 
viability was low but absolute cell count high (n=11). These data are summarised in Table 
2.3. Percoll enhanced purity of human hepatocyte isolates but at the expense of cell count, 
hence the need for a relatively high absolute cell count after the initial liver preparation. 
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All donor liver tissue, resections performed for benign liver disease (recurrent cholangitis, 
focal nodular hyperplasia and haemangiomas), in-situ splits and cut down specimens were 
classified arbitrarily as ‘normal’ liver tissue. These livers had no macroscopic signs of 
intrinsic liver disease. This group was analysed as a whole and as a sub-group, where donor 
liver tissue was compared to normal liver tissue (resections from benign liver disease, in-situ 
splits and cut down specimens). Sub-group analysis was carried out to determine whether the 
level of steatosis had an effect upon absolute cell count, cell viability and success rate of 
subsequent human hepatocyte culture. The level of steatosis in the two groups is shown in 
Table 2.4. No differences in absolute cell count and cell viability between the donor liver 
and normal liver groups. The success of isolating human hepatocytes from this group as a 
whole was good (43%) but normal liver tissue obtained from hepatic resections carried out 
for benign disease, in-situ splits and cut-down specimens had a statistically higher success 
rate (50%) when compared to donor liver tissue (20%).  
The reported data is the largest series within the literature of human hepatocyte isolations 
from cirrhotic end-stage liver disease (n=73). A median success rate of 42% was observed 
when isolating hepatocytes from cirrhotic livers. Indeed, as Table 2.1 shows liver wedges 
from biliary cirrhosis (PBC and PSC) had the highest success rate of all livers used in the 
study (71%). For all liver isolations, univariate analysis showed a significant difference in 
time delay between hepatectomy and beginning of liver perfusion (p<0.001, Mann-Whitney 
test), perfusion time (p<0.05, Mann-Whitney test) and disease type (p<0.05, Fisher’s Exact 
test) between the groups of successful and unsuccessful isolations. Multivariable analysis 
revealed disease type (p<0.05) and time delay between hepatectomy and beginning of 
perfusion (p<0.05) were significant factors affecting successful human hepatocyte isolation. 
As described above for cell viability, success is significantly dependent upon time delay 
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(p<0.01), with a delay of less than 3 hours resulting in improved success rates compared to 
those of more than 5 hours (p<0.05, Odds Ratio = 3.735).  
Absolute cell count after isolation was an important parameter on which to assess efficacy of 
the procedure. Univariable analysis revealed that disease type (p<0.001, Fisher’s Exact test) 
was the only factor to have a significant bearing upon total cell count after primary isolation. 
Multivariable analysis showed that ALD livers have a significantly lower cell yield when 
compared to other liver categories (p<0.15 – Table 2.1).  
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Table 2.1 The Type of Livers used and the Main Results of All Human Hepatocyte 
Liver Type Time Delay 
 
(hrs) 
Weight 
 
(g) 
Perfusion Time 
 
(min) 
Absolute Cell Count 
After Perfusion 
x103 
Viability 
 
(%) 
Success 
Rate 
(%) 
Normal (n=49) 
 
Donor Liver (n=17)  
 
Normal Liver (n=32) 
2.5 
(1-14) 
6.5 
(2-14) 
2 
(1-4) 
110 
(66-413) 
117 
(101-150) 
121 
(66-413) 
1.5 
(1-11) 
2 
(1-11) 
2.5 
(1-7) 
75  
(57-200,000) 
1500 
(25-200,000) 
420 
(75-32,000) 
46 
(0-100) 
16 
(0-60) 
51 
(10-100) 
43 
 
20 
 
50 
Resected (n=27)  2.5 
(1-16) 
 90 
(50-180) 
 1.5 
(1-5) 
220 
(50-6,000) 
50 
(0-100) 
53 
Biliary Cirrhosis 
(n=31) 
1.5 
(1-11) 
98 
(78-200) 
1.5 
(1-8.5) 
980  
(200-7,000) 
57 
(0-100) 
71* 
ALD (n=30) 2.5 
(1-13) 
110 
(64-220) 
4 
(1-19) 
90** 
(20-3,000) 
35 
(0-100) 
26 
Others (n=12) 4.5 
(1-12) 
102 
(56-115) 
 5.5 
(3-17) 
180 
(40-3,000) 
6 
 (0-70) 
8 
 
TOTAL (149) 
 
2 
(1-16) 
 
115 
(50-413) 
 
2.5 
(1-19) 
 
370 
(20-200,000) 
 
37 
(0-100) 
 
45 
The time delay, weight of liver wedges, perfusion time, absolute cell count after perfusion, cell viability and success rate are shown 
for various liver categories; Normal (donor liver tissue, normal benign tissue, in-situ splits and cut-down specimens), normal resected 
liver tissue, biliary tissue (PBC and PSC), ALD and others (cystic fibrosis 2, cryptogenic fibrosis 3, alpha-1-antitypsin deficiency 1, 
autoimmune hepatitis 1, primary graft non-function 1 and non-alcoholic Steatohepatitis 4). All values are represented as medians and 
the values in parentheses represent the range. n, number of cases. 
** p<0.05, multivariable analysis showing ALD livers yield significantly lower cell yields when compared to other liver diseases. 
* p<0.05, multivariable analysis showing biliary cirrhosis yielded a higher success rate of human hepatocyte isolation when compared 
to other liver diseases. 
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Table 2.2 Effect of Time Delay Between Hepatectomy and Beginning of the Perfusion 
Procedure Upon Human Hepatocyte Cell Viability Following Isolation 
 
Time Delay 
(hrs) 
Median Cell Viability  
(%) 
<3 57 
3-5 22 
>5 20 
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Table 2.3 Effect of Percoll upon Cell Viability and Absolute Cell Count 
 
Absolute Cell 
Count after 
Preparation 
x103 
Viability 
 
 
(%) 
Absolute Cell 
Count after 
Percoll 
x103 
Viability after 
Percoll 
 
(%) 
490 
(200-200,000) 
32 
(10-50) 
195 
(100-400) 
87 
(55-90) 
 
The effects of Percoll upon human hepatocyte isolation procedures. Percoll was used after 
eleven human hepatocyte isolation procedures (normal resected liver tissue 1, biliary 
cirrhosis 7, donor liver tissue 1, cryptogenic cirrhosis 1 and normal benign liver tissue 1). All 
values are represented as medians and the values in parentheses represent the range. 
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Table 2.4 The Level of Steatosis in Liver Wedges Taken from Donor Liver Tissue and 
Normal Liver Tissue 
 
 Minimal/None Mild Moderate Severe 
Donor liver tissue 
(n=17) 
1 5 7 4 
Normal liver tissue 
(n=32) 
16 8 4 - 
 
The level of steatosis in liver wedges taken from normal liver tissue. The level of steatosis 
was classified as minimal/none=0-5%, mild=5-33%, moderate=33-66% and severe=≥66% 
after histological analysis of paraffin embedded sections. Classification of the level of 
steatosis was not possible in three liver wedges (1 donor liver and 4 normal livers) as the 
tissue from those particular livers was not available. n, number of livers. 
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2.3.3 Phenotype of Isolated Primary Human Hepatocytes 
Isolated cells from human liver tissue showed 100% positivity for the hepatocyte cell 
marker, Cytokeratin 18 (CK 18) upon Immunostaining (Figure 2.5). Isolated human 
hepatocytes also show strong colometric absorbance with Cytokeratin 18 upon ELISA 
(Figure 2.6). Moreover, isolated hepatocytes showed no staining with the biliary epithelial 
cell marker, Cytokeratin 19 (CK 19), or the hepatic progenitor cell marker, CD326 
(EpCAM) (Figure 2.5). Isolated human hepatocytes demonstrated no staining with the 
biliary epithelial cell marker CK19 and hepatic sinusoidal endothelial cell (HSEC) marker 
CD31 upon ELISA. In contrast, HSEC, which were isolated using a well-established 
isolation technique [157] demonstrate strong positivity for CD31 and no staining with CK 
18. These findings show that the isolation technique isolates human hepatocytes of a high 
purity with little or no contamination from other liver cells.     
Furthermore, all hepatocytes isolated from normal and diseased liver tissue demonstrated 
albumin and urea synthesis in the first week after isolation (Figure 2.7). Human hepatocytes 
isolated from normal, normal resected and biliary cirrhosis demonstrated significantly 
greater albumin synthesis after two days in culture. Interestingly, human hepatocytes isolated 
from ALD livers demonstrated significantly reduced levels of albumin production when 
compared to other hepatocytes. Urea synthesis by human hepatocytes demonstrated similar 
characteristics, with production of urea being significantly higher on day 2 when compared 
to other days in culture. Of note biliary cirrhosis and normal resected human hepatocytes 
produce significant greater amounts of urea in culture when compared to other human 
hepatocytes. 
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Figure 2.5 Immunostaining of CK18, CK19 and CD326 in Primary Human Hepatocytes Isolated from Normal and Diseased Liver 
Tissue  
(a) Human hepatocytes isolated from normal, PBC, ALD and normal resected liver tissue show strong staining for the intracellular hepatocyte 
marker Cytokeratin 18 (CK18). In contrast, isotype matched controls immunoglobulin showed no positivity. Furthermore, isolated human 
hepatocytes showed no staining with the biliary epithelial cell marker Cytokeratin 19 (CK19) or hepatic progenitor cell marker CD326 
(EpCAM). Cytospins of human hepatocytes were made immediately after successful cell isolation, fixed in acetone for 5 min and stored at -
20oC until immuno-staining was performed. (n=3).  
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Figure 2.6 Primary Human Hepatocytes Express CK18 but not CD31 or CK19 
The cell specific markers, Cytokeratin 18, Cytokeratin 19 and CD31 were determined using 
cell based ELISA as described in the Methods and Materials section. Primary human 
hepatocytes isolated using the protocol detailed above demonstrate strong staining for the 
hepatocyte specific marker, Cytokeratin 18. These cells show no staining for the biliary 
epithelial marker, Cytokeratin 19 or endothelial cell marker, CD31. In contrast, hepatic 
sinusoidal endothelial cells show strong positivity for the marker CD31 and no positivity for 
either Cytokeratin 18 or Cytokeratin 19. Data are expressed as mean ± S.E. (n= 5-7).  
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Figure 2.7 Albumin Synthesis and Urea Secretion by Primary Human Hepatocytes in Culture after Isolation  
Following successful isolation, human hepatocytes isolated from normal, PBC/PSC, ALD or normal resected liver tissue were able to synthesise 
albumin (i) for at least one week demonstrating active metabolic activity in culture. Human hepatocytes isolated from normal, PBC/PSC and 
normal resected liver tissue show significantly greater albumin synthesis after two days in culture (*p<0.05). Moreover, human hepatocytes 
isolated from ALD livers synthesised significantly less albumin than other types of human hepatocytes (p<0.05). In addition, human 
hepatocytes isolated from normal resected liver tissue synthesised significantly greater amounts of albumin than normal hepatocytes (p<0.037). 
(n=3-4 separate samples). Human hepatocytes isolated from normal, PBC/PSC, ALD and normal resected liver tissue were also able to 
synthesise urea (ii) for at least one week following successful cell isolation. Human hepatocytes isolated from both normal and diseased liver 
tissue synthesised significantly lower levels of urea one day after isolation (§p<0.001) compared to the remainder of the culture period, but all 
human hepatocytes produced significantly more urea on day 2 when compared to other days (*p<0.001). Finally, PBC/PSC and normal resected 
human hepatocyte synthesis significantly greater amounts of urea when compared to the other human hepatocytes (p<0.05) but there was no 
significant difference between PBC/PSC and normal resected human hepatocytes. Data are expressed as mean ± S.E. (n=3-4 separate samples). 
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2.4 Discussion 
There are numerous studies assessing the isolation of human hepatocytes from normal 
resected or donor liver tissue [34, 150, 151]. The preparation of primary human hepatocytes 
is a time consuming, logistically demanding, and expensive process. The demand for high 
quality human hepatocytes for cell transplantation and pharmo-toxicological studies 
continues to rise [143]. However, the availability of human liver tissue for laboratory 
investigation remains limited. Therefore, cirrhotic end-stage livers, which are more readily 
available to researchers, represent another potential source of human hepatocytes. No 
previous studies have systematically evaluated the isolation of human hepatocytes from all 
available livers, including end-stage liver disease, using one standardised isolation protocol 
and cohorts of specimens large enough to permit meaningful statistical analysis. The 
experience outlined above highlights some fundamental issues that are required for making 
isolation of primary human hepatocytes from normal or diseased livers a viable proposition.  
The data suggests that isolating human hepatocytes from ALD livers is technically 
challenging even in experienced hands. With a success rate of 26%, the lowest success rate 
aside from the group containing ‘other’ liver types. The use of ALD livers for hepatocyte 
isolation is a questionable proposition. This may in part be explained by the variable disease 
stage of the ALD cohort that would have included in the analysis. These livers would have 
been from advanced stages of cirrhosis and would have sustained toxicological cell damage 
resulting from the effects of excessive alcohol. Excluding the ‘other’ disease categories, 
ALD livers had the longest median perfusion time again presumably reflecting that these 
livers were from patients with more advanced liver cirrhosis. Moreover, human hepatocytes 
isolated from ALD demonstrate significantly less albumin production when compared to the 
other human hepatocytes cohorts. This latter point would certainly support hypothesis of 
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alcohol having a directly toxic effect upon these hepatocytes. The presented data further 
highlights that patients in whom the primary cause of cirrhosis is biliary (PBC or PSC) 
human hepatocyte isolation can be very efficacious (success rate 71%). Furthermore, human 
hepatocytes isolated from biliary cirrhosis demonstrate the highest levels of albumin and 
urea production. As discussed below, this success rate is at least equivalent to normal benign 
resections and cut-down specimens despite having advanced end stage liver disease. In 
biliary cirrhosis cytoprotective agents such as ursodeoxycholic acid (UDCA) are routinely 
used therapeutically. Certainly, UDCA is known to inhibit the accumulation of ROS [158] 
and has anti-apoptotic effects upon hepatocytes [159]. These agents may therefore aid 
human hepatocytes isolation in an analogous way to that suggested in recent reports which 
show that the antioxidant, N-acetylcysteine (NAC), aids human hepatocyte isolation from 
donor liver disease [148]. Conversely, alcohol consumption increases ROS production and is 
known to be of the instigators of hepatocyte injury during ALD [160]. Furthermore, alcohol 
induces a plethora of toxic metabolites and cytokines that perpetuate hepatocyte injury. 
Hence the contact between end-stage ALD hepatocytes and enzymes used in the digestion 
process may create additional cellular stresses that precipitate human hepatocyte cell death 
and hence lower cell viability and cell yields. Human hepatocyte isolation from end-stage 
cirrhotic livers other than ALD and biliary cirrhosis had very poor results (success rate 8%) 
and hence the use of these particular livers would not be recommended for cell isolation.  
A success rate of 53% for human hepatocyte isolation from normal resected livers was 
observed, which is lower than that reported by other authors [151, 161]. There are several 
potential explanations for this. Other studies have used different enzyme cocktails and may 
have been more selective initially when deciding which livers to process [34]. Recent studies 
have used the enzyme Liberase to isolate human hepatocytes from normal resected liver 
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tissue and have reported higher cell viabilities and cell yields [34]. The presented data does 
concur with previous studies that suggest normal resected tissue is a good source of human 
hepatocytes. Whether human hepatocytes isolated from normal resected liver tissue differ 
functionally in their response to physiological stimuli when compared to other human 
hepatocytes is not known (see Chapter 3). Most authors accept that there was no objective 
evidence that the function of human hepatocytes isolated from normal resected liver tissue 
was altered although this has not been objectively tested [161].  
The reported successful isolation from normal liver tissue, both donor liver tissue and benign 
resection and cut down specimens is also lower than that reported by previous authors [151]. 
However, when this group was further analysed the isolations performed upon liver wedges 
from benign resections and cut down specimens gave good success rates (53%) compared to 
donor liver tissue (20%). Previous authors have also noted that the best results of human 
hepatocyte isolations, in terms of high cell viability and cell yield, were achieved with tissue 
removed from patients with benign liver diseases [34, 161]. The donor livers used in the data 
presented above had been turned down for transplantation as a result of macrosteatosis and 
as Table 2.4 demonstrates human hepatocytes from these steatotic livers also exhibit micro-
vesicular steatosis. The rate of successful human hepatocyte isolation in livers with a low 
level of steatosis was greater than in those with a high level of steatosis (64% vs. 20%), 
although this was not statistically significant (p=0.118). The reason for the non-significance 
is likely to be down to the small sample size. Previous authors have also noted that high 
degrees of steatosis generally did not favour successful cell isolation [150, 151]. Certainly, 
steatotic hepatocytes have higher intracellular ROS levels and more susceptible to damage 
[148]. The recent work of Sagias et al suggests that the addition of NAC to perfusion fluids 
may improve hepatocyte yields from steatotic livers [148]. Another, contributory factor for 
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the lower cell viability and cell yield of human hepatocytes from donor liver is the longer 
cold ischaemic time that donor livers have been exposed to when compared to normal livers 
(Table 2.1).  
Previous authors have suggested that the optimal liver wedge weight for human hepatocyte 
isolation is approximately 100 g [34]. The majority of liver wedges used in the data 
presented above were between 80-120 g. Therefore a relatively consistent liver wedge 
weight was used thus the effect of this parameter upon human hepatocyte isolation could not 
be evaluated. 
A median perfusion time of 2.5 min was required to digest livers, as judged by the admission 
of a digit into the liver substance. Other studies report digestion times ranging from 20-47 
min [34, 162]. This could simply be a reflection of different enzyme types, different enzyme 
concentrations and different enzyme lots. In the reported data series all enzyme lots and 
batches were kept constant. Certainly, this enzyme cocktail allowed isolation of cells from 
end-stage cirrhotic livers and it remains possible that this enzyme concentration may be 
excessive for normal resected and donor liver tissue thereby explaining the lower yield and 
viability compared with other reports. 
Perfusion time, whilst being significant in the univariable analysis, was not found to be 
significant in the multivariable analysis. The reason for this is likely to be the fact that the 
variable is significantly correlated with the time delay between hepatectomy and beginning 
of liver perfusion (Spearman’s Rho = 0.377, p<0.01). In the logistic regression model, time 
delay between hepatectomy and beginning of liver perfusion, remained significant even after 
adjusting for perfusion time.  
Therefore, the presented data shows that for successful human hepatocyte isolation time 
delay between hepatectomy and beginning of liver perfusion should be kept to less than 3 
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hours. Perfusion time (p<0.01) and type of hepatic disease (p<0.01) both have significant 
effects upon successful human hepatocyte isolation. However, the fact that neither was 
significant in the multivariate analysis shows that the majority of this effect can be explained 
by other variables. The crucial factors for isolating human hepatocytes from all livers and 
especially cirrhotic livers appears to be that after an initial learning curve, operators become 
skilled at recognising when a cirrhotic have become adequately digested allowing the 
termination of the liver perfusion and avoiding overdigestion of tissue leading to reduced 
cell viability. 
In conclusion, the time delay between hepatectomy and beginning of liver perfusion is the 
most important factor in determining good cell viability and likelihood of success of the 
procedure. Furthermore, the shortest possible digestion time is desirable. In terms of 
cirrhotic livers, biliary cirrhosis appears to have a better success rate when compared to 
ALD. In addition a unified protocol can be used to successfully isolate human hepatocytes 
from all liver types.  
In the experience outlined above it is clear that a challenging operator learning curve has to 
be overcome before routine isolation of human hepatocytes from cirrhotic livers can yield 
acceptable success rates. Each study, detailing the procedure of human hepatocyte isolation 
brings us closer to improving the existing technologies and therefore aiding future research.  
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CHAPTER 3 - THE RESPONSE OF PRIMARY HUMAN HEPATOCYTES 
ISOLATED FROM NORMAL AND DISEASED LIVER TISSUE TO HYPOXIA AND 
HYPOXIA-REOXYGENATION 
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3.1 Introduction 
3.1.1 Hepatocyte Responses to Hypoxia and H-R 
Most studies that have investigated the mechanisms of liver damage that occur as a result of 
IRI have focused upon the broad setting of liver transplantation [16, 163, 164]. It is equally 
possible that relatively hypoxic conditions can occur during other episodes of hepatic 
inflammation and/or established chronic disease. Hepatocytes exposed to a hypoxic 
microenvironment would therefore be potentially sensitised to cell death, although no studies 
have yet explored this process in primary human hepatocytes. Previous studies have 
explored the responses of rodent and murine hepatocytes to hypoxia but these studies in 
general have failed to explore the effects that subsequent H-R has upon the same hepatocytes 
following hypoxia/ischaemia [21, 22, 117]. Moreover, it is well appreciated that there is 
considerable inter-species variability of hepatocytes to the same microenvironment and/or 
extracellular cues [165, 166]. Therefore, generalisation cannot be made about the 
physiological responses of hepatocytes based upon experimental findings from one species. 
As discussed earlier, despite considerable advances in surgical practice and more judicious 
use of immunosuppression, hepatic IRI continues to adversely affect allograft function and 
patient survival following OLT. The work of Toledo-Pereyra et al established the 
detrimental effects of IRI during experimental liver transplantation [38]. Indeed as a result of 
this work and more recent studies hepatic IRI is now understood to be a pro-inflammatory, 
antigen-independent process that culminates in parenchymal injury [40]. The primary 
cellular target during hepatic IRI is the hepatocyte. Hepatocyte cell death seen during the 
hypoxic and reperfusion phases of IRI occurs within a relatively hypoxic environment and 
occurs during both phases of hepatic IRI. The early phase of IRI is thought to involve 
activation of KCs and other liver resident macrophages, which release pro-inflammatory 
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cytokines and ROS [6, 7]. The late phase is characterised by increased expression of 
chemokines and adhesion molecules and hepatic recruitment of effector cells that amplify 
the tissue damage (see Section 1.1.2). The latter phenomenon is a feature common to many 
other hepatic diseases such as cirrhosis. There is evidence to suggest that hepatocyte injury 
occurs during the relatively hypoxic early phase of IRI [163]. ROS, primarily in the form of 
hydrogen peroxide, is released and is one of the earliest and most important components of 
tissue injury after reperfusion of ischemic organs and a major contributor to hepatocyte death 
during reperfusion [167]. Moreover, diseases such as ALD are characterised by the chronic 
accumulation of ROS [160]. The source of hepatic ROS during liver injury remains 
controversial. Numerous studies suggest that KC derived extracellular ROS is the key trigger 
for hepatocyte damage [168, 169] whereas other studies have shown that 
absence/elimination of KCs does not prevent tissue damage in IRI [170]. This latter 
observation suggests that other cells within the liver, including hepatocytes, may be involved 
in the pathophysiological production of ROS during IRI and chronic hepatic inflammation.  
Early work using rat hepatocytes suggested that XO was the main generator of ROS [69]. 
However the XO inhibitors used in these early studies such as allopurinol are now known to 
inhibit mitochondrial function too. Indeed, more recent studies have shown that the 
mitochondria are the main source of ROS within hepatocytes [71]. Furthermore, inhibition 
of mitochondrial complex I and III can ameliorate ROS production in human hepatoma cell 
lines [27] and rat hepatocytes [171]. Other enzymes such as the flavoenzyme NADPH 
oxidase can also produce ROS in rat hepatocytes [172]. Despite these observations the 
precise mechanisms involved in the generation of ROS within human hepatocytes remains 
elusive and no studies thus far have investigated this. 
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The accumulation of excess intracellular ROS induces cell death and during hepatic IRI and 
hepatocytes undergo cell death in the form of both apoptosis and necrosis [173]. Some 
studies support apoptosis and others necrosis as the primary mode of cell death [174]. In 
reality it is uncertain whether apoptosis and necrosis observed in liver tissue are separate 
processes since the terms primarily represent a morphological description, and it has been 
suggested that apoptotic cells not effectively cleared from inflammatory sites may eventually 
assume a necrotic appearance (so called secondary necrosis). This led Lemasters to propose 
the term necro-apoptosis, and it may be that both forms of cell death are in part related 
sharing some common intracellular pathways [175]. The key regulators of molecular 
switching between these different forms of cell death remain to be identified.   
Despite the above observations, little is known about the relative contribution of endogenous 
hepatocyte ROS production and its potential impact upon hepatocyte cell death following 
hypoxia and H-R. Much of the understanding of hepatic IRI comes from studies of rodent 
hepatocytes and rodent experimental models. The response of human hepatocytes to hypoxia 
and H-R is unknown.  In addition, the research that has been performed using human 
hepatocytes has used cells isolated from normal resected liver tissue from patients with 
neoplastic disease. As discussed in Chapter 2, whether cells from such sources can be 
considered to truly reflect normal hepatocytes has never been objectively studied.  
 
3.1.2 Response of Peri-portal and Peri-venous Hepatocytes to Hypoxia and H-R 
The functional unit of the liver is the acinus, which extends from the portal venule along the 
sinusoids to the terminal hepatic venule (Figure 3.1). The liver acinus in rodents extends for 
approximately 20 hepatocytes [176]. Peri-portal (PP) hepatocytes (zone 1) which are near 
the portal venule tend to be of a smaller in size than peri-venous (PV) hepatocytes (zone 3) 
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which are located near the terminal hepatic vein [177]. Indeed, some studies define and 
isolate large/PV and small/PP hepatocyte populations upon the basis of size [178]. 
Furthermore, these studies have utilised the technique of fluorescent-activated cell sorting 
(FACs) to consistently differentiate between large/PV and small/PP hepatocytes and study 
their respective metabolic functions [179-181]. Moreover, these studies have demonstrated 
that these hepatocytes have distinct and separate cellular functions. Whether large/PV and 
small/PP hepatocytes exhibit differential responses to hypoxia and H-R is not known.  
There is a large body of evidence to support the concept of morphological, biochemical and 
metabolic heterogeneity of large/PV and small/PP hepatocytes [42, 169, 182, 183]. Indeed, 
various functions have been ascribed to specific zones of the liver acinus. Specifically, 
oxidative metabolism, gluconeogenesis, urea synthesis and bile formation are predominantly 
small/PP hepatocyte activities whereas glutamine synthesis, xenobiotic metabolism and 
ketogenesis are particularly prevalent in the large/PV hepatocytes [184, 185]. Moreover, 
studies have shown these differences in hepatocyte function are attributable to differences in 
enzyme expression [182, 183].  
These differences in hepatocyte function are also likely to be important determinants in the 
evolution of liver injury. For instance, in rodent models, it is well documented that following 
ischemic liver injury, hepatocyte cell death is seen predominantly observed around the peri-
venular region were the large/PV hepatocytes are located [186]. As discussed above ROS is 
thought to be one of the key regulators of IRI. However, whether small/PP and large/PV 
hepatocytes have differential ROS accumulation during hypoxia and H-R is not known. In 
particular, whether small/PP or large/PV human hepatocytes exhibit differential responses to 
hypoxia and H-R remains to be ascertained.  
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Previous studies have utilized various techniques to investigate the different functions of 
small/PP and large/PV hepatocytes. These include retrograde digitonin perfusion of livers 
[169] and elutriation [182]. However, as stated above FACs allows the differentiation 
between different sized hepatocytes on the basis of size and offers a method to study 
small/PP and large/PV human hepatocyte cell function using the isolation protocol detailed 
in Chapter 2.  
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Figure 3.1 The Liver Acinus 
Schematic of the liver operational unit the classic lobule and the acinus. The lobule is 
centered on the terminal hepatic vein (Central vein), where the blood drains out of the 
lobule. The acinus has its base the penetrating vessels where blood supplied by the portal 
vein and hepatic artery flows down the acinus past the cords of hepatocytes. Zone 1, 2 and 3 
of the acinus represent metabolic regions that are increasingly distant from the blood supply. 
BD, bile duct, PV, Portal vein, HA, hepatic vein, THV, terminal hepatic vein.  
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3.1.3 Hepatic IRI and Autophagy 
Whilst hepatocyte apoptosis and necrosis have been shown to occur during hypoxia, the role 
of hepatocyte autophagy during IRI remains controversial [187]. It is now widely recognised 
that autophagy is required for protein and organelle turnover and is typically a homeostatic 
cellular response to starvation [188]. Furthermore, autophagy degrades both long-lived 
cytoplasmic proteins and surplus or dysfunctional organelles by lysosome-dependent 
mechanisms [188]. Nearly all hepatocyte derived proteins are long-lived and autophagy is 
thought to be the primary process for hepatic protein catabolism [189]. Recent studies 
suggest that autophagy is another distinct and separate form of cell death that hepatocytes 
sustain when exposed to oxidative stress [190] but it has not been conclusively shown that 
cells undergoing autophagy are not committed irreversibly to death. The role of autophagy in 
liver disease has been comprehensively presented in recent reviews [187, 189, 191]. 
Autophagy is being shown to play an increasingly important role in many liver diseases 
[187, 189]. Indeed, Hepatitis B and C viruses may exploit the autophagy pathway to escape 
the innate immune response and to promote their own replication [192, 193]. Autophagy is 
decreased in response to chronic alcohol consumption [194]. In ALD autophagy is decreased 
and promotes cell death. Finally defective autophagy may promote the development of 
hepatocellular carcinoma [187].   
Autophagy is an active process that involves sequestration of parts of the cytoplasm in 
double membrane vesicles that then fuse with lysosomes forming the autophagosome. The 
cytoplasmic material engulfed is then hydrolysed permitting recycling of amino acids and 
other macromolecular precursors. In contrast to classical apoptosis, the cellular machinery 
that regulates autophagy is known to be lysosomal proteinase-dependent and caspase-
independent. In particular the Autophagy-related protein (Atg) proteins and 
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phosphatidylinositol 3-kinase (PI3-K) are crucial for autophagosome assembly. The initial 
step of autophagosome formation requires class III PI3-K and Beclin 1/Atg6 protein [195]. 
The assembly of the autophagosome can be inhibited pharmacologically by the specific class 
III PI3-K inhibitor 3-methyladenine (3-MA) [196, 197]. The formation and expansion of the 
autophagosome requires two further protein conjugation systems that involve several of 
members of the Atg protein superfamily [198], namely the Atg8/LC3-PE and Atg5-Atg12 
conjugation systems (Figure 3.2). These conjugation events are regulated and involve Atg3, 
Atg4 and Atg10 [199]. In particular Atg8 serves as a substrate for the Atg4 family of 
cysteine proteases. Many Atg proteins can be regulated by ROS [198] and may mean that the 
increases in ROS observed during IRI may also regulate hepatocyte autophagy. Once 
activated Atg8 is able to associate with autophagosomes and remain there until fusion with 
lysosomes [189, 200].  
Under starvation, cellular generation of ROS is essential for autophagosome formation and 
autophagic degradation. As stated above ROS is a common feature to many liver diseases. 
Therefore defining the relationship of ROS and autophagy would provide important 
mechanistic links between these two entities and provide important insights into the potential 
role of autophagy during hepatic IRI.  
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Figure 3.2 The Molecular Regulators of Autophagy 
Autophagy induction requires the release of Beclin from Bcl-2, which is then free to form a 
complex with the Class III PI3K that contributes to the formation of the nucleation complex. 
Two independent conjugation cascades, the LC3-II and the Atg5-12 cascades, serve to 
elongate the nucleation complex to generate the limiting membrane. The sole 
transmembrane Atg, Atg9, delivers additional membranes for limiting membrane formation. 
The limiting membrane then sequesters cytosolic cargo and seals upon itself to form an 
autophagosome. The fusion of autophagosomes to lysosomes results in cargo degradation 
and release of nutrients into the cytosol. Atg: autophagy gene, LC3: light chain-3, PI3K: 
phosphoinositide 3-kinase, vps: vacuolar protein sorting. 
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3.2 Material & Methods  
3.2.1 In vitro Model of Warm Hypoxia and H-R 
In experiments using the in vitro model of warm IRI, successfully isolated primary human 
hepatocytes were cultured for 2 days at 370C, 5% CO2 in Williams E media (Sigma) on rat 
type 1 collagen-coated plates. Hepatocytes were either maintained in normoxia or placed 
into hypoxia for 24 hours, or placed into hypoxia for 24 hours followed by 24 hours of 
reoxygenation. Hypoxia was achieved by placing cells in an airtight incubator (RS Mini 
Galaxy A incubator, Wolf Laboratories, UK) flushed with 5% CO2 and 95% N2 until oxygen 
content in the chamber reached 0.1%, as verified by a dissolved oxygen monitor (DOH-247-
KIT, Omega Engineering, UK). No previous studies have evaluated primary human 
hepatocytes response to hypoxia and H-R. Therefore a well-established model of warm in 
vitro IRI was modified for the experiments described below. 0.1% oxygen was used in all 
experiments using the in vitro of IRI for 24 hours (see below). Additionally, Williams E 
media was pre-incubated in the hypoxic chamber in a sterile container, which allowed gas 
equilibration, for 8 hours before experiments were carried out, resulting in a final oxygen 
concentration of <0.1% as measured with the dissolved oxygen meter. Where appropriate, 
after 24 hours of hypoxia media was aspirated and replaced with fresh, warmed, oxygenated 
medium, and the cells were returned to normoxic conditions. This was defined as the 
beginning of reoxygenation. In experiments involving ROS 
inhibitors/antioxidants/autophagy inhibitors all reagents were made fresh as stock solutions 
and added using the correct dilutional factor to the relevant experimental wells. Specifically, 
100 mM NAC (Sigma) was dissolved in molecular grade water, 1 mM rotenone (Sigma) was 
dissolved in chloroform, 1 mM diphenyliodonium (DPI) (Sigma) was dissolved in DMSO 
and 30 mM 3-MA was dissolved in DMSO and were diluted appropriately to give working 
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concentrations of 20 mM, 2 μM, 10 μM and 5 mM respectively. In experiments using 
inhibitors/antioxidants, solvent alone controls were used to ensure no vehicle effects. In 
addition, in experiments using inhibitors/antioxidants agents were added at the time of 
placement of the cells into hypoxia or into reoxygenation.  
 
3.2.2 Flow Cytometric Assessment of ROS, Apoptosis, Necrosis and Autophagy in 
Primary Human Hepatocytes during Hypoxia and H-R 
ROS production, apoptosis, necrosis and autophagy were determined by using a four-colour 
reporter assay system (Figure 3.3). ROS accumulation was determined using the fluorescent 
probe 2’,7’-dichlorofluorescin-diacetate (Merck, Nottingham, UK, Catalogue Number 
287810) [201]. This probe is cell permeable and once inside the cell is cleaved by 
intracellular esterases to 2’,7’-dichlorofluorescin (DCF) and becomes cell impermeable. 
DCF is then able to react with intracellular ROS, specifically hydrogen peroxide, to give a 
fluorescent signal detectable on the Fluorescein Isothiocyanate (FITC) channel. The signal is 
directly proportional to the level of intracellular ROS present. 
MitoSox Red is a mitochondrial superoxide indicator dye (Molecular Probes, Invitrogen, 
Catalog Number M36008) and was used as means to determine ROS in the mitochondria. 
Cells were treated as described above in the in vitro model and then loaded with 5μM 
MitoSox Red in HBSS (Gibco) for 30 min at 37°C in the dark. Cells were washed as 
described below. MitoSox Red fluorescent intensity was determined by fluorescence with 
excitation at 510 nm and emission at 580 nm. Mitosox was used alone in parallel 
experiments with DCF to determine the relative contribution of the mitochondrion to human 
hepatocyte ROS generation and not used in the four-colour reporter assay system described 
below.   
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Apoptosis was determined by labelling cells with Annexin-V (Molecular Probes, Invitrogen, 
Catalogue Number A35122), which detects exposed phosphatidylserine on the cell 
membrane. 7-Amino-Actinomycin D (7-AAD) (Molecular Probes, Invitrogen, Catalog 
Number A1310) is a vital dye that binds to DNA, only entering cells once the cell membrane 
is disrupted and is indicative of cellular necrosis. Autophagy formation was determined by 
using the fluorescent dye monodansylcadaverine (MDC) (Sigma-Aldrich, Catalogue Number 
30432). This dye selectively labels autophagic vacuoles [202] and has been previously used 
in hepatoma cell lines [203] and primary hepatocytes [204] to detect autophagy.  
Following desired experimental treatment; cell media was aspirated and replaced with HBSS 
without calcium and magnesium. DCF (30 μM) and MDC (1 µM) were added and the cells 
were incubated for 20 min in the dark at 370C. The cells were then trypsinsed and washed 
extensively in FACs buffer (phosphate-buffered saline pH 7.2 with 10% v/v heat inactivated 
foetal calf serum (Gibco). Cells were then labelled with Annexin-V (0.25 µg/ml) and 7-AAD 
(1 µg/ml) for 15 min whilst on ice and then samples were immediately subjected to flow 
cytometry. At least 20,000 events were recorded within the gated region of the flow 
cytometer for each human hepatocyte cell preparation in each experimental condition. Only 
the cells within the gated region were used to calculate Mean Fluorescence Intensity (MFI). 
To ensure consistency of the flow cytometric data, each human hepatocyte preparation was 
labelled with DCF alone, Annexin-V alone, 7-AAD alone and MDC alone to ensure that 
cells had become labelled and that the flow cytometry data could be compensated for 
crossover of fluorophore emission spectra (Figure 3.4 & 3.5). The same flow cytometry 
protocol was used for all experiments shown within the study, i.e. voltages for all markers 
were constant for all human hepatocyte preparation ensuring inter and intra-experimental 
consistency.  Specifically, for each experiment a cell only sample was used to ensure that 
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there was no staining of primary human hepatocytes with each specific dye/probe (Figure 
3.4). This sample was also used to ensure that the MFI reading was placed in the first decade 
for each dye/probe. Also these cells were used to place a flow cytometric gate for subsequent 
samples. Human hepatocytes vary considerable in size depending upon whether they are 
derived from the peri-venular region of the liver or peri-portal region of the liver. Therefore 
Forward Scatter (FS) and Side Scatter (SS) plots shown in Figure 3.4 demonstrate a 
heterogeneous cell population. A gate was therefore placed in FS versus SS that included all 
cells. Clearly, the sample includes cell debris that by necessity is included within the large 
gate applied in the analysis. Also, the gate will include small hepatocytes and hepatocytes 
that attain lower intensity of staining with probes/dyes and do not respond to hypoxia and H-
R in the same way as the highly stained species. Therefore, peaks seen adjacent to the peaks 
within the vertical ellipses represent cell debris and hepatocytes that have different responses 
to hypoxia and H-R.   
In preliminary experiments, primary human hepatocytes were exposed to 5% and 1% oxygen 
for 24 hours, and no increase in ROS accumulation was noted (Figure 3.6). Therefore as 
described above the in vitro model utilised 0.1% oxygen throughout the studies.  
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Figure 3.3 Four-Colour Reporter Assay  
In the four-colour reporter assay Annexin-V, 7-AAD and MDC were combined with DCF to assess apoptosis, necrosis and autophagy 
respectively. (A) Apoptosis was assessed using Annexin-V. In a healthy cell phosphatidylserine (shown in red) is usually present only on the 
inner membrane of the cell. However when the cell is committed to apoptosis the phosphatidylserine moiety is translocated and expressed upon 
the outer cell membrane. This can be then detected by Annexin-V and is early marker of apoptosis and occurs temporally much earlier than 
caspase activation. Annexin-V gives rise to a signal on the Violet 1 channel of the flow cytometre. 7-AAD is a specific marker of necrosis. This 
molecule relies upon disruption of the cellular membrane to gain access to the intracellular compartment. Once inside the cell 7-AAD forms 
irreversible covalent bonds to DNA and gives a fluorescent signal detectable upon the PECy5 channel of the flow cytometre. The specific 
autophagy marker MDC can detect autophagy. MDC is able to diffuse freely across the cell membrane and bind to assembled autophagosomes. 
This binding is irreversible and gives rise to a signal on the Violet 2 channel of the flow cytometer.  
(B) 2,7,-dichlorofluorescin-diacetate (DCFHA) is a cell permeable ester that diffuses freely across the cell membrane. Once inside the cell 
DCFHA is acted upon by intracellular esterases that convert DCFHA to 2,7,-dichlorofluorescin and diacetate. This renders both molecules cell 
impermeant. DCFHA is then able to react with ROS (hydrogen peroxide) within the cell that then gives rise to a fluorescent signal detectable 
upon the FITC channel of the flow cytometre.  
7-AAD Annexin-V 
MDC 
Autophagosome
A. B. 
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Figure 3.4 Setting up of the Flow Cytometry Protocol 
The above panel shows how DCF was used in flow cytometric analysis for the assessment of ROS in primary human hepatocytes during hypoxia 
and H-R. Panel A shows the typical FS and SS scatter of primary human hepatocytes during H-R. Similar plots were obtained during normoxia 
and hypoxia. DCF is detectable upon the FITC channel of the flow cytometre. In the absence of DCF human hepatocytes show no fluorescence 
in the FITC channel and this signal was arbitrarily set to the first decade, as demonstrated in Panel A. As Panel B demonstrates staining of 
primary human hepatocyte with DCF showed typically three separate peaks upon the flow cytometre when no gate was applied. Human 
hepatocytes vary considerably in size ranging from 10 μm to 50 μm and including all hepatocytes within the analysis as shown in Panel C 
maintains all three peaks. Panel D shows how the three peaks are derived in the analysis. The left hand panel shows that when only the larger 
hepatocytes are included within the analysis, the majority show staining with DCF with a smaller population showing little staining. These 
former hepatocytes are the one of interest for subsequent studies as these show increases in intracellular ROS and have been indicated with the 
vertical ellipse. As the middle panel shows due to the trypinisation of human hepatocytes a large amount of debris is included within the 
analysis. This will represent cellular fragments that have stained with DCF and hence a fluorescent signal is seen. The right hand panel show the 
gating protocol that can be applied to obtain the signal from small hepatocytes. This shows that a small population of these hepatocytes increase 
ROS. To detect apoptosis, necrosis and autophagy similar flow cytometric analysis were used.
A B C
D 
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Violet 1
Figure 3.5 Compensation of the Flow Cytometric Fluorophore 
To ensure that flow cytometry experiments were correctly performed and correctly 
compensated initially unlabelled hepatocytes were run through the flow cytometer as 
illustrated in Figure 3.4A. Following this the FS and SS parameter voltages were adjusted to 
enable appropriate gating of cells as demonstrated in Figure 3.4. In the example discussed 
below the compensation of Violet 1 (Annexin-V) and Violet 2 (MDC) is described. Similar 
compensation protocols were followed to ensure all fluorophore were correctly compensated 
for in the four-colour reporter assay. Following the above steps, voltages on the Violet 1 and 
Violet 2 parameters were adjusted to place the unlabelled cells within the first decade of the 
logrhythmic scale as displayed below. 
 
 
 
 
 
Figure 3.5A. Demonstrates the initial step up for the compensation procedure. Unlabelled 
hepatocytes were arbitrarily placed with the first decade of the flow cytometry plot. This was 
performed for both Violet 1 and Violet 2.  
 
Following this human hepatocytes labelled with the Violet 1 fluorophore were run on the 
flow cytometre to check that no final adjustments to voltage were required to the Violet 1 
channel. Violet 1 positive events were separate from the negative population (Figure 3.5B). 
Next human hepatocytes labelled with the Violet 2 fluorophore were run on the flow 
cytometer and check that no final adjustments to voltage are required to the Violet 2 channel. 
Violet 2 positive events were separate from the negative population.  
 
A Violet 2 
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Figure 3.5B. Violet 1 and Violet 2 positive human hepatocytes were clearly distinct from the 
negative population demonstrated in Figure 3.5A. This ensured that the positive population 
of cells could be clearly distinguished from the negative cells.  
 
The voltage settings were not then changed, as subsequent compensation would not be valid 
if instrument settings for fluorescence channels were changed. The same protocol and 
method was used to ensure correct voltages for DCF and 7-AAD. 
Once the voltages were set for each of the fluorophore, compensation is applied to the data. 
Firstly, after gating on the human hepatocyte population of interest on the relevant FS vs. SS 
dot-plot (see Figure 3.4), the Violet 1 and Violet 2 data was displayed in a plot of Violet 1 
vs. Violet 2 as shown below. 
 
 
 
 
 
 
 
Figure 3.5C. Demonstrates the uncompensated data from Violet 1 and Violet 2 on a quadrant 
analysis. Violet 1 positive cells show positivity within the Violet 2 channel during normoxia. 
Although human hepatocytes show Violet 2 positivity under basal conditions, cells also 
showed positivity within the Violet 1 channel. Without compensation, cells that were not 
stained with the relevant fluorophore would appear positive giving rise to spurious results. 
B 
C 
Violet 1 Violet 2 
Violet 1 Positive Cells Violet 2 Positive Cells
R0 R1 R0 R1 
R2 R3 R2 R3 
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Quadrant analysis of this uncompensated data shows the negative cells in the origin (R0) 
with the Violet 1 and Violet 2 stained cells in the double positive quadrant (R3). This 
demonstrates the Violet 1 and Violet 2 spectral overlap (or bleed through) with Violet 2 and 
Violet 1 respectively. Compensation was applied to the data to ensure correctly stained cells 
were analysed as shown below (Figure 3.5D).  
 
 
 
 
 
 
 
Figure 3.5D. Demonstrates the compensated Violet 1 and Violet 2 data. Compensation was 
applied to ensure that only cells positive for Violet 1 and Violet 2 were contained within the 
positive quadrant. Hence under normoxic conditions human hepatocytes show minimal 
positivity with Annexin-V (Violet 1) and strong positivity with MDC (Violet 2). 
 
MFI was used to analyse data as the parameters assessed were normally distributed. Thus the 
Violet 2 stained human hepatocytes are now correctly compensated against Violet 1 and vice 
versa (Figure 3.5E). 
 
 
 
 
 
 
Figure 3.5E. Following correct compensation only cells that are dual positive for Annexin-V 
and MDC are present within R4. This data was from human hepatocytes exposed to hypoxia 
and show that that hypoxia induces both apoptosis and autophagy in these cells. 
D 
E 
R0 R0
R0
R1 R1 
R2 R2R3 R3 
R2 
R1
R3 
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Figure 3.6 ROS Accumulation in Human Hepatocytes in Response to 5%, 1% and 
0.1% Hypoxia 
To date no studies have examined the effects of hypoxia upon human hepatocytes. Therefore 
to establish the effects of oxygen concentration upon intracellular human hepatocyte ROS 
production, human hepatocytes were exposed to 5%, 1% and 0.1% hypoxia for 24 hours. 
The accumulation of intracellular ROS was determined using DCF as detailed above. As 
Panel A and B demonstrate 5% and 1% oxygen respectively induced no intracellular ROS 
accumulation within human hepatocytes relative to normoxia whereas 0.1% oxygen (Panel 
C) did induce an increase. Therefore for subsequent experiments 0.1% oxygen for 24 hours 
was used in the in vitro model. (n=3).  
A 
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ROS 
               Normoxia (21% Oxygen)                   Hypoxia 
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3.2.3 Western Blotting for Atg Proteins 
For Western immunoblotting studies, human hepatocytes were lysed at the end of the 
relevant experimental period using Nonident P-40 (NP-40) lysis buffer (20 mM Tris-HCl pH 
8 (Sigma-Aldrich, Catalog Number T3253), 137 mM NaCl (Sigma-Aldrich, Catalog Number 
S3014), 10% glycerol (Sigma-Aldrich Catalog Number G5516), 1% Nonidet P40 (Sigma-
Aldrich, Catalog Number 18896), 2 mM EDTA (Sigma-Aldrich, Catalog Number E6758). 
Protein concentration was determined by Bradford protein assay and 25 μg of protein was 
resolved on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane (Hybond; 
Amersham Biosciences, UK, Catalog Number RPN3032D). The blotted membrane was 
blocked for 1 h at room temperature in TBS pH 7.4/Tween 0.1% (Sigma-Aldrich, Catalog 
Number P9416) containing 5% (wt/vol) bovine serum albumin (BSA) (Sigma-Aldrich, 
Catalog Number A9418). All primary antibody incubations were carried out at overnight at 
40C in TBS-Tween 0.1% containing 5% BSA (wt/vol). The incubation steps were followed 
by three washing steps of 5 min with TBS containing 0.1% Tween. All primary antibodies 
were purchased from New England Biolabs (Hitchin, UK) and used at a dilution of 1:1000 
as per manufacturer’s instructions. Specific primary antibodies used included: 1) Beclin-1 
(catalog number. 3495) 2) LC3A (catalog number. 4599) 3) Atg5 (catalog number. 8540) 4) 
Atg12 (catalog number. 4180) 5) Atg7 (catalog number. 2631).   
Binding of specific monoclonal antibodies was detected with a horseradish peroxidase-
conjugated anti-rabbit IgG at a dilution of 1:2000 for 1 h (Sigma-Aldrich, Catalog Number 
A8792) Protein bands were visualized using the enhanced chemiluminescence detection 
system (Amersham Biosciences, Catalog Number RPN2109) followed by exposure of the 
membranes to Hyperfilm-ECL (Amersham Biosciences, Catalog Number 28-9068-37). 
Equality of protein loading on were checked by immunoblotting for β-actin (Sigma-Aldrich, 
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Catalog Number A2228) (dilution 1:20000). All Western immunoblots were performed at 
least three times from different liver preparations for each liver cell type.  
 
3.2.4 Assessment of Mitochondrial Membrane Potential and Labelling of Autophagic 
Vacuoles with MDC 
To measure the mitochondrial membrane potential (ΔΨm) in human hepatocyte during 
normoxia, hypoxia and H-R, 5,5',6,6'-tetrachloro-1,1',3,3'-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1) (Molecular Probes, Invitrogen, 
Catalogue Number M34152), a sensitive fluorescent probe for ΔΨm was used [205]. Probes 
such as JC-1 that detect mitochondrial membrane potential are positively charged, this 
property allows the probes to accumulate in the electronegative interior of the mitochondria. 
JC-1 dye exhibits potential-dependent accumulation in mitochondria, indicated by a 
fluorescence emission shift from green (530 nm) to red (590 nm) [206]. Consequently 
mitochondrial depolarisation is indicated by a decrease in the red/green fluorescence 
intensity ration. The potential-sensitive colour shift is due to concentration dependent 
formation of red fluorescent J-aggregates. In the studies detailed below JC-1 was used in 
conjunction with MDC to delineate the effects of autophagy upon mitochondrial function. 
Human hepatocytes were used in in vitro experiments as described above. At the end of the 
specific experimental procedure, cells were then rinsed with PBS twice and then stained with 
5 μM JC-1 and/or 1 µM MDC for 30 min at 37°C. Cells were rinsed with ice-cold PBS 
twice, resuspended in 1 mL ice-cooled PBS, and immediately analysed with a fluorescence 
microscope (Nikon Eclipse TE 300, Japan). A 488 nm filter was used for the excitation of 
JC-1. Emission filters of 535 nm and 595 nm were used to quantify the population of 
mitochondria with green (JC-1 monomers) and red (JC-1 aggregates) fluorescence, 
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respectively. MDC staining was assessed with a filter system (V-2A excitation filter: 
380/420 nm, barrier filter: 450 nm).[207] Images were captured with a CCD camera and 
imported into Adobe Photoshop. 
 
3.2.5 Luminex Assay (Multiplex-30 bead assay) 
The Luminex assay system is a flexible analyser based upon the principles of flow 
cytometry. The system allows the simultaneous measurement of numerous analytes in a 
single microplate well using very small biological sample volumes. The technology uses 5.6 
μm polystyrene microspheres, which are internally dyed with red and infrared fluorophores. 
Using different amounts of the two dyes for different batches of the microspheres up to 100 
different microsphere sets can be created. Each bead is unique with a spectral signature 
determined by a red and infrared dye mixture. The bead is filled with a specific known ratio 
of the two dyes. As each microsphere carries a unique signature the detection system can 
identify to which set it belongs. Therefore multiplexing up to 100 tests in a single reaction 
volume is possible. The Luminex reader combines two lasers, fluidics and real time digital 
signal processing to distinguish up to 100 different sets of colour-coded polystyrene beads 
each bearing a different assay. The reader detects individual beads by flow cytometry. The 
fluidics system of the reader aligns the beads into single file as they enter a stream of sheath 
fluid and then enter a flow cell. Once the beads are in a single file within the flow cell, each 
bead is individually interrogated for bead colour (analyte) and assay signal strength (R-
phycoerythrin (PE) fluorescence intensity). The reader uses a 532 nm green laser (assay 
laser) to excite the PE dye of the assay (streptavidin-PE). The 635 nm solid-state laser (red 
classify laser) is used to excite the dyes inside the beads to determine their colour or region 
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and is also used for doublet discrimination by light scatter. The reader has four detectors one 
for each of the optical paths. 
The human cytokine multiplex-30 bead array assay kit for Luminex was purchased from 
Invitrogen (Carlsbad, CA, USA) to measure the following cytokines: IL-1α, IL-1β, IL-2, IL-
3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, Interferon-γ 
induced protein-10 (IP-10), Monocyte chemoattractant protein-1 (MCP-1), Macrophage 
Interacting Protein-1α (MIP-1α), Regulated upon Activation, Normal T-cell Expressed, and 
Secreted (RANTES), TNF-α, IFN-α2, IFN-γ, Granulocyte macrophage- colony stimulating 
factor (GM-CSF) and Eotaxin. The protocol was performed as per the manufacturer’s 
instructions. Appropriate dilutions of the human hepatocyte supernatants in assay diluents 
were made. The assay was performed in a 96-well filter plate, using all the assay 
components provided. All incubation steps were performed at room temperature and in the 
dark to protect the beads from light. All washes were performed using a vacuum manifold. 
For the detection of cytokines and chemokines, the samples were finally incubated for 30 
minutes with streptavidin conjugated to the fluorescent protein, R-PE (Streptavidin-RPE, 
diluted 1:10). After washing to remove the unbound Streptavidin-RPE, the beads (minimum 
of 50 beads per cytokine) were analysed in the Luminex 100 instrument, which monitored 
the spectral properties of the beads while simultaneously measuring the amount of 
fluorescence associated with R-PE. Raw data was analyzed using Bio-Plex Manager 
software, v4.1 (Bio-Rad). Each undiluted plasma sample was assayed in duplicate, and 
cytokine standards supplied by the manufacturer were used to calculate the concentrations of 
the samples. 
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3.2.6 Statistical analysis 
Data analysis was carried out using SPSS version 13.0 software. All values are presented as 
means ± S.E. unless otherwise noted. Statistical analysis was carried using Student’s t test. 
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3.3 Results 
3.3.1 Variable ROS Responses to Hypoxia and H-R of Human Hepatocytes Isolated 
from Patients with Different Liver Diseases 
Primary human hepatocytes were isolated from normal liver wedges that were obtained from 
in-situ liver splits or explanted diseased livers from patients with ALD, PBC and PSC. 
Hepatocytes were also isolated from tissue taken from patients who had undergone hepatic 
resections for liver metastasis from colorectal carcinoma. Table 3.1 shows ROS 
accumulation within human hepatocytes isolated from normal, normal resected and 
explanted livers. Figure 3.7 show ROS production and accumulation in normal human 
hepatocytes. The response of human hepatocytes isolated from ALD, PBC, PSC and normal 
resected is shown in Appendix I. As discussed earlier, the mitochondrion is the main source 
of ROS in hepatocytes and hypoxia leads to increased generation of ROS that is further 
increased by H-R. These findings were confirmed by the use of the specific mitochondrial 
ROS dye MitoSox Red, which demonstrated that hypoxia and H-R resulted in an increase in 
mitochondrial ROS production with the increase in ROS accumulation during H-R being 
greater than that observed in hypoxia (Figure 3.8). Indeed, mitochondrial ROS production 
accounts for the vast majority of ROS production in human hepatocytes during hypoxia and 
H-R.  
Hepatocytes isolated from normal livers, ALD and normal resected liver tissue showed this 
classical response to hypoxia and H-R. Interestingly, there was little basal intracellular ROS 
within normal hepatocytes during normoxia. However, hypoxia and H-R induced a 
significant increase in ROS accumulation. Hepatocytes isolated from ALD and normal 
resected liver tissue showed similar responses in ROS accumulation during hypoxia and H-R 
but had greater basal intracellular ROS content, possibly reflecting their continual exposure 
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to an inflammatory microenvironment. Hepatocytes isolated from biliary disease (PBC and 
PSC) showed very low basal levels of ROS production, similar to hepatocytes isolated from 
normal livers. These hepatocytes showed a 22-fold increase in ROS production during 
hypoxia but a reduction in ROS accumulation in H-R. This may be a reflection of increased 
engagement of hepatocyte cytosolic antioxidant defences in these particular disease settings 
or a consequence on cholestasis, which is a feature of these diseases.
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Figure 3.7 Hypoxia and H-R Mediate ROS Accumulation in Human Hepatocytes 
Representative flow cytometry plots are shown to illustrate the effects of hypoxia and H-R on ROS accumulation in normal human hepatocytes. 
A vertical ellipse marks the area of interest within the plots. The area on the left of each ellipse represents cell debris. The reason why the cell 
debris is included within the plot is that human hepatocytes vary considerably in size and therefore to include all viable human hepatocytes in the 
analysis a large gate is required on the flow cytometer and by necessity includes the cell debris. The gate used is shown on the corresponding FS 
versus SS plots located on the left of each flow cytometric plot. The FS versus SS plots are from the H-R samples of each preparation but similar 
plots were obtained during normoxia and hypoxia. Details regarding the flow cytometric protocol are in Section 3.5. (n=4). 
Normoxia Hypoxia H-R 
ROS
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Table 3.1 ROS Accumulation in Human Hepatocytes during Hypoxia and H-R 
 
 
 
 
 
 
 
 
 
 
 
The mean ROS accumulation for human hepatocytes isolated from normal, diseased and normal resected liver tissue is shown in each of the 
three experimental conditions. Data is expressed as the MFI. Figures in parentheses represent the range of MFI readings in each experimental 
condition. MFI values are derived from the cells within the ellipse shown in Figure 3.7. The data is representative of 4 normal hepatocyte, 4 
biliary disease, 3 ALD and 9 normal resected liver preparations. (*p<0.05 when compared to normoxia, †p<0.05 when compared to hypoxia) 
 Normal Biliary Cirrhosis ALD Resected
Normoxia 30.3 
(13.3-53.5) 
11.9 
(6.2-21.1) 
226.5 
(217.1-247.1) 
352.8 
(256.4-450.5) 
Hypoxia 121.9* 
(39.6-166.18) 
255.2* 
(139.9-444.0) 
259.5 
(229.2-281.2) 
377.1 
(284.3-547.2) 
H-R 271.1*† 
(217.7-370.0) 
102.6* 
(35.2-151.0) 
294.7 
(278.15-311.1) 
506.1 
(332.2-874.0) 
 90
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 The Accumulation of ROS in Human Hepatocytes is Mitochondrial 
Dependent 
Composite bar charts illustrate the effects of hypoxia and H-R upon ROS production in 
human hepatocytes isolated from benign liver diseases using DCF and Mitosox Red. DCF is 
measure of hydrogen peroxide production in human hepatocytes. Hydrogen peroxide is the 
main ROS generated within hepatocytes. Mitosox Red detects ROS generated specifically by 
the mitochondrion. In these experiments human hepatocytes were isolated from the same 
liver wedges and then used simultaneously in the in vitro model of hypoxia and H-R to 
determine DCF and Mitosox Red staining during normoxia, hypoxia and H-R. Data are 
expressed as MFI. Data are expressed as the mean ± S.E. Human hepatocytes used for these 
experiments were isolated from benign liver diseases (n=4). (*p<0.05 relative to normoxia, 
**p<0.05 relative to hypoxia, ***p<0.01 relative to normoxia, Mann-Whitney test).  
 
 
 
 
 
 
 
 
 
Mitosox Red DCF 
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3.3.2 PP and PV Human Hepatocytes Exhibit Differential ROS Accumulation during 
Hypoxia and H-R 
As discussed earlier, FACs analysis is able to discriminate between large or PV and small or 
PP human hepatocytes using appropriate FS and SS gating strategies (see Figure 3.4). 
Accordingly, using appropriate flow cytometric gating protocols the response of large/PV 
and small/PP hepatocytes to hypoxia and H-R could be ascertained and defined.   
Large/PV hepatocytes, isolated from benign liver resections, normal donor tissue and biliary 
cirrhosis (primary biliary cirrhosis and primary sclerosing cholangitis) showed a significant 
increase in ROS accumulation during hypoxia (Figure 3.9). Exposure of human hepatocytes 
to H-R further accentuated intracellular ROS accumulation. In contrast, small/PP 
hepatocytes, showed no increase in intracellular ROS accumulation during hypoxia and H-R. 
These observations show that ROS accumulation seen in the whole hepatocyte population 
during hypoxia and H-R (Figure 3.7) is largely due to large/PV human hepatocytes.      
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Figure 3.9 Intracellular ROS Accumulation within Large/PV and Small/PP Human 
Hepatocytes during Hypoxia and H-R 
Demonstrates a representative flow cytometry plot of ROS accumulation in large/PV and 
small/PP primary human hepatocytes during normoxia, hypoxia and H-R. The plot on the 
left hand side of each flow cytometric plot represents a typical FS versus SS plot of primary 
human hepatocytes. The FS versus SS plots shown is from the H-R sample of a liver 
preparation but similar plots were obtained during normoxia and hypoxia. The top panel 
shows the gating protocol applied to human hepatocytes to analyse large/PV human 
hepatocytes and the bottom panel shows the protocol used to analyse small/PP human 
hepatocytes. The areas of interest on the flow cytometric plots are marked by the vertical 
ellipses. The origins of each of the peaks seen on the flow cytometry plot are discussed in 
detail in section 3.2.2. (n=6).  
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3.3.3 Cytokine and Chemokine Responses of Human Hepatocytes during Hypoxia and 
H-R 
It is well appreciated that hepatocytes may secrete and sequester many pro-inflammatory 
chemokine and cytokines during inflammatory processes such as IRI [51]. There is no clear 
evidence as to whether hepatocytes secrete or produce pro-inflammatory chemokines and/or 
cytokines during IRI. Importantly, these soluble mediators are likely to shape the hepatic 
microenvironment and influence the type and magnitude of cell infiltrates observed during 
liver disease in general and IRI in particular. Of the 30 chemokines and cytokines assessed 
using the multiplex luminex analysis only two demonstrated significant changes during 
hypoxia and H-R. MCP-1 and IL-8 both showed increased levels within supernatants from 
human hepatocytes isolated from normal and biliary cirrhosis. Interestingly, ALD 
hepatocytes showed no changes in any of the 30 parameters measured. This may reflect the 
reduced metabolic activity of these cells (see Figure 3.10). Human hepatocytes isolated from 
normal resected tissue demonstrated elevated levels of both MCP-1 and IL-8 during 
normoxia but these decreased significantly during hypoxia and H-R. 
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Figure 3.10 Chemokine and Cytokine Responses of Human Hepatocytes during 
Hypoxia and H-R 
Luminex assays were utilised to assess cytokine and chemokine secretion from human 
hepatocytes during normoxia, hypoxia and H-R. Supernatants from normal human 
hepatocytes and human hepatocytes isolated from biliary liver disease and normal resected 
liver tissue were analysed. Of the 30 cytokines and chemokines assessed only IL-8 and 
MCP-1 showed significant changes. The levels of MCP-1 and IL-8 in human hepatocyte 
supernatants during normoxia, hypoxia and H-R are illustrated above. (*p<0.05, Students t 
test). (n=7-12). 
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3.3.4 ROS Accumulation Mediated Human Hepatocyte Apoptosis, Necrosis and 
Autophagy 
The effect of hypoxia and H-R on human hepatocyte cell death was assessed using the four-
colour reporter assay described in Section 3.2.2. Previous in vitro studies have shown that 
human hepatoma cell lines [26], murine [208] and rodent hepatocytes [209] undergo cell 
death during hypoxia and H-R. However, many of these studies have not assessed the 
relative contributions of apoptosis and necrosis to cell death in hepatocytes during oxidative 
stress. Moreover the function of autophagy in primary hepatocytes still remains to be 
determined.  
Hypoxia and H-R both increased apoptosis, necrosis and autophagy of normal human 
hepatocytes (Figure 3.11). The level of apoptosis and necrosis in ALD, PSC, PBC and 
normal resected hepatocytes in shown in Appendix I and the response of autophagy in the 
various types of human hepatocytes is shown in Appendix V. The level of apoptosis, 
necrosis and autophagy during hypoxia and H-R mirrored the relative levels of intracellular 
ROS production within each specific hepatocyte subset. The decrease in ROS production 
observed in hepatocytes isolated from biliary diseases was accompanied by a concomitant 
decrease in apoptosis and necrosis confirming the association of ROS with apoptotic and 
necrotic cell death. The highest basal levels of ROS were seen in hepatocytes isolated from 
normal resected liver tissue. Despite the increase in intracellular ROS in normal resected 
hepatocytes, the level of apoptosis or necrosis did not increase suggesting an important 
difference in the biology and metabolic activity of these cells. It is important to note that 
normal resected human hepatocytes did have a higher basal level of both apoptosis and 
necrosis. The composite data for human hepatocyte apoptosis and necrosis during hypoxia 
and H-R is shown hypoxia and H-R in Appendix I. 
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The autophagic response as assessed by MDC staining was greater in human hepatocytes 
during H-R than hypoxia. Furthermore, human hepatocytes isolated from normal liver tissue 
and diseased liver tissue show markedly different autophagic responses during hypoxia and 
H-R (Appendix V). While human hepatocytes isolated from biliary cirrhosis show a similar 
autophagic response to those isolated from normal human hepatocytes (Appendix V) those 
hepatocytes isolated from ALD show very little staining with MDC during hypoxia and H-R 
indicating the lack of autophagy within these particular hepatocytes. Finally, human 
hepatocytes isolated from normal resected liver tissue that have been exposed to 
chemotherapy showed a very different autophagic response to hypoxia and H-R. These 
hepatocytes had a much higher basal autophagy level that was maintained throughout 
hypoxia and H-R.  
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Figure 3.11 Hypoxia and H-R Induce Human Hepatocyte Apoptosis, Necrosis and Autophagy 
Representative flow cytometry plots are shown to illustrate the effect of hypoxia and H-R on human hepatocytes apoptosis, necrosis and 
autophagy that were isolated from normal liver tissue. The vertical ellipse marks the area of interest within the plots. Data is representative of 4 
normal human hepatocyte liver preparations. 
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3.3.5 Large/PV and not Small/PP Human Hepatocytes Undergo Apoptosis and Necrosis 
during Hypoxia and H-R 
As the data illustrated in Figure 3.7 & 3.11 demonstrates there is an association between 
intracellular ROS accumulation and the induction of both apoptosis and necrosis. Despite 
this, the relationship between these ROS and cell death in human hepatocytes remains to be 
clearly established in the morphologically and metabolically distinct large/PV and small/PP 
hepatocytes. As Figure 3.12 demonstrates large/PV human hepatocytes, in line with their 
propensity to generate ROS during hypoxia and H-R (see Figure 3.9), sustained significant 
levels of cell death during hypoxia and H-R in the form of both apoptosis and necrosis 
(Figure 3.12). In contrast, small/PP hepatocytes did not undergo any apoptosis or necrosis in 
line with their lack of ROS generation during hypoxia and H-R.  
 
 
 
 
 
 
 
 
 99
 
 
Figure 3.12 Large/PV and not Small/PP Undergo Cell Death during Hypoxia and H-R 
Representative flow cytometry plots to illustrate the level of apoptosis and necrosis in small/PP and large/PV human hepatocyte during 
hypoxia and H-R. The flow cytometric gating protocol used to analyse primary human hepatocytes was the same as that shown in Figure 
3.9. The areas of interest within the flow cytometric plots are marked by the vertical ellipses. Appendix III show a bar charts with the 
pooled data of five separate experiments illustrating the level of apoptosis and necrosis in small/PP and large/PV human hepatocytes during 
hypoxia and H-R. (n=5). 
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3.3.6 The Effect of ROS Inhibitors on ROS Accumulation  
Anti-oxidants and inhibitors of ROS generation have been shown to abrogate human 
hepatoma cell death during hypoxia [26]. Figure 3.13 shows the effects of antioxidants, 
mitochondrial chain inhibitors and NADPH oxidase inhibitors on primary human hepatocyte 
ROS production during H-R. Similar results were observed in normoxia and hypoxia. NAC 
acts as a glutathione precursor that enters cells and interacts and detoxifies free radicals by 
non-enzymatic reactions. It is deacetylated to form cysteine, which supports the biosynthesis 
of glutathione, one of the most important components of the intracellular antioxidant system 
in hepatocytes [210]. NAC almost completely inhibited ROS production in all hepatocytes 
during H-R. Rotenone, a mitochondrial complex I inhibitor, was also able to inhibit ROS 
production in hepatocytes from all sources, confirming the mitochondria as a major source of 
endogenous ROS in human hepatocytes. The inhibition of ROS by rotenone was substantial 
but not as great as that observed with NAC. The production of ROS in the presence of 
mitochondrial inhibition implies the involvement of other mechanisms in human 
hepatocytes. Accordingly, the flavoenzyme NADPH oxidase was also involved in ROS 
production within the hepatocyte. The specific NADPH oxidase inhibitor DPI significantly 
decreased ROS production in all human hepatocytes. Thus although the overall effect was 
not as great as that of rotenone, DPI inhibition of NADPH oxidase function suggests that this 
enzyme is also an important source of ROS in human hepatocytes. 
Mitochondrial function was also inhibited within large/PV human hepatocytes using 
rotenone. As Figure 3.14 demonstrates, rotenone significantly reduced ROS accumulation in 
large/PV human hepatocytes during normoxia, hypoxia and H-R. Rotenone had no effect 
upon ROS accumulation in small/PP human hepatocytes. Coupled together with the data in 
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Figure 3.8 these observation shows that the mitochondrion within human hepatocytes is a 
key ROS generator. 
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Figure 3.13 Anti-oxidants, Mitochondrial Chain Inhibitors and NADPH Oxidase 
Inhibitors Reduce Human Hepatocyte ROS Production during H-R 
Human hepatocytes isolated from normal, diseased and normal resected livers were treated 
with 20 mM NAC, 2 μM rotenone (Rot) or 10 μM DPI during H-R. ROS accumulation was 
determined by flow cytometry as described in the Materials and Methods section. ROS 
production is shown as MFI and is based upon the MFI readings taken from cells within the 
ellipse region shown in Figure 3.7. Data are expressed as mean ± S.E. Data is representative 
3 normal hepatocyte, 3 biliary disease, 3 ALD and 5 normal resected liver preparations. 
(*p<0.01, **p<0.01, Student’s t test). 
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Figure 3.14 The Role of the Mitochondrion in ROS Accumulation in Large/PV Human 
Hepatocytes  
Representative flow cytometric plots show the effect of 2 µM rotenone upon large/PV 
human hepatocytes ROS accumulation during normoxia, hypoxia and H-R. Human 
hepatocytes were treated with 2 µM rotenone at the time of placement into normoxia, 
hypoxia or H-R. Rotenone was dissolved in chloroform to make a stock solution of 1 mM 
and diluted appropriately. Vehicle alone was shown not to have any effect upon ROS 
production. Data is expressed as MFI and readings are based upon values taken from cells 
within the gated region shown in Figure 3.9. Composite data from three experiments is 
presented in Appendix II.  
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3.3.7 The effects of ROS Inhibitors on Human Hepatocyte Apoptosis, Necrosis and 
Autophagy 
NAC, rotenone and DPI all inhibited ROS (Figure 3.13) and the effect of this decreased 
intracellular ROS production upon human hepatocyte apoptosis, necrosis and autophagy was 
assessed. Data for H-R is shown with similar results obtained during normoxia and hypoxia. 
The reduction in endogenous ROS in human hepatocytes treated with the various inhibitors 
led to significantly decreased hepatocyte apoptosis, necrosis and autophagy (Figure 3.15). 
The effects of NAC were the greatest, in line with its more potent effect on ROS inhibition. 
Rotenone and DPI also decreased apoptosis necrosis and autophagy during H-R. It is 
important to note that ROS inhibition abrogated apoptosis, necrosis and autophagy in human 
hepatocyte isolated from the different types of hepatic disease. Although ROS inhibition 
abrogated necrosis there was a proportion of the hepatocyte necrosis response that ROS 
inhibition did not reverse. These data provide clear evidence that endogenous ROS 
production by mitochondria and NADPH oxidase drives human hepatocyte apoptosis, 
necrosis and autophagy during H-R. These observations clearly demonstrate the central role 
of ROS in regulating all three cellular processes in human hepatocytes during normoxia, 
hypoxia and H-R in vitro.  
As Figure 3.16 illustrates, NAC, rotenone and DPI significantly reduces large/PV human 
hepatocyte apoptosis, necrosis and autophagy during H-R. Similar results were observed 
during normoxia and hypoxia. These findings demonstrate that in large/PV human 
hepatocytes ROS production and in particular mitochondrial ROS generated during hypoxia 
and H-R drives cell death in the form of apoptosis and necrosis and also autophagy.
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Figure 3.15 ROS Accumulation in Human Hepatocytes during H-R Mediates Apoptosis, Necrosis and Autophagy 
Human hepatocytes isolated from normal liver tissue were treated with 20 mM NAC, 2 μM rotenone or 10 μM DPI during H-R and the effects 
upon ROS production, necrosis and apoptosis was assessed using flow cytometry. Data is representative of human hepatocytes isolated from 
normal livers. (n=4-7) 
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Figure 3.16 ROS Accumulation in PV Human Hepatocytes during H-R Mediates Apoptosis, Necrosis and Autophagy 
Large/PV human hepatocytes isolated from normal liver tissue were treated with 20 mM NAC, 2 μM rotenone or 10 μM DPI during H-R and 
the effects upon ROS production, necrosis and apoptosis was assessed using flow cytometry. Data is representative of human hepatocytes 
isolated from normal livers. (n=4-7) 
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3.3.8 Inhibition of Autophagy was Associated with a Concomitant Increase in 
Hepatocyte Apoptosis during H-R 
The specific class III PI-3K inhibitor 3-MA was used to elucidate the role of autophagy in 
human hepatocytes during hypoxia and H-R. As discussed above 3-MA inhibits the early 
formation of the autophagosome. Accordingly 3-MA significantly reduced hepatocyte 
autophagy during H-R. However whilst autophagy was inhibited in human hepatocytes 
during H-R the number of cells undergoing apoptosis increased (Figure 3.17). Similar data 
was obtained during normoxia and hypoxia.  No significant change in the number of cells 
undergoing necrosis was observed during H-R with 3-MA pre-treatment (Appendix V). 
Interestingly inhibition of class III PI3-K also decreased ROS accumulation within human 
hepatocytes during H-R (Appendix V). These observations suggest that autophagy induction 
in human hepatocytes during hypoxia and H-R may be a cyto-protective mechanism.  
As discussed earlier autophagy is regulated by a number of Atg proteins but whether these 
Atg proteins are modulated by hypoxia and/or H-R within primary human hepatocytes is not 
known. As Figure 3.18 demonstrates Beclin-1, an early regulator of autophagy, is induced by 
hypoxia and H-R. Interestingly, 3-MA reduces Beclin-1 protein levels during normoxia, 
hypoxia and H-R. Similarly Atg 5, Atg 7, Atg12 and LC3A were also increased during 
hypoxia and H-R. 3-MA pre-treatment of hepatocytes reduced the protein levels of these Atg 
proteins. Additionally, cells treated with 3-MA during normoxia, hypoxia and H-R showed 
the characteristic morphological appearance of the cells undergoing apoptosis (see Appendix 
V). Hepatocytes appeared phase bright, small and shrunken. Taken together, these 
observations demonstrate that autophagy promotes survival of human hepatocytes during 
hypoxia and H-R in vitro. 
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Much recent work has focused upon the role of mitochondrial autophagy or mitophagy 
during oxidative stress [211-213]. Indeed the mitochondrion is an important ROS generator 
during IRI and regulates cell death as demonstrated above. Accordingly, the specific 
mitochondrial dye JC-1 was used as measure of the mitochondrial membrane potential 
within human hepatocytes during hypoxia and H-R. Red fluorescence of the JC-1 probe 
represents normal mitochondrial membrane potential whereas green fluorescence represents 
low mitochondrial potential and is indicative of the onset of cell death. Furthermore, human 
hepatocytes were co-stained with MDC. As Figure 3.19 shows during normoxia human 
hepatocytes have normal mitochondrial membrane potential as demonstrated by red 
fluorescence with no evidence of staining with MDC. Interestingly, incubation of cells with 
3-MA markedly increased the green fluorescence of human hepatocytes indicating a 
lowering of mitochondrial potential and the onset of cell death. Furthermore, hypoxia and H-
R lower mitochondrial membrane potential further with a concomitant increase in MDC 
staining. Moreover, pre-treatment of cells with 3-MA during hypoxia and H-R, whilst 
reducing MDC staining markedly lowered mitochondrial membrane potential and increased 
cell death. Finally, MDC and green JC-1 staining were observed to co-localise in these 
samples indicating that autophagy was occurring in the mitochondrion. 
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Figure 3.17 Inhibition of Autophagy Increases Apoptosis in Human Hepatocytes 
during Hypoxia and H-R 
Representative flow cytometry plots demonstrate the effects of the pre-treatment of primary 
human hepatocytes with 3-MA and the resultant effects upon apoptosis and autophagy 
during H-R. The level of apoptosis and autophagy during H-R are shown in blue and the 
effects of 3-MA pre-treatment are shown in solid grey. The area of interest is marked with a 
vertical ellipse. The bar charts to the right of each flow cytometry plot show pooled data 
from three separate experiments. Data are expressed as increase or decrease relative to basal, 
where basal refers to the level of apoptosis or autophagy during H-R. Data are expressed as 
mean ± S.E. (*p<0.05 relative to basal, Mann-Whitney test). Human hepatocytes used for 
these experiments were isolated from benign liver diseases (n=3). 
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Figure 3.18 Beclin-1, LC3A, Atg5, Atg7 and Atg12 are Induced by Hypoxia and H-R in 
Human Hepatocytes 
Illustrates the induction of various Atg proteins involved in the regulation of autophagy 
during normoxia, hypoxia and H-R. The effects of the PI3-K inhibitor 3-MA on Atg protein 
induction during normoxia, hypoxia and H-R are also shown. All Western blots were 
performed at least three times and presented blots are representative of all samples (n=3).    
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Figure 3.19 Autophagy is Primarily Carried out in Mitochondrion in Human Hepatocytes during Hypoxia and H-R 
Demonstrates the effects of hypoxia and H-R upon human hepatocyte mitochondrial membrane potential and MDC staining. Mitochondrial 
membrane potential was determined using the specific dye JC-1. When mitochondrial membrane potential is normal JC-1 appears red but once 
membrane potential is lowered or lost the dye become green. MDC staining is detected within the DAPI channel and appears blue. Composite 
overlay images are shown at the bottom of the figure. Additionally unstained images are provided with stained images to highlight the cellular 
location of immunofluorescence. In normoxia, as expected there was a normal mitochondrial membrane potential and no autophagy noted. 
During hypoxia and H-R there was a progressive loss of red JC-1 staining and an increase in green JC-1 staining indicating loss of 
mitochondrial potential and onset of cell death. In addition there was an increase in MDC staining in human hepatocytes during hypoxia and H-
R. Moreover, MDC staining and green JC-1 staining co-localised in human hepatocytes during hypoxia and H-R. (n=3)  
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3.3.9 Large/PV Human Hepatocytes Preferentially Undergo Autophagy during H-R 
As discussed earlier human hepatocytes located within the PV region of the liver tend to be 
larger in size than their PP counterparts and as shown in Figure 3.9 large/PV human 
hepatocytes accumulate ROS and are more prone to cell death during oxidative stress 
making them the targets of hypoxic injury. As demonstrated in Figure 3.20 large/PV 
hepatocytes increase autophagy significantly more than small/PP human hepatocytes during 
H-R (Appendix V). As expected, these increased levels of autophagy are sensitive to 3-MA 
pre-treatment. Indeed, inhibition of autophagy in large/PV human hepatocyte significantly 
increased apoptosis during H-R (Figure 3.20). These findings collectively illustrate that 
although large/PV human hepatocytes are prone to increased intracellular ROS production 
during hypoxia and H-R that then induce cell death, these hepatocytes also concomitantly 
increase the induction of the cytoprotective mechanism of autophagy.   
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Figure 3.20 Large/PV Human Hepatocytes Requires Autophagosome to Survive H-R 
The top panel demonstrates a representative flow cytometry plot to illustrate the levels of 
MDC staining of large/PV human hepatocytes during normoxia (blue), hypoxia (hatched 
red) and H-R (solid grey). The plot on the left hand side of the flow cytometric plot 
represents a typical FS versus SS plot, similar to that shown in Figure 3.9. The FS versus SS 
plot is from an H-R sample but similar plots were obtained during normoxia and hypoxia. 
The gating protocol applied to human hepatocytes to analyse PV/large human hepatocytes is 
shown on the FS versus SS plot. A vertical ellipse marks the area of interest of each flow 
cytometry plot. The bottom panel illustrates the effects of 3-MA pre-treatment upon 
large/PV human hepatocyte autophagy and apoptosis during H-R. The effects of H-R alone 
are shown in blue and the effects of 3-MA pretreatment are shown in solid grey. 
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3.4 Discussion 
3.4.1 The Role of ROS in Human Hepatocytes during Hypoxia and H-R 
Whilst hypoxia is a feature of hepatic IRI associated with hepatic surgery, it may also occur 
during chronic liver inflammation or infection.  Therefore, defining the effects of hypoxia 
upon liver physiology and in particular hepatocyte responses to hypoxia offers important 
information regarding the development of future therapeutics.  
Hepatocytes were conventionally considered relatively insensitive to IRI because of their 
extensive antioxidant defence mechanisms, and their existence within the comparatively 
hypoxic hepatic environment [164]. However, numerous in vitro and in vivo studies have 
reported deleterious effects of IRI upon hepatocytes although the effect of hypoxia and H-R 
upon human hepatocytes is not known. The presented data reveals that hepatocytes are 
susceptible to apoptotic and necrotic cell death induced in response to hypoxia and H-R. 
Moreover human hepatocytes isolated from different hepatic diseases show variable 
responses to hypoxia and H-R. Furthermore, human hepatocytes also increase the formation 
of autophagosomes in a ROS-dependent manner during hypoxia and H-R with the latter 
mechanism being cytoprotective.  
Hypoxia is known to cause dysfunction of the mitochondrial electron transport chain leading 
to an increase in ROS (Chapter 1), which is accentuated by reoxygenation and can result in 
cell death [88]. Hepatocytes isolated from normal donor liver, ALD and uninvolved liver 
from hepatic resections exhibit this classical response to hypoxia and H-R. Interestingly, 
human hepatocytes isolated from ALD and normal resected liver tissues have high basal 
levels of ROS production which are then augmented by hypoxia and H-R whereas normal 
hepatocytes and hepatocytes isolated from the livers of patients with biliary cirrhosis show 
very little basal ROS production. These differences are likely to be due to the particular 
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inflammatory microenvironment and milieu that each hepatocyte population has been 
exposed to. For example, many mediators found in ALD patients are known to increase ROS 
[214] and hepatocytes isolated from hepatic resections will have been exposed to 
chemotherapy, a treatment known to increase intracellular ROS [215]. Hepatocytes isolated 
from biliary cirrhosis had lower levels of ROS during H-R possibly reflecting the 
upregulation of the antioxidant defences in these particular cells. The differential responses 
of hepatocytes isolated from different hepatic diseases are unlikely to be attributable to the 
method of isolation as liver tissue was procured and processed according to an identical and 
stringent protocol detailed in Chapter 2.  
It has been suggested previously that hepatocytes are bystanders in IRI, being targeted by the 
inflammatory process [42]. However the presented data proposes that hepatocytes have the 
capacity to actively participate in the IRI process primarily through the production of ROS 
but also the production of pro-inflammatory cytokines. The finding emphasises the 
functional relevance of ROS in that increased levels of endogenous hepatocyte ROS are 
clearly linked to hepatocyte apoptosis and necrosis. This has particular relevance for liver 
diseases were hepatocytes are exposed to relative hypoxia and which may be responsible for 
perpetuating injury. ROS can directly activate apoptosis and necrosis thereby supporting the 
suggestion of Lemasters et al that common pathways may at least in part regulate both 
processes [175]. Moreover, ROS derived from mitochondria and cytosolic NADPH oxidase 
is crucial for regulating both apoptosis and necrosis. Inhibiting the function of mitochondria 
and NADPH oxidase with rotenone and DPI respectively significantly improved human 
hepatocyte viability during hypoxia and H-R. The final mode of cell death that hepatocytes 
are committed to is likely to be dictated by intracellular ATP content [216]. Interestingly, 
ROS inhibition had a greater effect upon reducing human hepatocyte apoptosis and only 
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partially inhibited hepatocyte necrosis. Although ROS does contribute to human hepatocyte 
necrosis, it is likely that a number of factors, including calcium overload, calpain activation 
and lysosome rupture commit the cell to undergo necrosis [217]. In contrast, Wang et al 
have demonstrated in Chang human hepatocytes, mitochondrial derived ROS directly 
activates apoptosis [218]. Accordingly, the inhibition of ROS and in particular mitochondrial 
ROS had a greater effect upon reducing hepatocyte apoptosis. As previously noted 
hepatocytes undergoing necrosis will release intracellular ROS into the liver parenchyma 
and induce both hepatocyte injury and endothelial cell activation [219]. Therefore these 
observations not only have implications for hepatic IRI but also in liver diseases where 
chronic hypoxia will lead to continued ROS production and on-going liver damage. On the 
basis of the presented data it can be speculated that in warm IRI hepatocyte ROS derived 
may be an important regular of hepatic injury. Furthermore human hepatocytes, with the 
exception of hepatocytes isolated from normal resected liver and ALD, increase the secretion 
of MCP-1 and IL-8. These pro-inflammatory cytokines will increase the chemotaxis of 
leukocytes into the liver during IRI and perpetuate hepatocyte cell death and liver injury. 
Importantly, whether these cytokines are synthesised or stored and released by human 
hepatocytes cannot be determined by the presented data. 
In rat livers, treatment with antioxidants can prevent IRI [220]. In limited human studies, 
ischemia induced the expression ROS scavengers within the liver [16]. Despite the presence 
of antioxidants within hepatocytes, human hepatocytes isolated from normal, ALD and 
biliary cirrhosis do not appear to be protected against cell death during hypoxia and H-R. 
Hepatocytes isolated from normal resected liver tissue were however surprisingly resistant to 
ROS-mediated apoptosis and necrosis. This finding has important implications for research 
involving human hepatocytes and suggests that studies should be interpreted in the context 
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of the source of hepatocytes used and those isolated from normal resected hepatic tissues in 
patients with liver tumours are likely to respond differently to physiological stress. As 
eluded to earlier, the reason for this difference remains unknown. Furthermore which 
hepatocyte responses reflect the true physiological response remains to be determined. 
Although previous studies have shown the cytoprotective effects of anti-oxidants and ROS 
inhibitors, the presented data for the first time show that inhibition of mitochondrial and 
NADPH oxidase derived ROS reduces primary human hepatocyte apoptosis and necrosis.   
A single strategy aimed at amelioration of the harmful effects brought on by IRI has not yet 
been adopted into general clinical practice. Experimental interventions to reduce ROS have 
shown potential to minimise liver injury in various models. ROS scavengers [221], 
thioredoxin mimetics [222] and delivery of anti-oxidant genes [223] have been shown to 
partially suppress the effects of IRI. However the clinical application of such compounds has 
been limited for toxicological and technical reasons. NAC however has clinical potential 
because it is well tolerated at doses that should be clinically effective. Indeed, NAC is used 
clinically in several setting including as a hepatoprotective agent in acute liver failure and 
acetaminophen toxicity. Furthermore, although NAC administration has been shown to 
improve hepatic microcirculation and bile flow after hepatic IRI [163], the presented data 
shows that NAC can also reduce all ROS production in human hepatocytes with a 
concomitant decrease in apoptosis and necrosis in normoxia, hypoxia and HR. Recent 
studies have suggested that pleiotropic compounds are required to treat IRI due to the 
diverse nature of IRI [224]. The data presented here suggests exogenous NAC could be a 
straightforward practical and beneficial strategy to ameliorate human hepatocyte cell death 
during IRI. Indeed, a recent study showed that NAC dependent reduction of oxidative stress 
reduced liver injury in a rat model of non-alcoholic steatohepatitis. [225].  
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Although some authors challenge the pathophysiological relevance of intracellular oxidant 
stress during reperfusion [226], it is clearly shown that hepatocyte ROS generated by 
mitochondria and NADPH oxidase can lead directly to significant hepatocyte cell death 
suggesting other sources of ROS, such as neutrophils and KCs whilst capable of contributing 
to tissue ROS accumulation in IRI may not be the only pathway leading to ROS mediated 
hepatocyte damage. An important caveat to the presented data is that oxidative stress in 
human hepatocytes after hypoxia and H-R may differ between hypoxia at 40C and that at 
370C [227]. Therefore, these data can only be tentatively applied to the transplant setting as 
they are not wholly reflective of the in vivo scenario after OLT. 
In summary, human hepatocytes responses to hypoxia and H-R are determined by the 
particular microenvironment that they have been exposed to. Endogenous human hepatocyte 
ROS regulates both apoptosis and necrosis and inhibitors of ROS generation significantly 
improve hepatocyte viability by reducing ROS generation. The use of NAC offers an 
opportunity to modulate hepatic IRI and improve patient outcome following OLT by 
possible by addition to preservation fluids. In addition it is clear that hepatocytes taken from 
normal, normal resected and diseased tissues may vary considerably in their functional and 
metabolic responses to hypoxic stress. 
 
3.4.2 The Response of Small/PP and Large/PV Human Hepatocytes to Hypoxia and H-
R 
Exposure of hepatocytes to hypoxia and H-R are very frequent in several hepatic diseases as 
discussed above. Whilst pathological processes such as haemodynamic shock, septicemia 
and post liver transplantation will affect the entire liver it is likely that hepatocytes based 
upon their variable anatomical locations within the liver will sustain differing levels of 
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injury. Indeed, death of hepatocytes during hypoxia and H-R injury is a multifactorial event 
including alteration of the plasma membrane, rupture of blebs on the cell surface, calcium 
accumulation and mitochondrial damage [42]. Whilst the common mediator to these death 
processes as demonstrated above maybe the accumulation of ROS whether small/PP and 
large/PV human hepatocytes exhibit differential ROS accumulation during hypoxia and H-R 
is not known [228]. Studies in rodent models suggest that large/PV hepatocytes are more 
vulnerable to damage during hepatic injury [169]. Moreover, hepatocyte proliferation, which 
is an important determinant of patient survival after major hepatic resection, is suggested to 
occur from the small/PP to large/PV hepatocytes. Therefore, an understanding of the 
differential vulnerability of hepatocytes to liver injury would provide an important basis for 
preventing liver failure caused by cirrhosis, hepatic resection, liver transplantation and may 
even aid the understanding of liver regeneration [169]. The data presented here clearly 
shows that large/PV hepatocytes are the most susceptible to hypoxic injury. Moreover, this 
susceptibility is due to the greater propensity of the mitochondria of these large/PV 
hepatocytes to produce and accumulate intracellular ROS during hypoxia and H-R [229]. It 
must be noted however, that inhibiting mitochondrial function does not completely abrogate 
large/PV human hepatocyte apoptosis and necrosis. Indeed, as demonstrated above other 
enzymes, such as NADPH oxidase, are involved in ROS generation and are also involved in 
regulating human hepatocyte apoptosis. Accordingly inhibiting NADPH oxidase function in 
large/PV human hepatocytes also inhibits ROS and decreases apoptosis and necrosis during 
hypoxia and H-R. 
The increased level of apoptosis and necrosis seen in large/PV human hepatocytes in vitro in 
the present study would concur with in vivo models of murine and rodent liver injury, where 
cell death is observed in the peri-venular regions of the liver [186]. A possible explanation 
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for this observation may well be that glutathione levels in rodent hepatocytes vary 
considerably between hepatocytes isolated from the small/PP and large/PV regions [230]. 
Specifically, large/PV hepatocytes have less intracellular glutathione when compared to 
small/PP hepatocytes. Moreover, following stimulation with amino acids larger hepatocytes 
generate less intracellular glutathione when compared to small hepatocytes [230]. These 
findings would potentially explain the increased susceptibility of large/PV human 
hepatocytes to hypoxic injury in vitro.  
The data presented also shows that mitochondrial inhibition and anti-oxidants inhibit ROS 
accumulation in human hepatocytes during hypoxia and H-R. However, the present data 
builds upon this observation, showing that mitochondrial electron transport chain inhibitors 
specifically reduce ROS accumulation in the large/PV hepatocytes and consequently reduce 
apoptosis in large/PV hepatocytes during hypoxia and H-R. Many studies have suggested 
that liver resident macrophages or KCs located in the peri-venous region of liver are 
activated during ischaemia and release ROS, leading to hepatocyte damage primarily within 
the peri-venular region of the liver [169]. Taken together these observations suggest that the 
peri-venous region of the liver is the site of inflammation and ROS generation during 
hypoxic liver injury. However, some studies in rodent hepatocytes have suggested that 
small/PP hepatocytes are more vulnerable to hypoxic injury due to their higher requirement 
of oxygen [169]. These discrepancies are likely to represent inter-species variability of 
small/PP and large/PV hepatocytes. 
In conclusion, large/PV human hepatocytes are the most susceptible to hypoxic damage. 
This suggests that therapeutics used in the treatment of liver disease may primarily act upon 
PV or large hepatocytes.  
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3.4.3 The Role of Autophagy in Human Hepatocytes During Hypoxia and H-R 
While autophagy is an important mechanism by which the cell rids itself of potentially 
harmful constituents and helps maintain normal cellular functioning and homeostasis, its 
precise role during liver injury and disease remains uncertain. A consensus is now emerging 
that autophagy does not precede cell death but may be a physiologically protective 
mechanism that favours cell survival [231]. The diverse role of autophagy in liver diseases 
has been recently reviewed [231, 232]. Certainly in liver IRI autophagy mainly has a pro-
survival activity allowing the cell to cope with hypoxia. However autophagy is also known 
to regulate hepatic steatosis and hepatitis virus replication [233]. The reported data is the 
first to demonstrate autophagy is a cytoprotective mechanism in isolated primary human 
cells under conditions of oxidative stress. This has potential implications for the 
understanding of the hepatocyte response to liver injury and development of chronic liver 
disease.  
Previous tissue based studies have shown autophagic hepatocytes within liver allografts are 
increased following liver transplantation. However these studies failed to show a causal link 
between oxidative stress, induction of cell death and autophagy [234]. Instead it was 
suggested that dying hepatocytes also increased autophagy and hence autophagy was thought 
to represent another mode of cell death. However whether inhibition of autophagy promoted 
cell death or survival was not demonstrated. Recent studies have shown that the severity and 
duration of an ischaemic insult determine whether autophagy is induced or not. Indeed these 
studies have shown that autophagy can delay the decision for a cell to die via apoptosis or 
necrosis [235]. Using the four-colour reporter assay described here, it is evident that 
hepatocytes subjected to oxidative stress demonstrate features consistent with increased ROS 
generation, induction of autophagy and induction of apoptosis. However, crucially the 
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inhibition of early autophagy with the class PI3-K inhibitor, 3-MA, induces increased levels 
apoptosis during H-R. 3-MA was the only inhibitor of autophagy used in the presented data. 
siRNA knockdown or transfection of human hepatocytes was not used to manipulate the 
autophagy pathway as these are notoriously difficult and inefficient techniques [236-238].  
Importantly, inhibiting autophagy causes the lowering of human hepatocyte mitochondrial 
membrane potential and leads to cell death. Previous authors have also reported that 
autophagy is responsible for maintaining mitochondrial potential [232]. Importantly, in the 
data presented above it was shown that human hepatocytes isolated from normal and 
diseased liver tissues have different autophagy responses during hypoxia and H-R. 
Specifically, human hepatocytes isolated from normal resected tissue, where livers would 
have been treated with chemotherapy, showed MDC staining that was consistently high 
throughout hypoxia and H-R. Coupled with the other findings it is clear that these 
hepatocytes are resistant to cell death during hypoxia and H-R. Indeed, the reduction in cell 
death observed in these hepatocytes maybe in part due to the induction of autophagy. This is 
consistent with previous work performed in human livers [239]. Moreover human 
hepatocytes isolated from ALD livers showed no autophagy induction during hypoxia and 
H-R possibly reflecting the extent of damage to these livers. To corroborate this latter point 
further it is clear from Figure 2.7 that these hepatocytes are metabolically less active than 
other isolated human hepatocytes and also these hepatocytes have relatively high 
intracellular ROS content even under basal conditions. Human hepatocytes isolated from 
biliary cirrhosis and normal benign liver showed similar autophagy responses in an 
analogous manner to the accumulation of ROS within these cells during hypoxia and H-R. 
These observations show that the varying levels of intracellular ROS within human 
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hepatocytes isolated from different liver diseases correlates positively with intracellular 
MDC staining and hence autophagy.  
During hypoxic stress, autophagy appears to occur within the mitochondrion and the 
presented data shows that this process is likely to be mediated by Beclin-1, LC3A, Atg 5, 
Atg 7 and Atg 12 although other Atg proteins such as Atg 8 and Atg 9 were not assessed. 
These findings corroborate those in HeLa cells where inhibition of autophagy also led to an 
increase in apoptosis [240]. It can be seen from the experimental data presented above the 
induction of autophagy within human hepatocytes during oxidative stress is essential for cell 
survival. Previous work by Kohli et al in hepatocytes has shown that ROS production lies 
upstream of PI3-K activation [241]. Indeed, inhibition of PI3-K with 3-MA did not lead to 
an increase in Beclin-1, LC3A, Atg 5, Atg7 and Atg 12 protein levels which were otherwise 
seen during hypoxia and H-R. Coupled together these findings suggest that ROS activates 
PI3-K, which subsequently activates the remaining autophagy machinery. As stated above in 
hepatocytes, autophagy targets mitochondria for degradation, a process known as mitophagy. 
Indeed inhibiting ROS can regulate autophagy, apoptosis and necrosis. Inhibiting ROS 
inhibits all three cellular processes, but selective inhibition of human hepatocyte autophagy 
promotes apoptosis.   
Furthermore, PV/large human hepatocytes increased levels of autophagy much more than 
PP/small human hepatocytes during hypoxia and H-R in line with their greater susceptibility 
to hypoxic injury. Moreover, inhibition of autophagy in PV/large human hepatocytes 
increased apoptosis during H-R, demonstrating the link between autophagy and cell survival.  
Central regulators of autophagy are the evolutionarily conserved Atg genes and recent 
studies have shown that some Atg proteins can be regulated by ROS [198]. Beclin-1, an 
essential regulator of early autophagy was induced by hypoxia and H-R and efficiently 
 124
inhibited by 3-MA. Indeed, recent reviews have detailed the essential role of Beclin-1 in IRI 
[242] as well as its central role in mediating autophagy during oxidative stress [243]. 
Moreover, under stress hepatocytes utilise the LC3 protein to induce mitophagy within the 
dysfunctional mitochondrion [244]. This latter observation is probably the role of increased 
LC3 seen in the in vitro model used here. In an experimental rat model, short term anoxia 
increases the expression of Atg7 in hepatocytes and protects against anoxia-reoxygenation 
mediated apoptosis and necrosis [245]. In the model of IRI detailed above an induction of 
Atg 7 was also found. Furthermore, induction of Atg5 and Atg 12 was also observed. These 
two Atg proteins are involved in the latter processes of autophagy. Recent studies have 
shown the integral role Atg 5 in regulating menadione-induced oxidative stress [246]. In this 
study knockdown of Atg 5 in the rat hepatocyte line RALA255-10G sensitized cells to both 
apoptotic and necrotic cell death. In addition Atg 12, along with other Atg proteins, is 
required for the protection of anoxic rat hepatocytes from cell death [247].  
While the presented data does not conclusively show which signaling pathways are activated 
by ROS in human hepatocytes to induce autophagy, it does demonstrate that ROS is a key 
mediator of autophagy during oxidative stress. Furthermore in accordance with the data 
presented here previous authors have shown that the general anti-oxidants, catalase and NAC 
reduce autophagy [198]. Mitochondrial and NADPH oxidase derived ROS are critical for the 
induction of autophagy in human hepatocytes. In addition previous studies have shown that 
H-R induces increased manganese superoxide dismutase expression in hepatocytes [248]. 
Taken together these studies show that ROS derived from many sources within hepatocytes 
can regulate autophagy. Moreover this generated ROS has pro-survival effects in activating 
autophagy but also signals to cell death in the form of apoptosis and necrosis. The increase 
in antioxidant defences within hepatocytes is likely to protect from cell death and the 
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inhibition of autophagy may not be detrimental as autophagy can be regulated by other 
system besides ROS [249]. These observations provide interesting insights to the function of 
ROS in determining human hepatocyte fate during oxidative stress. Taken together, these 
observations clearly point to ROS regulating diverse and different signaling pathways within 
human hepatocytes during oxidative stress. These pathways appear to regulate both cell 
death and cell survival. It is likely that either the absolute level of intracellular ROS, the type 
of ROS sub-species generated or duration of ROS generation may be the critical factors in 
determining cell fate. The precise mechanistic pathways remain to be elucidated but may 
ultimately provide insights which may inform the development of therapeutic strategies 
aimed at limiting the cellular damage associated with liver injury. Previous authors have 
reported that inhibiting autophagy within rat hepatocytes leads to necrosis [250]. Moreover, 
in a model of ischaemic preconditioning Esposti et al reported that autophagy may switch 
necrosis and/or apoptosis on and off by modulating intracellular signaling [251]. This was 
not observed in the presented data and it is likely that this represents species-specific effects 
of autophagy as no previous studies have evaluated autophagy in human hepatocytes. It may 
also represent a difference between the induction of autophagy in the in vitro and in vivo 
setting. 
The data also demonstrates that ROS production decreased within human hepatocytes after 
3-MA pre-treatment during H-R. One would expect that in hepatocytes in which autophagy 
were inhibited damaged mitochondria would continue to form ROS and induce cell death. 
However, the particular model described here utilised experiments assessing cell death and 
ROS production at 24 hours of hypoxia and/or H-R. The significant levels of apoptosis seen 
after 3-MA pretreatment during H-R suggests that a significant number of hepatocytes were 
already dead hence intracellular ROS had reduced. 
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The data demonstrates that within human hepatocytes, autophagy is a cell survival 
mechanism during periods of oxidative stress. Moreover, taken together with previous 
studies, it is clear that PV/large human hepatocytes increase autophagy significantly more in 
H-R relative to PP/small human hepatocytes. This is in accordance with previous 
observations that the PV/large peri-venular human hepatocytes are more susceptible to 
oxidative stress. These observations suggest that the pharmacological activation of P13-K or 
other autophagy machinery, particularly within PV/large human hepatocytes may prove 
effective strategies in ameliorating human hepatocyte cell death in chronic liver disease as 
well as following liver transplantation.  
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4.1 Introduction 
4.1.1 The CD40:CD154 Receptor Ligand Dyad 
The TNFα super-family consists of at least 50 different receptors and ligands as discussed in 
Chapter 1. The members of this super-family are known to be integrally involved in the 
regulation of diverse cellular processes such as cell death, adhesion molecule expression and 
the regulation of lymphoid cell activation [123]. Despite the initial suggestion that CD40 
exists as a dimer that trimerised after CD154 binding, it is now known that CD40 is 
expressed as a trimeric complex upon the cell surface of many cells [252]. CD40 is a type I 
trans-membrane protein receptor. The gene for CD40 is located in chromosome 20 (q12-
q13.2) [253]. The B-lymphocyte is the main cell type expressing CD40 but its expression is 
much more diverse than first thought [254]. Other cells expressing CD40 include other 
immune cells, epithelial cells, fibroblasts, vascular endothelial cells and smooth muscle cells 
and platelets. Expression of CD40 is induced by pro-inflammatory stimuli, such as IL-1, IL-
3, and IL-4, TNFα and IFNγ [254]. In general, CD40 can be up-regulated within 6-12 hours 
of pro-inflammatory stimulation and can remain expressed for up to 72-hours. Many 
transcription factors are thought to be important in the regulation of CD40 expression but 
NFκB is known to be a key regulator of the process. Activation of CD40 can regulate a 
number of diverse signalling pathways and lead to a number of different functional outcomes 
[255]. CD40 has no intrinsic kinase activity and following activation is reliant upon the 
recruitment of the TRAFs family of adapter proteins to the cell membrane that stimulate 
downstream signalling pathways [252, 256, 257]. The precise mechanisms involved in CD40 
signalling pathways within the liver are discussed below.  
CD154, a type II trans-membrane protein, has its gene located on chromosome X (q26.3-
q27.1) [258]. CD154 is a 39-kD glycoprotein. Originally, CD154 was thought to function 
 129
only in stimulated CD4-positive lymphocytes [259, 260], mast cells and basophils [261]. 
The cellular expression of CD154 can be up-regulated by pro-inflammatory cytokines and 
lipo-proteins. In contrast the expression of CD154 is much more restricted than that of 
CD40. CD154 is expressed by platelets, T-lymphocytes and macrophages [121]. 
Specifically, liver resident macrophages or Kupffer cells express CD154 whilst activated 
platelets can release soluble CD154 after their activation [253]. 
Initially, the CD40:CD154 interaction was primarily investigated in connection with T-
lymphocyte activation and co-stimulation, B-lymphocyte proliferation and differentiation 
and switching of antibodies from IgM to IgG [262]. Subsequently the CD40:CD154 
receptor-ligand dyad has been shown to play a part in infection, inflammation and many 
other biological processes [124]. Moreover the CD40:CD154 interaction has been shown to 
play important roles in atherosclerosis [263], diabetes mellitus [264] and hyper IgM 
syndrome [265].  
 
4.2 CD40:CD154 and the Liver 
4.2.1 Introduction 
The CD40:CD154 receptor-ligand dyad has particular relevance to liver disease and hepatic 
patho-physiology including hepatic IRI. Whilst the function and role of TNFα in liver 
disease has been well studied [266], the role of CD40 and CD154 remains enigmatic. Within 
the liver, hepatocytes, cholangiocytes, HSEC and hepatic stellate cells (HSC) express CD40 
[118-120]. CD154 is expressed by CD4-positive T-lymphocytes, liver resident macrophages 
or Kupffer cells and platelets within the liver [124]. Platelets also release CD154 in a soluble 
form following their activation [253]. Thus numerous interactions between the different cells 
expressing CD40 and CD154 will have undoubted implications for the initiation and 
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progression of acute and chronic liver disease. Specifically, the consequence of the 
CD40:CD154 interaction upon hepatocytes, cholangiocytes, HSEC and HSC will shape the 
response of the liver to pro-inflammatory stimuli. The signalling pathways employed by 
these various cells in response to CD40 stimulation by CD154 are discussed below. 
 
4.3 CD40 Signaling within Different Liver Cells 
4.3.1 Hepatocytes 
At least 70% of the liver parenchyma consists of hepatocytes. As discussed in Chapter 1 the 
functional unit of the liver is the acinus (see Figure 2.1) and as a consequence hepatocytes 
derive a zonal distribution; zone 1, zone 2 and zone 3 as discussed in Chapter 3. A growing 
body of evidence suggests that the zonal distribution of hepatocytes not only influences the 
morphology of cells but also the functional capabilities of these hepatocytes [42, 169, 178, 
182, 183]. As stated above hepatocytes and in particular human hepatocytes express CD40 
upon their cell surface under basal conditions in cell culture [122]. CD40 is pivotal in 
regulating hepatic inflammatory responses. Indeed, in vitro studies show that pro-
inflammatory stimulation of human hepatoma cells lines increases cellular expression of 
CD40 [267] and in vivo studies demonstrate that CD40 is widely expressed upon human 
hepatocytes during inflammatory liver diseases [122]. Indeed CD40 positive hepatocytes are 
observed in both peri-portal (zone 1) and periveular areas (zone 3) areas during hepatic 
inflammation. Recent evidence also suggests that up-regulation of CD40 upon hepatocytes 
during hepatitis B virus infection may play a facilitating role in the pathogenesis of 
hepatocellular carcinoma [268]. Clearly, CD40 has an important role in liver 
pathophysiology. 
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Being the most abundant cell type within the liver, hepatocytes are targeted by many hepatic 
diseases including allograft rejection post liver transplantation, autoimmune liver disease and 
viral hepatitis [122, 269]. All these diseases are characterized by an inflammatory cell 
infiltrate associated with the loss of hepatocytes primarily by apoptotic mechanisms [119, 
122, 270, 271]. CD40 activation upon hepatocytes with either soluble recombinant CD40 
ligand or cross-linking monoclonal antibody initiates apoptosis, in the absence of any co-
factors, via Fas-dependent mechanisms [119, 122]. However, whether other signalling 
pathways are activated within hepatocytes following CD40 activation is not known. In 
particular, whether CD40 activation can couple to the generation of ROS or lead to the 
activation of the Janus Kinases (JAK) is not known. The regulation of the intracellular 
signalling pathways and transcription factors induced as a result of CD40 activation upon 
hepatocytes is likely to be as complex as that for other TNFα super-family members such as 
TNFα.  
It is known that following CD40 ligation and activation, the receptor is internalised within 
the cell. The cytoplasmic C terminus of the CD40 receptor, as stated above, lacks intrinsic 
kinase activity. Therefore, following CD40 activation, the adapter proteins of the TRAF 
family are recruited to the plasma membrane and are responsible for propagating signal 
transduction. The TRAF family of adapter proteins consist of six members; TRAF 1-6 [272]. 
The precise role of TRAFs and signalling events within hepatocytes remains to be fully 
ascertained. Following CD40 activation there is the sustained activation of Activator 
Protein-1 (AP-1) and the MAPKs, but not NFκB, with both AP-1 and MAPK being central 
to initiating apoptosis [157]. Furthermore, TRAF2 and TRAF6 have been postulated to 
mediate the activation of the MAPK sub-family, c-Jun NH2-terminal kinase (JNK), which 
then lead to activation of the transcription factors AP-1 and NFκB and subsequent apoptosis 
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[256, 257, 272]. However, it must be remembered that these latter experiments were not 
conducted in hepatocytes. However, both NFκB and AP-1 have been implicated in the 
control of epithelial proliferation or apoptosis [122, 252, 256, 257] with cell fate being 
determined by the level of activation of pro- or anti-apoptotic genes with NF-κB and AP-1-
sensitive promoters. Eliopoulos et al has further suggested TRAF2 is responsible for signal 
propagation with TRAF3 being a negative regulator of TRAF2 function [273]. However, 
CD40 activation can also increase the accumulation of intracellular ROS in lymphoid cell 
lines in a TRAF3 dependent manner [274]. Whether this process occurs in human 
hepatocytes is not known and the exact TRAF molecule that may regulate this process is not 
known. Obviously the accumulation of ROS secondary to CD40 activation has clear 
implications for hepatic IRI particularly in the context of the results presented in Chapter 3. 
In lymphoid cells the generation of ROS is dependent upon the recruitment of the 
flavoenzyme NADPH oxidase to the cell membrane, in a TRAF3 dependent process, which 
is then able to generate the ROS sub-species, hydrogen peroxide [274]. Therefore, the 
identity of the TRAF molecule critical for CD40 signalling in hepatocytes remains elusive. 
The possibility of different TRAFs recruitment leading to different cellular responses also 
remains plausible. 
CD40 activation ultimately leads to the activation of the MAPKs sub-families of JNK and 
p38, important regulators of cell death. AP-1 activation lie downstream of MAPK activation 
and therefore MAPK activation is likely to be a point of convergence for the CD40 
signalling pathway in hepatocytes. As Figure 4.1 illustrates the MAPK-AP-1 pathway is 
likely to be the common pathway that lies downstream of CD40 signals and is the point of 
convergence for signalling in hepatocytes and cholangiocytes (see below). Taken together, 
these studies highlight the complexities of the upstream CD40 signalling pathway and 
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suggest that CD40 can couple to AP-1 signalling pathways to regulate hepatocyte cell death. 
Whether CD40 ligation in human hepatocytes can also active the JAK-STAT signalling 
pathway, as seen in cholangiocytes (see below), remains to be ascertained. Finally, the 
CD40:CD154 signalling pathway has been shown to play important role in murine models of 
hepatic injury [19]. In these studies activation of CD40 results in hepatocyte apoptosis [19, 
169]. In summary, CD154 stimulation of CD40 plays a central role in hepatocyte death in a 
variety of liver diseases through direct and indirect pathways that may have the potential to 
be utilised as therapeutic targets in human disease. 
 
4.3.2 Cholangiocytes 
Within the liver, regulation of biliary epithelial cell or cholangiocyte survival is crucial for 
maintaining epithelial cell integrity in the biliary tract. Immune-mediated destruction of 
cholangiocytes in diseases including PBC, allograft rejection and graft versus host disease 
occurs as a result of increased apoptosis that can be mediated by CD40:CD154 [275]. As 
with hepatocytes, CD40 activation in cholangiocytes leads to induction of FasL and 
autocrine or paracrine activation of Fas and resultant apoptosis [118]. Again in an analogous 
mechanism to hepatocytes, CD40-activated Fas-dependent apoptosis requires sustained 
activation of the transcription factors of AP-1 but also the transcription factor STAT 3 to 
overcome transient, short lived NFκB activation and tip the balance away from survival 
towards apoptosis [120]. This suggests at least some conservation of signalling pathways 
between the epithelial cells derived hepatocytes and cholangiocytes. Additionally, in 
cholangiocytes, CD40 mediated apoptosis also requires the activation of the JAK2-STAT3 
pathway and the downstream activation of caspase-3 [120]. These observations suggest that 
CD40 initiates divergent signalling pathways that lead to apoptosis. Moreover, both primary 
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and malignant cholangiocytes are relatively resistant to Fas-mediated killing but show 
exquisite sensitivity to CD154, suggesting that the CD40 pathway is intact and fully 
functional in both primary and malignant cholangiocytes [118]. Furthermore, the relative 
insensitivity of cholangiocytes to Fas activation demonstrates the importance of CD40 
augmentation of Fas dependent death in these cells. Interestingly, C4 binding protein (C4BP) 
can modulate CD40:sCD154 interactions by presenting a high molecular weight multimeric 
sCD154:C4BP complex that suppresses activation of transcription factors that critically 
regulate cholangiocyte apoptosis permitting survival without proliferation [275]. Figure 4.1 
summarises the effects of CD40:CD154 upon cholangiocytes and hepatocytes. Importantly, 
these above studies have not evaluated whether CD40 activation can also drive 
cholangiocyte necrosis and whether CD40 can couple to other signalling pathways.  
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Figure 4.1 The Signalling Pathways Employed by CD40:CD154 to Induce Hepatocyte 
or Cholangiocytes Cell Death 
The likely signalling pathway initiated by CD40:CD154 in hepatocytes and cholangiocytes. 
After activation by trimeric CD154, CD40 is able to recruit members of TRAF family of 
adaptor proteins to the cell membrane. Once at the cell membrane TRAF molecules are able 
to recruit the JAK2-STAT3 complex and possibly NADPH oxidase to the plasma membrane, 
although it is likely that both these pathways are in operation in these cell types. The 
upstream signalling pathways are likely to converge at the level of the MAPKs p38 and 
JNK. Following AP-1 assembly hepatocytes and cholangiocytes undergo apoptosis via a 
FasL-Fas-dependent process or via activation of the caspases.  
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4.3.3 Human Sinusoidal Endothelial Cells (HSEC) 
The function of HSEC within the liver is diverse including the recruitment of inflammatory 
cells, immuno-regulation and biosynthesis. It has long been known that the activation of 
CD40 on endothelial cells results in increased chemokine secretion and adhesion molecule 
expression [276]. The role of CD40 ligation upon vascular endothelium has been extensively 
studied and recently reviewed [124]. In contrast to the epithelial cell types in the liver, HSEC 
do not undergo apoptosis in response to CD40 activation but instead proliferate. Although 
the mechanisms responsible for CD40-mediated proliferation of HSEC remain to be fully 
elucidated, NF B activation is likely to play a key role in regulating this process as 
demonstrated by sustained up-regulation of NF B activity in HSEC for >24 hours in 
response to CD154 [157]. In addition, inhibiting NF B leads to marked increases in 
endothelial cell apoptosis at 24 hours suggesting that this prolonged NF B activation protects 
HSEC from apoptosis. NF B also binds to promoters of pro-inflammatory genes such as IL-
8, MCP-1, ICAM-1, and vascular cell adhesion molecule (VCAM), and the sustained NF B 
up-regulation in HSECs could explain why chemokine and adhesion molecule expression are 
up-regulated in endothelial cells after CD40 ligation [262]. Endothelial cell proliferation in 
response to CD40 could be important not only in chronic hepatic inflammation but also in 
angiogenesis and tumour vascularisation where 60% of hepato-cellular carcinomas express 
high levels of CD40 [267]. CD40 ligation on HSEC can modulate other endothelial cell 
functions, including expression of adhesion molecules and chemokines in a manner similar to 
that reported with endothelial cells from other tissues [262]. This indicates that CD40 
expression by HSEC may have multiple roles beyond regulation of cell fate.  
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4.3.4 Hepatic Stellate Cells 
The liver reacts to tissue injury with a well-defined wound-healing response that is initially 
directed at removing damaged tissue through infiltration of inflammatory cells, followed by 
a second phase that is characterized by the proliferation of myofibroblasts and increased 
matrix production, and a final phase of tissue remodeling and regeneration [277, 278]. 
Whereas acute liver injury usually resolves, chronic liver injury leads to an uncoordinated 
response that is characterised by parallel occurrence of inflammation and matrix production 
with insufficient remodeling leading to progressive scarring. HSCs are at the centre of this 
fibrogenic response [268]. Upon activation, HSCs change their phenotype from retinoid-
storing quiescent cell to extracellular matrix-producing myofibroblasts. HSCs perpetuate 
their activation through autocrine and paracrine mechanisms that involve the secretion of 
pro-inflammatory cytokines and chemokines. There has been only limited studies of CD40 
function in HSC but activated HSCs do express moderate levels of CD40 when compared 
with an isotype-matched control antibody [279]. Furthermore, pro-inflammatory micro-
environments increase CD40 expression upon HSC, and in comparison to hepatocytes and 
HSEC, HSC are the major CD40-expressing cells in cirrhotic livers [279]. On fibroblasts, 
activation of CD40 by CD154 induces NFκB activation and cytokine secretion [280], and 
may up-regulate the production of extracellular matrix [281]. Ligation of CD40 on HSCs 
induces the activation of NFκB and JNK and enhanced IL-8 and MCP-1 secretion [279]. The 
secretion of MCP-1 is critically dependent upon IKK2 and TRAF2 whereas IL-8 secretion is 
TRAF2 independent [279]. Therefore, CD40 may be an important mediator of the cross-talk 
between HSCs and immune effector cells and contribute to maintaining HSCs in an activated 
state. HSC may fulfill a novel role in the regulation of immune response in the liver through 
CD40.  
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4.4 The Sources of CD154 within the Liver 
4.4.1 Platelets 
Recent evidence indicates platelets play a key role in regulating inflammatory processes via 
CD40:CD154 interactions [125]. Platelets express CD154 that is cryptic in unstimulated 
platelets but is expressed at the platelet surface upon platelet activation. When expressed at 
the platelet surface and exposed to CD40-expressing cells, the platelet-associated CD154 
triggers a variety of pro-inflammatory and pro-coagulant responses including induction of 
adhesion receptors, release of cytokines and chemokines and induction of tissue 
metalloproteinases [253]. Platelets are also a rich source of CD154 and within seconds of 
activation CD154 is translocated to the platelet surface then cleaved to produce soluble 
CD154 [253].  Platelet-associated CD154 has been shown to have immune competence both 
in vitro and in vivo, observations that open new fields of research on the potential 
implications of platelets in the immune response and auto-immune diseases [282]. Platelets 
have been implicated in preservation injury during liver transplantation and in other 
conditions including immune mediated damage in hepatitis although the mechanisms of the 
effect are poorly understood [125, 283, 284]. This finding provides a novel mechanism to 
explain the effector function of platelets in liver injury and suggests that anti-platelet therapy 
may be warranted not only to prevent reperfusion injury but also to reduce liver injury in 
chronic hepatitis and cirrhosis in which platelets are found in close proximity to hepatocytes 
[283]. Whilst important in the regulation of acute and chronic liver injury, the findings that 
platelets are adherent to hepatocytes and HSEC very early after injury suggesting that 
CD154-derived from platelets may be a regulator of acute liver injury. 
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4.4.2 Macrophages 
Macrophages are an abundant source of CD154 in the chronically inflamed liver [121, 124]. 
Indeed, the vanishing bile duct syndromes (VBDS), PBC and chronic allograft rejection and 
cholangiocyte apoptosis is associated with sustained macrophage infiltration of the liver, 
suggesting that these cells may mediate tissue damage and contribute to bile duct 
destruction. Moreover, LPS and IFNγ can induce sustained expression of CD154 on liver-
derived macrophages or Kupffer cells [121]. Co-culture of these activated liver derived 
macrophages or Kupffer cells expressing high levels of CD154 with human cholangiocytes 
induces both CD40-dependent secretion of pro-inflammatory cytokines and cholangiocyte 
apoptosis. This is likely to amplify chronic inflammation and bile duct destruction in liver 
disease. These data suggest that effective targeting strategies to antagonise CD40:CD154 
may have beneficial effects in patients suffering from chronic liver disease [121]. 
 
4.4.3 T-lymphocytes 
The vast majority of research focusing upon CD40:CD154 function in T-lymphocytes has 
centred upon their role as a co-stimulatory signal in T-lymphocyte activation. Indeed, T-
lymphocytes expression of CD154 is transient requiring the constant presence of cytokines 
such as IFNγ and contact dependent mechanisms to permit mRNA stabilisation and 
sustained expression of the protein [285]. Moreover, murine models deficient in CD40 and 
CD154 are protected from acute liver injury, with the defective priming of T-lymphocytes 
by dendritic cells being cited as the main mechanism of protection [19]. Although 
undoubtedly this mechanism plays a pivotal role in regulating liver injury, the effect of 
CD154 from platelets, macrophages and T-lymphocytes on CD40 present on the various 
liver cells cannot be underestimated. To this end, agonist anti-CD40 antibodies restore liver 
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injury following ischaemia in otherwise protected CD4-deficient mice, suggesting CD154 
may well be interacting with CD40 expressed upon hepatocytes and inducing cell death. 
FACs analysis of liver CD4-positive T-lymphocyte revealed the selective infiltration of 
effector cells, which constitutively expressed a higher level of CD154 in comparison with 
their peripheral counterparts. These findings provide evidence that CD4-positive T-
lymphocytes function in liver injury via CD154 without de novo antigen-specific activation, 
and innate immunity-induced CD40 up-regulation may trigger the engagement of 
CD154:CD40 to facilitate tissue inflammation and injury [117].  
Moreover, fulminant hepatitis of various aetiologies is characterised by a hepatic influx of 
CD154-expressing T-lymphocytes and an up-regulation of CD40 expression upon liver-
resident macrophages or Kupffer cells and hepatocytes, also implicating this pathway in the 
pathogenesis of fulminant hepatitis [286]. A significant influx of CD154-expressing T-
lymphocytes into the livers of mice treated with concavalin A was associated with markedly 
increased expression of CD40 restricted mainly to hepatocytes in damaged areas of the liver 
[286]. Furthermore, in vitro studies demonstrated that TNFα induces CD40 expression in 
hepatocytes and that subsequent activation of CD40 results in hepatocyte apoptosis mediated 
at least in part by enhanced hepatocyte expression of FasL [122]. In conclusion, CD154 
stimulation of CD40 plays a central role in hepatocyte death in fulminant and chronic liver 
injury through direct and indirect pathways that may have direct therapeutic implications in 
humans [286]. 
 
4.5 CD40:CD154 and Hepatic IRI 
As well as not understanding the response of primary human hepatocytes to hypoxia and H-
R it is not known which inflammatory cytokines and ligands may be responsible for 
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perpetuating liver injury during IRI. Many receptor-ligand dyads have been proposed to be 
of importance in regulating hepatocytes cell death during hypoxia and H-R as discussed in 
Chapter 1. The regulation of hepatic IRI by the TNFα super-family members CD40:CD154 
receptor-ligand has been the subject of intense recent research. As stated above, the recent 
demonstrations that platelets are found adherent to hepatocytes during IRI and the fact that 
CD154 is also expressed by platelets and released in a soluble form following platelet 
activation opens up many potential mechanisms by which CD154 can induce liver injury.  
Over a decade ago, the first report of the ability of CD154 to induce human hepatocyte 
apoptosis was made [122]. In 2005 Ke et al demonstrated the integral importance of 
CD40:CD154 receptor-ligand interaction in the regulation of hepatic IRI using both CD40 
and CD154 knockout murine models [19]. However, the findings of this particular study 
should be treated with caution. Liver dendritic cells, HSEC, macrophages and hepatocytes 
all express CD40. Therefore, it remains to be determined as to which cell types absence of 
CD40 is most important to the propagation of hepatic IRI.  
Given the observation that CD40 mediates human hepatocyte apoptosis, one of the 
possibilities is that CD40 expressed upon hepatocytes may be a key regulator of hepatic IRI. 
CD40 is known to mediate ROS accumulation in lymphoid cell lines were it induces 
proliferation [274], and in renal endothelial cells were it promotes apoptosis [287]. This 
suggests that CD40 activation by CD154 may mediate hepatocyte apoptosis through a 
similar mechanism. An abundance of direct and indirect evidence also suggests that the 
CD40:CD154 interaction might generate ROS and oxidative stress in vascular endothelial 
cells [124]. Therefore it is possible that CD40:CD154 mediated generation of ROS might 
play a significant role in modulating hepatic IRI. Indeed it is well appreciated that in 
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arthrosclerosis, CD40:CD154 forms a common link between oxidative stress and 
inflammation [124]. 
One of the mechanism by which ROS may mediate apoptosis is by the activation of the 
MAPK. MAPKs are evolutionarily conserved in all eukaryotic cells and consist sequentially 
of MAP3K, MAP2K/MEK and MAPK. ROS can activate a MAPK3K known as Apoptosis 
Signalling Kinase-1 (ASK1) [288]. ASK1 can then activate the MAP2K/MEK 4/7 and 3/6 
which stimulate the JNK and p38 respectively [288]. Both JNK and p38 have been shown to 
be important in regulation of hepatic IRI [289-291]. However, injury to hepatocytes during 
IRI is not limited to apoptosis. Hepatocyte necrosis is also seen during and after IRI [99]. 
Therefore, the consequence of CD40 activation upon human hepatocytes forms an important 
question with regard to liver patho-physiology.  
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4.6 Material & Methods  
4.6.1 In Vitro Model of hypoxia and H-R injury 
The same model of in vitro hypoxia and H-R that was described in Chapter 3 was used for 
the experimental data presented below. In experiments involving the NADPH oxidase 
inhibitor, DPI; JNK inhibitor SP600125, or p38 inhibitor, PD169316, all reagents were made 
fresh as stock solutions and added using the correct dilutional factor to the relevant 
experimental wells. Specifically, 10 µg DPI (Sigma) was dissolved in molecular grade 
DMSO, 10 µg rotenone (Sigma) was dissolved in chloroform (Sigma), 50 µg SP600125 
(Sigma) was dissolved in DMSO and 50 µg PD169316 (Sigma) was dissolved in DMSO and 
were diluted appropriately to give working concentrations of 10 µM, 2 µM, 10 μM and 10 
μM respectively. In experiments using inhibitors/antioxidants, solvent alone wells were used 
to control for vehicle effects. In experiments using inhibitors/antioxidants hepatocytes were 
pre-treated with agents for up to 4 hours before placement of the cells into normoxia and 
hypoxia. For H-R experiments fresh inhibitor/antioxidants were added at the time of 
placement into reoxygenation. Recombinant human soluble CD154 (1µg/mL, Enzo Life 
Sciences, UK) and 1 µg/mL Cross-linker for Ligands (Enzo Life Sciences, UK) were added 
to cells at the time of entry into hypoxia or H-R. Where cells had been pre-treated with 
inhibitors/antioxidants CD154 and Cross-linker for Ligands were added after 4 hours. 
 
4.6.2 Determination of Human Hepatocyte CD40 Expression and FasL Expression 
Following appropriate incubation of human hepatocytes within normoxia, hypoxia and H-R, 
cells were trypinised and washed in FACs buffer (Phosphate-buffered saline (PBS) pH 7.2 
with 10% v/v heat inactivated foetal calf serum (Gibco). For CD40 expression, cells were 
then incubated with anti-human CD40 antibody that was conjugated to the allophycocyanin 
 144
(APC) fluorophore (1:100 dilution; Caltag, UK) for 45 min at 40C. Mouse IgG1-APC (1:100 
dilution; Caltag, UK) was used as a negative control. For FasL expression, cells were 
incubated with anti-human FasL antibody that was conjugated to the FITC fluorophore 
(1:100 dilution; Abcam, UK) for 45 min at 40C. Mouse IgG2a-FITC (1:100 dilution; Abcam, 
UK) was used as a negative control.  Following this cells were washed in FACs buffer and 
resuspended in PBS, pH 7.2. At least 20,000 events were recorded within the gated region of 
the flow cytometer for each human hepatocyte cell preparation in each experimental 
condition. Only the cells within the gated region were used to calculate MFI as described in 
Chapter 3. 
 
4.6.3 Determination of Human Hepatocyte ROS Accumulation, Apoptosis and Necrosis 
ROS production, apoptosis and necrosis were determined using a three-colour reporter assay 
system as described in Chapter 3. In the experiments outlined below autophagy was not 
assessed. At least 20,000 events were recorded within the gated region of the flow cytometer 
for each human hepatocyte cell preparation in each experimental condition. Only the cells 
within the gated region were used to calculate MFI. 
 
4.6.4 Platelet isolation and activation 
Platelets were isolated by modifying a previously published method from fully consenting 
healthy individuals [292]. All adults were healthy volunteers that had not been taking any 
anti-platelet therapy. Following venesection platelet-rich plasma (PRP) was prepared by 
centrifuging 5 mL of heparinised blood for 5 min at 300 x g. The platelet layer was a distinct 
yellow layer within the vacutainer. Following this the PRP was withdrawn by aspiration. 10 
μl of the PRP was then withdrawn and added to 10 μl of trypan blue. Following 
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quantification the platelet count was adjusted to 1 x 106 platelets/mL in Williams E media. 
Platelets were then seeded at the aforementioned density onto plastic plates. Following 30 
min incubation at room temperature the platelets had settled, become activated and spread to 
form a confluent monolayer. The Williams E media was then aspirated and passed through a 
0.2 µm syringe filter. This media was now arbitrarily named platelet-conditioned media 
(PCM). The PCM was aliquoted into Eppendorfs and frozen at -700C until required. Media 
was thawed only once and added to cells as required. 
 
4.6.5 Determination of Soluble CD154 and Immunomagnetic Depletion of CD154 from 
PCM. 
To confirm the presence and quantity of CD154 in the PCM, a commercial sandwich ELISA 
kit was used to quantify levels of CD154 (Peprotech, CA, USA, Catalogue Number 900-
K145). Briefly, the capture antibody was made in PBS at a concentration of 1 μg/ml. This 
was then aliquoted onto the relevant wells in a 96-well plate. Following incubation at room 
temperature unbound antibody was washed off. Wells were then blocked using 5% BSA 
followed by addition of either control, standard or sample solution. Following incubation the 
biotinylated detection antibody was added. After incubation a solution of avidin-peroxidase 
conjugate was added and excess washed off. Finally the substrate of 2,2’-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid) (ABTS) was added and after a 5 minute period the 
plate read at 405 nm with a 650 nm wavelength correction. A standard curve was 
constructed and used to determine the concentration of soluble CD154 in the samples. 
Platelet-derived CD154 was removed from PCM via immuno-magnetic depletion. For 
immunomagnetic depletion of CD154, anti-human CD154 antibody (1 µg/mL; Abcam, UK) 
was complexed to pan-mouse IgG magnetic Dynabeads (Invitrogen, Paisley, UK) for 90 min 
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at room temperature. This ensured that the CD154 antibody was adequately complexed to 
the Dynabeads. Following this, the antibody-magnetic bead complexes were extensively 
washed in PBS, pH 7.2. Complexes were then incubated with PCM for a further 90 min at 
room temperature with continuous agitation. Finally, magnetic beads were retrieved from 
solutions and this media was subsequently used in experiments as CD154-depleted PCM. 
The content of soluble CD154 within CD154-depleted PCM was determined using the 
method listed above.  
 
4.6.6. Statistical Analysis 
All data are expressed as mean ± S.E. Statistical comparisons between groups were analysed 
by Student’s t test. All differences were considered statistically significant at a value of 
p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 147
4.7 Results  
4.7.1 CD40 Expression in Human Hepatocytes during Hypoxia and H-R 
Primary human hepatocytes constitutively expressed CD40 on the cell membrane in cell 
culture as previously reported [122]. Figure 3.7 demonstrates that ROS increases during 
hypoxia and H-R but this increased oxidative stress did not increase CD40 expression upon 
human hepatocytes in vitro (Figure 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 148
 
Figure 4.2 CD40 Expression upon Human Hepatocytes during Hypoxia and H-R 
(A) Demonstrates a representative flow cytometry plot of CD40 expression upon primary 
human hepatocytes during normoxia, hypoxia and H-R. The plot on the left hand side 
represents a typical FS versus SS plot of primary human hepatocytes. The FS versus SS plots 
shown is from the H-R sample of a liver preparation but similar plots were obtained during 
normoxia and hypoxia.  
(B) Bar chart with the pooled data of three separate experiments illustrating the level of 
CD40 expression on primary human hepatocytes. Data is expressed as MFI mean ± S.E. 
(n=4).  
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4.7.2 CD40:CD154 Stimulates ROS Accumulation in Human Hepatocytes in an 
NADPH-dependent Manner and Regulates Apoptosis and Necrosis 
Intracellular ROS accumulates in hypoxic human hepatocyte that is then further increased 
during H-R as demonstrated in Chapter 3. Whether CD154 can augment human hepatocyte 
ROS production during normoxia, hypoxia and H-R is not known. Trimeric recombinant 
human CD154 significantly increased intracellular ROS accumulation within human 
hepatocytes during normoxia and H-R but not hypoxia. CD40:CD154 has been shown to 
mediate ROS accumulation via TRAF-dependent recruitment of the flavoenzyme NADPH 
oxidase in lymphoid cell lines [274]. Therefore the specific NADPH oxidase inhibitor DPI 
was used to assess the involvement of this pathway in ROS generation by human 
hepatocytes. DPI reduced hepatocyte CD154 mediated ROS production during normoxia, 
hypoxia and H-R (Figure 4.3 & Appendix IV).  
The increased level of intracellular ROS induced by CD154 stimulation, during normoxia 
and H-R, increased human hepatocyte apoptosis and to a lesser extent necrosis (Figure 4.4 & 
Appendix IV) and this was reduced by pre-treatment of human hepatocytes with DPI. 
CD154 also significantly increased human hepatocyte necrosis during normoxia and H-R 
that was inhibited by DPI demonstrating that the CD40:CD154:ROS signalling pathway is 
NADPH-dependent and results in hepatocyte death in the form of apoptosis and necrosis. 
Mitochondrial ROS has been implicated in hepatocyte apoptosis during hypoxia and H-R 
[105] and as demonstrated in Chapter 3 mitochondrial ROS is the principal form of ROS in 
human hepatocytes and leads to cell death. Therefore the effect of inhibiting mitochondrial 
ROS production upon CD154 mediated apoptosis with the complex I inhibitor, rotenone, 
was assessed. Inhibiting mitochondrial ROS production during normoxia and H-R did not 
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reduce human hepatocyte apoptosis in response to CD154 treatment but did reduce apoptosis 
during hypoxia (Figure 4.5 and Appendix IV). 
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Figure 4.3 CD40:CD154 Regulates ROS Accumulation within Human Hepatocytes in a 
NADPH Oxidase Dependent Manner during Normoxia and H-R  
The bar chart illustrates the pooled data of three separate experiments demonstrating the 
effects of CD154 and CD154+DPI upon human hepatocytes ROS accumulation. Data is 
expressed as MFI and readings are based upon values taken from cells within the gated 
region shown in Figure 3.7. Data is expressed as mean ± S.E. (*p<0.01 relative to basal, 
**p<0.05 relative to basal, ***p<0.001 relative to CD154). (n=3).   
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Figure 4.4 CD40:CD154 Mediated ROS Accumulation Induces Human Hepatocyte 
Apoptosis and Necrosis during Normoxia and H-R  
Demonstrates bar charts with the pooled data of three separate experiments illustrating the 
effects of CD154 and CD154+DPI upon human hepatocytes apoptosis and necrosis during 
normoxia, hypoxia and H-R. Data is expressed as increase/decrease relative to basal, where 
basal refers to the level of apoptosis or necrosis during normoxia alone. Data is expressed as 
mean ± S.E. (**p<0.01 relative to basal, *p<0.05 relative to basal, ***p<0.05 relative to 
CD154, ****p<0.05 relative to basal). (n=4).  
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Figure 4.5 The Effect of Mitochondrial ROS Inhibition upon CD40:CD154 Mediated 
Human Hepatocyte Apoptosis during Normoxia, Hypoxia and H-R 
Human hepatocytes were treated with CD154 or CD154 following pre-treatment with 
rotenone (Rot) during normoxia, hypoxia and H-R. The percentages of cells staining with 
both the ROS probe DCF and apoptotic marker, Annexin-V, were assessed by flow 
cytometry. The percentage of human hepatocytes that stain for both DCF and Annexin-V are 
shown in parentheses. Data are representative of 3 separate experiments (**p<0.05 relative 
to basal, *p<0.05 relative to CD154). (n=4).  
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4.7.3 JNK and p38 Regulate Apoptotic but not Necrotic Cell Death in Human 
Hepatocytes 
ROS accumulation in human hepatocytes induced by CD40:CD154 clearly resulted in cell 
death but whether this was associated with involved the MAPKs was investigated. MAPKs 
consist of three sequentially activated kinase modules, namely mitogen-activated protein 
kinase kinase kinases (MAPKKK/MAP3K) followed by the mitogen-activated protein 
kinase kinases (MAPKK/MEKK) and finally the MAPKs. The MAPKs superfamily consists 
of three separate sub-families; extra-cellular regulated protein kinase (ERK), c-Jun N-
terminal kinase (JNK) and p38. ERK is generally involved in the regulation of cell 
proliferation and differentiation, whereas JNK and p38 are involved in the regulation of cell 
death [291].  
Unfortunately, primary human hepatocytes are not amenable to siRNA transfection or 
protein labelling. Therefore to investigate the effects of JNK and p38 inhibition upon 
CD40:CD154:ROS mediated human hepatocyte cell death specific JNK and p38 inhibitors 
were used. Inhibition of JNK and p38 in hepatocytes using the specific inhibitors SP600125 
and PD169316 had no effect on ROS accumulation during normoxia, hypoxia and H-R 
whereas they significantly decreased CD40:CD154 mediated human hepatocyte apoptosis 
during normoxia, hypoxia and H-R (Figure 4.6 & Appendix V). Inhibition of p38 had a 
greater effect on hepatocyte apoptosis than JNK inhibition. Neither inhibitor reduced CD154 
mediated hepatocyte necrosis under any of the experimental conditions (Figure 4.6). This 
suggests that CD40:CD154 mediated human hepatocyte apoptosis during normoxia and H-R 
is ROS, JNK and p38-dependent whilst necrosis is ROS-dependent but MAPK-independent.  
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Figure 4.6 The Regulation of Human Hepatocyte Apoptosis but not Necrosis by JNK 
and p38 
Bar charts with the pooled data of three separate experiments illustrating the effects of both 
SP600125 and PD169316 upon CD40:CD154 mediated human hepatocyte apoptosis and 
necrosis during normoxia, hypoxia and H-R. Data are expressed as increase/decrease relative 
to basal, where basal refers to the level of apoptosis or necrosis during normoxia alone. Data 
are expressed as mean ± S.E. (**p<0.01 relative to basal, *p<0.05 relative to basal, 
***p<0.05 relative to CD154, ****p<0.05 relative to basal). (n=3).  
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4.7.4 CD40:CD154:NADPH oxidase Stimulate Hepatocyte Fas ligand Expression  
Fas is a cell surface receptor of the TNF receptor superfamily which, when activated by 
FasL, induces apoptosis on a wide range of cells including hepatocytes [293]. Previous 
studies have reported that CD40 activation on human hepatocytes results in Fas-mediated 
apoptosis. Whether similar phenomenon operates during hypoxia or H-R alone or in 
association with CD154 was investigated. Neither hypoxia nor H-R increased hepatocyte 
cell surface FasL expression (Figure 4.7 & Appendix V). However, CD40:CD154 increased 
FasL expression during hypoxia and H-R, with a greater effect during hypoxia. Inhibiting 
NADPH oxidase function with DPI reduced CD40:CD154 mediated FasL expression during 
hypoxia and H-R, with a greater effect noted during H-R.  
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Figure 4.7 CD40:CD154 Mediated FasL Expression upon Human Hepatocytes during 
H-R 
Demonstrates a representative flow cytometry plot of FasL expression on primary human 
hepatocytes during normoxia, hypoxia and H-R. Hypoxia and H-R did not increase the 
expression of FasL upon human hepatocytes. CD154 stimulation of human hepatocytes did 
increase FasL expression upon human hepatocytes during hypoxia and H-R. This increase 
was partially inhibited by pre-treatment of cells with DPI. Composite data is shown in 
Appendix V.  (n=3).  
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4.7.5 Platelet-derived Soluble CD154 Mediates Hepatocyte Apoptosis and Necrosis 
Platelets are the source for 95% of circulating soluble CD154 [283] and may be found in the 
liver parenchyma during inflammatory processes. Whether activated platelets may be a 
potential source of functionally active CD154 during hypoxia and H-R was investigated. 
Immuno-magnetic depletion reduced soluble CD154 released by activated platelets by > 
70% (Platelet Conditioned Media (PCM) soluble CD154 concentration 2251 ± 310 pg/mL; 
CD154-depleted PCM CD154 concentration 590 ± 79 pg/mL) (Figure 4.8). PCM increased 
hepatocyte intracellular ROS accumulation during normoxia, hypoxia and H-R (Figure 4.9). 
When CD154 was depleted from PCM, intracellular ROS accumulation was significantly 
reduced during H-R. PCM increased human hepatocyte apoptosis during H-R mirroring the 
increasing in intracellular ROS (Figure 4.10). However, in line with the decrease in ROS 
seen during H-R, CD154-depleted PCM decreased human hepatocyte apoptosis during H-R 
(Figure 4.10).  
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Figure 4.8 PCM and CD154-depleted PCM Soluble CD154 Content 
Platelets were isolated from healthy volunteers and plated onto plastic for 30 minutes to 
allow activation. The supernatants were then collected and the content of soluble CD154 
within the supernatants was assessed. An immuno-magnetic technique was used to deplete 
the soluble CD154 within the supernatants. Sandwich ELISA was used in all cases to assess 
the content of soluble CD154. Data are expressed as the mean ± S.E. (n=8).   
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Figure 4.9 The Effects of PCM and PCM-depleted CD154 upon Human Hepatocyte 
ROS Production 
Demonstrates representative flow cytometry plots to illustrate the effect of PCM (hatched 
red) and PCM CD154-depleted (solid grey) upon human hepatocyte ROS accumulation 
during normoxia, hypoxia and H-R. The gate used to analyse primary human hepatocytes is 
the same as that shown in Figures 3.7. The vertical ellipse marks the area of interest within 
the flow cytometric plots. (n=4). 
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Figure 4.10 The Effects of PCM and PCM-depleted CD154 upon Human Hepatocyte 
Apoptosis during Normoxia, Hypoxia and H-R 
Human hepatocytes were treated with PCM or PCM CD154-depleted during normoxia, 
hypoxia and H-R. The percentages of cells staining with both the ROS probe DCF and 
apoptotic marker, Annexin-V, were assessed by flow cytometry. The percentage of human 
hepatocytes that stain for both DCF and Annexin-V are shown in parentheses. Data is 
representative 3 separate experiments (*p<0.05 relative to basal, **p<0.05 relative to PCM). 
(n=3).  
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4.8 Discussion 
Tissue hypoxia is a key feature of hepatic inflammation and disease and one of the central 
regulators of hepatic injury and cell death is the accumulation of intracellular ROS [40, 42, 
43]. Building upon the model presented in Chapter 3 the data above details that ROS 
accumulation in human hepatocytes during hypoxia and H-R is increased by CD154 
mediated activation of human hepatocyte CD40. This augmented ROS production induced 
by CD154 ultimately results in increased human hepatocyte cell death. This link between 
CD40 activation, intracellular ROS generation and cell death has implications for other 
inflammatory diseases characterised by local hypoxia and pro-inflammatory 
microenvironment such as liver cirrhosis.  
CD40:CD154 receptor-ligand interactions have been associated with parenchymal injury 
during hypoxia and H-R in many organs [19, 125, 294] and disruption of CD40:CD154 
signalling in mice improves liver function following hypoxia [19]. However until now it was 
thought that CD40:CD154 mediates its actions through effects on T-lymphocyte priming 
whereas the data presented above suggests another distinct mode of action through direct 
effects on hepatocyte survival. Previous reports have shown that CD40 activation mediates 
Fas dependent apoptosis in human hepatocytes through induction of autocrine FasL 
expression [122]. The new data demonstrates that CD40:CD154 can also mediate human 
hepatocyte apoptosis and necrosis in a NADPH Oxidase:ROS-dependent manner. This 
introduces a previously unknown CD40 dependent pathway to cell death and implicates 
CD40 in the regulation of cell survival during tissue hypoxia and H-R.  
This data also supports and further emphasises an important role for intrinsic ROS 
accumulation in human hepatocytes as opposed to the current model which suggests that 
ROS is derived only from leukocytes [169]. CD40 activation did not increase ROS 
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accumulation or cell death in human hepatocytes during hypoxia. Although not evaluated in 
the data presented here several previous studies have shown that during ischaemic/hypoxic 
conditions hepatocytes increase intracellular antioxidant defences principally in the form of 
glutathione [16]. This may also explain why FasL has little effect upon increasing human 
hepatocyte apoptosis during hypoxia (see below). Furthermore, hypoxia alone did not 
increase hepatocyte cell surface CD40 implying that the lack of effect of CD154 during 
hypoxia was probably a consequence of the modulation of intracellular signalling pathways 
by antioxidants rather than changes in CD40 receptor bioavailability. 
The increases in intracellular ROS induced by CD154 within human hepatocytes are 
dependent upon NADPH Oxidase. This finding is consistent with previous studies 
implicating NADPH Oxidase in intracellular ROS accumulation. Studies in WEHI 231 cells 
and endothelial cells have shown that following activation, CD40 recruits NADPH Oxidase 
to the plasma membrane via a mechanism involving TRAF3 [274, 295-297]. Once at the 
plasma membrane the p40phox subunit of NADPH oxidase can generate ROS leading to 
activation of a number of downstream cell death signalling pathways (Figure 4.13). In 
primary human hepatocytes CD40:NADPH oxidase:ROS initiated apoptosis and to a lesser 
extent necrotic cell death. The mode of hepatocyte cell death stimulated by hypoxia remains 
controversial and the data presented would corroborate this notion. Both apoptosis and 
necrosis have been implicated as the primary form of cell death during IRI [99] and within 
transplant models consistent with our findings and in support of Lemasters proposal that a 
common mediator regulates both forms of cell death during hypoxia and H-R [175]. On the 
basis of the data presented above it is clear that CD40:CD154 activation in hepatocytes has 
at least three downstream consequences 1) initiation of apoptosis mediated via ROS 2) 
initiation of apoptosis mediated via FasL induction and 3) necrosis.  
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CD40 activation results in apoptotic death in many cells of epithelial lineage [120, 122]. 
Indeed, CD40 activation induces human hepatocyte apoptosis via up-regulation of FasL 
expression and subsequent Fas-mediated apoptosis [122]. Moreover, in human hepatocytes, 
it is the sustained activation of AP-1 and MAPKs, and not NFκB, which is central to 
initiating apoptosis [157]. A similar signalling pathway has been reported in mediating 
cholangiocytes apoptosis after CD40 ligation [119]. Additionally, in cholangiocytes, CD40 
mediated apoptosis also requires the activation of the JAK2-STAT3 pathway and the 
downstream activation of caspase-3 [120]. However, the data presented, for the first time, 
implicates ROS in this process of epithelial and specifically human hepatocyte, apoptosis. 
ROS can activate the MAPKs sub-families of JNK and p38, important regulators of cell 
death. Specifically, ROS can activate the MAP3K, ASK1 resulting in phosphorylation of 
MEK 3/6 [298] and MEK 4/7 [298] which respectively activate p38 and JNK although this 
has not conclusively been shown here. Inhibition of p38 [290] and JNK [289] improves 
hepatocyte viability after hypoxia and during H-R in rodent models. CD40:CD154 mediated 
human hepatocyte apoptosis is reduced by JNK inhibition and prevented by p38 inhibition. 
The precise mechanism of JNK mediated apoptosis is controversial. JNK can act upstream 
of mitochondria by activating the pro-apoptotic Bcl2 family [299] and also increases 
turnover of the anti-apoptotic protein c-FLIP [300]. p38 is thought to mediate apoptosis via 
phosphorylation of Bcl2 family members [301] and CD40-mediated-NADPH oxidase 
generated ROS is upstream of p38 activation in WEHI 231 cells [274]. Thus a mechanistic 
link between CD40:CD154 mediated ROS generation, MAPK activation and cell death is in 
operation in human hepatocytes during hypoxia and H-R. Taken together, these studies 
highlight the complexities of the upstream CD40 signalling pathway and suggest that CD40 
can couple to at least ROS and AP-1 signalling pathways to regulate apoptosis. Whether 
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CD40 ligation in human hepatocytes can also activate the JAK-STAT pathways, as seen in 
cholangiocytes, remains to be ascertained.  
CD40 ligation by CD154 is known to increase FasL expression resulting in 
autocrine/paracrine Fas-mediated apoptosis in human hepatocytes [122]. However, in 
contrast to in vivo studies [302], hypoxia and H-R did not result in increased hepatocyte 
FasL expression in the presented in vitro model of IRI. CD154 induced cell surface 
expression of FasL in human hepatocytes and this was in part dependent on NADPH oxidase 
particularly during H-R. This suggests that other mechanisms are involved in regulating 
ROS-independent FasL expression. As discussed above, although CD40:CD154 did not 
increase ROS during hypoxia, it did increase FasL expression although without a 
concomitant increase in apoptosis. However, the inhibition of mitochondrial ROS 
significantly reduced hepatocyte apoptosis during hypoxia. Fas mediated apoptosis in 
hepatocytes requires the downstream accumulation of mitochondrial ROS [303] and together 
with likely increases in hepatocyte antioxidant levels during hypoxia explains why increased 
FasL expression was seen in the absence of apoptosis in response to CD40 activation [42, 
304]. This also suggests that different apoptotic signalling pathways may be initiated in 
response to CD40 activation under different conditions in distinct microenvironments.  
Hypoxia, which precedes reoxygenation during preservation of an organ allograft for 
transplantation, can increase FasL expression thereby initiating liver damage before ROS 
generation during reperfusion has occurred. FasL is also increased on hepatocytes in 
chronically inflamed livers, a situation characterised by tissue hypoxia.  Thus the mechanism 
described above is likely to operate in the chronic inflammation where large numbers of 
CD154 expressing effector cells can activate CD40 in a hypoxic environment [130].  
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As demonstrated in Chapter 3, ROS generation can induce human hepatocyte necrosis 
during hypoxia and H-R and hepatocyte necrosis has been induced experimentally during 
hypoxia followed by reoxygenation [175]. ROS generated by CD40:CD154 not only induces 
hepatocyte apoptosis but also necrosis during normoxia and H-R. This process is NADPH 
oxidase dependent as shown by the decrease in necrosis in the presence of DPI but in 
contrast to CD154-mediated hepatocyte apoptosis, necrosis is MAPK-independent. This 
suggests that NADPH oxidase generated ROS induces divergent signalling pathways leading 
to both forms of cell death (see Figure 4.13).  
CD154:CD40:ROS stimulates the activation of JNK and p38, which subsequently leads to 
cell death. The JAK2-STAT3 signalling pathway also regulates CD40 mediated apoptosis 
[120] that may also be activated by ROS. In addition, FasL is up-regulated following CD40 
activation. Therefore CD40 regulates multiple death signalling pathways in liver epithelial 
cells. 
Macrophages and T-lymphocytes are an abundant source of CD154 in the chronically 
inflamed liver [121] and are also important mediators of liver injury during hepatic IRI. 
However, platelets are also a rich source of CD154 [305] and within seconds of activation 
CD154 is translocated to the platelet surface then cleaved to produce soluble CD154.  
Platelets have been implicated in preservation injury during liver transplantation and in other 
conditions including immune mediated damage in hepatitis although the mechanisms of the 
effect are poorly understood [284, 306, 307]. In the data presented here activated platelets 
secrete functional CD154 that is capable of inducing ROS accumulation in human 
hepatocytes during H-R leading to hepatocyte apoptosis. This finding provides a novel 
mechanism to explain the effector function of platelets in liver injury and suggests that anti-
platelet therapy together with anti-oxidants may be warranted not only to prevent reperfusion 
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injury but also to reduce liver injury in chronic hepatitis and cirrhosis in which platelets are 
found in close proximity to hepatocytes [283, 308]. Although these findings suggest that 
platelets are a major source of CD154 capable of inducing injury as previously suggested 
[125] CD154 depletion from platelet-conditioned medium reduced but did not abolish 
human hepatocyte apoptosis suggesting either that there was residual CD154 activity in the 
PCM or that platelets release other active mediators of apoptosis [284].  
In conclusion, these findings support the role of CD40:CD154 mediated ROS in mediating 
hepatocyte cell death by both apoptosis and necrosis in the hypoxic liver microenvironment. 
The ability of platelets as well as infiltrating T-lymphocytes and macrophages to deliver 
functional CD154 to hepatocytes suggests several potential mechanisms through which 
hepatocyte CD40 can be activated in the inflamed and hypoxic liver.  The work supports the 
use of therapeutic intervention with anti-platelet and anti-oxidant therapy in liver disease.  
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Figure 4.11 Proposed Mechanism of Regulation of Human Hepatocyte Cell Death by 
CD40:CD154 
During normoxia (blue arrows) activation of CD40 expressed upon human hepatocyte by 
CD154 results in the translocation of the TRAF adaptor molecules to the cell membrane. The 
TRAF molecules are then responsible for the recruitment of the flavoenzyme NADPH 
Oxidase to the CD40:TRAF complex. Here NADPH Oxidase can induce the production of 
ROS, primarily in the form of hydrogen peroxide. The NADPH Oxidase inhibitor DPI can 
inhibit this process. The resultant accumulation of ROS can result directly in necrotic cell 
death or it can activate the MAPK members, JNK and p38, to induce human hepatocyte 
apoptosis. However, during hypoxia (red arrows) CD40 activation on human hepatocytes 
does not result in ROS accumulation but can induce FasL expression via mechanisms that 
NADPH Oxidase-dependent and ROS-independent (dotted black line). This increased FasL 
expression can result in autocrine (green arrow) and/or paracrine (orange arrows) Fas-
mediated apoptosis. Due to the increases in intracellular antioxidants levels during hypoxia 
CD154 does not increase apoptosis. However, mitochondrial ROS does contribute to 
apoptosis during hypoxia.  During H-R, CD40 activation can lead to NADPH Oxidase-ROS-
JNK/p38 dependent apoptosis, NADPH Oxidase-ROS-dependent necrosis and NADPH 
Oxidase:ROS:FasL expression with resultant Fas-mediated apoptosis. Figure 4.13 highlights 
the importance of local microenvironment in shaping the effects of CD40:CD154.    
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CHAPTER 5 - THE IN VIVO REGULATION OF HEPATIC IRI BY CD40 AND 
CD154 
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5.1 Introduction 
As discussed in Chapter 1, hepatic IRI is an antigen independent pro-inflammatory process. 
As demonstrated in Chapter 3 and 4 intracellular ROS generation is an important regulator 
and mediator of hepatocyte injury in vitro. Indeed, in in vitro conditions at least, CD40 
activation upon human hepatocytes can augment intracellular ROS during hypoxia and H-R 
with resulting apoptotic and necrotic cell death. However in vivo hepatocytes will be subject 
to a different inflammatory microenvironment including exposure to and interaction with a 
variety of cell types. As discussed in Chapter 1 of these cells T-lymphocytes and in 
particular CD4-positive T-lymphocytes are central to the development of liver IRI. 
Furthermore, it has postulated that prolonged liver ischaemia results in an allograft becoming 
more susceptible to T-lymphocyte mediated immune responses [309].  
The first study to demonstrate the infiltration of T-lymphocytes into the liver after ischaemia 
was reported in the early 1990’s. Although this study by Zwacka et al demonstrated the 
presence of T-lymphocytes in the liver [310] the precise role of this cell was not fully 
understood until more recent studies demonstrated the central role of T-lymphocytes in 
mediating the liver injury seen after IRI. The role of T-lymphocytes is further emphasised by 
the reduction in liver injury observed after OLT by specific T-lymphocyte targeted therapies 
such as cyclosporine and tacrolimus [311]. More recent studies have assessed the effects of 
modulating specific T-lymphocytes signalling pathways to elucidate the important regulators 
hepatic IRI. These studies have demonstrated that disruption of the T-lymphocyte co-
stimulatory signalling pathways CD40:CD154 [19] and B7:CD28 [312] all ameliorate 
hepatic IRI. The reduced levels of liver injury reported within these studies were associated 
with reduced T-lymphocyte infiltration into the liver, reduced levels of pro-inflammatory 
cytokine production and increased anti-apoptotic factors [19]. Hence, the role of T-
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lymphocytes derived CD28, CD154 and IFNγ in liver IRI has been demonstrated in both 
mouse and rodent models [313]. Furthermore, CD28 [314] and CD154 [19] are integral in 
activating the pro-inflammatory response seen during liver IRI and are central to triggering 
hepatocellular injury. Indeed, murine models of in vivo liver IRI utilising CD154 and CD40 
knockout mice have demonstrated almost complete protection of livers from IRI. Moreover, 
wild-type mice used in the same studies treated with anti-CD154 antibody or cytotoxic T-
lymphocyte antigen-4 (CTLA-4) immunoglobulin were also protected from IRI [19, 314]. 
These effects were principally ascribed to the inhibition of CD4-positive T-lymphocytes 
function within the liver without the requirement of de novo antigen-specific activation that 
is dependent upon CD40:CD154 signalling [117].  
The studies discussed above have exclusively focused upon the role of CD40:CD154 
signalling in T-lymphocytes but as discussed in Chapter 4 the expression of CD40 and 
CD154 within the liver is relatively diverse. Therefore, whilst the interaction of 
CD40:CD154 upon the surface DC and T-lymphocytes respectively is undoubtedly 
important in the propagation of liver injury following ischaemia the role CD40 expressed 
upon hepatocytes is yet to be firmly established. Chapter 4 demonstrates that CD40 
activation upon human hepatocytes leads to ROS accumulation and subsequent cell death. 
Whether CD40 activation upon human hepatocytes in vivo results in oxidative stress is not 
known. Investigating this in vivo is problematic as murine CD40 and CD154 knockout 
models ensure the complete absence of all liver expression of the receptor and ligand and 
therefore the cell type that is of importance with regard to the regulation of liver injury is 
difficult to assess. Selective gene or cell deletion does offer the opportunity to investigate the 
role of specific cells in a particular pathological process. However, before such techniques 
can be utilised a satisfactory model of liver IRI is required to be established.  
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5.2 Methods & Materials 
5.2.1 Murine Model of Partial Hepatic IRI 
Wild-type C57 Black 6 (C57/B6) mice were anesthetised with isofluorane inhalation. Once 
the animal was anesthetised, the limbs of the animal were immobilized by taping the 
animal’s legs and arms to a clean flat surface with the abdomen facing up. The abdomen was 
then shaved up to the xiphoid process and was cleaned by swabbing the skin with a 70% 
ethanol solution. Excess hair was removed prior to the commencement of the surgical 
procedure.  
Sharp dissection was then used to open the abdomen at the midline to expose the abdominal 
contents. This incision was then extended so that the entire abdomen beginning at the 
xiphoid process to the pelvic bones was opened (Figure 5.1). Custom made retractors were 
then used to retract each half of the abdominal wall and secured to produce elevation of the 
abdomen and aid in expose of the liver and pull the abdominal cavity open (Figure 5.1).  
Two moistened cotton swabs were utilised to carefully externalise the murine intestines as 
gently as possible from the cavity and place them on pre-moistened (sterile 0.9% saline) 
gauze to expose the portal vein and associated structures. The quadrate lobe was carefully 
dissected from its attachment with the left lateral lobe by using blunt dissection with a pair 
of fine forceps. The aforementioned retractors were re-positioned to elevate the median and 
left liver lobes against the diaphragm to identify the connection between the left lateral and 
quadrate lobes. This allowed the direct visualisation of the portal triad (portal vein, hepatic 
artery and bile duct) (Figure 5.2). At this point an atraumatic clip was placed across the 
portal vein, hepatic artery, and bile duct just above the branching to the right lateral lobe 
(Figure 5.2).  
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Figure 5.1 The Opening the Murine Abdomen Prior to Clamping the Hepatic Triad 
(A) Following isofluorane inhalation the animal was immobilised by taping the arms and tail 
to a clean surface. The abdomen was clean and shaved and opened from the xiphoid to the 
pelvis. This allowed inspection of the intra-abdominal contents. (B) Following laparotomy 
retractors are placed under the abdominal muscles to aid exposure of the liver and allow 
subsequent liver ligament dissection.  
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Figure 5.2 Clamping of the Portal Triad in the Murine Liver 
Following opening of the abdomen the portal triad was isolated using blunt dissection. With 
the portal triad isolated atraumatic clips were used to stop vascular inflow into the superior 
to lobes of the murine liver while the inferior two lobes of the liver remained perfused. This 
is illustrated in the above photograph.  
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The median and left lateral lobes (approximately 70% of the murine liver mass) rapidly 
showed significant blanching. This was manifest visually as a change from the normal 
reddish brown colour of the liver to a pale brown or cream colour (Figure 5.2). In cases were 
the above blanching was not observed the atraumatic clip was removed and then reapplied. 
To achieve satisfactory clamping a specialised clamp holder was utilised. Following 
satisfactory clamp placement, the intestines were placed back into the abdominal cavity 
carefully and covered with a well-moistened gauze with saline. The animal was placed under 
a heat lamp to maintain body temperature at 37°C and monitored closely during the ischemic 
period making sure the covering gauze remains moist with saline. The ischaemic time used 
for the experiments was 90 minutes. During this time, additional anaesthesia was 
occasionally required. This was achieved by placing the animals back into the isofluorane 
chamber. 
Following the 90 minute period of ischemia, the animal was placed back onto the washable 
plastic and the moisten gauze removed from the intestines. The retractors were placed onto 
the median and left liver lobes to once again gain access to the portal triad. At this point the 
atraumatic clamp was carefully removed. 500 μL of sterile saline was infiltrated into the 
peritoneal cavity to replenish any fluid loss during surgery. Successful reperfusion was 
visually verified as the blanched colour of the ischemic liver lobes rapidly showed the 
restoration of the normal reddish-brown colour within a few seconds of clamp removal. At 
this point suturing the muscle layer with 4/0 vicryl closed the abdomen and then the skin 
with 4-0 silk sutures and the animal was allowed to recover for the required reperfusion time 
that was 6 hours. The animals were then placed into heated chambers were free access to 
chow and free water. Sham operated animals were handled in exactly the same manner other 
than undergoing clamping of the portal triad.  
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Immediately following the reperfusion period of 6 hours the animals were again 
anaesthetised with isofluorane. The animals were then transferred to the washable plastic and 
the limbs once again immobilised with tape. The laparotomy wound was opened and the 
intestine displaced in the caudal direction and the inferior vena cava (IVC) visualised. 10 μl 
of heparinised saline was injected directly into the IVC and then venous blood collected into 
a microsyringe. The samples are allowed to clot on ice for approximately 10 minutes after 
which they are centrifuged at 4,000 × g for 10 minutes. Serum was removed and frozen at     
-80°C.  
The animal was then euthanised by exsanguination. Following this a thoractomy was 
performed and the diaphragm divided. The liver was then removed. Representative samples 
of the post-ischemic liver (and/or bypass lobes) were immediately frozen in liquid nitrogen 
and stored at -80°C. 
 
5.2.2 Serum Preparation and Quantification of Liver Transaminase Levels 
Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were 
quantitative indices of liver damage used to assess liver injury and could be quantified in 
serum obtained from mice subjected to liver IRI. The sample were processed and quantified 
at the University Medical Centre Groningen (UMCG) biochemical laboratory using standard 
operating protocols.  
 
5.2.3 Histopathology 
Following exsanguinations, representative pieces of ischemic, IRI or bypass lobes were 
quickly removed and fixed in ice cold 10% phosphate-buffered formalin for 24 hours at 4°C. 
The tissue is then partially dehydrated with ethanol and embedded in JB4 plastic mounting 
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media using standard histological methods. Five-micrometer sections cut and stained with 
haematoxylin and eosin (H&E).  
 
5.2.4 Statistical Analysis 
All values are presented as mean ± SEM. Data are analyzed using Students t test or analysis 
of variance where significance was set at p<0.05. 
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5.3 Results 
5.3.1 CD40:CD154 Signalling Regulates Hepatic IRI in vivo 
Depriving 70% of the murine liver of blood flow for 90 minutes followed by 6 hours of 
reperfusion significantly increased serum ALT and AST levels in wild-type C57B/6 (Figure 
5.3). Sham operated animals did not show any increase in either serum ALT or AST levels. 
There was a significant reduction in ALT and AST in both CD40 and CD154 knockout 
mice. 
Histopathological evaluation of the murine livers revealed that sham operated animals 
sustained no parenchymal injury as assessed by H&E staining (Figure 5.4). Wild-type 
C57/B6 animals however sustained marked injury of the liver particularly within the peri-
venular regions of the liver that was consistent with the significantly elevated serum ALT 
and AST levels. Consistent with the reduced injury seen in the CD40 and CD154 knockout 
mice these mice sustained less injury as demonstrated by Figure 5.4.  
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Figure 5.3 CD40 and CD154 Mice have Lower Serum AST and ALT Levels after 
Hepatic IRI 
Following 90 minutes of liver ischaemia and 6 hours of liver reperfusion, serum was 
withdrawal from sham operated, wild-type, CD40 knockout and CD154 knockout mice via 
IVC punctuate. Serum was then used to determine the concentration of AST and ALT in the 
different murine groups. Data are expressed as the mean ± S.E.  *p<0.05, Student’s t test. 
(n=8-12). 
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Figure 5.4 CD40 and CD154 Knockout Mice Sustain Less Hepatocellular Injury after Hepatic IRI 
Panel (A) demonstrates a representative H&E stain of wild-type C57/B6 mice subjected to sham operation. There is no disruption to 
hepatocellular plate. Panel (B) illustrates the effects of IRI upon the liver. There is haemorrhagic necrosis and also congestion within the liver 
around the perivenular region. Panel (C) CD40 knockout mice and Panel (D) CD154 knockout mice show features of hepatocellular injury 
however there is substantially reduced injury when compared to Panel (B). (magnification 20x). (n=8-12).  
A B 
C D 
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5.4 Discussion  
The mouse model of liver IRI utilised here has proven invaluable for the understanding of 
the role that the CD40:CD154 signalling pathway plays in modulating and mediating liver 
tissue injury in vivo [18]. It is clear that hepatic IRI induces significant liver injury as 
assessed by serum AST, serum ALT and histological examination of the liver. These 
changes are completely absent in sham-operated animals and significantly reduced in CD40 
and/or CD154 knockout mice. The data presented above further demonstrates the key role of 
the CD40:CD154 interaction in mediating liver injury after IRI in vivo. Previous studies 
have ascribed the protection from liver injury in CD40 and CD154 knockout mice following 
IRI to a reduction in T-lymphocyte co-stimulation [19]. This particular study showed almost 
complete amelioration of liver injury following IRI in CD40 and CD154 knockout mice. 
This is in contrast to the data presented here. Although the same in vivo IRI model was used 
in the presented data a lesser degree of protection was afforded in the knockout animals in 
the presented data. This discrepancy in these observations is likely to be due to the 
difference in susceptibility of murine species to IRI. It is clear however that the 
CD40:CD154 receptor ligand does promote parenchymal injury after liver IRI.  
The data presented in Chapter 3 and 4 clearly shows that ROS is an important mediator of 
hepatocyte injury during hypoxia and H-R. The assessment of ROS accumulation in tissues 
as opposed to cells is technically much more challenging. No studies have investigated ROS 
accumulation within tissue in real-time. DCF can be utilised in conjunction with intra-vital 
microscopy to determine intracellular ROS accumulation but this is currently only possible 
over short time courses in the order of 5 minutes. Therefore many in vivo studies have 
utilised surrogate markers of ROS to indirectly assess tissue hypoxia. These markers include 
carbonic anhydrase IX [315], pimonidazole [316] and HIF-1α [317]. Therefore although 
 182
these makers do not assess ROS accumulation they do imply ROS production. Previous 
studies have shown that hypoxia does increase pimonidazole staining of liver tissue after 
hypoxia [318, 319]. Whether CD40 activation increases parenchymal hypoxia or ischaemia 
cannot be stated on the basis of the presented data. 
The CD40:CD154 receptor ligand dyad does mediate post-ischemic liver damage within the 
liver but as stated in Chapter 1 there does exist numerous differences between hepatocytes 
from different species. Hence although in murine livers CD40 and CD154 mediate 
parenchymal injury whether the same occurs in human livers in not known. More 
specifically, although the data presented in Chapter 3 and 4 revealed the in vitro and 
intracellular mechanisms by which ROS and CD154-mediated ROS mediate post-hypoxic 
hepatocyte injury whether CD40:CD154 also caused similar effects in vivo was not known. 
As discussed in Chapter 4 hepatocytes, HSEC, HSC and cholangiocytes all express CD40 
while macrophages, T-lymphocytes and platelets express CD154. Which of these potential 
interactions is the important key interaction in vivo cannot be determined on the basis of the 
presented data. CD40:CD154 certainly regulate parenchymal injury but whether this is a 
result of numerous co-ordinated interaction or as a result of a specific interaction is not 
known. Certainly platelet depleted mice [306], T-lymphocyte knockout mice [117] and 
Kupffer cell/macrophage knockout mice [320] are all protected from a variety of liver 
injuries and this therefore suggests redundancy within the CD40:CD154 signalling system 
and implies numerous CD154 bearing cells can induce hepatocyte injury via CD40 
activation. Hence the findings presented here should be treated with caution. In CD40 and/or 
CD154 knockout animals the receptor and ligand will also be absent upon macrophages, 
KCs, liver resident immune cells and DCs. This will also lead to defective priming of these 
immune cells some of which can release extracellular ROS and hence perpetuate 
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hepatocellular injury. The lack of effective cell activation and priming will also lead to less 
tissue hypoxia, less cell death and reduced serum transaminases. Coupled with in vitro data 
presented earlier an additional plausible mechanism of the action of CD40:CD154 is that 
reduced CD40 activation upon hepatocytes during hepatic IRI led to reduced tissue hypoxia 
and reduced cell death.  
Importantly, antagonism of the CD40:CD154 signalling pathway is now being used in the 
clinic. While CD28 blockade has been successfully translated to the clinic, translation of 
blockade of the CD40:CD154 pathway has been less successful, in large part due to 
thromboembolic complications associated with anti-CD154 antibodies [321]. The efficacy of 
CD154 targeted therapies has been established in murine models of cardiac transplantation 
[125]. Indeed 3A8, a human CD40-specific monoclonal antibody, has been shown to prolong 
islet cell allograft survival without depleting B-lymphocytes [322]. Furthermore 3A8 in 
combination with CTLA4Ig and sirolimus prolonged engraftment in a well-established 
primate bone marrow chimerism-induction model [323]. 
Previous studies have also shown that within CD40 and CD154 knockout animals there is 
reduced intrahepatic T-lymphocyte sequestration after hepatic IRI, decreased production of 
Th1 pro-inflammatory cytokines and reduction of pro-apoptotic caspase proteins [19]. 
Coupled with the findings presented within this Chapter it is demonstrated that the 
CD40:CD154 receptor-ligand dyad is likely to employ diverse mechanisms to cause liver 
injury during IRI.  
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6.1 Overview 
 
The initial aim of this study was to investigate the effects of CD40 activation upon 
hepatocyte survival in vitro and in vivo. However, it quickly became apparent that it was 
important to define the effects of oxidative stress upon hepatocyte susceptibility to cell death 
and whether ROS was involved in cellular signalling events following CD40 activation upon 
hepatocytes. Therefore by necessity a substantive section of the study focused upon 
assessing the role of oxidative stress in regulating hepatocyte cell death and survival. 
The data highlights the key role of intracellular ROS accumulation in mediating human 
hepatocyte cell death during hypoxia and H-R and in vivo following liver IRI. Importantly 
the findings illustrate that human hepatocytes have differential vulnerability to undergo cell 
death in response to oxidative stress. Human hepatocytes were isolated from a variety of 
sources including normal, normal resected and end-stage cirrhotic liver disease. It is clear 
from the data those normal hepatocytes and hepatocytes isolated from biliary cirrhotic livers 
and ALD increase intracellular ROS during hypoxia and H-R, and undergo both apoptotic 
and necrotic cell death as a result. Human hepatocytes isolated from normal resected liver 
tissue also accumulated ROS during hypoxia and H-R but were not susceptible to cell death. 
These observations reveal considerable heterogeneity in the physiological responses of 
human hepatocytes to oxidative stress and that these responses are dependent on the source 
of tissue. Therefore, studies utilising human hepatocytes need to be analysed within the 
context of the type of liver from which cells were isolated. It is likely that the local tissue 
microenvironment affects the way that hepatocytes respond to oxidative stress. For instance, 
hepatocytes isolated from ALD livers show significantly lower albumin production, 
significantly lower urea synthesis and increased basal ROS levels probably reflecting the 
continual exposure to alcohol. These observations suggest that further studies are warranted 
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to discern the precise molecular mechanisms that govern the regulation of the oxidative 
stress responses of hepatocytes from different diseases and indeed different regions of the 
hepatic lobule. These differences in human hepatocyte physiology are likely to be real as a 
uniform stringent protocol for human hepatocyte isolation was adopted and therefore any 
difference observed in hepatocyte responses to the in vitro IRI model were unlikely to be 
explicable by technical variance in isolation procedure, culture conditions or manipulation of 
liver tissue. 
Building on these above observations the present study shows that, large/PV human 
hepatocytes were more susceptible to cell death during hypoxia and H-R than small/PP 
human hepatocytes. These findings are at variance with previous studies where small/PP 
hepatocytes were found to be more susceptible to hypoxia [169]. There are several 
explanations for these observations including inter-species variability and the method 
employed to isolate hepatocytes. In this study hepatocytes isolated from normal liver, normal 
resected liver or end-stage cirrhotic liver suggested that large/PV human hepatocytes show 
greater intracellular ROS accumulation when compared to small/PP human hepatocytes. 
This observation has important implications for the pathophysiology of ischaemic liver 
disease. As demonstrated in Chapter 5 following in vivo IRI murine livers sustain injury 
predominantly within the peri-venular region of the liver. Therefore large/PV human 
hepatocytes propensity to increase intracellular ROS production during hypoxia may 
underlie the reason why zone 3 of the liver acinus is the area of liver damage associated with 
ischaemia. Furthermore, Zone 3 hepatocytes exist in a relatively hypoxic micro-environment 
under normal physiological conditions [99] and therefore increased levels of hypoxia may 
disrupt oxidative phosphorylation within large/PV human hepatocytes mitochondria leading 
to ROS accumulation and resultant cell death. It is important to note that ROS accumulation 
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in large/PV human hepatocytes is also NADPH oxidase dependent and this pathway is likely 
to contribute to cell death as well. Other studies examining liver injury from a variety of 
sources including IRI [43], viral hepatitis [324] and cirrhosis [325] all report cellular damage 
predominantly in the peri-venular region. Although these are important observations with 
regard to liver patho-physiology it is likely that the delivery of pharmacological therapeutics 
that target all hepatocytes will offer potential treatment to ameliorate IRI in the future [326].  
ROS accumulation in human hepatocytes during oxidative stress can be derived from a 
variety of sources. The mitochondrion has previously been shown to be the main cellular 
source of ROS accumulation in the hepatocyte [71]. Consistent with these previous 
observations the specific mitochondrial dye MitoSox Red demonstrated that mitochondrial 
superoxide production is an important and abundant source of ROS in human hepatocytes 
during hypoxia and H-R. This observation is further corroborated with experiments using the 
complex I inhibitor rotenone which significantly reduced human hepatocyte ROS 
production. In addition inhibition of the cytosolic enzyme NADPH oxidase also reduced 
human hepatocyte ROS production. Therefore taken together with other studies, it is likely 
that hepatocyte mitochondrion [71], NADPH oxidase [327], XO [328] and peroxisomes 
[329] are responsible for ROS production (Figure 6.1).  
This study provides evidence that extracellular signals such as exogenous TNFα ligand 
CD154 can augment intracellular ROS generation. Following activation of CD40 by CD154, 
the flavoenzyme NADPH oxidase is recruited to the plasma membrane and induces the 
formation of ROS [274]. TNFα recruits the TRAF-XO complex to induce ROS formation 
[78]. Hence the TNFα super-family of ligands and receptors may have a diverse range of 
mechanisms of ROS production. It is possible to speculate that these mechanisms may 
operate synergistically during pro-inflammatory processes such as IRI and perpetuate liver 
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injury although only the effects of CD154 have been assessed within this study. Moreover in 
this study, CD40 and/or CD154 knockout mice sustained less liver injury following hepatic 
IRI than wild-type mice as assessed by histology and liver serum transaminases. Although 
this suggests that CD40:CD154 is involved in the regulation of hepatic IRI as previously 
suggested [19] the presence of liver injury in the knockout mice also suggests other 
mechanisms are involved in mediating hepatic IRI such as those described in Chapter 1. This 
suggests that hepatic IRI is a multi-factorial process in accordance with recent reviews [40]. 
An important caveat to these observations is that the in vitro experiments conducted here 
were in human hepatocytes whereas in vivo experiments were conducted in a murine model. 
As discussed earlier there maybe significant differences between hepatocytes from different 
species meaning data from this study should be interpreted cautiously.  
The accumulation of ROS within human hepatocytes triggers at least three separate and 
distinct downstream signalling functional events. Intracellular ROS accumulation during 
hypoxia and H-R induces cellular apoptosis, necrosis and also promotes the cyto-protective 
mechanism of autophagy. Therefore intracellular ROS accumulation within human 
hepatocytes as a result of oxidative stress paradoxically promotes both cell death and cell 
survival. Specifically, ROS induces autophagy in a PI3-K-Atg dependent manner promoting 
cell survival during hypoxia and H-R as well as inducing apoptosis and necrosis. In line with 
their greater propensity to produce ROS large/PV human hepatocytes are much more 
sensitive to induction of apoptosis, necrosis and autophagy than small/PP human hepatocytes 
during hypoxia and H-R. The linkage between intracellular ROS and apoptosis, necrosis and 
autophagy is clearly demonstrated by the pre-treatment of human hepatocytes with NAC. 
ROS production by human hepatocytes was completely inhibited by NAC that also 
completely abrogated human hepatocyte apoptosis and autophagy and significantly reduced 
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necrosis during hypoxia and H-R. This finding suggests that during in vitro IRI, intracellular 
ROS is the key mediator of human hepatocyte apoptosis and autophagy and also inhibits 
necrosis. The downstream signalling pathways activated by ROS are likely to be numerous 
but the MAPKs, caspases and calpains are likely to be among the most important effectors 
[291]. Specifically, ROS is likely to activate MAPK, caspases and calcium to regulate 
apoptosis [330] and the presented data shows ROS is also likely to activate PI3-K and Atg 
proteins to regulate autophagy. Therefore, death inducing mechanisms involving caspases, 
calpain, cathepsins, calcium, mitochondrial permeability transition and endoplasmic 
reticulum stress all regulate cell death [188] and it maybe that these downstream effectors all 
share a common signalling pathway. This is partly confirmed by the presented data because 
inhibiting ROS completely abrogated hepatocyte apoptosis. Therefore ROS is likely to be a 
central cellular mechanism for regulation of apoptosis.   
The data demonstrates the role of the TNFR/TNF super-family members CD40 and CD154 
in mediating hepatocyte cell death and injury both in vitro and in vivo following IRI. CD154 
stimulation of human hepatocytes augmented ROS accumulation in a NADPH oxidase 
dependent manner. Intracellular ROS then induced human hepatocytes apoptosis and 
necrosis. The stimulation of these hepatocytes with recombinant human CD154 
demonstrated that CD40 activation could augment ROS levels within human hepatocytes 
during normoxia and H-R. Although activated platelets can be one potential source of 
CD154 during pro-inflammatory liver processes, macrophages [121] and T-lymphocytes will 
also be important effectors cells inducing parenchymal injury. It is likely that the 
augmentation of intracellular ROS within hepatocytes is a common mechanism shared by 
pro-inflammatory signals [331]. However, CD154 activation of CD40 upon human 
hepatocytes was unable to augment ROS accumulation in hypoxia. Certainly CD40 
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expression is not altered during hypoxia and numerous studies have shown that hepatocytes 
are able to up-regulate intracellular antioxidant defences during hypoxia and it is likely that 
this buffers the increases in intracellular ROS induced by CD154 during hypoxia. 
Furthermore, murine model of IRI demonstrate that CD40 and CD154 regulate hepatocyte 
injury in vivo although the precise mechanism underlying this protection remains to be fully 
ascertained [19].   
The in vitro IRI model does however illustrate the complexity of the CD40:CD154 
signalling pathways in human hepatocytes. ROS generated by CD154 stimulation of 
hepatocytes appears to regulate apoptosis via two different mechanisms. CD154 activated 
the MAPK sub-families p38 and JNK and also induced human hepatocyte FasL expression. 
Therefore ROS regulation of human hepatocyte apoptosis is complex with possible 
redundant signalling pathways that have a high degree of cross-talk [43]. This latter 
mechanism maybe highly advantageous at the tissue and organ level as it would enable the 
elimination of diseased cells via multiple pathways. The induction of human hepatocyte 
necrosis by intracellular ROS is likely to be a degenerative process as previously observed 
[217] but can be reduced with a variety of antioxidants. Clearly apoptosis and necrosis are 
both induced following ROS accumulation in human hepatocytes. It is likely based upon the 
data that ROS-p38/JNK is integrally involved in the regulation of apoptosis whereas ROS 
alone induces human hepatocyte necrosis through direct toxic effects. Necrotic cell death is 
likely to be perpetuate the proinflammatory response during IRI through the release of 
cytokines and ROS itself following oncosis [219]. There are several potential mechanisms 
that may explain the cellular decision to undergo apoptosis or necrosis. Aside from cellular 
ATP content particular ROS sub-species [76] or relative and absolute levels of intracellular 
ROS [332] may govern the particular mode of cell death. In addition necrosis may 
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sequentially follow apoptosis [333]. However, taken together the presented data supports the 
role of both apoptosis and necrosis in mediating human hepatocyte cell death during hypoxia 
and H-R [52]. Taken together with previous studies it is probable that CD40 activation leads 
to ROS accumulation, JAK-STAT activation [120] and induction of NFκB signalling [157]. 
The precise outcome of these signalling pathways appears to be cell specific within the liver. 
Within the epithelial cell derived hepatocytes and cholangiocytes, ROS accumulation and 
JAK-STAT activation lead to cell death via both JNK activation and induction of FasL [118, 
120, 122]. CD40 activation on HSEC however leads to proliferation and secretion of pro-
inflammatory cytokines in a NFκB dependent manner [157]. Many of these studies have 
examined the role of a single signalling pathway in the liver cell of interest and thus the 
precise role of ROS in CD40 signalling in the liver remains to be fully ascertained. However, 
regardless as to the source of ROS it appear that at some point the cell has a decision to 
make about whether it will pursue cell survival or cell death in response to oxidative stress. 
The precise mechanism underlying these cell processes is not clear.  
Finally, the current paradigm that ROS is always detrimental to hepatocyte viability [43] is 
not supported by the data. Intracellular ROS accumulation in other cell types has been linked 
to cell survival [334] and in human hepatocytes intracellular ROS accumulation induced the 
formation the autophagic vacuoles in a PI3-K-Atg protein dependent manner. These 
autophagic vacuoles inhibit apoptosis by preventing mitochondrial depolarisation probably 
by mitophagy and enable hepatocytes to survive extreme/severe hypoxia [212]. The data 
suggests that during hypoxia and H-R human hepatocytes undergo autophagy primarily in 
the form of mitophagy to aid cell survival [212]. It is likely that if ROS generation continues 
this overwhelms the cyto-protective cellular machinery and the hepatocyte then undergoes 
cell death in the form of both apoptosis and necrosis although the molecular switch 
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governing the precise mode of cell death remains to be fully ascertained. These key 
questions will remain unanswered until intracellular probes are developed that can assess the 
formation of different ROS sub-species.  
In conclusion, the mitochondrion, ROS production and human hepatocyte cell death and 
survival are intimately linked as illustrated in Figure 6.1. Taken together these findings 
demonstrate that during hepatic IRI, ROS production is the key and seminal event in the 
initiation and propagation of the injury. Whether ROS is important in the resolution of injury 
and regeneration of the injured liver cannot be answered by the present study and remain an 
important area of research. The continued development of therapeutic strategies that 
ameliorate the development and production of ROS holds considerable promise for the 
treatment of liver disease with the caveat that ROS also appears to be an important regulator 
of cell survival. 
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Figure 6.1 The Role of ROS and CD40:CD154 in Mediating Human Hepatocyte Cell 
Death and Survival 
The above model illustrates the likely mechanism of action of the intracellular ROS 
generated within human hepatocytes during IRI. Intracellular ROS can be generated by a 
number of sources within hepatocytes. As discussed above hypoxia and H-R generate ROS 
primarily via the mitochondria but cytosolic NADPH oxidase can also stimulate ROS 
accumulation. Inhibition of mitochondrial electron transport chain with rotenone (red arrow) 
or ROS in general with NAC (red arrow) reduces cell death within human hepatocytes. 
Other systems within hepatocytes such as XO and cyclooxygenase can also stimulate ROS 
accumulation. As shown in Chapter 4 the CD40:CD154 receptor ligand interaction can 
stimulate ROS production in a NADPH oxidase dependent manner. Once generated ROS 
accumulation has at least three downstream signalling pathways. The first pathway to be 
activated during hypoxia and H-R is the stimulation of the pro-survival pathway of 
autophagy in a PI-3K-Atg dependent manner. Inhibition of the autophagic pathway with 3-
MA commits the hepatocyte to cell death in the form of apoptosis (green arrow). If oxidative 
stress within human hepatocytes continues the autophagic response is overwhelmed and the 
cell is committed to cell death in the form of both apoptosis and necrosis.  
 
rotenone NAC 3-MA 
DPI 
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6.2 Future Work 
The data presented above has added further evidence for the role of oxidative stress and 
CD40:CD154 mediated ROS accumulation in the development of hepatic injury following 
IRI. Additional work would shed light on the wider role of both ROS and CD40:CD154 
during IRI and may lead to the identification of important signalling pathways and 
therapeutic targets.   
- The molecular mechanism regulating the processes of ROS-dependent human hepatocyte 
apoptosis, necrosis and autophagy.  
Although the link between ROS and apoptosis, necrosis and autophagy has been 
established by the present study the precise mechanisms governing cell fate and the 
decision as to when to abandon cell survival in favour of cell death remain to be fully 
ascertained. The use of specific inhibitors such caspase inhibitors, cathepsin 
inhibitors and intracellular calcium probes will further map the signalling pathways 
involved and add to the fundamental understanding to cell and hepatocyte biology.  
- The precise nature of upstream CD40 signalling. 
The presented data show that CD40 activation upon human hepatocytes leads to cell 
death in a NADPH Oxidase-ROS dependent manner. However which TRAF 
molecule is involved in this process remains to be confirmed. The controversy 
surrounding this latter point makes this an important question to answer for CD40 
biologists. Using immunofluorescence and cellular tagging of the different TRAF 
molecules would answer this question conclusively.  
- The effect of cold IRI upon human hepatocyte ROS production and cell death.  
The data presented in this thesis has assessed the effects of warm IRI in vitro and in 
vivo. Whilst this has revealed important insights into hepatocyte responses to a 
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specific set of conditions in vitro, this model is not akin to many clinical scenarios 
such as OLT were cold IRI is encountered. The effect of cold IRI upon hepatocytes 
and livers would be of unquestionable value to clinicians. Furthermore whether 
CD40:CD154 signalling events are altered by hypothermia could also be assessed. 
- The kinetics of Reactive Nitrogen Species generation (RNS) in determining human 
hepatocytes cell death during hypoxia and H-R. 
 Although ROS is an important regulator of IRI, RNS, which have only briefly been 
discussed here, are also likely to be important regulators of hepatic injury after IRI. 
There are commercially available RNS probes that could be used alone or in parallel 
with ROS probes to delineate the relationship between RNS and ROS and cell death. 
Peroxynitrites, formed in part by RNS, are becoming increasingly seen as important 
regulators of injury seen after oxidative stress and establishing their role will allow 
the delineation of other therapeutic targets to ameliorate hepatic IRI. 
- The factors determining the increased propensity of PV/large human hepatocytes to 
produce ROS and induce cell death.  
The data also demonstrate for the first time with human primary cells that large/PV 
human hepatocytes are susceptible to hypoxic injury. The precise mechanism 
underlying the latter observation remains to be delineated. Using FACs to separate 
cells and study large/PV human hepatocyte in isolation would answer these questions 
and add significantly to the understanding of liver biology.   
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Reactive Oxygen Species Mediate Human
Hepatocyte Injury During
Hypoxia/Reoxygenation
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Increasing evidence shows that reactive oxygen species (ROS) may be critical mediators of liver damage during the relative hy-
poxia of ischemia/reperfusion injury (IRI) associated with transplant surgery or of the tissue microenvironment created as a
result of chronic hepatic inﬂammation or infection. Much work has been focused on Kupffer cells or liver resident macrophages
with respect to the generation of ROS during IRI. However, little is known about the contribution of endogenous hepatocyte
ROS production or its potential impact on the parenchymal cell death associated with IRI and chronic hepatic inﬂammation. For
the ﬁrst time, we show that human hepatocytes isolated from nondiseased liver tissue and human hepatocytes isolated from
diseased liver tissue exhibit marked differences in ROS production in response to hypoxia/reoxygenation (H-R). Furthermore,
several different antioxidants are able to abrogate hepatocyte ROS–induced cell death during hypoxia and H-R. These data
provide clear evidence that endogenous ROS production by mitochondria and nicotinamide adenine dinucleotide phosphate
oxidase drives human hepatocyte apoptosis and necrosis during hypoxia and H-R and may therefore play an important role in
any hepatic diseases characterized by a relatively hypoxic liver microenvironment. In conclusion, these data strongly suggest
that hepatocytes and hepatocyte-derived ROS are active participants driving hepatic inﬂammation. These novel ﬁndings high-
light important functional/metabolic differences between hepatocytes isolated from normal donor livers, hepatocytes isolated
from normal resected tissue obtained during surgery for malignant neoplasms, and hepatocytes isolated from livers with end-
stage disease. Furthermore, the targeting of hepatocyte ROS generation with antioxidants may offer therapeutic potential for
the adjunctive treatment of IRI and chronic inﬂammatory liver diseases. Liver Transpl 16:1303-1313, 2010. VC 2010
AASLD.
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Most studies that have investigated the mechanisms of
liver damage occurring as a result of ischemia/reperfusion
injury (IRI) have focused on the setting of liver transplanta-
tion. It is equally possible that relatively hypoxic conditions
can occur during other episodes of hepatic inﬂammation
or established chronic disease. Hepatocytes exposed to a
hypoxic microenvironment would therefore be potentially
sensitized to cell death, although no studies have yet
explored this process in primary human hepatocytes.
Despite considerable advances in surgical practice
and more judicious use of immunosuppression, he-
patic IRI continues to adversely affect allograft func-
tion and survival after orthotopic liver transplantation
(OLT). Toledo-Pereyra et al.1 in 1975 were among the
ﬁrst to note the detrimental effects of IRI during ex-
perimental liver transplantation. IRI is a proinﬂamma-
tory, antigen-independent process that culminates in
hepatocyte injury. The potential processes regulating
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hepatic IRI have been summarized in recent
reviews.2,3 Recent studies have suggested that hepatic
IRI accounts for up to 10% of early allograft failures
and is associated with a higher incidence of both
acute and chronic rejection.4 The primary cellular tar-
get during IRI is the hepatocyte. Hepatocyte death
seen during the hypoxic and reperfusion phases of IRI
occurs within a relatively hypoxic environment, and
hepatic IRI can be divided into 2 phases. The early
phase is thought to involve the activation of Kupffer
cells (KCs), which release proinﬂammatory cytokines
and reactive oxygen species (ROS).5,6 The late phase
is characterized by increased expression of chemo-
kines and adhesion molecules and hepatic recruit-
ment of effector cells, which amplify the tissue dam-
age. The latter phenomenon is a feature common to
many other hepatic diseases. There is evidence sug-
gesting that hepatocyte injury occurs during the rela-
tively hypoxic early phase of IRI.7 ROS release is one
of the earliest and most important components of tis-
sue injury after the reperfusion of ischemic organs
and is a major contributor to hepatocyte death during
reperfusion.8 Moreover, diseases such as alcoholic
liver disease (ALD) are characterized by the chronic
accumulation of ROS. The source of hepatic ROS
remains controversial. Numerous studies have sug-
gested that hepatocyte damage is triggered by KC-
derived ROS,9,10 whereas others have shown that the
absence or elimination of KCs does not prevent tissue
damage in IRI.11 This suggests that other cells within
the liver, including hepatocytes, may be involved in
the pathophysiological production of ROS during IRI
and chronic hepatic inﬂammation.
Early work with rat hepatocytes suggested xanthine
oxidase as the main generator of ROS.12 However, the
xanthine oxidase inhibitors used in these studies are
now known to inhibit mitochondrial function, and mi-
tochondria are now accepted as the main source of
ROS within hepatocytes.13 Furthermore, the inhibition
of mitochondrial complexes I and III can ameliorate
ROS production in human hepatoma cell lines14 and
rat hepatocytes.15 Other enzymes, such as the ﬂavoen-
zyme nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase, can also produce ROS in rat hepato-
cytes.16 The accumulation of excess intracellular ROS
induces cell death, and during hepatic IRI, hepatocytes
undergo both apoptosis and necrosis.17 Some studies
have supported apoptosis as the primary mode of
death,18 and others have supported necrosis.19 In real-
ity, it is uncertain whether the apoptosis and necrosis
observed in liver tissue are separate processes because
the terms primarily represent morphological descrip-
tions, and it has been suggested that apoptotic cells
not effectively cleared from inﬂammatory sites may
eventually assume a necrotic appearance (so-called
secondary necrosis). This led Jaeschke and Lemas-
ters20 to propose the term necroapoptosis, and it may
be that the 2 forms of cell death are in part related and
share some common intracellular pathways.
Despite these observations, little is known about the
relative contribution of endogenous hepatocyte ROS
production and its potential impact on hepatocyte cell
death after hypoxia and hypoxia/reoxygenation (H-R).
Much of our understanding of hepatic IRI comes from
studies of rodent hepatocytes and experimental models.
However, the response of human hepatocytes to hypoxia
and H-R is unknown. In addition, the research per-
formed with human hepatocytes has used cells isolated
from resected liver tissue from patients with neoplastic
disease.21 Whether cells from such normal sources can
be considered to truly reﬂect normal hepatocytes has
never to our knowledge been objectively studied.
The aim of our study was to characterize the
responses of human hepatocytes isolated from normal
liver tissue and diseased liver tissue to hypoxia and
H-R. Speciﬁcally, we delineated intracellular ROS
accumulation and cell death in primary human hepa-
tocytes isolated from normal liver tissue and diseased
liver tissue during hypoxia and H-R. Using an in vitro
model of warm hepatocyte IRI, we show for the ﬁrst
time highly variable responses of primary human he-
patocytes isolated from normal liver tissue, surgically
resected liver tissue, and diseased liver tissue to hy-
poxia and H-R. Although these ﬁndings have obvious
clinical implications within the transplant setting,
they are equally important for diseases in which local
cellular responses to hypoxia may shape the inﬂam-
matory and regenerative microenvironment. The appa-
rent variable responses of primary hepatocytes iso-
lated from normal tissue, resected normal tissue, and
diseased tissue are also important to workers study-
ing hepatocyte physiology and function ex vivo.
MATERIALS AND METHODS
Isolation of Human Hepatocytes
Liver tissue was obtained from fully consenting patients
undergoing transplantation for a variety of end-stage
liver diseases and from patients undergoing hepatic
resection for liver metastasis; normal donor tissue
exceeding surgical requirements was also used. Speciﬁ-
cally, normal donor tissue was obtained from the in situ
splitting of adult livers used for pediatric OLT. These
patients were 19 to 31 years old. The left lateral segment
was used for pediatric OLT, and this meant that tissue
could be procured from the right lobe. Human hepato-
cytes were isolated from explanted diseased livers from
patients with ALD, primary biliary cirrhosis, or primary
sclerosing cholangitis. Hepatocytes were also isolated
from tissue taken from patients who had undergone he-
patic resection for liver metastasis from colorectal carci-
noma. Liver tissue was obtained from surgical proce-
dures carried out at Queen Elizabeth Hospital
(Birmingham, United Kingdom). Ethical approval for the
study was granted by the local research ethics commit-
tee (reference number 06/Q702/61).
Importantly, all liver tissue, including explants, nor-
mal donor tissue, and normal resected tissue, was
obtained from patients with the same rigorous stand-
ard protocol. Brieﬂy, each liver specimen was in circuit
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and was supplied with blood under normoxic condi-
tions until the liver was explanted, split, or resected.
The only technical difference was that normal resected
tissue involved the removal of a speciﬁc portion of the
liver (usually right hemihepatectomy rather than the
whole organ). When liver tissue was obtained from
patients undergoing hepatic resection, all the patients
had received preoperative chemotherapy. After liver
explantation, splitting, or resection, all specimens were
placed on ice, immediately transported, and processed
within the laboratory. All hepatocyte isolation was car-
ried out within 6 hours of surgical explantation, split-
ting, or resection. Strict adherence to the procurement
and processing protocols ensured that any differences
observed between hepatocytes were results of disease
or altered physiology and were not explainable by dif-
ferences in the method of surgical tissue procurement
or subsequent processing.
Hepatocytes were isolated from fresh liver wedges
(60-156 g) with a 2-step collagenase protocol. Each
liver wedge was ﬁrst perfused with a nonrecirculating
wash buffer [10 mM 4-(2-hydroxyethyl)-1-piperazine
ethanesulfonic acid (pH 7.2), Sigma, Dorset, United
Kingdom] at 37C with a ﬂow rate of 75 mL/minute in
order to remove remaining blood within the liver. After
this, the wedge was perfused with a nonrecirculating
chelating solution [10 mM 4-(2-hydroxyethyl)-1-piper-
azine ethanesulfonic acid and 0.5 mM ethylene glycol
tetraacetic acid (pH 7.2), Sigma]. This was followed by
further perfusion with a nonrecirculating wash buffer
to remove any remaining ethylene glycol tetraacetic
acid. After this, the tissue was perfused with a recir-
culating enzymatic dissociation solution (Hank’s bal-
anced salt solution, Gibco, Paisley, United Kingdom)
with 5 mM calcium chloride (Sigma), 5 mM magne-
sium chloride (Sigma), 0.5% wt/vol collagenase
(Roche, Hertford, United Kingdom), 0.25% wt/vol pro-
tease (Sigma), 0.125% wt/vol hyaluronidase (Sigma),
and 0.05% wt/vol deoxyribonuclease (Sigma) at 37C
with a ﬂow rate of 75 mL/minute for 1 to 7 minutes.
After manual dissociation of the liver wedge, the sus-
pension was passed through a 250-lm nylon mesh
and then a 60-lm nylon mesh. The suspension was
then washed at 50g for 10 minutes at 4C in a supple-
mented medium (Dulbecco’s modiﬁed Eagle’s me-
dium, Gibco) with 10% vol/vol heat-inactivated fetal
calf serum (Gibco), 2 mM glutamine (Gibco), 20,000
U/L penicillin, and 20 mg/L streptomycin (Gibco). Im-
mediately after the washing, the cell viability was
determined by trypan blue dye exclusion. Hepatocytes
were plated in a supplemented medium and left for
2 hours. After this period, the medium was changed
to Williams’ E medium (Sigma) with 2 lg/mL hydro-
cortisone, 0.124 U/mL insulin, 2 mM glutamine,
20,000 U/L penicillin, and 20 mg/L streptomycin.
Cells were cultured for another 2 days before use.
Model of Warm H-R Injury
In experiments, hepatocytes were grown for 2 days at
37C with 5% CO2 in Williams’ E medium (Sigma) on
rat type 1 collagen-coated plates. Hepatocytes were
maintained in normoxia, placed into hypoxia for
24 hours, or placed into hypoxia for 24 hours and
then reoxygenated for 24 hours. Hypoxia was
achieved by the placement of cells in an airtight incu-
bator (RS Mini Galaxy A incubator, Wolf Laboratories,
United Kingdom) ﬂushed with 5% CO2 and 95% N2
until the oxygen content in the chamber reached
0.1%; this was veriﬁed with a dissolved-oxygen moni-
tor (DOH-247-KIT, Omega Engineering, United King-
dom). No previous studies had evaluated the response
of primary human hepatocytes to hypoxia and H-R.
Therefore, we modiﬁed a well-established model of
warm in vitro IRI.22,23 In preliminary experiments,
primary human hepatocytes were exposed to 5% or
1% oxygen for 2 or 24 hours, and no increase in ROS
accumulation or cell death was noted (data not
shown). Therefore, we used 0.1% oxygen in all subse-
quent experiments for 24 hours. Additionally, Wil-
liams’ E medium was preincubated in the hypoxic
chamber in a sterile container (which allowed gas
equilibration) for 8 hours before experiments were
carried out; this resulted in a ﬁnal oxygen concentra-
tion of <0.1% as measured with the dissolved-oxygen
meter. When it was appropriate, after 24 hours of hy-
poxia, the medium was aspirated and replaced with a
fresh, warmed, oxygenated medium, and the cells
were returned to normoxic conditions. This was
deﬁned as the beginning of reoxygenation. In experi-
ments involving ROS inhibitors/antioxidants, all
reagents were made fresh as stock solutions and were
added with the correct dilutional factor to the relevant
experimental wells. Speciﬁcally, 100 mM N-acetylcys-
teine (NAC; Sigma) was dissolved in molecular-grade
water, 1 mM rotenone (Rot; Sigma) was dissolved in
chloroform, and 1 mM diphenyliodonium (DPI; Sigma)
was dissolved in dimethyl sulfoxide; they were diluted
appropriately to produce working concentrations of
20 mM, 2 lM, and 10 lM, respectively. In experiments
using inhibitors/antioxidants, solvent-alone controls
were used to ensure no vehicle effects. In addition, in
experiments using inhibitors/antioxidants, agents
were added at the time of placement of the cells into
hypoxia or reoxygenation.
Flow Cytometry
ROS production, apoptosis, and necrosis were deter-
mined with a 3-color reporter assay system. ROS accu-
mulation was determined with the ﬂuorescent probe
20,70-dichloroﬂuorescin diacetate.24 This probe is cell-
permeable and, once inside a cell, is cleaved by intracel-
lular esterases into 20,70-dichloroﬂuorescin (DCF; Merck,
Nottingham, United Kingdom), which is then rendered
cell-impermeable. DCF is then able to react with intra-
cellular ROS (speciﬁcally hydrogen peroxide) and pro-
duce a ﬂuorescent signal detectable on the ﬂuorescein
isothiocyanate (FITC) channel. The signal is directly pro-
portional to the level of intracellular ROS present.
Apoptosis was determined via the labeling of cells
with annexin V (Molecular Probes, Paisley, United
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Kingdom), which detects exposed phosphatidylserine
on the cell membrane. 7-Aminoactinomycin D (7-AAD;
Molecular Probes) is a vital dye that binds to DNA,
enters cells only once the cell membrane is disrupted,
and is indicative of cellular necrosis. To ensure the
consistency of the ﬂow cytometry data, each human
hepatocyte preparation was labeled with DCF alone,
annexin V alone, and 7-AAD alone to ensure that the
cells were labeled and that the ﬂow cytometry data
could be compensated for the crossover of ﬂuorophore
emission spectra. The same ﬂow cytometry protocol
was used for all experiments of the study; this meant
that voltages for all markers were constant for all
human hepatocyte preparations, so the internal con-
sistency of the experiments was ensured.
After appropriate treatment of the cells, the medium
was aspirated and replaced with Hank’s balanced salt
solution (Gibco) without calcium or magnesium. DCF
(30 lM) was added, and the cells were incubated for
20 minutes in the dark at 37C. Next, the cells were
trypsinized and washed extensively in a ﬂuorescence-
activated cell sorting buffer [phosphate-buffered sa-
line (pH 7.2) with 10% vol/vol heat-inactivated fetal
calf serum, Gibco]. Cells were then labeled with
annexin V and 7-AAD for 15 minutes while they were
on ice, and samples were immediately subjected to
ﬂow cytometry. At least 20,000 events were recorded
within the gated region of the ﬂow cytometer for each
human hepatocyte cell preparation under each experi-
mental condition. Only the cells within the gated
region were used to calculate the mean ﬂuorescence
intensity (MFI).
Statistical Analysis
Data analysis was carried out with SPSS software
(version 13.0). All values are presented as means and
standard errors unless otherwise noted. Statistical
analysis was carried out with the Student t test.
RESULTS
Variable ROS Responses to Hypoxia and H-R of
Human Hepatocytes Isolated From Patients
With Different Liver Diseases
Figure 1 and Table 1 show ROS production and accu-
mulation in primary human hepatocytes isolated from
normal liver tissue, normal resected liver tissue, and
diseased liver tissue. Hepatocytes isolated from nor-
mal livers, ALD liver tissue, and normal resected liver
tissue showed similar and consistent responses to hy-
poxia and H-R. Interestingly, normal human hepato-
cytes had little basal intracellular ROS. However, after
Figure 1. Hypoxia and H-R mediate ROS accumulation in human hepatocytes. Representative flow cytometry plots are shown to
illustrate the effects of hypoxia and H-R on ROS accumulation in human hepatocytes isolated from normal liver tissue, diseased
liver tissue, and normal resected liver tissue. Vertical ellipses mark the areas of interest within the plots. The area to the left of
each ellipse represents cell debris. The reason that the cell debris is included within the plots is that human hepatocytes vary
considerably in size; therefore, to include all viable human hepatocytes in the analysis, a large gate was required on the flow
cytometer, and this by necessity included the cell debris. The gate is shown on the corresponding representative FS-SS plots
located to the left of each flow cytometry plot. The FS-SS plots are from the H-R samples of each preparation, but similar plots
were obtained during normoxia and hypoxia (data not shown). Although in the flow cytometry plot of the normal resected liver
tissue there are 2 peaks to the left of the ROS peak, these both represent debris; this has been confirmed by 7-AAD staining and
their size on the FS-SS plots. The data are representative of 4 normal hepatocyte preparations, 4 biliary disease preparations, 3
ALD preparations, and 9 resected normal liver preparations.
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exposure to hypoxia and H-R, normal human hepato-
cytes had signiﬁcantly increased intracellular ROS
accumulation. Hepatocytes isolated from ALD liver
tissue and normal resected liver tissue showed similar
responses with respect to ROS accumulation during
hypoxia and H-R but had greater basal intracellular
ROS contents; this possibly reﬂected their continual
exposure to an inﬂammatory microenvironment.25 He-
patocytes isolated from the tissue of patients with the
biliary diseases, primary biliary cirrhosis and primary
sclerosing cholangitis, had very low basal levels of
ROS production similar to those detected in hepato-
cytes from normal livers, but they showed a 22-fold
increase in ROS production during hypoxia and a
reduction in ROS accumulation during H-R. This may
be a reﬂection of increased engagement of hepatocyte
cytosolic antioxidant defenses, which is possibly a
result of cholestasis, a common feature of these
diseases.
ROS Activation Mediated Hepatocyte Apoptosis
and Necrosis
We next assessed the effects of hypoxia and H-R on
human hepatocyte cell death. Previous in vitro studies
have shown that human hepatoma cell lines26 and
murine27 and rodent hepatocytes28 undergo cell death
during hypoxia and H-R. We have found that human
hepatocytes isolated from normal liver tissue and dis-
eased liver tissue experience increased apoptosis and
necrosis during hypoxia and H-R (Fig. 2A,B). The level
of human hepatocyte apoptosis and necrosis during
hypoxia and H-R mirrored the level of intracellular
ROS production within the particular type of hepato-
cyte. The decrease in ROS production observed in he-
patocytes isolated from the tissue of patients with bili-
ary diseases was accompanied by a concomitant
decrease in apoptosis and necrosis; this conﬁrmed
the association of ROS with apoptotic and necrotic
cell death. The highest levels of ROS were seen in he-
patocytes isolated from normal resected liver tissue.
Despite the increase in intracellular ROS in normal
hepatocytes isolated from resected liver tissue, the
level of apoptosis or necrosis did not increase; this
suggested an important difference in the metabolic ac-
tivity or protective mechanisms of these cells. More-
over, hepatocytes from normal resected tissue did
have higher basal levels of both apoptosis and
necrosis.
Effect of ROS Inhibitors on ROS Accumulation
Antioxidants and inhibitors of ROS generation have
been shown to abrogate human hepatoma cell line
death during hypoxia.26 Figure 3 shows the effects of
antioxidants, mitochondrial chain inhibitors, and
NADPH oxidase inhibitors on primary human hepato-
cyte ROS production during H-R. Similar results were
observed during normoxia and hypoxia (data not
shown). NAC acts as a glutathione precursor; it enters
cells and interacts with and detoxiﬁes free radicals by
nonenzymatic reactions. It is deacetylated to form cys-
teine, which supports the biosynthesis of glutathione,
one of the most important components of the intracel-
lular antioxidant system.29 NAC almost completely
inhibited ROS production in all hepatocytes during
H-R. Rot, a mitochondrial complex I inhibitor, was
also able to inhibit ROS production in hepatocytes
isolated from all sources, and this conﬁrmed mito-
chondria as a major source of endogenous ROS in
human hepatocytes. The inhibition of ROS by Rot was
substantial but not as great as that observed with
NAC. The production of ROS in the presence of mito-
chondrial inhibition implies the involvement of other
mechanisms in human hepatocytes. Accordingly, we
found that the ﬂavoenzyme NADPH oxidase was also
involved in ROS production within the hepatocyte.
The speciﬁc NADPH oxidase inhibitor DPI signiﬁcantly
decreased ROS production in all human hepatocytes.
Thus, although the overall effect was not as great as
that of Rot, NADPH oxidase is also an important
source of ROS in human hepatocytes. In all cases, ve-
hicle controls caused no inhibition of intracellular he-
patocyte ROS levels (data not shown).
Effects of ROS Inhibitors on Human Hepatocyte
Apoptosis and Necrosis
Because NAC, Rot, and DPI all inhibited ROS, we
assessed whether this decrease in ROS affected
TABLE 1. ROS Accumulation in Human Hepatocytes During Hypoxia and H-R
Normal Biliary Cirrhosis ALD Resected
Normoxia 30.3 (13.3-53.5) 11.9 (6.2-21.1) 226.5 (217.1-247.1) 352.8 (256.4-450.5)
Hypoxia 121.9 (39.6-166.2)* 255.2 (139.9-444.0)* 259.5 (229.2-281.2) 377.1 (284.3-547.2)
H-R 271.1 (217.7-370.0)*,† 102.6 (35.2-151.0)* 294.7 (278.2-311.1) 506.1 (332.2-874.0)
NOTE: The mean ROS accumulation for human hepatocytes isolated from normal liver tissue, diseased liver tissue, and
normal resected liver tissue is shown for each of the 3 experimental conditions. Data are expressed as MFIs. Numbers in
parentheses are the ranges of MFI readings for each experimental condition. The MFI values have been derived from the
cells within the ellipses shown in Fig. 1. The data are representative of 4 normal hepatocyte preparations, 4 biliary disease
preparations, 3 ALD preparations, and 9 normal resected liver preparations.
*P < 0.05 versus normoxia.
†P < 0.05 versus hypoxia.
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Figure 2. Hypoxia and H-R induce human hepatocyte apoptosis and necrosis. (A) Representative flow cytometry plots are shown
to illustrate the effects of hypoxia and H-R on the apoptosis and necrosis of human hepatocytes isolated from normal liver tissue,
diseased liver tissue, and normal resected liver tissue. The areas of interest within the plots are marked by vertical ellipses. Just as
in the ROS plots shown in Fig. 1, the area to the left of each vertical ellipse represents cell debris. The data are representative of 4
normal hepatocyte preparations, 4 biliary disease preparations, 3 ALD preparations, and 9 normal resected liver preparations. (B)
The bar charts show pooled data illustrating the level of apoptosis and necrosis in human hepatocytes isolated from normal tissue,
diseased tissue, and normal resected tissue during hypoxia and H-R. The data are shown as fold over the basal level. The levels of
apoptosis and necrosis occurring during normoxia have been taken as the basal levels. The data are expressed as means and
standard errors. The data are representative of 4 normal hepatocyte preparations, 4 biliary disease preparations, 3 ALD
preparations, and 9 normal resected liver preparations. *P < 0.05; **P < 0.05.
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human hepatocyte apoptosis and necrosis. Data for
H-R are shown in Fig. 4; similar results were observed
during normoxia and hypoxia (data not shown). The
reduction in endogenous ROS levels in human hepa-
tocytes treated with the various inhibitors led to sig-
niﬁcantly decreased hepatocyte apoptosis (Fig. 4A)
and necrosis (Fig. 4B). In line with the more potent
effect of NAC on ROS inhibition, the effects of NAC
were the greatest. Rot and DPI also decreased apopto-
sis and necrosis during H-R. Moreover, ROS inhibition
abrogated apoptosis in human hepatocytes isolated
from tissue taken from patients with different types of
hepatic diseases but only partially inhibited hepato-
cyte necrosis. These data provide clear evidence that
endogenous ROS production by mitochondria and
NADPH oxidase drives human hepatocyte apoptosis
and necrosis during H-R.
DISCUSSION
Although hypoxia is a feature of hepatic IRI associated
with hepatic surgery, it may also occur during chronic
liver inﬂammation or infection. Therefore, by deﬁning
the effects of hypoxia on liver physiology, we can
obtain important information regarding the develop-
ment of future therapeutics.
Hepatocytes have conventionally been considered
relatively insensitive to IRI because of their extensive
antioxidant defense mechanisms and their existence
within the comparatively hypoxic hepatic environ-
ment.30 However, numerous in vitro and in vivo stud-
ies have reported deleterious effects of IRI on hepato-
cytes, although the effects of hypoxia and H-R on
human hepatocytes are unknown. Our data reveal
that hepatocytes are susceptible to apoptosis and
necrosis induced in response to hypoxia and H-R, and
we report for the ﬁrst time that human hepatocytes
isolated from patients with different hepatic diseases
show variable responses to hypoxia and H-R.
Hypoxia is known to cause dysfunction of the mito-
chondrial electron transport chain and thus lead to
an increase in ROS; this is accentuated by reoxygena-
tion and can result in cell death.31 Hepatocytes iso-
lated from normal donor livers, ALD livers, and unin-
volved livers from hepatic resections exhibit this
classic response to hypoxia and H-R. Interestingly,
hepatocytes isolated from ALD livers and resected
liver tissue have high basal levels of ROS production,
and these are then augmented by hypoxia and H-R;
however, normal hepatocytes and hepatocytes isolated
from the livers of patients with biliary cirrhosis show
very little basal ROS production. These differences are
likely due to the particular inﬂammatory microenvir-
onment and milieu to which each hepatocyte popula-
tion has been exposed. For example, many mediators
found in ALD patients are known to increase ROS,25
and hepatocytes isolated from hepatic resections will
have been exposed to chemotherapy, a treatment
known to increase intracellular ROS.32 Hepatocytes
isolated from patients with biliary cirrhosis had lower
levels of ROS during H-R, and this possibly reﬂected
the up-regulation of the antioxidant defenses in these
particular cells. The differential responses of hepato-
cytes isolated from patients with different hepatic dis-
eases are unlikely to be attributable to the method of
isolation because the liver tissues were procured and
processed according to an identical and stringent pro-
tocol. The precise cellular mechanisms underlying he-
patocyte responses to hypoxia and H-R remain the
subject of ongoing research within our laboratory.
It has been suggested previously that hepatocytes
are bystanders in IRI and are targeted by the inﬂam-
matory process.2 We now propose that they have the
capacity to actively participate in it primarily through
the production of ROS. The functional relevance of
ROS is emphasized by our ﬁnding that increased lev-
els of endogenous ROS are clearly linked to hepato-
cyte apoptosis and necrosis. This has particular rele-
vance for liver diseases in which hepatocytes are
exposed to relative hypoxia and may be responsible
for perpetuating injury. We have demonstrated that
ROS can directly activate apoptosis and necrosis and
thereby support the suggestion of Jaeschke and
Lemasters20 that common pathways may at least in
part regulate both processes. Moreover, ROS derived
from mitochondria and cytosolic NADPH oxidase are
crucial for regulating both apoptosis and necrosis,
and their inhibition signiﬁcantly improves human he-
patocyte viability during hypoxia and H-R. The ﬁnal
mode of cell death is likely to be dictated by the intra-
cellular adenosine triphosphate content.33 Interest-
ingly, ROS inhibition had a greater effect on reducing
human hepatocyte apoptosis and only partially inhib-
ited hepatocyte necrosis. Although ROS does contrib-
ute to human hepatocyte necrosis, it is likely that a
Figure 3. Antioxidants, mitochondrial chain inhibitors, and
NADPH oxidase inhibitors reduce human hepatocyte ROS
production during H-R. Human hepatocytes isolated from
normal livers, diseased livers, and normal resected livers were
treated with 20 mM NAC, 2 lM Rot, or 10 lM DPI during H-R.
ROS accumulation was determined by flow cytometry as
described in the Materials and Methods section. ROS production
data are shown as MFIs and are based on the MFI readings
taken from cells within the ellipse region shown in Fig. 1. The
data are expressed as means and standard errors. The data are
representative of 3 normal hepatocyte preparations, 3 biliary
disease preparations, 3 ALD preparations, and 5 normal
resected liver preparations. *P < 0.01; **P < 0.01.
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number of factors, including calcium overload, cal-
pain activation, and lysosome rupture, force the cell
to undergo necrosis.34 In contrast, Wang et al.35 dem-
onstrated that ROS derived from mitochondria
directly activated apoptosis in Chang human hepato-
cytes. Accordingly, the inhibition of ROS and, in par-
ticular, mitochondrial ROS had a greater effect on
reducing hepatocyte apoptosis. As previously noted,
hepatocytes undergoing necrosis will release intracel-
lular ROS into the liver parenchyma and induce both
hepatocyte and endothelial cell activation.36 There-
fore, our observations have implications not only for
hepatic IRI but also for liver diseases in which chronic
hypoxia leads to continued ROS production and
ongoing liver damage. In separate experiments, we
exposed human hepatic sinusoidal endothelial cells
(HSECs) to the same in vitro model of warm IRI.
HSECs did not increase intracellular ROS during hy-
poxia and H-R and did not undergo any signiﬁcant
level of cell death during hypoxia and H-R (R.H.B.,
unpublished data, 2010). These observations show
that liver epithelial and endothelial cells have different
responses to hypoxia and H-R, and these differences
are likely to shape the hepatic inﬂammatory microen-
vironment. On the basis of our data, we speculate
that in warm IRI, hepatocyte ROS (not HSEC-derived
ROS) may be important regulators of hepatic injury.
The precise role of HSECs during warm IRI is beyond
the scope of this particular study.
In rat livers, treatment with antioxidants can pre-
vent IRI.37 In limited human studies, ischemia has
induced the expression of ROS scavengers within the
liver.38 Despite the presence of induced antioxidant
mechanisms, human hepatocytes isolated from nor-
mal livers, the livers of patients with ALD, and the
livers of patients with biliary cirrhosis do not appear
to be protected against cell death during hypoxia
and H-R. Hepatocytes isolated from normal resected
liver tissue were, however, surprisingly resistant to
ROS-mediated apoptosis and necrosis. This ﬁnding
has important implications for research involving
human hepatocytes and suggests that studies should
be interpreted in the context of the hepatocyte
source; hepatocytes isolated from resected hepatic
tissues of patients with liver tumors are likely to
respond differently to physiological stress. As men-
tioned earlier, the reason for this difference remains
unknown. Furthermore, which hepatocyte response
reﬂects the true physiological response remains to be
determined. In separate experiments, NAC, Rot, and
DPI were used to treat HepG2, Huh7, and PLC/PRF/
5 human hepatoma cell lines during hypoxia and H-R.
These inhibitors induced overwhelming cell death in
these particular cell lines, and this indicated vastly dif-
ferent responses to hypoxia and H-R in comparison
with primary hepatocytes (data not shown). Therefore,
although previous studies have shown cytoprotective
effects of antioxidants and ROS inhibitors, we report
here for the ﬁrst time that the inhibition of mitochon-
drial and NADPH oxidase–derived ROS reduces pri-
mary human hepatocyte apoptosis and necrosis.
A single strategy aimed at the amelioration of the
harmful effects produced by IRI has not yet been
adopted into general clinical practice. Experimental
interventions to reduce ROS have shown potential for
minimizing liver injury in various models. ROS scav-
engers,39 thioredoxin mimetics,40 and the delivery of
antioxidant genes41 have been shown to partially sup-
press the effects of IRI. However, the clinical applica-
tion of such compounds has been limited for toxico-
logical and technical reasons. NAC, however, has
clinical potential because it is known to be well toler-
ated at doses that should be clinically effective.
Indeed, NAC is used clinically in several settings; for
example, it is used as a hepatoprotective agent for
acute liver failure and acetaminophen toxicity. Fur-
thermore, although NAC administration has been
shown to improve hepatic microcirculation and bile
ﬂow after hepatic IRI,7 we now show that NAC can
also reduce all ROS production in human hepatocytes
with a concomitant decrease in apoptosis and necro-
sis during normoxia, hypoxia, and H-R. Recent stud-
ies have suggested that pleiotropic compounds are
required to treat IRI because of the diverse nature of
the problem.42 We suggest that exogenous NAC could
be a straightforward, practical, and beneﬁcial strategy
for ameliorating human hepatocyte cell death during
IRI. Indeed, a recent randomized study showed that
the systemic infusion of NAC before liver procurement
reduced graft dysfunction and early graft loss after
liver transplantation.43
Although some authors have challenged the patho-
physiological relevance of intracellular oxidant stress
during reperfusion,44 we have clearly shown that he-
patocyte ROS generated by mitochondria and NADPH
oxidase can lead directly to signiﬁcant hepatocyte cell
death; we suggest that although other sources of
ROS, such as neutrophils and KCs, are capable of
contributing to tissue ROS accumulation in IRI, they
may not be the only pathways leading to ROS-
Figure 4. (A) ROS accumulation in human hepatocytes during
H-R mediates apoptosis. Human hepatocytes isolated from
normal tissue, diseased tissue, and normal resected tissue were
treated with 20 mM NAC, 2 lM Rot, or 10 lM DPI during H-R,
and the percentages of cells that were stained with both the ROS
probe DCF and the apoptotic marker annexin V were assessed
by flow cytometry. The cross-plots show ROS on the x axis and
apoptosis on the y axis. The percentages of human hepatocytes
that were stained with both DCF and annexin V are shown in
parentheses. The data are representative of 3 normal hepatocyte
preparations, 3 biliary disease preparations, 3 ALD
preparations, and 5 normal resected liver preparations. *P <
0.001. (B) ROS accumulation in human hepatocytes during H-R
mediates necrosis. Human hepatocytes isolated from normal
tissue, diseased tissue, and normal resected tissue were treated
with 20 mM NAC, 2 lM Rot, or 10 lM DPI during H-R, and the
percentages of cells that were stained with both the ROS probe
DCF and the necrotic marker 7-AAD were assessed by flow
cytometry. The cross-plots show ROS on the x axis and necrosis
on the y axis. The percentages of human hepatocytes that were
stained with both DCF and 7-AAD are shown in parentheses.
The data are representative of 3 normal hepatocyte preparations,
3 biliary disease preparations, 3 ALD preparations, and 5
normal resected liver preparations. *P < 0.01.
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mediated hepatocyte damage. An important caveat to
our data is that oxidative stress in human hepato-
cytes after hypoxia and H-R may differ between hypoxia
at 4C and hypoxia at 37C.45 Therefore, although these
data can be applied to the transplant setting, they are
not wholly reﬂective of the in vivo situation.
In summary, our data show that human hepatocyte
responses to hypoxia and H-R are determined by their
particular microenvironment. Both apoptosis and ne-
crosis are regulated by endogenous human hepato-
cyte ROS, and inhibitors of ROS generation signiﬁ-
cantly improve hepatocyte viability by reducing ROS
generation. The use of NAC offers an opportunity to
modulate hepatic IRI and improve patient outcomes
after OLT, possibly through its addition to preserva-
tion ﬂuids. In addition, our studies demonstrate for
the ﬁrst time that hepatocytes taken from normal tis-
sue, normal resected tissue, and diseased tissue may
vary considerably in their functional and metabolic
responses to hypoxic stress.
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The functional unit of the liver is the acinus, which extends
from the portal venule along the sinusoids to the terminal hepatic
venule. The liver acinus in rodents extends for approximately 20
hepatocytes [1]. Peri-portal (PP) hepatocytes (zone 1) which are
near the portal venule tend to be of a smaller size than peri-venous
(PV) hepatocytes (zone 3) which are located near the terminal he-
patic vein [2]. Indeed, some studies deﬁne and isolate PP and PV
hepatocyte populations upon the basis of size [3]. Furthermore,
these studies have utilised the technique of ﬂuorescent-activated
cell sorting (FACs) to consistently differentiate between PV and
PP hepatocytes and study their metabolic function [4–6]. More-
over, these studies have demonstrated that these hepatocytes have
distinct and separate cellular functions [3,7].
There is a large body of evidence to support the concept of mor-
phological, biochemical and metabolic heterogeneity of small/PP
and large/PV hepatocytes [7–10]. Indeed, various functions have
been ascribed to speciﬁc zones of the liver acinus. Speciﬁcally, oxi-
dative metabolism, gluconeogenesis, urea synthesis and bile for-
mation are predominantly small/PP hepatocyte activities whereas
glutamine synthesis, xenobiotic metabolism and ketogenesis are
predominant functions of the large/PV hepatocytes [11,12].chemical Societies. Published by E
.
.Moreover, studies have shown these differences in hepatocyte
function are attributable to differences in the enzyme expression
[7,10].
These differences in hepatocyte function are also likely to be
important determinants in the evolution of liver injury. For in-
stance, in rodent models, it is well documented that following
ischaemic liver injury, hepatocyte cell death is predominantly ob-
served around the peri-venular region where the PV hepatocytes
are located [13]. The ischaemic injury, within the liver, is regulated
by the accumulation of intracellular reactive oxygen species (ROS)
[14]. However, whether small/PP and large/PV hepatocytes have
differential ROS accumulation during hypoxia and H–R is not
known. In particular, whether small/PP or large/PV human hepato-
cytes exhibit differential responses to hypoxia and H–R remains to
be ascertained.
Previous studies have utilised various techniques to investigate
the different functions of small/PP and large/PV hepatocytes. These
include retrograde digitonin perfusion of livers [8] and elutriation
[7]. However, FACS analysis allows discrimination between hepa-
tocyte subpopulations on the basis of size. Previous studies have
consistently shown that the PV hepatocytes are larger in size than
the PP hepatocytes [4–6]. Thus we used this latter approach to
investigate whether PP or small and PV or large human hepato-
cytes exhibit differential responses to hypoxia and hypoxia–reoxy-
genation (H–R). Speciﬁcally, we investigated whether small/PP and
large/PV human hepatocytes exhibit differential levels of ROSlsevier B.V. All rights reserved.
Fig. 1. The morphology and phenotype of isolated human hepatocytes. (a) Demon-
strates the phenotypic features characteristic of human hepatocytes isolated using
our protocol. The cell speciﬁcmarkers, cytokeratin 18, cytokeratin 19 and CD31were
determined using cell based ELISA as described in theMethods andMaterials section.
Human hepatocytes demonstrate a uniform staining for the hepatocyte speciﬁc
marker, cytokeratin 18. These cells show no staining for the biliary epithelial marker,
cytokeratin 19 or endothelial cell marker, CD31. In contrast, hepatic sinusoidal
endothelial cells show strong positivity for the marker CD31 and no positivity for
either cytokeratin 18 or cytokeratin 19. (b) Illustrates a representative image of
human hepatocytes following successful isolation. These cells have been allowed to
adhere to rat type 1 collagen for 2 h. There is a clear difference in size between the
isolated hepatocytes. As previous authors have shown the smaller hepatocytes are
likely to be derived from the peri-portal area and the larger hepatocytes are likely to
be derived from the peri-venous region [4–6].
936 R.H. Bhogal et al. / FEBS Letters 585 (2011) 935–941accumulation during hypoxia and H–R and whether this had an
impact upon apoptosis and necrosis.
2. Materials and methods
2.1. Human hepatocyte isolation
Liver tissue was obtained from fully consenting patients under-
going transplantation, hepatic resection for benign liver disease or
normal donor tissue surplus to surgical requirements. Liver tissue
was obtained from surgical procedures carried out at the Queen
Elizabeth Hospital, Birmingham, UK. Ethical approval for the study
was granted by the Local Research Ethics Committee (LREC) (refer-
ence number 06/Q702/61). Human hepatocytes were isolated
using a method that we have described previously [14]. Hepato-
cytes were isolated from fresh liver wedges weighing between 60
and 156 g using a two-step collagenase protocol. Liver wedges
were ﬁrst perfused with non-recirculating wash buffer (10 mM
HEPES pH 7.2) (Sigma, Dorset, UK) at 37 C using a ﬂow rate of
75 mL/min in order to remove the remaining blood within the li-
ver. After this, the wedge was perfused with a chelating solution
(non-recirculating) (10 mM HEPES, 0.5 mM EGTA, pH 7.2) (Sigma).
This was followed by further perfusion with [non-recirculating]
wash buffer to remove any remaining EGTA. Following this the tis-
sue was perfused with recirculating enzymatic dissociation solu-
tion (Hank’s Balanced Salt Solution (HBSS) (Gibco, Paisley, UK)
with calcium chloride (5 mM) (Sigma), magnesium chloride
(5 mM) (Sigma), 0.5% w/v collagenase (Roche, Hertford, UK),
0.25% w/v protease (Sigma), 0.125% w/v hyaluronidase (Sigma)
and 0.05% w/v DNase (Sigma)) at 37 C using a ﬂow rate 75 mL/
min for between 1 and 7 min. Following manual dissociation of
the liver wedge the suspension was passed through a nylon mesh
of 250 lm followed by a nylon mesh of 60 lm. Suspensions were
then washed at 50g for 10 min at 4 C in supplemented media
(Dulbecco’s Modiﬁed Eagle Medium (DMEM) (Gibco) with 10% v/
v heat inactivated foetal calf serum (Gibco), 2 mM glutamine (Gib-
co), 20,000 units/L penicillin and 20 mg/L streptomycin (Gibco)).
Immediately after washing cell viability was determined by trypan
blue dye exclusion. Hepatocytes were plated out in supplemented
media and left for 2 h. After this period, the media were changed to
Williams E media (Sigma) containing hydrocortisone (2 lg/ml),
insulin (0.124 U/ml), glutamine (2 mM), penicillin (20,000 units/
L) and streptomycin (20 mg/L). Cells were cultured for further
2 days prior to use. Only viable cells are able to adhere to rat type
1 collagen-coated plates and hence all cells were viable at the com-
mencement of the experiments.
Enzyme-linked immunosorbent assay (ELISA) of human hepato-
cytes and human hepatic sinusoidal endothelial cells (HSEC) for
Cytokeratin 18, Cytokeratin 19 and CD31were performed.
Cells (hepatocytes or HSEC) were plated on rat type 1 collagen-
coated 96-well ﬂat-bottomed plates for 24 h following isolation.
Cells were then ﬁxed in ice cold methanol for 5 min. Non-speciﬁc
binding of mAb was inhibited by pre-incubation of cells for 1 h
at 37 C with 4% goat serum (Sigma) before the addition of mouse
anti-human mAb (IgG Isotype-matched control (Invitrogen) CD31
(Dako), cytokeratin 19 (Dako), cytokeratin 18 (Invitrogen) for 1 h
at 37 C. The cells were then washed thoroughly before incubation
with peroxidase-conjugated goat anti-mouse secondary Ab (Dako).
The enzyme-linked immunosorbent assay (ELISA) was developed
using O-phenylenediamine substrate (OPD, Dako) according to
the manufacturer’s instructions and the enzymatic reaction was
stopped using 0.5 mol/L H2SO4 (Fisher Scientiﬁc, Leicestershire,
UK). Colorimetric analysis was performed by measuring absor-
bance values at 490 nm using a Dynatech Laboratories MRX plate
reader. All treatments were performed in triplicate for each
experiment.2.2. Model of hypoxia and H–R injury
We utilised a model of warm in vitro hypoxia and H–R that we
have described previously [14]. Brieﬂy, in experiments, hepato-
cytes were cultured for 2 days at 37 C, 5% CO2 in Williams E media
(Sigma) on rat type 1 collagen-coated plates. Hepatocytes were
either maintained in normoxia or placed into hypoxia for 24 h, or
placed into hypoxia for 24 h followed by 24 h of reoxygenation.
Hypoxia was achieved by placing cells in an airtight incubator
(RS Mini Galaxy A incubator, Wolf Laboratories, UK) ﬂushed with
5% CO2 and 95% N2 until oxygen content in the chamber reached
0.1%, as veriﬁed by a dissolved oxygen monitor (DOH-247-KIT,
Omega Engineering, UK). In preliminary experiments, human
hepatocytes were exposed to 5% and 1% oxygen and no increase
in ROS accumulation or cell death was noted. Therefore, we used
0.1% oxygen in all subsequent experiments for 24 h, similar to pre-
viously published studies. Additionally, Williams E media were
pre-incubated in the hypoxic chamber in a sterile container, which
allowed gas equilibration, for 8 h before experiments were carried
out, resulting in a ﬁnal oxygen concentration of <0.1% as measured
with the dissolved oxygen metre. Where appropriate, after 24 h of
hypoxia media were aspirated and replaced with fresh, warmed,
oxygenated medium, and the cells were returned to normoxic con-
ditions. This was deﬁned as the beginning of reoxygenation. In
experiments involving ROS inhibitors, reagents were made fresh
as stock solutions and added using the correct dilutional factor to
the relevant experimental wells. Speciﬁcally, 1 mM rotenone (Sig-
ma) was dissolved in chloroform and was diluted appropriately to
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none, solvent alone controls were used to ensure no vehicle effects
(data not shown). Rotenone was added at the time of placement of
the cells into conditions of hypoxia or reoxygenation.
2.3. Determination of human hepatocyte ROS accumulation and
apoptosis
ROS production, apoptosis and necrosis were determined by
using a three-colour reporter assay system. ROS accumulationFig. 2. Intracellular ROS accumulation within PP and PV human hepatocytes during
accumulation in PP and PV primary human hepatocytes during normoxia, hypoxia and H
forward scatter (FS) versus side scatter (SS) plot of primary human hepatocytes. The FS v
were obtained during normoxia and hypoxia (data not shown). The top panel shows the g
areas of interest on the ﬂow cytometric plots are marked by the vertical ellipses. The are
plot as human hepatocytes vary considerably in size and, therefore, to include all viable h
by necessity includes the cell debris. The bottom panel shows the gating protocol applie
chart with the pooled data of ﬁve separate experiments illustrating the accumulation o
separate experiments here as human hepatocytes isolated from separate livers (normal a
are based upon values taken from cells within the gated region shown in Fig. 1a. Data
hypoxia, ⁄⁄⁄P < 0.001 relative to normoxia, Mann–Whitney test).was determined using the ﬂuorescent probe 20,70-dichloroﬂuores-
cin-diacetate [14]. This probe is cell permeable and once inside
the cell is cleaved by intracellular esterases to 20,70-dichloroﬂuores-
cin (DCF) (Merck, Nottingham, UK) which is then rendered cell
impermeable. DCF is then able to react with intracellular ROS, spe-
ciﬁcally hydrogen peroxide, to give a ﬂuorescent signal detectable
on the FITC channel. The signal is directly proportional to the level
of intracellular ROS present.
Apoptosis was determined by labelling cells with Annexin-V
(Molecular Probes, Paisley, UK) which detects exposedhypoxia and H–R. (a) Demonstrates a representative ﬂow cytometry plot of ROS
–R. The plot on the left hand side of each ﬂow cytometric plot represents a typical
ersus SS plots shown is from the H–R sample of a liver preparation but similar plots
ating protocol applied to human hepatocytes to analyse PV human hepatocytes. The
a on the left of each ellipse represents cell debris. Cell debris is included within the
uman hepatocytes in the analysis a large gate is required on the ﬂow cytometre, this
d to human hepatocytes to analyse PP human hepatocytes (n = 5). (b) Shows a bar
f ROS within PV and PP human hepatocytes during hypoxia and H–R. We refer to
nd diseased), used in separate experiments. Data are expressed as MFI and readings
are expressed as mean ± S.E. (⁄P < 0.01 relative to normoxia, ⁄⁄P < 0.01 relative to
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D (7-AAD) (Molecular Probes, Paisley, UK) is a vital dye that binds
to DNA, only entering cells once the cell membrane is disrupted
and is indicative of cellular necrosis. To ensure consistency of the
ﬂow cytometric data, each human hepatocyte preparation was la-
belled with DCF alone, Annexin-V alone and 7-AAD alone to ensure
that cells had become labelled and that the ﬂow cytometry data
could be compensated for crossover of ﬂuorophore emission spec-
tra. The same ﬂow cytometre protocol was used for all experiments
shown within the study, meaning that voltages for all markers
were constant for all human hepatocyte preparation ensuring
internal consistency of experiments.
Following appropriate treatment of cells, media were aspirated
and replaced with HBSS (Gibco) without calcium and magnesium.
DCF (30 lM) was added and the cells were incubated for 20 min in
the dark at 37 C. Next the cells were trypinsed (0.05% with EDTA,
Gibco) for 5 min and washed extensively in FACs buffer (Phos-
phate-buffered saline pH 7.2 with 10% v/v heat inactivated foetal
calf serum (Gibco). Cells were then labelled with Annexin-V and
7-AAD for 15 min whilst on ice and samples were immediately
subjected to ﬂow cytometry. At least 20,000 events were recorded
within the gated region of the ﬂow cytometre for each human
hepatocyte cell preparation in each experimental condition. Only
the cells within the gated region were used to calculate mean ﬂuo-
rescence intensity (MFI).Fig. 3. Mitochondrial dependent ROS production in PV human hepatocytes during hypo
effect of rotenone (solid grey) upon PV human hepatocyte ROS accumulation during norm
by the vertical ellipses. The gating protocol applied to PV human hepatocytes is the s
represents cell debris. Fig. 3b shows a bar chart with the pooled data of ﬁve separate exp
accumulation during normoxia, hypoxia and H–R. Human hepatocytes were treated w
dissolved in chloroform to make a stock solution of 1 mM and diluted appropriately. Veh
Data are expressed as MFI and readings are based upon values taken from cells within the
basal, ⁄⁄P < 0.001 relative to basal).2.4. Statistical analysis
All data are expressed as mean ± S.E. Statistical comparisons be-
tween groups were analysed by using the Mann–Whitney test. All
differences were considered statistically signiﬁcant at a value of
P < 0.05.
3. Results
3.1. Isolated human hepatocytes exhibit typical features of
hepatocytes
The isolated human hepatocytes consistently showed typical
morphological and phenotypic features of hepatocytes (Fig. 1).
The cell preparations were uniformly positive for the speciﬁc intra-
cellular hepatocyte marker Cytokeratin 18 whilst demonstrating
no staining with the biliary epithelial cell marker Cytokeratin 19
of the hepatic sinusoidal endothelial cell (HSEC) marker CD31. In
contrast control HSEC demonstrates strong positivity for CD31
and no staining with Cytokeratin 18.
In addition, the isolated hepatocytes demonstrated consistent
heterogeneity in terms of size. Fig. 1b clearly shows that viable
intact cells were of two different size populations. As previous
studies have demonstrated the small hepatocytes are highly likely
to represent cells originating from the peri-portal region of thexia and H–R. (a) Demonstrates representative ﬂow cytometry plots to illustrate the
oxia, hypoxia and H–R. The areas of interest on the ﬂow cytometric plots are marked
ame as that shown within Fig. 2a. Once again, the area on the left of each ellipse
eriments illustrating the effects of 2 lM rotenone upon PV human hepatocytes ROS
ith 2 lM rotenone at the time of placement into hypoxia or H–R. Rotenone was
icle alone was shown not to have any effect upon ROS production (data not shown).
gated region shown in Fig. 2a. Data are expressed as mean ± S.E. (⁄P < 0.01 relative to
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venular region [4–6]. These data demonstrate that our isolation
technique yielded human hepatocytes of a high purity with little
or no contamination with other cell types and that using FACS
we could discriminate effectively between small/PP and large/PV
human hepatocytes.
3.2. Small (PP) and large (PV) human hepatocytes exhibit differential
ROS accumulation during hypoxia and H–R
FACs analysis was able to discriminate between large or PV
and small or PP human hepatocytes using appropriate forward
scatter (FS) and side scatter (SS) plots (Fig. 2). Accordingly, using
suitable ﬂow cytometric gating protocols the response of large/PV
and small/PP hepatocytes to hypoxia and H–R could be
ascertained.Fig. 4. PV human hepatocytes undergo apoptosis and necrosis during hypoxia and H–R. (
necrosis in PP and PV human hepatocytes during hypoxia and H–R. The gate used to an
interest within the ﬂow cytometric plots are marked by the vertical ellipses. (b) Shows a
apoptosis and necrosis in PP and PV human hepatocytes during hypoxia and H–R. Data a
apoptosis and necrosis during normoxia alone. Data are expressed as mean ± S.E. (P <
cytometry plots to illustrate the effects of rotenone upon the level of PV human hepatoc
used to analyse large human hepatocytes is the same as that shown in Fig. 2. The area
Shows a bar chart with the pooled data of ﬁve separate experiments illustrating the
normoxia, hypoxia and H–R. Data are expressed as increase/decrease relative to basal, w
are expressed as mean ± S.E. (P < 0.05 relative to no treatment in the same experiment
⁄⁄P < 0.001 relative to no treatment in the same experimental condition).PV hepatocytes, isolated from benign liver resections, normal
donor tissue and biliary cirrhosis (primary biliary cirrhosis and
primary sclerosing cholangitis) showed signiﬁcant increase in
ROS accumulation during hypoxia (Fig. 2a and b). Exposure of hu-
man hepatocytes to H–R further accentuated intracellular ROS
accumulation. In contrast, PP hepatocytes, showed no increase in
intracellular ROS accumulation during hypoxia and H–R.
3.3. ROS production in large (PV) hepatocytes is mitochondrial
dependent
Numerous previous studies have shown that the mitochondrion
is the central source of ROS during hypoxia and H–R [14–16].
Therefore, mitochondrial function was inhibited within large/PV
human hepatocytes using the complex I mitochondrial chain
inhibitor, rotenone. As Fig. 3a and b demonstrates, rotenonea) Shows representative ﬂow cytometry plots to illustrate the level of apoptosis and
alyse primary human hepatocytes are the same as that shown in Fig. 2. The area of
bar chart with the pooled data of ﬁve separate experiments illustrating the level of
re expressed as increase/decrease relative to basal, where basal refers to the level of
0.05 relative to basal, ⁄P < 0.01 relative to basal). (c) Shows representative ﬂow
yte apoptosis and necrosis during normoxia, hypoxia and H–R. The gating protocol
of interest within the ﬂow cytometric plots are marked by the vertical ellipses. (d)
effect of rotenone upon the level of PV hepatocyte apoptosis and necrosis during
here basal refers to the level of apoptosis and necrosis during normoxia alone. Data
al condition, ⁄P < 0.01 relative to no treatment in the same experimental condition,
Fig. 4 (continued)
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cytes during normoxia, hypoxia and H–R. Rotenone had no effect
upon ROS accumulation in small/PP human hepatocytes (data not
shown).
3.4. Large (PV) and not small (PP) human hepatocytes undergo
apoptosis and necrosis during hypoxia and H–R
The relationship between intracellular ROS accumulation and
apoptosis and necrosis has been clearly established within human
hepatocytes [14]. Accordingly, we found that large/PV human
hepatocytes, in line with their propensity to generate ROS during
hypoxia and H–R, underwent signiﬁcant levels of apoptosis and
necrosis (Fig. 4a and b). In contrast, small/PP hepatocytes did notundergo any apoptosis or necrosis in line with their lack of ROS
generation during hypoxia and H–R. We ﬁnally investigated
whether mitochondrial generated ROS during hypoxia and H–R
was responsible for regulating human hepatocyte apoptosis and
necrosis. As Fig. 4c and d illustrates, rotenone signiﬁcantly reduces
large/PV human hepatocyte apoptosis and necrosis during nor-
moxia, hypoxia and H–R. These ﬁndings clearly demonstrate that
in PV human hepatocytes mitochondrial ROS generated during hy-
poxia and H–R drives cell death.
4. Discussion
Exposure of hepatocytes to pathological conditions in a micro-
environment of hypoxia and H–R is very frequent in several hepa-
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shock, septicaemia and liver transplantation. Death of hepatocytes
by hypoxia and H–R injury is a multifactorial event including alter-
ation of the plasma membrane, increase of autophagic vacuoles,
rupture of blebs on the cell surface, calcium accumulation and
mitochondrial damage [9]. The common mediator of these death
pathways appears to be the accumulation of ROS [17]. Studies in
rodent models suggest that large/PV hepatocytes are more vulner-
able to damage during hepatic injury [8]. Moreover, hepatocyte
proliferation, which is an important determinant of patient
survival after major hepatic resection, occurs from the small/PP
to large/PV hepatocytes. Therefore, an understanding of the differ-
ential vulnerability of hepatocytes to liver injury would provide an
important basis for preventing loss of liver function and/or failure
caused by cirrhosis, hepatic resection and liver transplantation [8].
Common factors to most liver injuries are hypoxia and the gener-
ation of ROS [14,17]. However, the susceptibility of hepatocytes,
and in particular human hepatocytes, to oxidative stress has not
been assessed directly. We show for the ﬁrst time to our knowl-
edge, clear evidence that large/PV hepatocytes are the most sus-
ceptible to hypoxic injury. Moreover, this susceptibility is due to
the greater propensity of the mitochondria of these large/PV hepa-
tocytes to produce and accumulate intracellular ROS [18]. It must
be noted however, that inhibiting mitochondrial function does
not completely abrogate large/PV human hepatocyte apoptosis
and necrosis. Indeed, previous studies have shown that other en-
zymes involved in ROS generation are also involved in regulating
human hepatocyte apoptosis [14].
The increased level of apoptosis and necrosis seen in large/PV
human hepatocytes seen in vitro in the present study would con-
cur with in vivo models of murine and rodent liver injury, where
cell death is observed in the peri-venular regions of the liver
[13]. A possible explanation for this observation may well be that
the powerful antioxidant glutathione (in rodent models) varies
considerably in concentration between hepatocytes isolated from
the small/PP and large/PV regions [19]. Speciﬁcally, large/PV hepa-
tocytes have less intracellular glutathione when compared to
small/PP or small hepatocytes. Moreover, following stimulation
with amino acids larger hepatocytes are able to generate less intra-
cellular glutathione than small hepatocytes [19]. These ﬁndings
could in theory explain the increased susceptibility of large/PV hu-
man hepatocytes to hypoxic injury.
Previous studies have shown that mitochondrial inhibitors and
anti-oxidants inhibit ROS accumulation in human hepatocytes dur-
ing hypoxia and H–R [14–16]. Our present study builds upon this
observation, demonstrating that mitochondrial electron transport
chain inhibitors speciﬁcally reduce ROS accumulation in the
large/PV hepatocytes and consequently reduce apoptosis in this
population during hypoxia and H–R. Many studies have suggested
that resident liver macrophages (Kupffer cells) located in the PV re-
gion of liver are activated during ischaemia and release ROS, lead-
ing to hepatocyte damage [8]. Taken together with our study this
suggests that the PV region of the liver is the preferential site of he-
patic inﬂammation and ROS generation during hypoxic liver injury.
Contrastingly, some studies in rodent hepatocytes have suggested
that small/PP hepatocytes are more vulnerable to hypoxic injury
due to their higher requirement of oxygen [8]. We remain uncer-
tain about the explanation for these discrepancies which may rep-
resent inter-species differences of unknown aetiology.
In conclusion, large/PV human hepatocytes are the most sus-
ceptible to hypoxic damage. This suggests that therapeutics usedin the treatment of liver disease may primarily act upon PV or large
human hepatocytes. In the future, therapeutic strategies used to
treat hepatic inﬂammationmay require novel drug targeting meth-
ods that allow the delivery of the drug preferentially to the PV or
large hepatocytes.Acknowledgements
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Abstract
Successful and consistent isolation of primary human hepatocytes remains a challenge for both cell-based therapeutics/
transplantation and laboratory research. Several centres around the world have extensive experience in the isolation of
human hepatocytes from non-diseased livers obtained from donor liver surplus to surgical requirement or at hepatic
resection for tumours. These livers are an important but limited source of cells for therapy or research. The capacity to
isolate cells from diseased liver tissue removed at transplantation would substantially increase availability of cells for
research. However no studies comparing the outcome of human hepatocytes isolation from diseased and non-diseased
livers presently exist. Here we report our experience isolating human hepatocytes from organ donors, non-diseased
resected liver and cirrhotic tissue. We report the cell yields and functional qualities of cells isolated from the different types
of liver and demonstrate that a single rigorous protocol allows the routine harvest of good quality primary hepatocytes
from the most commonly accessible human liver tissue samples.
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Introduction
High quality primary human hepatocytes are a valuable
resource for biomedical research, the pharmaceutical industry
and therapeutic purposes [1–4]. It is becoming widely accepted
that the majority of hepatocyte cell lines lack many important
aspects of primary cell function and are unlikely to be used
therapeutically. Primary hepatocytes are thus becoming increas-
ingly used in drug development to evaluate key human-specific
drug properties such as metabolic fate, drug-drug interactions, and
drug toxicity. However the quality and metabolic/functional
activity of the cells is variable. Thus human hepatocyte research
would be greatly assisted if hepatocytes could be consistently
isolated from human liver tissue obtained through hepatobiliary
and transplant programs. Previously authors have suggested
protocols for successful human hepatocyte isolation but these
have applied exclusively to tissue obtained from organ donors [5–
6] or from non-diseased tissue removed at surgical resection for
liver tumours [1,7–10]. Recent work conducted within our
laboratory has shown for the first time that human hepatocytes
isolated from various cohorts of non-diseased and diseased livers
exhibit different responses when used in functional studies [4].
Thus comparative studies need to be carried out in cells isolated
from different hepatic diseases.
The isolation of human hepatocytes from steatotic liver tissue
has been difficult [6] and although detailed protocols have been
described [3] the overall results are so variable in terms of yield
and quality of cells that it has been suggested it is not economically
viable to attempt hepatocytes isolation from diseased liver tissue
[6]. Most published studies have reported outcomes of human
hepatocyte isolation from normal resected [1] and donor liver
tissue [2,3]. Here we report our experience of isolating human
hepatocytes from all types of livers including normal donor tissue,
cut-down liver, normal resected liver tissue and cirrhotic liver
disease. We do so in the hope that other researchers in this
challenging field may benefit from our experience and make
informed decisions on how best to isolate cells for their own
studies.
Methods
Ethics Statement
Liver tissue was obtained from surgical procedures carried out
at the Queen Elizabeth Hospital, Birmingham, UK. Ethical
approval for the study was granted by the Local Research Ethics
Committee (LREC) (reference number 06/Q702/61). Informed
written consent was obtained from all participants involved in the
study.
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All liver tissue was obtained from fully consenting patients
undergoing liver transplantation for a variety of end-stage liver
diseases. Human hepatocytes were isolated from explanted
diseased livers from patients with alcoholic liver disease (ALD),
biliary cirrhosis (primary biliary cirrhosis (PBC) and primary
sclerosing cholangitis (PSC) and a variety of other end-stage liver
diseases (Cystic Fibrosis, Cryptogenic Fibrosis, Alpha-1-antitypsin
Deficiency, Autoimmune Hepatitis and Non-alcoholic Steatohe-
patitis). Hepatocytes were also isolated from tissue taken from
patients who had undergone hepatic resections for liver metastasis
from colorectal carcinoma, hepatic resections carried out for
benign disease (recurrent cholangitis, focal nodular hyperplasia
and haemangiomas), cut-down specimens and normal donor tissue
surplus to surgical requirements. For the purposes of the study,
liver tissue obtained from resections for benign lesions was
included in the normal liver group whereas liver tissue obtained
from hepatic resections carried out for metastatic disease was
classified as normal resected tissue as is referred to as this hereafter.
All the patients included in this latter group had received pre-
operative chemotherapy to reduce tumour mass prior to surgery.
For all liver tissue specimens we adopted a stringent and rigorous
procurement and isolation protocol. Following explantation or
resection, specimens were immediately placed on ice in a sterile
sealed draw string bag and processed within 1 hour. There were
however exceptions to this, in cases were hepatic resections or liver
transplants were carried out at in the late evening or at night, liver
tissue was kept sterile on ice overnight. The significant exception to
this protocol was in the use of donor liver tissue. In all cases the donor
liver was assessed for transplantation by the clinical team at the
Queen Elizabeth Hospital, Birmingham and if deemed unsuitable for
liver transplantation it was then used for hepatocyte isolation. Precise
time between explantation or resection of the liver and commence-
ment of the isolation procedure was recorded in each case.
In isolation procedures where donor liver or liver explants were
used, liver wedges were obtained from either the segments II/III
or segments V/VI. In procedures where normal resected tissue
was used for isolating human hepatocytes, only patients who had
undergone right hemihepatectomies were deemed suitable by our
pathologist to obtain normal resected liver tissue from. This was
obtained in all cases from segments V/VI. Liver wedges were cut
and weighed by a trained pathologist. To eliminate interperson
variability, the subsequent hepatocyte isolation procedures were
carried out by a single individual (R.H.B).
Hepatocyte isolations were carried out using a modified ‘two-
stage’ collagenase procedure developed by Berry and Friend [11].
This method has been adapted by several laboratories to isolate
human hepatocytes [12–14]. After the liver wedge was cut it was
placed into ice-cold Dulbecco’s Modified Eagles Medium (DMEM)
(Gibco, Paisley, UK). The liver was then washed through the
exposed, cut, vessels with Phosphate-buffered Saline (PBS), pH 7.2.
This was to remove any remaining blood from within the liver
wedge and to identify two suitable vessels that could be used for
cannulation and subsequent perfusion of buffers. The vessels for
cannulation were chosen using two criteria. Firstly, when washing
the liver through with PBS it is apparent which parts of the wedge
were being ‘perfused’ by that particular vessel, hence the greater the
liver area ‘perfused’ the more favourable the vessel was thought to
be and secondly the two vessels should be in different parts of the
liver wedge to ensure optimum perfusion of the whole wedge.
Subsequently two 20 gauge cannulae (Becton-Dickinson, Oxford,
UK) were sutured into the chosen vessels using a 3/0 prolene
(Covidien, Hampshire, UK) purse string suture (Figure 1). The
cannulae were then primed with PBS to ensure that subsequent
fluids used for perfusion would run correctly. The final stage of
preparing the liver wedge involved oversewing any major vessels
that were present on the cut surface of the liver wedge, to ensure
minimal loss of perfusion fluids. This also helped maintain pressure
within the liver wedge throughout the isolation procedure.
The perfusion circuit was set up according to the widely
established routine protocol. One end of the perfusion tube was
fed into the perfusion buffer, the central segment of the tubing was
within the pump (Model IP 505Du, Watson-Marlow Ltd,
Falmouth, UK), and the two outlets of the tubing were connected
to the sutured cannulae. The liver wedge was held over a
container during the procedure. This container also contained the
waste tubing which connected the container to the waste pot. At
the commencement of the procedure, all rubber tubing remained
‘open’ allowing the free flow of perfusion and waste fluids. All
buffers used in the isolation procedure were pre-warmed to 42uC
in a water bath. At this stage, liver wedges were first perfused with
‘non-recirculating’ wash buffer (10 mM 4-(2-hydroxylethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 7.2) (Sigma, Dorset,
UK) at room temperature using a flow rate of 75 ml/min,
ensuring flushing out of blood within the liver vasculature. After
this, the wedge was perfused with chelating solution (non-
recirculating) (10 mM HEPES, 0.5 mM Ethylene Glycol Tetra-
acetic Acid (EGTA), pH 7.2) (Sigma) in order to disrupt cell
adhesion to the underlying matrix. This was followed by further
perfusion with (non-recirculating) wash buffer to remove any
remaining EGTA from the liver as the enzymes used to dissociate
the liver are dependent upon calcium and magnesium for
activation. At this point the waste tubing was clamped to allow
recirculation of the enzymatic buffer. Enzyme buffer perfusion
solution was made up as follows: Fresh aliquots of enzymes were
removed from 220uC storage and dissolved in Hank’s Balanced
Salt Solution (HBSS) (Gibco, Paisley, UK) that had been
supplemented with calcium chloride (5 mM) and magnesium
chloride (5 mM). Following enzyme dissolution the solution was
Figure 1. Preparation of the Encapsulated Liver Wedge Prior to
Perfusion. Isolation of human hepatocytes was performed from liver
wedges (50–413 g). Liver wedges had one cut face (CF) with the
remainder of the hepatic capsule being left intact. After washing the
liver through exposed vessels with PBS, 20 G cannulae were sutured
into suitable vessels with 3/0 prolene purse string sutures. The
remaining vessels were oversewn using continuous 3/0 prolene sutures
(arrowed). The liver wedge was then ready to be used for the perfusion
isolation protocol.
doi:10.1371/journal.pone.0018222.g001
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filtered through a sterile filter (Miltenyi Biotec Ltd, Surrey, UK)
back into the HBSS solution. Specifically, 0.5% w/v Collagenase
A (from Clostridium Histolyticum, Roche, Hertford, UK, Lot
number 70273822), 0.25% w/v Protease (Type XIV from
Streptomyces Griseus, Sigma, Lot number 076K1177, 4.5 units/
mg), 0.125% w/v Hyaluronidase (from bovine testes, Sigma, Lot
number 025K7015, 451 units/mg) and 0.05% w/v Deoxyribo-
nuclease (from bovine pancreas, Sigma, Lot number 107K7013,
552 units/mg) were the enzymes used. The liver wedge was
perfused with the recirculating enzyme solution at 37uC using a
flow rate 75 ml/min for between 1–19 min, this time was
designated to be the perfusion time. The decision to stop perfusion
was made when the cut surface of the liver allowed the admission
of a digit. At this point the perfusion tubing and cannulae were
removed and the liver was then transferred to a sterile glass dish
and dissociated using manual force whilst in DMEM supplement-
ed with 10% v/v heat inactivated foetal calf serum (Gibco), 2 mM
glutamine (Gibco), 20,000 units/l Penicillin, and 20 mg/ml
Streptomycin (Gibco) and 2.5 mg/ml Gentamycin. Following
manual dissociation of the liver wedge the suspension was passed
through a sterile nylon mesh of 250 mm (John Staniar Ltd,
Manchester, UK) followed by a sterile nylon mesh of 60 mm (John
Staniar Ltd). Suspensions were then washed three times at 506g
for 10 min at 4uC in supplemented media.
Immediately after washing, cell viability was determined by
trypan blue dye exclusion and deemed acceptable if greater than
.50% at this stage. Hepatocytes were then plated out in
supplemented media. If viability was lower but total cell yield
was high, Percoll density gradient centrifugation of cell suspensions
was carried out to improve yield of viable cells. Percoll (Sigma) was
made by adding to PBS pH 7.2 to density of 4.5 g/ml. Percoll was
added to cell suspensions and washed at 3006g for 30 min at room
temperature. Cell viability was again determined by trypan blue
dye exclusion and if improved to .50% cells were plated out at
56105 per well in supplemented media for 2 hours onto type 1 rat
collagen coated plates to allow adherence of cells. After this period,
the media was changed to Arginine-free Williams E media (Sigma)
containing Hydrocortisone (2 ug/ml), Insulin (0.124 U/ml),
Glutamine (2 mM), Penicillin (20,000 units/l), Streptomycin
(20 mg/l) and Ornithine (0.4 mmol/l). The media was exchanged
every 24 hours and for subsequent functional studies, cells were
used within 2 days. Figure 2 shows the morphology of primary
human hepatocyte isolated from PBC livers at different time points
following successful isolation. The morphology of human hepato-
cytes isolated from normal tissue, biliary cirrhosis, ALD and
normal resected liver tissue three days after successful isolation are
also demonstrated (Figure 2b). As Figure 3 demonstrates, primary
human hepatocytes showed characteristic phenotypic features of
hepatocytes and were able to maintain urea and albumin synthesis
up to at least one week following successful isolation. Successful
human hepatocyte isolations were defined as successful plating of
cells that were used in subsequent functional studies.
Liver samples from the normal liver category were histopatho-
gically evaluated on formalin fixed paraffin-embedded sections by
G.M.R. Steatosis was reported by the percentage of steatotic
hepatocytes present and group accordingly: minimal/none=
0–5%, mild = 5–33%, moderate = 33–66% and severe =.66%.
Urea Synthesis Assay
Confirmation of urea synthesis by isolated human hepatocytes
was performed using quantitative colorimetric urea determination
(QuantiChromTM urea assay kit-DIUR-500) (Bioassay Systems,
Hayward, CA, USA).
Albumin Synthesis Assay
Albumin synthesis by isolated human hepatocytes was con-
firmed using a sandwich ELISA kit (Abnova, CA, USA).
Immunostaining human hepatocytes for Cytokeratin 18
Following successful isolations, cytospins of hepatocytes were
made on Poly-L-lysine coated glass slides and fixed for 5 min in
acetone. Cells were then incubated with 20% normal rabbit serum
(Dako, Cambridge, UK) in Tris-buffered saline pH 7.4 (TBS) for
30 min. Monoclonal antibody to Cytokeratin 18 diluted 1:100
(clone DC10, Dako) or monoclonal antibody to Cytokeratin 19
diluted 1:100 (clone RCK108, Dako) or monoclonal antibody to
CD326 (Epithelial Cell Adhesion Molecule (EpCAM) diluted
1:100 (clone HEA125, Progen, Heidelberg, Germany) was applied
for 60 min, followed by polyclonal rabbit-anti mouse IgG antibody
(1:25 dilution, Dako) for 30 min and finally anti-alkaline
phosphatise (APAAP) complex (1:50 dilution in TBS) for
30 min. After each incubation step cytospins were washed x3 in
TBS. Antibody binding was visualised with 0.2 mg/ml naphthol-
AS-MX-phosphate dissolved in Dimethylforamide, (Sigma),
1 mg/ml Fast Red (Sigma) in 0.1 M Tris buffer (pH 8.2) and
0.25 mg/ml Levamisole (Sigma) for 15 min followed by counter-
staining with Mayer’s haematoxylin (Dako). Control cytospins
were included where primary antibody was substituted for isotype
matched immunglobulin. Slides were then mounted with Immu-
noblot mounting medium (Dako) and assessed for positivity.
Statistical Analysis
Univariable analysis was performed to test the effect of specific
factors upon outcome measures, human hepatocyte cell viability
following a preparation, total cell count after preparation and
success. Success was defined as maintenance of cell adherence and
morphological integrity 48 hours after plating onto type I rat
collagen and their subsequent use in functional studies. The
specific factors we analysed were hepatic disease type, time delay
between hepatectomy and beginning of the liver perfusion, weight
of liver wedge, perfusion time, the level of steatosis in the normal
liver cohort, and the use of Percoll enrichment. In univariable
analysis, Mann-Whitney tests were used for the time and weight
variables, as they did not to follow a normal distribution, with
Fisher’s Exact test being used for the categorical variables.
Multivariable analysis was performed by considering all specific
factors simultaneously and assessing the effect upon the said
outcome measures. For this analysis logistic regression models
were used.
Repeated-measures ANOVA was utilised to analyse the
synthesis of albumin and urea by human hepatocytes isolated
from normal, PBC/PSC, ALD and normal resected liver tissue.
Results
Liver wedges were prepared as shown in Figure 1 and processed
as detailed in the Methods section. Figure 2a shows representative
images of primary human hepatocytes, isolated from a liver with
PBC, in culture for the first week after isolation. Similar
morphological changes were observed during the first week after
successful cell isolation from normal, PSC, ALD and normal
resected liver tissue. Figure 2b demonstrates the morphological
features of primary human hepatocytes isolated from these various
livers 3 days after isolation. The morphology of primary human
hepatocytes after 3 days in culture was maintained for at least one
week after successful isolation.
The type of livers used and the main results of all human
hepatocyte isolations are shown in table 1. We processed and
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isolated human hepatocytes from 104 liver wedges over a two year
period. A variety of liver diseases were used including, as detailed
above, ALD, biliary cirrhosis (PBC and PSC), normal resected
liver and normal liver tissue (donor liver tissue, resections for
benign liver disease and cut-down specimens). A large proportion
of livers used in our study were from cirrhotic, end stage liver
diseases (54%). Normal resected liver tissue was defined as liver
tissue from patients with colorectal metastasis accounted for 26%
of livers used. All these latter patients had received pre-operative
chemotherapy for reduction of tumour mass prior to surgery.
Isolated cells from human liver tissue were all positive for the
hepatocyte cell marker, Cytokeratin 18 and were negative for the
biliary epithelial cell marker, Cytokeratin 19, and the hepatic
progenitor cell marker, CD326 (EpCAM) (Figure 3a). Further-
more, all hepatocytes isolated from normal and diseased liver
tissue demonstrated albumin and urea synthesis in the first week
after isolation (Figure 3b). Human hepatocytes isolated from
normal, normal resected and biliary cirrhosis showed significantly
increased albumin synthesis after two days in culture. Interestingly,
human hepatocytes isolated from ALD livers demonstrated
Figure 2. Morphology of Primary Human Hepatocytes after Isolation in Culture. (a) Comparison of the morphological appearance of
primary human hepatocytes isolated from primary biliary cirrhosis (PBC) attached to collagen-coated plates at (i) 2 hours after isolation (magnification
206), (ii) 1 day after isolation, (iii) 2 days after isolation, (iv) 3 days after isolation and (v) 7 days after isolation using light microscopy. The
representative images show the change in morphology of primary human hepatocytes isolated from PBC livers during 1-week in culture. Immediately
after isolation, cells appear ovoid and phase bright. Following 1 day in culture the cells appear binucleate and have formed a confluent monolayer.
Primary human hepatocytes maintain this morphology throughout the one week culture period. Similar morphological changes were observed for
human hepatocytes isolated from normal, ALD and normal resected liver tissue (data not shown). (b) Representative images of the morphology of
human hepatocytes isolated from normal, PBC/PSC, ALD and normal resected liver tissue are shown in culture 3 days after successful cell isolation.
Human hepatocytes demonstrated and maintained this morphology for at least one week following successful isolation. (i) Demonstrates the
morphology of human hepatocytes isolated from normal liver tissue and macro-steototic liver tissue (magnification 206). Primary human
hepatocytes isolated from normal liver tissue display the typical cubic binucleate cell morphology. In contrast, primary human hepatocytes isolated
from overtly macro-steatotic livers demonstrate obvious micro-vesicular steotosis. (ii) Human hepatocytes isolated from end stage biliary cirrhosis
(PBC/PSC) again show the typical features of cells in culture with a cubic and binucleate morphology. (iii–iv) Cells isolated from ALD and normal
resected liver show similar morphological features to human hepatocytes isolated from normal non-steatotic livers and biliary cirrhosis but also
exhibit micro-vesicular steatosis.
doi:10.1371/journal.pone.0018222.g002
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significantly reduced levels of albumin production when compared
to other hepatocytes (p,0.05). Urea synthesis by human
hepatocytes demonstrated similar characteristics, with production
of urea being significantly greater on day 2 when compared to
other days in culture. Of note biliary cirrhosis and normal resected
human hepatocyte produce significantly more urea in culture
when compared to other human hepatocytes.
Absolute cell count after isolation was an important parameter
on which to assess efficacy of the procedure. Univariable analysis
revealed that disease type (p,0.001, Fisher’s Exact test) was the
only factor to have a significant bearing upon total cell count after
primary isolation. Multivariable analysis showed that ALD livers
have a significantly lower cell yield when compared to other liver
categories (p,0.15 – table 1).
Overall, for all human hepatocyte isolations we report a median
cell viability of 40%. Human hepatocytes isolated from biliary
cirrhosis (PBC and PSC) had the highest median cell viability
(55%). Univariable and Multivariable analysis showed the only
factor which had an effect upon improving cell viability was the
time delay between hepatectomy and beginning of the perfusion
procedure (p,0.05, Mann-Whitney test). Complete processing
within 3 hours resulted in a significantly higher cell viability
(.50%), compared to time delays greater than 5 hours (p,0.05,
Odds Ratio = 3.594). Whether the delay is 3–5 hours or more
Figure 3. Immunostaining of Cytokeratin 18, Cytokeratin 19 and CD326 and Metabolic Activity of Primary Human Hepatocytes
Isolated from Normal and Diseased Liver Tissue. (a) Human hepatocytes isolated from normal, PBC, ALD and normal resected liver tissue show
strong staining for the intracellular hepatocyte marker Cytokeratin 18 (CK18). In contrast, isotype matched controls immunoglobulin showed no
positivity. Furthermore, isolated human hepatocytes showed no staining with the biliary epithelial cell marker Cytokeratin 19 (CK19) or hepatic
progenitor cell marker CD326 (EpCAM). Cytospins of human hepatocytes were made immediately after successful cell isolation, fixed in acetone for
5 min and stored at 220uC until immuno-staining was performed. (b) Following successful isolation, human hepatocytes isolated from normal, PBC/
PSC, ALD or normal resected liver tissue were able to synthesise albumin (i) for at least one week demonstrating active metabolic activity in culture.
Human hepatocytes isolated from normal, PBC/PSC and normal resected liver tissue show significantly greater albumin synthesis after two days in
culture (*p,0.05). Morover, human hepatocytes isolated from ALD livers synthesised significantly less albumin than other types of human
hepatocytes (p,0.05). In addition, human hepatocytes isolated from normal resected liver tissue synthesised significantly greater amounts of
albumin than normal hepatocytes (p,0.037). (n = 3–4 separate samples). Human hepatocytes isolated from normal, PBC/PSC, ALD and normal
resected liver tissue were also able to synthesise urea (ii) for at least one week following successful cell isolation. Human hepatocytes isolated from
both normal and diseased liver tissue synthesised significantly lower levels of urea one day after isolation (1p,0.001) compared to the remainder of
the culture period, but all human hepatocytes produced significantly more urea on day 2 when compared to other days (*p,0.001). Finally, PBC/PSC
and normal resected human hepatocyte synthesis significantly greater amounts of urea when compared to the other human hepatocytes (p,0.05)
but there was no significant difference between PBC/PSC and resected human hepatocytes. (n = 3–4 separate samples).
doi:10.1371/journal.pone.0018222.g003
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than 5 hours did not have a significant effect on the likelihood of the
cell viability being greater than 50% (p=0.375, Odds Ratio =1.725).
These data are summarised in Table 2. In our study we used Percoll
density gradient centrifugation to enrich hepatocytes purity where cell
viability was low but absolute cell count high (n=8). These data are
summarised in Table 3. Percoll enhanced purity of human
hepatocyte isolates but at the expense of cell count, hence the need
for a relatively high absolute cell count after the initial liver
preparation.
We assigned all donor liver tissue, resections performed for
benign liver disease (recurrent cholangitis, focal nodular hyper-
plasia and haemangiomas) and cut down specimens as ‘normal’
liver tissue. These livers had no signs of intrinsic liver disease. This
group was analysed as a whole and as a sub-group, where donor
liver tissue was compared to normal liver tissue (resections from
benign liver disease and cut down specimens). Sub-group analysis
was carried out to determine whether the level of steatosis had an
effect upon absolute cell count, cell viability and success rate of
subsequent culture. The level of steatosis in the two groups is
shown in Table 4. We found no difference in absolute cell count,
cell viability, and success rate between the donor liver and normal
liver groups. The success of isolating human hepatocytes from this
group as a whole was good (53%) but normal liver tissue obtained
from hepatic resections carried out for benign disease and cut-
down specimens had a statistically higher success rate (64%) when
compared to donor liver tissue (20%).
Our series is the largest reported of human hepatocyte isolations
from cirrhotic livers (n = 55). We report a median success rate
when isolating hepatocytes from cirrhotic livers of 45%. Table 1
shows that liver wedges from biliary cirrhosis (PBC and PSC) had
the highest success rate of all livers used in our study (71%). For all
liver isolations, univariate analysis showed a significant difference
in time delay between hepatectomy and beginning of liver
perfusion (p,0.001, Mann-Whitney test), perfusion time
(p,0.05, Mann-Whitney test) and disease type (p,0.05, Fisher’s
Exact test) between the groups of successful and unsuccessful
isolations. Multivariable analysis revealed disease type (p,0.05)
and time delay between hepatectomy and beginning of perfusion
(p,0.05) were significant factors affecting successful human
hepatocyte isolation. As described above for cell viability, success
is significantly dependent upon time delay (p,0.01), with a delay
of less than 3 hours resulting in improved success rates compared
to those of more than 5 hours (p,0.05, Odds Ratio = 3.735).
Discussion
The preparation of primary human hepatocytes is a time
consuming, logistically demanding, and expensive process. The
demand for high quality human hepatocytes for cell transplanta-
tion and pharmo-toxicological studies continues to rise. However,
the availability of human liver tissue for laboratory investigation
remains limited. Therefore, cirrhotic end-stage livers, which are
more readily available to researchers, represent another potential
source of human hepatocytes. We know of no other studies which
evaluate and compare the outcome of human hepatocytes isolation
Table 1. The Type of Livers used and the Main Results of All Human Hepatocyte Isolations.
Liver Type
Time Delay
(hrs)
Weight
(g)
Perfusion Time
(min)
Absolute Cell Count
After Perfusion
6103
Viability
(%)
Success Rate
(%)
Normal (n = 21) 2.5
(1–14)
110
(66–413)
1.5
(1–11)
57
(75–200,000)
46
(0–100)
53
Donor Liver (n = 7) 4
(2–14)
117
(101–150)
1.5
(1–11)
1500
(75–200,000)
20
(0–60)
29
Normal Liver (n = 14) 2
(1–4)
105
(66–413)
2
(1–7)
505
(75–32,000)
50
(10–100)
64
Resected (n = 27) 2.5
(1–16)
90
(50–180)
1.5
(1–5)
220
(50–6,000)
50
(0–100)
53
Biliary Cirrhosis (n = 24) 2
(1–11)
106
(78–200)
1.5
(1–8.5)
720
(200–7,000)
55
(0–100)
71*
ALD (n = 24) 2.5
(1–13)
110
(64–220)
3
(1–19)
155{
(20–3,000)
40
(0–100)
29
Others (n = 8) 4.5
(1–12)
101
(56–115)
5.5
(3–17)
225
(40–3,000)
7.5
(0–70)
13
TOTAL (104) 2
(1–16)
110
(50–413)
2.5
(1–19)
350
(20–200,000)
40
(0–100)
51
The time delay, weight of liver wedges, perfusion time, absolute cell count after perfusion, cell viability and success rate are shown for various liver categories; Normal
(donor liver tissue, normal benign tissue and cut-down specimens), normal resected liver tissue, biliary tissue (PBC and PSC), ALD and others (cystic fibrosis 2,
cryptogenic fibrosis 2, alpha-1-antitypsin deficiency 1, autoimmune hepatitis 1 and non-alcoholic steatohepatitis 2). All values are represented as medians and the
values in parentheses represent the range. n, number of cases.
{p,0.05, multivariable analysis showing ALD livers yield significantly lower cell yields when compared to other liver diseases.
*p,0.05, multivariable analysis showing biliary cirrhosis yielded a higher success rate of human hepatocyte isolation when compared to other liver diseases.
doi:10.1371/journal.pone.0018222.t001
Table 2. Effect of Time Delay Between Hepatectomy and
Beginning of the Perfusion Procedure Upon Human
Hepatocyte Cell Viability Following Isolation Procedure.
Time Delay (hrs) Median Cell Viability (%)
,3 53
3–5 25
.5 20
doi:10.1371/journal.pone.0018222.t002
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from all sources, including end-stage liver disease, using one
standard isolation protocol. Our experience highlights that the
isolation of primary human hepatocytes from normal or diseased
livers is a viable proposition given appropriate methods.
Our data confirm that isolating human hepatocytes from ALD
livers is technically challenging and we had a success rate of only
29%. Thus the use of ALD livers for hepatocyte isolation is a
questionable proposition. This may in part be explained by the
variable disease stage of our ALD cohort which included patients
with advanced cirrhosis or it may reflect toxicological damage
resulting from the effects of alcohol. Excluding the ‘other’ disease
categories, ALD livers had the longest median perfusion time
again presumably reflecting that these livers were from patients
with more advanced liver cirrhosis. Moreover, human hepatocytes
isolated from ALD demonstrate significantly less albumin
production when compared to the other human hepatocytes
supporting the hypothesis that prior alcohol exposure may affect
the function of these hepatocytes. Our data further highlight that
tissue from patients with biliary cirrhosis (PBC or PSC) provides
high yields of hepatocytes (success rate 71%). Furthermore, such
hepatocytes demonstrate the highest levels of albumin and urea
production. As discussed below, this success rate was similar to that
we obtained using non-diseased liver tissue. In biliary cirrhosis
cytoprotective agents such as ursodeoxycholic acid (UDCA) are
routinely used therapeutically. The ability of UDCA to inhibit the
accumulation of reactive oxygen species (ROS) [15] and its known
anti-apoptotic effects may provide hepato-protection [16]. Indeed
in our reported series all patients with biliary cirrhosis were taking
UDCA at the time of liver transplantation. Thus UDCA may
promote human hepatocytes isolation in an analogous way to that
suggested for the antioxidant, N-acetylcysteine (NAC) [3].
Conversely, alcohol consumption increases ROS production
which instigates hepatocyte injury during ALD [17] as well as
inducing toxic metabolites and cytokines that perpetuate hepato-
cyte injury. It is thus possible that hepatocytes from patients with
ALD are sensitised to the cellular stress induced by enzymes used
in the digestion process resulting in increased hepatocyte cell death
and lower cell viability and yields. The yields from end-stage
cirrhotic livers other than ALD and biliary cirrhosis were very
poor results (success rate 13%) and we would not recommend the
routine use of such livers for cell isolation.
We report a success rate of 53% for hepatocyte isolation from
normal resected livers, which is lower than that reported by other
authors [7,18]. There are several potential explanations for this.
Other studies used different enzyme cocktails and may have been
more selective when deciding which livers to process [1]. Recent
studies have used the enzyme liberase to isolate hepatocytes from
normal resected liver tissue and have reported higher cell
viabilities and cell yields [1]. We concur with previous authors
that normal resected tissue is a good source of human hepatocytes.
However, our recent study suggests that human hepatocytes
isolated from normal resected liver tissue may differ functionally in
their response to physiological stimuli [4]. Most authors have
previously assumed that the function of human hepatocytes
isolated from normal liver tissue was consistent between different
sources [18]. In light of our findings further functional analyses of
human hepatocytes isolated from different liver diseases should be
carried out before conclusions can be drawn about their
‘normality’.
The isolations we carried out using liver wedges from benign
resections and cut down specimens gave good success rates (64%)
compared to donor liver tissue (29%) consistent with results reported
by others [7]. The donor livers used in our study had been turned
down for transplantation as a result of macrosteatosis and as
Figure 2b demonstrates human hepatocytes from these steatotic
livers also exhibit micro-vesicular steatosis. Within the steatotic
livers the rate of successful hepatocyte isolation was greater than in
those with mild compared with moderate or severe steatosis (70%
vs. 20%). Previous authors have also noted that high degrees of
steatosis generally did not favour successful cell isolation [6,7].
Steatotic hepatocytes have higher intracellular ROS levels and are
thus potentially more susceptible to damage [3]. The recent work of
Sagias et al suggests that the addition of NAC to perfusion fluids may
improve hepatocyte yields from steatotic livers. Another, contrib-
utory factor for the lower viability and yield of hepatocytes from
donor liver is the longer cold ischaemic time that donor livers have
been exposed to when compared to normal livers (Table 1).
Previous authors have suggested that the optimal liver wedge
weight for human hepatocyte isolation is approximately 100 g. We
agree with this and in the present study the majority of liver
wedges were between 80–120 g. In our study a median perfusion
time of 2.5 min was required to digest the livers, as judged by the
admission of a digit into the liver substance. Other studies report
digestion times ranging from 20–47 min (1) [19]. This could
simply be a reflection of different enzyme types, concentrations or
differences between batches. In our series the same enzyme
batches were used for all isolations. The enzyme cocktail we used
allowed isolation of cells from end-stage cirrhotic livers and it is
possible that this enzyme concentration may be excessive for
normal resected and donor liver tissue thereby contributing to our
low yield and viability compared with other reports.
Although perfusion time was significant in the univariable
analysis it fell out during multivariable analysis. The reason for this
Table 3. Effect of Percoll upon Cell Viability and Absolute Cell
Count.
Absolute Cell
Count after
Preparation
6103
Viability
(%)
Absolute Cell
Count after
Percoll
6103
Viability after
Percoll
(%)
550
(200–200,000)
35
(10–50)
175
(100–400)
85
(55–90)
The effects of Percoll upon human hepatocyte isolation procedures. We used
Percoll after eight human hepatocyte isolation procedures (normal resected
liver tissue 1, biliary cirrhosis 5, donor liver tissue 1 and normal benign liver
tissue 1). All values are represented as medians and the values in parentheses
represent the range.
doi:10.1371/journal.pone.0018222.t003
Table 4. The Level of Steatosis in Liver Wedges taken from
Donor Liver Tissue and Normal Liver Tissue.
Minimal/
None Mild Moderate Severe
Donor liver tissue
(n = 6)
1 1 3 1
Normal liver tissue
(n = 12)
10 1 1 -
The level of steatosis in liver wedges taken from normal liver tissue. The level of
steatosis was classified as minimal/none = 0–5%, mild = 5–33%, moderate = 33–
66% and severe =$66% after histological analysis of paraffin embedded
sections. We were unable to classify the level of steatosis in three liver wedges
(1 donor liver and 2 normal livers) as the tissue from those particular livers was
not available. n, number of cases.
doi:10.1371/journal.pone.0018222.t004
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is likely to be correlation with the time delay between hepatectomy
and beginning of liver perfusion (Spearman’s Rho = .377,
p,.001) which remained significant even after adjusting for
perfusion time.
Thus we provide evidence to suggest that the time delay
between hepatectomy and beginning of liver perfusion should be
kept to less than 3 hours. From our experience of isolating human
hepatocytes from cirrhotic livers after an initial learning curve the
operator becomes skilled at recognising when adequate digestion
has occurred thereby avoiding overdigestion of tissue.
In conclusion, we report that the time delay between
hepatectomy and beginning of liver perfusion is the most
important factor in determining the likelihood of success of the
procedure. Furthermore, we suggest the shortest possible digestion
time is desirable. If protocols similar to ours are followed human
hepatocytes can be isolated successfully from normal and diseased
liver tissue.
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Abstract
Background: Hypoxia and hypoxia-reoxygenation (H-R) are pathogenic factors in many liver diseases that lead to
hepatocyte death as a result of reactive oxygen species (ROS) accumulation. The tumor necrosis factor super-family member
CD154 can also induce hepatocyte apoptosis via activation of its receptor CD40 and induction of autocrine/paracrine Fas
Ligand/CD178 but the relationship between CD40 activation, ROS generation and apoptosis is poorly understood. We
hypothesised that CD40 activation and ROS accumulation act synergistically to drive human hepatocyte apoptosis.
Methods: Human hepatocytes were isolated from liver tissue and exposed to an in vitro model of hypoxia and H-R in the
presence or absence of CD154 and/or various inhibitors. Hepatocyte ROS production, apoptosis and necrosis were
determined by labelling cells with 29,79-dichlorofluorescin, Annexin-V and 7-AAD respectively in a three-colour reporter flow
cytometry assay.
Results: Exposure of human hepatocytes to recombinant CD154 or platelet-derived soluble CD154 augments ROS
accumulation during H-R resulting in NADPH oxidase-dependent apoptosis and necrosis. The inhibition of c-Jun N-terminal
Kinase and p38 attenuated CD154-mediated apoptosis but not necrosis.
Conclusions: CD154-mediated apoptosis of hepatocytes involves ROS generation that is amplified during hypoxia-
reoxygenation. This finding provides a molecular mechanism to explain the role of platelets in hepatocyte death during
ischemia-reperfusion injury.
Citation: Bhogal RH, Weston CJ, Curbishley SM, Adams DH, Afford SC (2012) Activation of CD40 with Platelet Derived CD154 Promotes Reactive Oxygen Species
Dependent Death of Human Hepatocytes during Hypoxia and Reoxygenation. PLoS ONE 7(1): e30867. doi:10.1371/journal.pone.0030867
Editor: Gordon Langsley, Institut National de la Sante´ et de la Recherche Me´dicale - Institut Cochin, France
Received September 2, 2011; Accepted December 29, 2011; Published January 25, 2012
Copyright:  2012 Bhogal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Mr. RH Bhogal’s work has been funded by a Wellcome Trust Fellowship (DDDP.RCXH14183). The authors would also like to thank the Birmingham
Biomedical Research Unit (BRU) and the National Institute Health Research (NIHR) for continued funding and help with research. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: balsin@hotmail.com
Introduction
Hepatocyte death is central to most liver diseases and is
frequently associated with tissue hypoxia. Hypoxia can also occur
as a result of ischaemia associated with hepatic surgery or liver
transplantation where reoxygenation follows hypoxia and may
further exacerbate tissue injury and promote liver inflammation.
Central mediators of hepatocyte cell death during hypoxia are the
reactive oxygen species (ROS) [1]. ROS, which include superox-
ide anions, hydrogen peroxide, hypohalus acid and hydroxyl
radicals, accumulate in the many liver diseases and have also been
implicated in the preservation/reperfusion injury that follows liver
transplantation [2].
Under physiological conditions hepatocytes exist in a relatively
hypoxic micro-environment [3] which promotes the generation of
ROS. Consequently hepatocytes have several cellular mecha-
nisms, including high intracellular glutathione levels, which
counteract increases in ROS and thereby limit parenchymal
injury [4,5]. It has long been assumed that extracellular ROS,
released by Kupffer cells (KCs) and infiltrating neutrophils are the
main contributors to hepatocyte injury [6]. However, we recently
reported that intracellular ROS can also regulate human
hepatocyte cell death during hypoxia and hypoxia-reoxygenation
(H-R) [2]. In this micro-environment, hepatocytes will be exposed
to an array of pro-inflammatory mediators including cytokines
which may augment intracellular ROS production and amplify
liver injury.
CD40 and its ligand CD154, members of the tumor necrosis
factor-(TNF) receptor/ligand superfamily are known to regulate
hepatocyte apoptosis [7] and have been implicated in hepatocyte
death during hypoxia [8]. CD40 is a type I trans-membrane
protein receptor and expressed as a trimeric complex upon the cell
surface of many cells including hepatocytes, endothelial cells and
cholangiocytes. CD154, a type II trans-membrane protein, is
expressed by CD4+ T-lymphocytes, macrophages, mast cells and
basophils. It is also expressed by platelets and released in a soluble
form following platelet activation. Studies in CD40 and CD154
deficient mice have implicated this pathway in hypoxic liver injury
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[8,9]. The mechanism was assumed to involve defective
CD40:CD154 priming of T-lymphocytes. However, we have
previously reported that activation of CD40 on hepatocytes or
cholangiocytes can induce Fas Ligand (FasL/CD178) expression
and autocrine/paracrine Fas-mediated apoptosis [7,10].
CD40:CD154 interactions have also been shown to mediate
ROS accumulation in the WEHI231 lymphoid cell line [11]
leading us to hypothesise that CD40 activation could be implicated
in ROS-mediated hepatocyte death.
Following ligation by trimeric CD154, CD40 is activated and
internalized. CD40 has no active intracellular kinase domain and
binds to members of the tumor necrosis factor receptor-associated
factor (TRAF) family which are responsible for activating
downstream signaling pathways. In lymphoid cells, TRAFs recruit
the cystolic enzyme nicotinamide adenine dinucleotide phosphate
oxidase (NADPH oxidase) to the plasma membrane providing a
potential mechanism to generate ROS [11]. We now report that in
primary human hepatocytes, CD40 ligation leads to NADPH-
dependent intracellular ROS generation and hepatocyte death in
hypoxic conditions demonstrating for the first time how TNF
receptor activation and ROS can co-operate to mediate epithelial
cell injury in chronic inflammation and hypoxia/reperfusion
injury.
Materials and Methods
Ethics Statement
Liver tissue was obtained from surgical procedures carried out
at the Queen Elizabeth Hospital, Birmingham, UK. Ethical
approval for the study was grant by the Local Research Ethics
Committee (LREC) (Leicestershire and Rutland Ethics Committee
- reference number 06/Q702/61). Informed written consent was
obtained from all participants involved in the study.
Human Hepatocyte Isolation
Liver tissue was obtained from fully consenting patients
undergoing transplantation, hepatic resection for liver metastasis,
hepatic resection for benign liver disease or normal donor tissue
surplus to surgical requirements. Human hepatocytes were isolated
using a method that we have described previously [2,12].
Model of hypoxia and H-R injury
We used a model of in vitro hypoxia and H-R that we have
described previously [2]. In experiments involving the NADPH
oxidase inhibitor, DPI; JNK inhibitor SP600125, or p38 inhibitor,
PD169316, all reagents were made fresh as stock solutions and
added using the correct dilutional factor to the relevant experi-
mental wells. Specifically, 10 mg DPI (Sigma) was dissolved in
molecular grade dimethyl sulfoxide (DMSO), 10 mg rotenone
(Sigma) was dissolved in chloroform (Sigma), 50 mg SP600125
(Sigma) was dissolved in DMSO and 50 mg PD169316 (Sigma) was
dissolved in DMSO and were diluted appropriately to give working
concentrations of 10 mM, 2 mM, 10 mM and 10 mM respectively. In
experiments using inhibitors/antioxidants, solvent alone wells were
used to control for vehicle effects. In experiments using inhibitors/
antioxidants hepatocytes were pre-treated with agents for up to
4 hours before placement of the cells into normoxia and hypoxia.
For H-R experiments fresh inhibitor/antioxidants were added at
the time of placement into reoxygenation. Recombinant human
soluble CD154 (1 mg/mL, Enzo Life Sciences, UK) and 1 mg/mL
Cross-linker for Ligands (Enzo Life Sciences, UK) were added to
cells at the time of entry into hypoxia or H-R. Where cells had been
pre-treated with inhibitors/antioxidants CD154 and Cross-linker
for Ligands were added after 4 hours.
Determination of Human Hepatocyte CD40 Expression
and FasL Expression
Following appropriate incubation of human hepatocytes within
normoxia, hypoxia and H-R, cells were trypinised and washed in
FACs buffer (Phosphate-buffered saline (PBS) pH 7.2 with 10% v/
v heat inactivated foetal calf serum (Gibco). For CD40 expression,
cells were then incubated with anti-human CD40 antibody that
was conjugated to the APC fluorophore (1:100 dilution; Caltag,
UK) for 45 min at 4uC. Mouse IgG1-APC (1:100 dilution; Caltag,
UK) was used as a negative control. For FasL expression, cells
were then incubated with anti-human FasL antibody that was
conjugated to the FITC fluorophore (1:100 dilution; Abcam, UK)
for 45 min at 4uC. Mouse IgG2a-FITC (1:100 dilution; Abcam,
UK) was used as a negative control. Following this cells were
washed in FACs buffer and resuspended in PBS, pH 7.2. At least
20,000 events were recorded within the gated region of the flow
cytometer for each human hepatocyte cell preparation in each
experimental condition. Only the cells within the gated region
were used to calculate Mean Fluorescence Intensity (MFI) as
described in our previous study [2].
Determination of Human Hepatocyte ROS Accumulation,
Apoptosis and Necrosis
ROS production, apoptosis and necrosis were determined using
a three-colour reporter assay system as previously described [2]. At
least 20,000 events were recorded within the gated region of the
flow cytometer for each human hepatocyte cell preparation in
each experimental condition. Only the cells within the gated
region were used to calculate MFI.
Platelet isolation and activation
Platelets were isolated by modifying a previously published
method from fully consenting healthy individuals [13]. Platelet-rich
plasma (PRP) was prepared by centrifuging 5 mL of heparinised
blood for 5 min at 3006 g. Following this the PRP was withdrawn
and the platelet count adjusted to 16106 platelets/mL inWilliams E
media. Platelets were then seeded onto plastic. Following 30 min
incubation at room temperature the platelets had settled, become
activated and spread to form a confluent monolayer. The Williams
media was then aspirated and passed through a 0.2 mm syringe
filter. The PCM was aliquoted and frozen at270uC until required.
Media was thawed and added to cells as required.
Determination of Soluble CD154 and Immunomagnetic
Depletion of CD154 from PCM
To confirm the presence and quantity of CD154 in the PCM
levels were quantified by ELISA and platelet-derived CD154 was
removed via immuno-magnetic depletion. Briefly, soluble human
CD154 was measured in both PCM and CD154-depleted PCM
using a sandwich ELISA kit (Peprotech, UK). For immunomag-
netic depletion of CD154, anti-human CD154 antibody (1 mg/
mL; Abcam, UK) was complexed to pan-mouse IgG magnetic
Dynabeads (Invitrogen, Paisley, UK) for 90 min at room
temperature. Following this, the antibody-magnetic bead com-
plexes were extensively washed. Complexes were then incubated
with PCM for a further 90 min at room temperature. Finally,
magnetic beads were retrieved from solutions and this media was
subsequently used in experiments as CD154-depleted PCM.
Statistical Analysis
All data are expressed as mean 6 S.E. Statistical comparisons
between groups were analysed by Student’s t test. All differences
were considered statistically significant at a value of p,0.05.
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Results
CD40 expression in human hepatocytes during hypoxia
and H-R
Primary human hepatocytes constitutively expressed CD40 on
the cell membrane as previously reported [14] but this did not
increase in response to hypoxia or H-R in vitro (Figure 1).
CD40:CD154 stimulates ROS accumulation in human
hepatocytes in an NADPH-dependent manner and
regulates apoptosis and necrosis
We have recently reported that intracellular ROS accumulate in
hypoxic human hepatocytes and that this is increased further during
H-R [2]. Here we investigated whether CD154 could augment
human hepatocyte ROS production during normoxia, hypoxia and
H-R. Trimeric recombinant human CD154 significantly increased
intracellular ROS accumulation within human hepatocytes during
normoxia and H-R but not hypoxia. Because CD40:CD154 has been
shown to mediate ROS accumulation via TRAF-dependent recruit-
ment of the flavoenzyme NADPH oxidase in lymphoid cell lines [11]
we used the specific NADPH oxidase inhibitor Diphenyliodonium
(DPI) to assess the involvement of this pathway in ROS generation by
human hepatocytes. DPI reduced hepatocyte CD154 mediated ROS
production during normoxia, hypoxia and H-R (Figure 2a & 2b).
The increased levels of intracellular ROS induced by CD154
stimulation, during normoxia and H-R, increased human
hepatocyte apoptosis and to a lesser extent necrosis (Figure 2c &
2d) and this were reduced by pre-treatment with DPI. CD154 also
significantly increased human hepatocyte necrosis during nor-
moxia and H-R that was inhibited by DPI demonstrating that that
the CD40:CD154:ROS signaling pathway is NADPH-dependent
and results in hepatocyte death.
Mitochondrial ROS has been implicated in hepatocyte apoptosis
during hypoxia and H-R [2] leading us to test the effect of inhibiting
mitochondrial ROS production upon CD154 mediated apoptosis
with the complex I inhibitor, rotenone. Inhibiting mitochondrial
ROS production during normoxia and H-R did not reduce human
hepatocyte apoptosis in response to CD154 treatment but did
reduce apoptosis during hypoxia (Figure 2e).
JNK and p38 regulate apoptotic but not necrotic cell
death in human hepatocytes
We next investigated whether CD40:CD154 generated ROS
and hepatocyte death was associated with activation of mitogen-
Figure 1. CD40 Expression on Primary Human Hepatocytes. Figure 1a demonstrates a representative flow cytometry plot of CD40 expression
on primary human hepatocytes during normoxia, hypoxia and H-R. The plot on the left hand side represents a typical forward scatter (FS) versus side
scatter (SS) plot of primary human hepatocytes. The FS versus SS plots shown is from the H-R sample of a liver preparation but similar plots were
obtained during normoxia and hypoxia (data not shown). Figure 1b shows a bar chart with the pooled data of three separate experiments illustrating
the level of CD40 expression on primary human hepatocytes. Data are expressed as MFI and readings are based upon values taken from cells within
the gated region in Figure 1a.
doi:10.1371/journal.pone.0030867.g001
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activated protein kinases (MAPKs). MAPKs consist of three
sequentially activated kinase modules, namely mitogen-activated
protein kinase kinase kinases (MAPKKK/MAP3K) followed by
the mitogen-activated protein kinase kinases (MAPKK/MEKK)
and finally the MAPKs. The MAPKs superfamily consists of three
separate sub-families; extra-cellular regulated protein kinase
(ERK), c-Jun N-terminal kinase (JNK) and p38. ERK is generally
involved in the regulation of cell proliferation and differentiation,
whereas JNK and p38 are involved in the regulation of cell death
[15].
Unfortunately, primary human hepatocytes are not amenable to
siRNA transfection or protein labeling [16,17,18]. Therefore to
investigate the effects of JNK and p38 inhibition upon
CD154:ROS mediated human hepatocyte apoptosis we used
specific JNK and p38 inhibitors [19,20,21]. Inhibition of JNK and
p38 in hepatocytes using the specific inhibitors SP600125 and
Figure 2. CD40:CD154 regulates ROS accumulation, apoptosis and necrosis within human hepatocytes in a NADPH Oxidase
dependent manner during normoxia and H-R. Figure 2a demonstrates representative flow cytometry plots to illustrate the effect of CD154
(hatched red) and CD154 in presence of DPI (solid grey) upon human hepatocyte ROS accumulation during normoxia, hypoxia and H-R. Typical FS
versus SS plots of primary human hepatocytes during normoxia, hypoxia and H-R are shown to the left of each flow cytometric plot. The FS versus SS
plots shown is from the H-R alone sample of a liver preparation but similar plots were obtained during normoxia and hypoxia (data not shown). The
areas of interest on the flow cytometric plots are marked by the vertical ellipses. The area on the left of each ellipse represents cell debris. Cell debris
is included within the plot as human hepatocytes vary considerably in size and therefore to include all viable human hepatocytes in the analysis a
large gate is required on the flow cytometer, this by necessity includes the cell debris. Figure 2b. shows a bar chart with the pooled data of three
separate experiments illustrating the effects of CD154 and CD154+DPI upon human hepatocytes ROS accumulation. Data is expressed as MFI and
readings are based upon values taken from cells within the gated region shown in Figure 2a. Data are expressed as mean 6 S.E. (*p,0.01 relative to
basal, **p,0.05 relative to basal, {p,0.001 relative to CD154). Figure 2c demonstrates representative flow cytometry plots to illustrate the effect of
CD154 (hatched red) and CD154 in presence of DPI (solid grey) upon human hepatocyte apoptosis and necrosis during normoxia, hypoxia and H-R.
Again, the area of interest within the flow cytometric plots is marked by the vertical ellipse. The same gate has been applied to primary human
hepatocytes for these plots as those shown in Figure 2a. Figure 2d. shows a bar chart with the pooled data of three separate experiments illustrating
the effects of CD154 and CD154+DPI upon human hepatocytes apoptosis and necrosis during normoxia, hypoxia and H-R. Data is expressed as
increase/decrease relative to basal, where basal refers to the level of apoptosis or necrosis during normoxia alone. Data are expressed as mean6 S.E.
(**p,0.01 relative to basal, *p,0.05 relative to basal, {p,0.05 relative to CD154, 1p,0.05 relative to basal). Figure 2e. Human hepatocytes were
treated with CD154 or CD154 following pre-treatment with rotenone (Rot) during normoxia, hypoxia and H-R. The percentage of cells staining with
both the ROS probe DCF and apoptotic marker, Annexin-V, were assessed by flow cytometry. The percentage of human hepatocytes that stain for
both DCF and Annexin-V are shown in parentheses. Data are representative of 3 separate experiments ({p,0.05 relative to basal, *p,0.05 relative to
CD154).
doi:10.1371/journal.pone.0030867.g002
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PD169316 had no effect on ROS accumulation during normoxia,
hypoxia and H-R (data not shown) whereas they significantly
decreased CD40:CD154 mediated human hepatocyte apoptosis
during normoxia, hypoxia and H-R (Figure 3a, 3b & 3c).
Inhibition of p38 had a greater effect on hepatocyte apoptosis
than JNK inhibition. Neither inhibitor reduced CD154 mediated
hepatocyte necrosis under any of the experimental conditions
(Figure 3). This suggests that CD40:CD154 mediated human
hepatocyte apoptosis during normoxia and H-R is ROS, JNK and
p38-dependent whilst necrosis is ROS-dependent but MAPK-
independent.
CD40:CD154:NADPH oxidase interactions stimulate
hepatocyte Fas ligand expression
Fas is a cell surface receptor of the TNF Receptor superfamily
which, when activated by FasL, induces apoptosis on a wide range
of cells including hepatocytes [7]. Because we have previously
reported the CD40 activation on human hepatocytes results in
Fas-mediated apoptosis, we investigated whether hypoxia or H-R
alone or in association with CD154 induced FasL expression.
Neither hypoxia nor H-R increased hepatocyte cell surface FasL
expression (Figure 4a). However, CD40:CD154 increased FasL
expression during hypoxia and H-R, with a greater effect during
hypoxia. Inhibiting NADPH oxidase function with DPI reduced
CD40:CD154 mediated FasL expression during hypoxia and H-
R, with a greater effect noted during H-R (Figure 4b & 4c).
Platelet-derived soluble CD154 mediates hepatocyte
apoptosis and necrosis
Finally, because platelets are the source for 95% of circulating
soluble CD154 and activated platelets may be found in the liver
parenchyma during damage [22] we determined whether
activated platelets may be a potential source of functionally active
CD154 during hypoxia and H-R.
Figure 3. JNK and p38 regulate CD40:CD154 mediated human hepatocyte apoptosis but not necrosis. Figure 3a show representative
flow cytometry plots to illustrate the effect of the JNK inhibitor SP600125 upon CD40:CD154 mediated apoptosis and necrosis during normoxia,
hypoxia and H-R. The gate used to analyse primary human hepatocytes is the same as that shown in Figures 1 & 2. The area of interest within the flow
cytometric plots are marked by the vertical ellipses. Figure 3b illustrates the effects of the p38 inhibitor P169316 upon CD40:CD154 mediated
apoptosis and necrosis during normoxia, hypoxia and H-R. Figure 3c shows a bar chart with the pooled data of three separate experiments illustrating
the effects of both SP600125 and PD169316 upon CD40:CD154 mediated human hepatocyte apoptosis and necrosis during normoxia, hypoxia and
H-R. Data are expressed as increase/decrease relative to basal, where basal refers to the level of apoptosis or necrosis during normoxia alone. Data are
expressed as mean 6 S.E. (**p,0.01 relative to basal, *p,0.05 relative to basal, {p,0.05 relative to CD154, {{p,0.05 relative to basal).
doi:10.1371/journal.pone.0030867.g003
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Immuno-magnetic depletion reduced soluble CD154 released
by activated platelets by .70% (Platelet Conditioned Media
(PCM) soluble CD154 concentration 22516310 pg/mL; CD154-
depleted PCM CD154 concentration 590679 pg/mL). PCM
increased hepatocyte intracellular ROS accumulation during H-R
(Figure 5a). When CD154 was depleted from PCM, intracellular
ROS accumulation was significantly reduced during H-R. PCM
increased human hepatocyte apoptosis during H-R mirroring the
increasing in intracellular ROS (Figure 5b). However, in line with
the decrease in ROS seen during H-R, CD154-depleted PCM
decreased human hepatocyte apoptosis during H-R (Figure 5b).
Discussion
Tissue hypoxia is a feature of hepatic inflammation and disease
[23] and we have recently shown the accumulation of intracellular
ROS is a critical mediator of hepatocyte death during hypoxia and
H-R [2]. In the present report we show that ROS accumulation in
human hepatocytes during hypoxia and H-R is increased by
CD154 mediated activation of hepatocyte CD40 resulting in
increased cell death. This link between CD40 activation,
intracellular ROS generation and cell death has implications for
other inflammatory diseases characterised by local hypoxia.
CD40:CD154 receptor-ligand interactions have been associated
with parenchymal injury during hypoxia and H-R in many organs
[8,24,25] and disruption of CD40:CD154 signaling in mice
improves liver function following hypoxia [8]. However until now
it was thought that CD40:CD154 mediates its actions through
effects on T-lymphocyte priming whereas our data suggest another
mode of action through direct effects on hepatocyte survival. We
have previously reported that CD40 activation mediates Fas
dependent apoptosis in human hepatocytes through induction of
autocrine FasL expression [7]. We now demonstrate that
CD40:CD154 can also mediate human hepatocyte apoptosis
and necrosis in a NADPH Oxidase:ROS-dependent manner. This
introduces a previously unknown CD40 dependent pathway to cell
Figure 4. FasL Expression on Primary Human Hepatocytes. Figure 4a demonstrates a representative flow cytometry plot of FasL expression
on primary human hepatocytes during normoxia, hypoxia and H-R. The gate used to analyse primary human hepatocytes is the same as that shown
in Figures 1 & 2. Figure 4b. demonstrates representative flow cytometry plots to illustrate the effect of CD154 (hatched red) and CD154 in presence of
DPI (solid grey) upon human hepatocyte FasL expression during normoxia, hypoxia and H-R. Figure 4c. shows a bar chart with the pooled data of
three separate experiments illustrating the effects of CD154 upon human hepatocyte FasL expression during normoxia, hypoxia and H-R. Data are
expressed as MFI and readings are based upon values taken from cells within the gated region in Figure 1a. Data are expressed as mean 6 S.E.
(*p,0.05 relative to basal, **p,0.05 relative to CD154).
doi:10.1371/journal.pone.0030867.g004
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death and implicates CD40 in the regulation of cell survival during
tissue hypoxia and H-R.
Our data also support an important role for intrinsic ROS
accumulation in hepatocytes as opposed to the current model
which suggests that ROS is derived from leukocytes [6]. CD40
activation did not increase ROS accumulation or cell death in
human hepatocytes during hypoxia and this is probably a
consequence of the increased antioxidant levels induced in
hepatocytes during hypoxia [26]. This may also explain why
FasL has little effect during hypoxia (see below). Furthermore,
hypoxia alone did not increase hepatocyte cell surface CD40
implying that the lack of effect of CD154 during hypoxia was
probably a consequence of the modulation of intracellular
signaling pathways by antioxidants rather than changes in CD40
receptor bioavailability.
Our data clearly show that increases in intracellular ROS
induced by CD154 are dependent upon NADPH Oxidase, this is
consistent with previous studies implicating NADPH in ROS
accumulation in hypoxic human hepatocytes during normoxia,
hypoxia and H-R [2]. Studies in WEHI 231 cells and endothelial
cells have shown that following activation, CD40 recruits NADPH
Oxidase to the plasma membrane via a mechanism involving
TRAF3 [11,27,28,29]. Once at the plasma membrane the p40phox
subunit of NADPH oxidase can generate ROS leading to
activation of a number of downstream cell death signaling
pathways (Figure 6). In our primary human hepatocyte model,
CD40:NADPH oxidase:ROS initiated apoptosis and to a lesser
extent necrotic cell death. The mode of hepatocyte cell death
stimulated by hypoxia remains controversial. Both apoptosis and
necrosis have been implicated in transplant models [30] consistent
Figure 5. The effects of PCM and PCM CD154-depleted upon human hepatocyte ROS accumulation and cell death. Figures 5a
demonstrates representative flow cytometry plots to illustrate the effect of PCM (hatched red) and PCM CD154-depleted (solid grey) upon human
hepatocyte ROS accumulation during H-R. The gate used to analyse primary human hepatocytes is the same as that shown in Figures 1 & 2. The area
of interest within the flow cytometry plots is marked by the vertical ellipse. The area on the left of each ellipse again represents cell debris. Figure 5b,
human hepatocytes were treated with PCM or PCM CD154-depleted during H-R and the percentage of cells staining with both the ROS probe DCF
and apoptotic marker, Annexin-V, were assessed by flow cytometry.. The percentage of human hepatocytes that stain for both DCF and Annexin-V
are shown in parentheses. Data is representative 3 separate experiments (*p,0.05 relative to basal, **p,0.05 relative to PCM).
doi:10.1371/journal.pone.0030867.g005
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with our findings and in support of Lemasters proposal that a
common mediator regulates both forms of cell death during
hypoxia and H-R [31]. We propose that CD40:CD154 activation
in hepatocytes has at least three downstream consequences 1)
initiation of apoptosis mediated via ROS 2) initiation of apoptosis
mediated via FasL induction and 3) necrosis.
CD40 activation results in apoptotic death in many cells of
epithelial lineage [7,14]. Indeed, CD40 activation induces human
hepatocyte apoptosis via up-regulation of FasL expression and
subsequent Fas-mediated apoptosis [7]. Moreover, in human
hepatocytes, it is the sustained activation of Activator Protein-1
(AP-1) and MAPKs, and not NF-kappaB, which is central to
initiating apoptosis [32]. A similar signalling pathway has been
reported in mediating cholangiocytes apoptosis after CD40
ligation [33]. Additionally, in cholangiocytes, CD40 mediated
apoptosis also requires the activation of the JAK2-STAT3
pathway and the downstream activation of caspase-3 [14].
However, our study is the first to implicate ROS in this process
of epithelial and specifically human hepatocyte, apoptosis. ROS
can activate the MAPKs sub-families of JNK and p38, important
regulators of cell death. Specifically, ROS can activate the
MAP3K, apoptosis signaling kinase 1 (ASK1) resulting in
phosphorylation of MEK 3/6 [34] and MEK 4/7 [34] which
respectively activate p38 and JNK. Inhibition of p38 [35] and JNK
[36] improves hepatocyte viability after hypoxia and during H-R
in rodent models. We now show that CD40:CD154 mediated
human hepatocyte apoptosis is reduced by JNK inhibition and
prevented by p38 inhibition. The precise mechanism of JNK
mediated apoptosis is controversial. JNK can act upstream of
mitochondria by activating the pro-apoptotic Bcl2 family [37] and
also increases turnover of the anti-apoptotic protein c-FLIP [38].
p38 is thought to mediate apoptosis via phosphorylation of Bcl2
family members [39] and CD40-mediated-NADPH oxidase
generated ROS is upstream of p38 activation in WEHI 231 cells
[11]. Thus our data report for the first time a mechanistic link
between CD40:CD154 mediated ROS generation, MAPK
activation and cell death. Taken together, these studies highlight
the complexities of the upstream CD40 signaling pathway and
suggest that CD40 can couple to at least ROS and AP-1 signaling
pathways to regulate apoptosis. Whether CD40 ligation in human
hepatocytes can also active the JAK-STAT pathways, as seen in
cholangiocytes, remains to be ascertained.
Figure 6. Proposed mechanism of CD40-CD154 mediated apoptosis and necrosis in human hepatocytes during normoxia, hypoxia
and H-R. During normoxia (blue arrows) activation of CD40 expressed upon human hepatocyte by CD154 results in the translocation of the TRAF
adaptor molecules to the cell membrane. The TRAF molecules are then responsible for the recruitment of the flavoenzyme NADPH Oxidase to the
CD40:TRAF complex. Here NADPH Oxidase can induce the production of ROS, primarily in the form of hydrogen peroxide. This process can be
inhibited by the NADPH Oxidase inhibitor DPI. The resultant accumulation of ROS can result directly in necrotic cell death or it can activate the MAPK
members, JNK and p38, to induce human hepatocyte apoptosis. However, during hypoxia (red arrows) CD40 activation on human hepatocytes does
not result in ROS accumulation but can induce FasL expression via mechanisms that NADPH Oxidase-dependent and ROS-independent (dotted black
line). This increased FasL expression can result in autocrine (green arrow) and/or paracrine (orange arrows) Fas-mediated apoptosis. Due to the
increases in intracellular antioxidants levels during hypoxia CD154 does not increase apoptosis. However, mitochondrial ROS does contribute to
apoptosis during hypoxia. During H-R, CD40 activation can lead to NADPH Oxidase-ROS-JNK/p38 dependent apoptosis, NADPH Oxidase-ROS-
dependent necrosis and NADPH Oxidase:ROS:FasL expression with resultant Fas-mediated apoptosis. Figure 6 highlights the importance of local
microenvironment in shaping the effects of CD40:CD154.
doi:10.1371/journal.pone.0030867.g006
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CD40 ligation by CD154 is known to increase FasL expression
resulting in autocrine/paracrine Fas-mediated apoptosis in human
hepatocytes [7]. However, in contrast to in vivo studies [40],
hypoxia and H-R did not result in increased hepatocyte FasL
expression in our study. We confirmed that CD154 induced cell
surface expression of FasL in human hepatocytes and showed for
the first time that this is in part dependent on NADPH oxidase
particularly during H-R. This suggests that other mechanisms are
involved in regulating ROS-independent FasL expression. As
discussed above, although CD40:CD154 did not increase ROS
during hypoxia, it did increase FasL expression although without a
concomitant increase in apoptosis. However, the inhibition of
mitochondrial ROS significantly reduced hepatocyte apoptosis
during hypoxia. Fas mediated apoptosis in hepatocytes requires
the downstream accumulation of mitochondrial ROS [41] and
together with likely increases in hepatocytes antioxidant levels
during hypoxia explains why we saw increased FasL expression in
the absence of apoptosis in response to CD40 activation [4,5].
This also suggests that different apoptotic signaling pathways may
be initiated in response to CD40 activation under different
conditions in distinct microenvironments.
Our data suggest that hypoxia, which precedes reoxygenation
during preservation of an organ allograft for transplantation, can
increase FasL expression thereby initiating liver damage before
ROS generation during reperfusion has occurred. FasL is also
increased on hepatocytes in chronically inflamed livers a situation
characterized by tissue hypoxia. Thus the mechanism we describe
is likely to operate in the chronic inflammation where large
numbers of CD154 expressing effector cells can activate CD40 in
a hypoxic environment [42].
We have previously reported that ROS generation can regulate
human hepatocyte necrosis during hypoxia and H-R [2] and
hepatocyte necrosis has been induced experimentally during
hypoxia followed by reoxygenation [31]. We show that ROS
generated by CD40:CD154 not only induces hepatocyte apoptosis
but also necrosis during normoxia and H-R. This process is
NADPH Oxidase dependent as shown by the decrease in necrosis
in the presence of DPI but in contrast to CD154-mediated
hepatocyte apoptosis, necrosis is MAPK-independent. This
suggests that NADPH oxidase generated ROS regulates divergent
signaling pathways leading to both forms of cell death.
Therefore, coupled with previous work regarding CD40
mediated death of liver epithelial cells it is clear that the signaling
pathways regulating this process are diverse. Clearly, in the
present manuscript we demonstrate that CD154:CD40:ROS is an
important activator of JNK and p38 which subsequently leads to
cell death. However the JAK2-STAT3 is also important CD40
mediated apoptotic pathway [14] that may also be activated by
ROS. Furthermore FasL is also up-regulated following CD40
activation. Therefore CD40 regulates multiple death signaling
pathways in liver epithelial cells.
We have shown that macrophages and T-lymphocytes are an
abundant source of CD154 in the chronically inflamed liver [43].
However platelets are also a rich source of CD154 [22] and within
seconds of activation CD154 is translocated to the platelet surface
then cleaved to produce soluble CD154. Platelets have been
implicated in preservation injury during liver transplantation and
in other conditions including immune mediated damage in
hepatitis although the mechanisms of the effect are poorly
understood [44,45,46]. We now show that activated platelets
secrete functional CD154 that is capable of inducing ROS
accumulation in human hepatocytes during H-R leading to
hepatocyte apoptosis. This finding provides a novel mechanism
to explain the effector function of platelets in liver injury and
suggests that anti-platelet therapy together with anti-oxidants may
be warranted not only to prevent reperfusion injury but also to
reduce liver injury in chronic hepatitis and cirrhosis in which
platelets are found in close proximity to hepatocytes [47,48].
Although our findings suggest that platelets are a major source of
CD154 capable of inducing injury as previously suggested [25]
CD154 depletion from platelet-conditioned medium reduced but
did not abolish human hepatocyte apoptosis suggesting either that
there was residual CD154 activity in the PCM or that platelets
release other active mediators of apoptosis [44].
In conclusion, we have shown that CD40:CD154 mediated
generation of ROS contributes to hepatocyte cell death by both
apoptosis and necrosis in the hypoxic liver microenvironment. The
ability of platelets as well as infiltrating T-lymphocytes and
macrophages to deliver functional CD154 to hepatocytes suggests
several potential mechanisms through which hepatocyte CD40
can be activated in the inflamed and hypoxic liver. The work
supports therapeutic intervention with anti-platelet and anti-
oxidant therapy in liver disease.
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The role of autophagy in the response of human hepatocytes to oxidative stress remains unknown. Understanding this
process may have important implications for the understanding of basic liver epithelial cell biology and the responses of
hepatocytes during liver disease. To address this we isolated primary hepatocytes from human liver tissue and exposed
them ex vivo to hypoxia and hypoxia-reoxygenation (H-R). We showed that oxidative stress increased hepatocyte
autophagy in a reactive oxygen species (ROS) and class III PtdIns3K-dependent manner. Specifically, mitochondrial ROS
and NADPH oxidase were found to be key regulators of autophagy. Autophagy involved the upregulation of BECN1,
LC3A, Atg7, Atg5 and Atg 12 during hypoxia and H-R. Autophagy was seen to occur within the mitochondria of the
hepatocyte and inhibition of autophagy resulted in the lowering a mitochondrial membrane potential and onset of cell
death. Autophagic responses were primarily observed in the large peri-venular (PV) hepatocyte subpopulation. Inhibition
of autophagy, using 3-methyladenine, increased apoptosis during H-R. Specifically, PV human hepatocytes were more
susceptible to apoptosis after inhibition of autophagy. These findings show for the first time that during oxidative stress
autophagy serves as a cell survival mechanism for primary human hepatocytes.
Introduction
Tissue hypoxia is a feature common to many liver diseases
including cirrhosis and cancer. It also occurs as a consequence
of hemodynamic shock and liver surgery. At the subcellular
level hepatocyte hypoxia causes depletion of glycolytic substrates,
loss of adenosine triphosphate and intracellular acidosis.
Moreover, following liver surgery/transplantation, the restoration
of blood flow, although restoring normal oxygen saturation
and acid-base balance paradoxically induces and augments
hepatocellular injury.1 The key mediator of these events is
accumulation of intracellular reactive oxygen species (ROS).2
Furthermore, ROS can regulate both human hepatocyte
apoptosis and necrosis during hypoxia and hypoxia-reoxygenation
(H-R).2
While hepatocyte apoptosis and necrosis have been shown to
occur during hypoxia, the role of hepatocyte autophagy remains
controversial. It is now widely recognized that autophagy is
required for protein and organelle turnover and is typically a
homeostatic cellular response to starvation. Furthermore, auto-
phagy degrades both long-lived cytoplasmic proteins and surplus
or dysfunctional organelles by lysosome-dependent mechanisms.3
Nearly all hepatocyte-derived proteins are long-lived and auto-
phagy is thought to be the primary process for hepatic protein
catabolism.4 Recent studies suggest that autophagy is another
distinct and separate form of cell death that hepatocytes sustain
when exposed to oxidative stress but it has been conclusively
shown that cells undergoing autophagy are not committed
irreversibly to death.5 The role of autophagy in liver disease has
been comprehensively presented in recent reviews.6,7
Autophagy is an active process which involves sequestration of
parts of the cytoplasm in double-membrane vesicles which then
fuse with lysosomes forming the autophagosome. The cytoplasmic
material engulfed is then hydrolysed permitting recycling of
amino acids and other macromolecular precursors.
In contrast to classical apoptosis, the cellular machinery that
regulates autophagy is known to be lysosomal proteinase-dependent
and caspase-independent. In particular the Atg proteins and
phosphatidylinositol 3-kinase (PtdIns3K) are crucial for autophago-
some assembly. The initial step of autophagosome formation
requires class III PtdIns3K and BECN1/Atg6 protein.8 The
assembly of the autophagosome can be inhibited pharmacologi-
cally by 3-methyladenine (3-MA), a specific class III PtdIns3K
inhibitor.9,10 The formation and expansion of the autophagosome
requires two protein conjugation systems that involve several of
members of the Atg protein superfamily,11 namely the Atg8/LC3-
PE and Atg12–Atg5 conjugation systems. These conjugation events
are regulated and involve Atg3, Atg4, Atg10.12 In particular Atg8
serves as a substrate for the Atg4 family of cysteine proteases.11 Many
Atg proteins can be regulated by ROS.11 Once activated Atg8 is
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able to associate with autophagosomes and remain there until fusion
with lysosomes.3,6
Under starvation, cellular generation of ROS is essential for
autophagosome formation and autophagic degradation. Because
we have observed that hepatocyte ROS generation is enhanced
during hypoxia, we wished in the present study, to define and
assess the role of hepatocyte autophagy during hypoxia and H-R.
We demonstrate for the first time that autophagy is essential for
protection of human hepatocytes against oxidative stress and
ROS-mediated cell death.
Results
Intracellular ROS accumulation is associated with increased
autophagy within human hepatocytes. Consistent with our
previous studies we show that exposure of human hepatocytes to
hypoxia and H-R increased human hepatocyte accumulation of
intracellular ROS as detected by DCF (Fig. 1A). These findings
were confirmed by the use of the mitochondrial ROS dye Mitosox
where we found that hypoxia and H-R also resulted in an increase
in mitochondrial ROS production (Fig. 1B). Indeed, mitochon-
drial ROS production accounts for the vast majority of ROS
production in human hepatocytes during hypoxia and H-R. This
increase in intracellular ROS accumulation during hypoxia and
H-R was also associated with an increase in the number of cells
undergoing autophagy as demonstrated by increased staining of
human hepatocytes with MDC (Fig. 2). The autophagic response
was greater during H-R than hypoxia. Furthermore, human
hepatocytes isolated from normal liver tissue and diseased liver
tissue show markedly different autophagic responses during
Figure 1. Intracellular ROS accumulation in primary human hepatocytes is mitochondrial dependent during hypoxia and H-R. (A) demonstrates
representative flow cytometry plots to illustrate the effects of normoxia (blue), hypoxia (hatched red) and H-R (solid gray) upon human hepatocyte ROS
production as assessed by DCF staining. A typical FS vs. SS plots of primary human hepatocytes during H-R is shown to the left of the flow cytometric
plot. Human hepatocytes are known to vary considerably in size and hence a large gate is required to include all cells in the analysis. Refer to
the Methods and Materials section for further details of the gating procedure and protocol. Similar FS vs. SS plots were obtained during normoxia and
hypoxia (data not shown). The areas of interest on the flow cytometric plots are marked by vertical ellipses. The area on the left of each ellipse represents
cell debris. Cell debris is included within the plot as human hepatocytes vary considerably in size and therefore to include all viable human hepatocytes
in the analysis a large gate is required on the flow cytometer, this by necessity includes the cell debris. The representative plot is of normal human
hepatocytes that have been isolated from benign liver diseases (n = 7). (B) shows composite bar charts to illustrate the effects of hypoxia and H-R upon
ROS production in human hepatocytes isolated from benign liver diseases using DCF and Mitosox. DCF is measure of hydrogen peroxide production
in human hepatocytes. Hydrogen peroxide is the main ROS generated within hepatocytes. Mitosox detects ROS generated specifically by
the mitochondrion. In these experiments human hepatocytes were isolated from the same liver wedges and then used simultaneously in our in vitro
model of hypoxia and H-R to determine DCF and Mitosox staining during normoxia, hypoxia and H-R. Data are expressed as mean fluorescence intensity
(MFI) and the values are derived from the gates shown in (A). Human hepatocytes used for these experiments were isolated from benign liver diseases
(n = 3–4). (*p , 0.05 relative to normoxia, **p , 0.05 relative to hypoxia, ***p , 0.01 relative to normoxia, Mann-Whitney test).
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hypoxia and H-R (Fig. 3). While human hepatocytes isolated
from biliary cirrhosis show a similar autophagic response to those
isolated from normal human hepatocytes (Fig. 2) those hepato-
cytes isolated from alcoholic liver disease (ALD) show very little
staining with MDC during hypoxia and H-R indicating the lack
of autophagy within these particular hepatocytes. Finally, human
hepatocytes from normal resected liver tissue that have been
exposed to chemotherapy showed a very different autophagic
response to hypoxia and H-R. These hepatocytes had a much
higher basal autophagy level that was maintained throughout
hypoxia and H-R. For the remainder of the experiments presented
in this study we used human hepatocytes isolated from normal
benign liver tissue.
Mitochondrial and NADPH oxidase mediate autophagy in
human hepatocytes during H-R. It has been previously shown
that ROS are critical regulators of autophagy.11 Accordingly,
during H-R, inhibition of ROS production inhibits autophagy in
primary human hepatocytes (Fig. 4). Specifically, inhibition of
mitochondrial complex I with rotenone and cytoplasmic NADPH
oxidase with diphenyliodonium significantly reduced MDC
staining of human hepatocytes, as assessed by flow cytometry.
Moreover, the general antioxidant N-acetylcysteine, which has the
greatest effect upon human hepatocyte ROS production,2 almost
completely inhibited autophagy in human hepatocytes. These
observations clearly demonstrate the central role of ROS in
regulating autophagy in human hepatocytes.
Inhibition of autophagy was associated with a concomitant
increase in hepatocyte apoptosis during H-R. We utilized the
specific class III PtdIns3K inhibitor 3-MA to elucidate the role of
autophagy in human hepatocytes. 3-MA significantly reduced
hepatocyte autophagy during H-R while the number of cells
undergoing apoptosis increased (Fig. 5). Similar data was obtained
during normoxia and hypoxia (data not shown). No significant
change in the number of cells undergoing necrosis was observed
during H-R with 3-MA pretreatment (Fig. 6). Similar data was
obtained during hypoxia (data not shown). Interestingly inhibi-
tion of class III PtdIns3K also decreased ROS accumulation
within human hepatocytes during H-R (Fig. 6).
Given that autophagy is regulated by a number of Atg proteins
we investigated whether these Atg proteins were modulated by
hypoxia and/or H-R. As Figure 7 demonstrates BECN1, an early
regulator of autophagy, is induced by hypoxia and H-R.
Interestingly, 3-MA reduces BECN1 protein levels during
normoxia, hypoxia and H-R. Similarly we found that Atg 5,
Figure 2. Intracellular ROS accumulation is associated with increased autophagy during hypoxia and H-R in human hepatocytes. This figure demonstrates
a representative flow cytometry plot to illustrate the effect of normoxia (blue), hypoxia (hatched red) and H-R (solid gray) upon autophagy within human
hepatocytes isolated from benign liver disease. Again, the areas of interest within the flow cytometry plots are marked by vertical ellipses. The same gate
has been applied to primary human hepatocytes for these plots as those shown in Figure 1A. The bar chart shows pooled data of five separate
experiments illustrating the effects of hypoxia and H-R upon human hepatocyte autophagy (n = 5). Data are expressed as increase relative to basal,
where basal refers to the level of autophagy during normoxia alone. Data are expressed as mean ± SE (*p , 0.05 relative to basal, Mann-Whitney test).
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Atg 7, Atg12 and LC3A were also increased during hypoxia, and
H-R and 3-MA pre-treatment of hepatocytes reduced the protein
levels of these Atg proteins. Additionally, cells treated with 3-MA
during normoxia, hypoxia and H-R showed the characteristic
morphological appearance of the cells undergoing apoptosis.
Hepatocytes appeared phase bright, small and shrunken (Fig. 8).
These observations clearly demonstrate that autophagy promotes
survival of human hepatocytes during hypoxia and H-R in vitro.
Much recent work has focused upon the role of mitochondrial
autophagy or mitophagy during oxidative stress.13-15 Indeed the
mitochondrion is an important ROS generator during IRI and is
known to regulate human hepatocyte apoptosis and necrosis.2
Figure 3. Differential levels of autophagy induction in human hepatocytes isolated from different liver diseases. This figure illustrates the level
of autophagy in human hepatocytes isolated from different liver diseases. The FS and SS plots for these hepatocytes are the same as those shown
in Figure 1A (n = 3–6).
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Accordingly, we used the specific mitochondrial dye JC-1 as a
measure of the mitochondrial membrane potential within
hepatocytes during hypoxia and H-R. Red fluorescence represents
normal mitochondrial membrane potential whereas green fluore-
scence represents low mitochondrial potential. In addition, human
hepatocytes were co-stained with MDC. As Figure 9 shows, during
normoxia human hepatocytes have normal mitochondrial
membrane potential with no staining for MDC. Interestingly,
incubation of cells with 3-MA markedly increased the green
fluorescence of human hepatocytes indicating a lowering of
mitochondrial potential and is indicative of cell death.
Furthermore, hypoxia and H-R lower mitochondrial membrane
potential further with a concomitant increase in MDC staining.
Moreover, pre-treatment of cells with 3-MA during hypoxia and
H-R, while reducing MDC staining markedly lowered mitochon-
drial membrane potential and increased cell death. Finally, MDC
and green JC-1 staining were observed to colocalize in these samples
indicating that autophagy was occurring in the mitochondrion.
Large peri-venular human hepatocytes preferentially undergo
autophagy during H-R. Our group has recently reported that
human hepatocytes located within the peri-venular (PV) region of
the liver, which tend to be larger in size than their peri-portal (PP)
counterparts, are the targets of hypoxic injury.16 Here we
demonstrate that large/PV hepatocytes (Fig. 10) increase auto-
phagy significantly more than PP/small human hepatocytes
during H-R (Fig. 11). As expected, these increased levels of
autophagy are sensitive to 3-MA pre-treatment. However,
inhibition of autophagy in large/PV human hepatocyte signifi-
cantly increased apoptosis during H-R (Fig. 4A).
Discussion
While autophagy is an important mechanism by which the cell
rids itself of potentially harmful constituents and helps maintain
normal cellular functioning and homeostasis, its precise role
during liver injury and disease where hepatocytes are involved
remains uncertain. A consensus is now emerging that autophagy
does not precede cell death but may be a physiologically protective
mechanism which favors cell survival.17 The diverse role of
autophagy in liver diseases has been recently reviewed.6,18,19
Certainly in liver IRI autophagy mainly has a prosurvival activity
allowing the cell to cope with hypoxia. However autophagy is also
Figure 4. Mitochondrial and NADPH oxidase mediate autophagy in human hepatocytes during H-R. This figure demonstrates representative flow
cytometry plots to illustrate the effects of NAC, rotenone and DPI upon human hepatocyte autophagy during H-R. The staining of cells with MDC during
H-R is shown in blue and the effects of NAC, rotenone and DPI are shown in solid gray. Similar data were obtained during normoxia and hypoxia
(data not shown). Again, the area of interest within the flow cytometry plots is marked by a vertical ellipse. The same gate has been applied to primary
human hepatocytes for these plots as those shown in Figure 1A. The bar chart shows pooled data of three separate experiments illustrating the effects
of NAC, rotenone, DPI upon human hepatocyte autophagy during H-R. Similar data were obtained during normoxia and hypoxia (data not shown).
Data are expressed as percentage inhibition relative to H-R, where the level of autophagy during H-R alone represents 100%. Data are expressed as
mean ± SE (*p , 0.05 relative to H-R alone, **p , 0.01 relative to H-R alone, Mann-Whitney test). Human hepatocytes used for these experiments were
isolated from benign liver diseases (n = 3–5).
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known to regulate hepatic steatosis and hepatitis virus replica-
tion.18 To our knowledge this is the first study to conclusively
demonstrate autophagy in isolated primary human cells under
conditions of hypoxic stress. This has potential implications for
our understanding of the hepatocyte response to liver injury and
development of chronic liver disease.
Previous tissue-based studies have shown autophagic hepato-
cytes within allografts are increased following liver transplantation.
However these studies failed to show a causal link between
oxidative stress, induction of cell death and autophagy.5 Instead it
was suggested that dying hepatocytes also increased autophagy.
However whether inhibition of autophagy promoted cell death or
survival was not demonstrated. Recent studies have shown that
the severity and duration of an ischemic insult determine whether
autophagy is induced or not. Indeed these studies have shown that
autophagy can delay the decision for a cell to die via apoptosis or
necrosis.20 We clearly show, using our novel four-color reporter
assay, that hepatocytes subjected to oxidative stress demonstrated
features consistent with increased ROS generation, autophagy and
apoptosis. However, crucially we show that inhibition of early
autophagy with the class PtdIns3K inhibitor, 3-MA, induces
increased levels apoptosis during H-R. For our presented study
we used 3-MA only and not siRNA knockdown or transfection
of human hepatocytes as these are notoriously difficult and
inefficient techniques.21-23 Importantly, inhibiting autophagy
causes the lowering of mitochondrial membrane potential and
leads to cell death. Previous authors have also reported that
autophagy is responsible for maintaining mitochondrial poten-
tial.19 Importantly, in the present study we have shown that
human hepatocytes isolated from normal and diseased liver tissues
have different autophagy responses during hypoxia and H-R.
Specifically, human hepatocytes isolated from normal resected
tissue, where livers would have been treated with chemotherapy,
showed MDC staining that was consistent throughout hypoxia
and H-R. Coupled with the findings of our previous study2 it can
be seen that these hepatocytes are also resistant to cell death
during hypoxia and H-R. Indeed, the reduction in cell death
maybe in part due to the induction of autophagy. This is
consistent with previous work performed in human livers.24
Moreover human hepatocytes isolated from ALD livers showed
no autophagy response during hypoxia and H-R possibly
reflecting the extent of damage to these livers. Human hepatocytes
isolated from biliary cirrhosis and normal benign liver showed
similar autophagy responses in an analogous manner to the
accumulation of ROS within these cells.2 These observations
show that the varying levels of intracellular ROS within human
hepatocytes isolated from different liver diseases correlates
positively with intracellular MDC staining and hence autophagy.
Figure 5. Inhibition of autophagy increases apoptosis in human hepatocytes during H-R. This figure illustrates representative flow cytometry plots to
demonstrate the effects of the pre-treatment of primary human hepatocytes with 3-MA and the resultant effects upon apoptosis and autophagy during
H-R. The level of apoptosis and autophagy during H-R are shown in blue and the effects of 3-MA pre-treatment are shown in solid gray. The area of
interest is marked with a vertical ellipse. The same gate has been applied to primary human hepatocytes for these plots as those shown in Figure 1A.
The bar charts to the right of each flow cytometry plot show pooled data from three separate experiments. Data are expressed as increase or decrease
relative to basal, where basal refers to the level of ROS production, apoptosis, necrosis or autophagy during H-R. Data are expressed as mean ± SE
(*p , 0.05 relative to basal, Mann-Whitney test). Human hepatocytes used for these experiments were isolated from benign liver diseases (n = 3).
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This finding also suggests that autophagy is differential induced in
different liver diseases and may have important implications for
disease pathogenesis.
During hypoxic stress, autophagy appears to occur within the
mitochondrion and our data shows that this process is likely to be
mediated by BECN1, LC3A, Atg 5, Atg 7 and Atg 12. Our
findings corroborate those in HeLa cells where inhibition of
autophagy also led to an increase in apoptosis.25 We illustrate, for
the first time, that the induction of autophagy within human
hepatocytes during oxidative stress is essential for cell survival.
Previous work by Kohli et al. in hepatocytes has shown that ROS
production lies upstream of PtdIns3K activation.26 Indeed,
inhibition of PtdIns3K with 3-MA did not lead to an increase
in BECN1, LC3A, Atg 5, Atg7 and Atg 12 protein levels which
were otherwise seen during hypoxia and H-R. Coupled together
these findings suggest that ROS activates PtdIns3K which sub-
sequently activates the remaining autophagy machinery (Fig. 12).
As stated above in hepatocytes autophagy targets mitochondria for
degradation, a process known as mitophagy. The finding that the
mitochondrion is the main ROS generator within human
hepatocytes would also fit with this observation particularly in
light of our previous findings that ROS can regulate autophagy,
apoptosis and necrosis. Inhibiting ROS inhibits all three cellular
processes, but selective inhibiting autophagy promotes apoptosis.
Furthermore, we demonstrate that the PV/large human hepato-
cytes increased levels of autophagy much more than PP/small
human hepatocytes in line with their greater susceptibility to
hypoxic injury. Moreover, inhibition of autophagy in PV/large
human hepatocytes increased apoptosis during H-R, clearly
demonstrating the link between autophagy and cell survival.
Central regulators of autophagy are the evolutionarily con-
served Atg genes and recent studies have shown that some Atg
proteins can be regulated by ROS.11 BECN1, an essential
regulator of early autophagy was induced by hypoxia and H-R and
efficiently inhibited by 3-MA. Recent reviews have detailed the
essential role of BECN1 in IRI27 as well as its central role in
mediating autophagy during oxidative stress.28 Moreover, under
stress hepatocytes utilize the LC3 protein to induce mitophagy
within the dysfunctional mitochondrion.29 This latter observation
is probably the role of increased LC3 seen in our in vitro model.
In an experimental rat model, short-term anoxia increases the
expression of Atg7 in hepatocytes and protects against anoxia-
reoxygenation mediated apoptosis and necrosis.1 We also found
an induction of Atg 7 during our model of IRI. Furthermore, we
found induction of Atg5 and Atg 12. These two Atg proteins are
involved in the latter processes of autophagy. Recent studies have
shown the integral role Atg 5 in regulating menadione-induced
oxidative stress.30 In this study knockdown of Atg 5 in the rat
hepatocyte line RALA255-10G sensitized cells to both apoptotic
and necrotic cell death. In addition Atg 12, along with other Atg
proteins, is required for the protection of anoxic rat hepatocytes
from cell death.31
Figure 6. Inhibition of autophagy reduces ROS production in human hepatocytes during H-R but does not affect necrosis. This figure illustrates
representative flow cytometry plots to demonstrate the effects of the pre-treatment of primary human hepatocytes with 3-MA and the resultant effects
upon intracellular ROS production and necrosis during H-R. The level of intracellular ROS production and necrosis during H-R are shown in blue and
the effects of 3-MA pre-treatment are shown in solid gray. The area of interest is marked with a vertical ellipse. The same gate has been applied to
primary human hepatocytes for these plots as those shown in Figure 1A. The bar charts to the right of each flow cytometry plot show pooled data from
three separate experiments. Data are expressed as increase or decrease relative to basal, where basal refers to the level of ROS production, apoptosis,
necrosis or autophagy during H-R. Data are expressed as mean ± SE (*p , 0.05 relative to basal, Mann-Whitney test). Human hepatocytes used for these
experiments were isolated from benign liver diseases (n = 3).
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Figure 7. BECN1, LC3A, Atg 5, Atg 7 and Atg 12 are induced by hypoxia and H-R in human hepatocytes. This figure illustrates the induction of various Atg
proteins involved in the regulation of autophagy during hypoxia and H-R. The effects of the PtdIns3K inhibitor 3-MA on Atg protein induction during
hypoxia and H-R are also shown. All western blots were performed at least three times and presented blots are representative of all samples (n = 3).
Figure 8. Inhibition of autophagy increases apoptosis in human hepatocytes during H-R. This figure shows representative light microscopy images of
primary human hepatocytes during normoxia, hypoxia and H-R in the presence and absence of 3-MA. In normoxia human hepatocytes are typical cuboid
morphology with many cells having the characteristic binucleate appearance. During hypoxia and H-R, cells lose this appearance and many cells appear
small shrunken in the confluent monolayer of cells, indicative of apoptotic bodies. Following 3-MA pretreatment in either normoxia, hypoxia or H-R many
more cells appear phase bright, small and shrunken. In addition there is disruption to the monolayer of hepatocytes. These light microscopy images have
been taken after 24 h incubation in hypoxia and H-R with and without the presence of 3-MA. (Magnification x20).
552 Autophagy Volume 8 Issue 4
While our study does not conclusively show which signaling
pathways are activated by ROS in human hepatocytes to induce
autophagy, it does clearly demonstrate that ROS is a key mediator
of autophagy during oxidative stress. Furthermore in accordance
with our study, previous authors have shown that the general anti-
oxidants, catalase and N-acetylcysteine reduce autophagy.11 We
now show that mitochondrial and NADPH oxidase derived ROS
are critical for the induction of autophagy in human hepatocytes.
In addition previous studies have shown that H-R induces
increased manganese superoxide dismutase expression in hepato-
cytes.32 Taken together these studies show that ROS derived from
many sources within hepatocytes can regulate autophagy.
Moreover this generated ROS has prosurvival effects in activating
autophagy but also signals to cell death in the form of apoptosis
and necrosis (Fig. 12). The increase in antioxidant defenses within
hepatocytes is likely to protect from cell death and the inhibition
of autophagy may not be detrimental as autophagy can be
regulated by other system besides ROS.33 These observations
provide interesting insights to the function of ROS in
determining human hepatocyte fate.2 Taken together, these
observations clearly point to ROS regulating diverse and different
signaling pathways within human hepatocytes during oxidative
stress. These pathways appear to regulate both cell death and cell
survival. It is likely that either the absolute level of intracellular
ROS, the type of ROS sub-species generated or duration of ROS
generation may be the critical factors in determining cell fate. The
precise mechanistic pathways remain to be elucidated but may
ultimately provide insights which inform the development of
therapeutic strategies aimed at limiting the cellular damage and
loss associated with liver injury. Previous authors have reported
that inhibiting autophagy within rat hepatocytes leads to
necrosis.34 Moreover, in a model of ischemic preconditioning
Esposti et al. reported that autophagy may switch necrosis and/or
apoptosis on and off by modulating intracellular signaling.35 We
did not find this and it is likely that this represents species-specific
effects of autophagy as no previous studies have evaluated
Figure 9. Autophagy is primarily performed inmitochondrion in human hepatocytes during hypoxia and H-R. This figure demonstrates the effects of hypoxia
and H-R upon human hepatocyte mitochondrial membrane potential and MDC staining. Mitochondrial membrane potential was determined using
the specific dye JC-1. When mitochondrial membrane potential is normal JC-1 appears red but once membrane potential is lowered or lost the dye become
green. MDC staining is detected within the DAPI channel and appears blue. Composite overlay images are shown at the bottom of the figure. Additionally
unstained images are provided with stained images to highlight the cellular location of immunofluorescence. In normoxia, as expected there was a normal
mitochondrial membrane potential and no autophagy noted. During hypoxia and H-R there was a progressive loss of red JC-1 staining and an increase in
green JC-1 staining indicating loss of mitochondrial potential and onset of cell death. In addition there was an increase inMDC staining in human hepatocytes
during hypoxia and H-R. Moreover, MDC staining and green JC-1 staining co-localized in human hepatocytes during hypoxia and H-R.
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autophagy in human hepatocytes. It may also represent a
difference between the induction of autophagy in the in vitro
and in vivo setting.
Our study demonstrates that ROS production decreased within
human hepatocytes after 3-MA pre-treatment during H-R. One
would expect that in hepatocytes in which autophagy was
inhibited damaged mitochondria would continue to form ROS
and induce cell death. However, the particular model utilized in
our experiments examines cell death and ROS production at 24 h
of hypoxia and/or H-R. The significant levels of apoptosis seen
after 3-MA pretreatment during H-R suggests that a significant
number of hepatocytes were already dead, hence intracellular
ROS had reduced. Importantly, our study showed no significant
effect of vehicle controls on human hepatocyte ROS production
during H-R.
We provide evidence that within human hepatocytes, auto-
phagy is a cell-survival mechanism during periods of oxidative
stress. Moreover, taken together with previous studies, we show
that the PV/large human hepatocytes increase autophagy signifi-
cantly more in H-R relative to PP/small human hepatocytes. This
is in accordance with our previous observations that the PV/large
peri-venular human hepatocytes are more susceptible to oxidative
stress. These observations suggest that the pharmacological
activation of P13-K or other autophagy machinery, particularly
within PV/large human hepatocytes may prove effective strategies
in ameliorating human hepatocyte cell death in chronic liver
disease as well as following liver transplantation.
Materials and Methods
Human hepatocyte isolation. Liver tissue was obtained via the
Hepatobiliary and Transplant surgery program at the Queen
Elizabeth Hospital Birmingham UK, from fully consenting
patients undergoing transplantation, hepatic resection for liver
metastasis, hepatic resection for benign liver disease or normal
donor tissue surplus to surgical requirements. Ethical approval for
Figure 10. Autophagic response in large human hepatocytes during hypoxia and H-R. The top panel demonstrates a representative flow cytometry plot
to illustrate the levels of MDC staining of PV/large human hepatocytes during normoxia (blue), hypoxia (hatched red) and H-R (solid gray). The plot
on the left hand side of the flow cytometric plot represents a typical FS vs. SS plot, similar to that shown in Figure 1A . The FS vs. SS plot is from a H-R
sample but similar plots were obtained during normoxia and hypoxia (data not shown). The gating protocol applied to human hepatocytes to analyze
PV/large human hepatocytes is shown on the FS vs. SS plot. The area of interest of each flow cytometry plot is marked by a vertical ellipse. The bottom
panel illustrates the effects of 3-MA pre-treatment upon PV/large human hepatocyte autophagy and apoptosis during H-R. The effects of H-R alone are
shown in blue and the effects of 3-MA pretreatment are shown in solid gray. The bar chart shows composite data from four separate experiments.
Data are expressed as mean ± SE (*p , 0.05 relative to basal, Mann-Whitney test).
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the study was grant by the Local Research Ethics Committee
(LREC) (reference number 06/Q702/61). Human hepatocytes
were isolated using the method that we have described
previously.36 Normal benign livers were classified as livers where
resection was performed for recurrent cholangitis, haemangioma
and focal nodular hyperplasia. Biliary cirrhosis livers included
livers with both primary biliary cirrhosis and primary sclerosing
cholangitis. Normal resected liver tissue was tissue taken from
surgical resections performed for metastatic disease. Tissue was
taken well away from the tumor site and all such patients had
received pre-operative chemotherapy.
Model of hypoxia and H-R. In experiments, human hepato-
cytes were grown for 2 d at 37°C, 5% CO2 in Williams E media
(Sigma-Aldrich, W4125) on rat type 1 collagen-coated plates.
Hepatocytes were either maintained in normoxia or placed into
hypoxia for 24 h, or placed into hypoxia for 24 h followed by 24 h
of reoxygenation. Hypoxia was achieved by placing cells in
an airtight incubator (RS Mini Galaxy A incubator, Wolf
Laboratories) flushed with 5% CO2 and 95% N2 until oxygen
content in the chamber reached 0.1%, as verified by a dissolved
oxygen monitor (DOH-247-KIT, Omega Engineering, UK). In
preliminary experiments, human hepatocytes were exposed to 5%
and 1% oxygen and no increase in ROS accumulation or cell
death was noted. Therefore, we used 0.1% oxygen in all
subsequent experiments. Additionally, Williams E media was
pre-incubated in the hypoxic chamber in a sterile container, which
allowed gas equilibration, for 8 h before experiments were
performed, resulting in a final oxygen concentration of, 0.1% as
measured with the dissolved oxygen meter. Where appropriate,
after 24 h of hypoxia media was aspirated and replaced with fresh,
warmed, oxygenated medium, and the cells were returned to
normoxic conditions. This was defined as the beginning of
reoxygenation. In experiments involving ROS inhibitors/antioxi-
dants all reagents were made fresh as stock solutions and added
using the correct dilution factor to the relevant experimental wells.
Specifically, N-acteylcysteine (Sigma-Aldrich, A9165) was dis-
solved in molecular grade water (Sigma-Aldrich, W4502) to a
concentration of 100 mM, rotenone (Sigma-Aldrich, R8875) was
dissolved in chloroform (Sigma-Aldrich, C2432) to a concentra-
tion of 1 mM and diphenyliodonium (Sigma-Aldrich, 43088) was
Figure 11. Autophagic response in small human hepatocytes during hypoxia and H-R. This figure demonstrates a representative flow cytometry plot to
illustrate the levels of MDC staining of PP/small human hepatocytes during normoxia (blue), hypoxia (hatched red) and H-R (solid gray). The FS vs. SS plot
is from a H-R sample but similar plots were obtained during normoxia and hypoxia (data not shown). The gating protocol applied to human hepatocytes
to analyze PP/small human hepatocytes is shown on the FS vs. SS plot. The areas of interest on the flow cytometric plots are marked by vertical ellipses.
The bottom panel illustrates the effects of 3-MA pre-treatment upon PP/small human hepatocyte autophagy and apoptosis during H-R. The effects of H-R
alone are shown in blue and the effects of 3-MA pretreatment are shown in solid gray. The bar chart shows composite data from four separate
experiments. Data are expressed as mean ± SE (*p , 0.05 relative to basal, Mann-Whitney test).
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dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, D2650)
to give a stock concentration of 1 mM, and these stocks were
diluted appropriately to give working concentrations of 20 mM,
2 mM and 10 mM respectively. In experiments using ROS
inhibitors/antioxidants, solvent alone controls were used to ensure
no vehicle effects. In addition, in experiments using ROS
inhibitors/antioxidants agents were added 4 h before the
placement of the cells into hypoxia or into reoxygenation.
In experiments involving the use of 3-MA (Merck,
Nottingham, 189490), stock solutions were made and added to
the correct final dilution factor in the relevant tissue culture wells.
3-MA is a specific class III PtdIns3K inhibitor and specifically
inhibits the early phases of autophagy. Specifically, 2 mg 3-MA
was dissolved in molecular grade DMSO (Sigma-Aldrich) and
were diluted appropriately to give working concentrations of
5 mM. In experiments using 3-MA, solvent alone wells were
included as vehicle only controls. Hepatocytes were pre-treated
with 3-MA for up to 4 h before placement of the cells into
normoxia and hypoxia. For H-R experiments fresh 3-MA was
added at the time of placement into reoxygenation.
Determination of human hepatocytes ROS accumulation,
apoptosis, necrosis and autophagy. ROS production, apoptosis,
necrosis and autophagy were determined by using
a four-color reporter assay system. ROS accu-
mulation was determined using the fluorescent
probe 2',7'-dichlorofluorescin-diacetate (Merck,
287810).37 This probe is cell permeable and once
inside the cell is cleaved by intracellular esterases
to 2',7'-dichlorofluorescin (DCF) and becomes
cell impermeable. DCF is then able to react with
intracellular ROS, specifically hydrogen peroxide,
to give a fluorescent signal detectable on the
FITC channel. The signal is directly proportional
to the level of intracellular ROS present.
MitoSox Red is a mitochondrial superoxide
indicator dye (Molecular Probes, Invitrogen,
M36008) and was used as an alternative means
to determine ROS in the mitochondria. Cells
were treated as described above in the in vitro
model and then loaded with 5 mM MitoSox Red
in Hank’s Balanced Salt Solution (HBSS) (Gibco,
14180046) for 30 min at 37°C in the dark. Cells
were washed as described below. MitoSox Red
fluorescent intensity was determined by fluore-
scence with excitation at 510 nm and emission at
580 nm.
Apoptosis was determined by labeling cells
with Annexin-V (Molecular Probes, Invitrogen,
A35122) which detects exposed phosphatidyl-
serine on the cell membrane. 7-Amino-
Actinomycin D (7-AAD) (Molecular Probes,
Invitrogen, A1310) is a vital dye that binds to
DNA, only entering cells once the cell membrane
is disrupted and is indicative of cellular necrosis.
Autophagy formation was determined by
using the fluorescent dye monodansylcadaverine
(MDC) (Sigma-Aldrich, 30432). This dye selectively labels
autophagic vacuoles38 and has been previously used in hepatoma
cell lines39 and primary hepatocytes40 to detect autophagy.
Following treatment, cell media was aspirated and replaced with
HBSS without calcium and magnesium. DCF (30 mM) and
MDC (1 mM) was added and the cells were incubated for 20 min
in the dark at 37°C. The cells were then trypsinized and washed
extensively in FACs buffer (phosphate-buffered saline pH 7.2
with 10% v/v heat inactivated fetal calf serum (Gibco) Sigma-
Aldrich, F6178). Cells were then labeled with Annexin-V
(0.25 mg/ml) and 7-AAD (1 mg/ml) for 15 min while on ice
and then samples were immediately subjected to flow cytometry.
At least 20,000 events were recorded within the gated region of
the flow cytometer for each human hepatocyte cell preparation in
each experimental condition. Only the cells within the gated
region were used to calculate Mean Fluorescence Intensity (MFI).
To ensure consistency of the flow cytometric data, each human
hepatocyte preparation was labeled with DCF alone, Annexin-V
alone, 7-AAD alone and MDC alone to ensure that cells had
become labeled and that the flow cytometry data could be
compensated for crossover of fluorophore emission spectra. The
same flow cytometry protocol was used for all experiments shown
Figure 12. The proposed regulation of autophagy in human hepatocytes during hypoxia
and H-R. Hypoxia and H-R leads to the generation of ROS in human hepatocytes
predominantly in a mitochondrial dependent manner. As our previous work has
demonstrated this increased ROS during hypoxia and H-R can lead to both apoptosis and
necrosis2 (black arrows). However, the increased ROS can also activate autophagy which
can be inhibited by the ROS inhibitors NAC, rotenone or DPI leading to reduced levels of
apoptosis, necrosis and autophagy. As Kohli et al. have demonstrated in hepatocytes, ROS
can activate PI3-K34, the essential first step in the assembly of the autophagosome.
Once activated a number of Atg proteins including BECN1, LC3A, Atg5, Atg7 and Atg12 are
involved in maturation of the autophagosome. It appears that the autophagy process
predominantly removes dysfunctional mitochondria in human hepatocytes during hypoxia
and H-R which in turns aids cell survival (green arrows). Inhibiting PtdIns3K with 3-MA
ensures that the autophagosome does not develop and that Atg proteins are not induced
in human hepatocytes during hypoxia and H-R (red arrows). Consequently, human
hepatocytes are not able to carry out autophagy and thus mitochondria lose their
membrane potential and are committed to cell death in the form of apoptosis.
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within the study, i.e. voltages for all markers were constant for
all human hepatocyte preparation ensuring inter- and intra-
experimental consistency. Specifically, for each experiment a cell-
only sample was used to ensure that there was no staining of
primary human hepatocytes with each specific dye/probe. This
sample was also used to ensure that the MFI reading was placed in
the first decade for each dye/probe. Also these cells were used to
place a flow cytometric gate for subsequent samples. Human
hepatocytes vary considerable in size depending upon whether
they are derived from the peri-venular region of the liver or peri-
portal region of the liver. Therefore forward scatter (FS) and side
scatter (SS) as shown in Figure 1A demonstrate a heterogeneous
cell population. A gate was therefore placed in FS vs. SS that
included all cells. Clearly, the sample includes cell debris that by
necessity is included within the large gate applied in the analysis.
Also, the gate will include small hepatocytes and hepatocytes that
attain lower intensity of staining with probes/dyes and do not
respond to hypoxia and H-R in the same way as the highly stained
species. Therefore, peaks seen adjacent to the vertical ellipses of
interest represent cell debris and hepatocytes that have different
responses to hypoxia and H-R.
Western blotting. For western immunoblotting studies, human
hepatocytes were lysed at the end of the relevant experimental period
using NP-40 lysis buffer (20 mM TRIS-HCl pH 8 (Sigma-Aldrich,
T3253), 137 mM NaCl (Sigma-Aldrich, S3014), 10% glycerol
(Sigma-Aldrich, G5516), 1%Nonidet P40 (Sigma-Aldrich, 18896),
2 mM EDTA (Sigma-Aldrich, E6758). Protein concentration was
determined by Bradford protein assay and 25 mg of protein was
resolved on a 10% SDS-PAGE gel and transferred to a nitrocellulose
membrane (Hybond; Amersham Biosciences, RPN3032D). The
blotted membrane was blocked for 1 h at room temperature in Tris-
buffered saline (TBS) pH 7.4/Tween 0.1% (Sigma-Aldrich, P9416)
containing 5% (wt/vol) bovine serum albumin (BSA) (Sigma-
Aldrich, A9418). All primary antibody incubations were performed
at overnight at 4°C in TBS-Tween 0.1% containing 5% BSA
(wt/vol). The incubation steps were followed by three washing steps
of 5 min with TBS containing 0.1% Tween. All primary antibodies
were purchased from New England Biolabs and used at a dilution
of 1:1000 as per manufacturer’s instructions. Specific primary
antibodies used included: (1) BECN1 (3495), (2) LC3A (4599), (3)
Atg5 (8540), (4) Atg12 (4180) and (5) Atg7 (2631).
Binding of specific mAb was detected with a horseradish
peroxidase-conjugated anti-rabbit IgG at a dilution of 1:2000 for
1 h (Sigma-Aldrich, A8792) Protein bands were visualized using
the enhanced chemiluminescence detection system (Amersham
Biosciences, RPN2109) followed by exposure of the membranes
to Hyperfilm-ECL (Amersham Biosciences, 28-9068-37).
Equality of protein loading on were checked by immunoblotting
for β-actin (Sigma-Aldrich, A2228) (dilution 1:20000). All
Western immunoblots were performed at least three times from
different liver preparations for each liver cell type.
Assessment of mitochondrial membrane potential and
labeling of autophagic vacuoles with MDC. To measure the
mitochondrial membrane potential (DYm), 5,5',6,6'-tetrachloro-
1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1)
(Molecular Probes, Invitrogen, M34152), a sensitive fluorescent
probe for DYm was used.41 Human hepatocytes were used in in
vitro experiments as described above. At the end of the specific
experimental procedure, cells were then rinsed with PBS twice
and then stained with 5 mM JC-1 and/or 1 mM MDC for 30 min
at 37°C. Cells were rinsed with ice-cold PBS twice, resuspended
in 1 mL ice-cooled PBS, and immediately analyzed with a
fluorescence microscope (Nikon Eclipse TE 300). A 488 nm filter
was used for the excitation of JC-1. Emission filters of 535 nm
and 595 nm were used to quantify the population of mito-
chondria with green (JC-1 monomers) and red (JC-1 aggregates)
fluorescence, respectively.42
MDC staining was assessed with a filter system (V-2A
excitation filter: 380/420 nm, barrier filter: 450 nm).43 Images
were captured with a CCD camera and imported into Adobe
Photoshop.
Statistical analysis. All data are expressed as mean ± SE.
Statistical comparisons between groups were analyzed by Mann-
Whitney test. All differences were considered statistically signifi-
cant at a value of p , 0.05.
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